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Ac acetyl 
AcOH acetic acid 
aq. aqueous 
Ar aryl 
Boc tert-butoxycarbonyl 
br broad 
Bu butyl 
nBu n-butyl 
tBu t-butyl 
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conc. concentrated 
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d doublet 
δ chemical shifts in parts per 
million 
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EI electron ionization 
ESI electrospray ionization 
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Et ethyl 
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h hour 
HRMS high resolution mass 
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m multiplet 
M molarity 
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Me methyl 
Met metal 
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p para 
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rt room temperature 
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1. Overview 
Due to an ever increasing demand of more complex molecular structures for the use in 
pharmaceutical and agrochemical industries, there is a high need for the development of 
novel, more efficient and, especially, more stereoselective synthetic methods.1 Thereby, one 
of the most important synthetic challenges is the control of the stereochemical information in 
a molecular framework.2 This can either be implemented by the use of stereoselective 
functionalizations making use of a chiral catalyst or auxiliary, as well as the stereogenic bias 
in a molecule or by the stoichiometric use of stereodefined reagents.2 Due to their superior 
reactivities and their versatile applicability, organometallic reagents are especially suitable 
and a considerable amount of effort has been put into the development of novel methods for 
the generation of stereodefined carbon-metal bonds using a wide variety of synthetic 
approaches.3 
 
 
2. Stereoselective Preparation of Organometallic Reagents 
2.1. Preparation of Stereodefined Carbon-Lithium Bonds 
 
Stereomeric organolithium compounds featuring a stereodefined carbon-lithium bond have 
been most studied.4 However, due to the low configurational stability of the C-Li bond with 
its high ionic character these studies were mostly restricted to stabilized reagents, such as α-
heteroatom substituted alkyl-,5 benzylic6 or allylic organolithiums.7 Moreover, these 
                                                 
1
 a) Shenvi, R. A., O'Malley, D. P. & Baran, P. S. Chemoselectivity: the mother of invention in total synthesis. 
Acc. Chem. Res. 42, 530-541 (2009); b) Young, I. S. & Baran, P. S. Protecting-group-free synthesis as an 
opportunity for invention. Nature Chem. 1, 193-205 (2009); c) Hoffmann, R. W. Protecting-group-free synthesis. 
Synthesis 21, 3531-3541 (2006); d) Nicolaou, K. C., Vourloumis, D., Winssinger, N. & Baran, P. S. The art and 
science of total synthesis at the dawn of the twenty-first chemistry. Angew. Chem. Int. Ed. 39, 44-122 (2000). 
2
 a) Asymmetric synthesis - The Essentials (Eds.: M. Christmann, S. Bräse), Wiley-VCH, 2007; b) A. G. 
O’Brien, A. G. Recent advances in acyclic stereocontrol. Tetrahedron 67, 9639-9667 (2011). 
3
 a) J. Clayden, J. Organolithiums: Selectivity for Synthesis, Elsevier, 2002; b) Carreira, E. M. & Kvaerno, L. 
Classics in Stereoselectivity, Wiley-VCH, 2009. 
4
 a) Topics in Stereochemistry - Stereochemical Aspects of Organolithium Compounds (R. E. Gawley, J. S. 
Siegel), Vol. 26, VHCA, Wiley-VCH, 2010; b) Basu, A. & Thayumanavan, S. Configurational stability and 
transfer of stereochemical information in the reactions of enantioenriched organolithium reagents. Angew. Chem. 
Int. Ed. 41, 716-738 (2002). 
5
 a) Cohen, T. & Lin, M.-T. Two flask preparation of α-lithio cyclic ethers from γ- and δ-lactones. Reductive 
lithiation as a route, via radical intermediates, to axial 2-lithiotetrahydropyrans and their equilibration to the 
equatorial isomers. J. Am. Chem. Soc. 106, 1130-1131 (1984); b) Still, W. C. & Sreekumar, C. α-
Alkoxyorganolithium reagents, a new class of configurationally stable carbanions for organic synthesis. J. Am. 
Chem. Soc. 102, 1201-1202 (1980); c) Hoppe, D., Hintze, F. & Tebben, P. Chiral lithium-1-oxyalkanides by 
asymmetric deprotonation; enantioselective synthesis of 2-hydroxyalkanoic acids and secondary alkanols. 
Angew.Chem. Int. Ed. Engl. 29, 1422-1424 (1990); d) Rychnovsky, S. D. & Mickus, D. E. Preparation of 2-
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organolithium reagents can be accessed more easily via conventional stereoselective 
deprotonation reactions featuring chiral amine ligands, such as (-)-sparteine (1).4b,7a Thus, 
Curtis and Beak have reported on the stereoselective generation of the configurationally stable 
benzylic and allylic organolithium species 2 and 3 via asymmetric deprotonation mediated by 
1 (Scheme 1).8 
                                                                                                                                                        
lithiotetrahydropyrans: Kinetic and thermodynamic generation of alkyllithium reagents. Tetrahedron Lett. 30, 
3011-3014 (1989); e) Rychnovsky, S. D., Buckmelter, A. J., Dahanukar, V. H. & Skalitzky, D. J. Synthesis, 
equilibration, and coupling of 4-lithio-1,3-dioxanes: synthons for syn- and anti-1,3-diols. J. Org. Chem. 64, 
6849-6860 (1999); f) Kapeller, D. C., Brecker, L. & Hammerschmidt, F. Configurational stability of 
oxymethyllithiums as intermediates in intramolecular rearrangements. Chem. Eur. J. 13, 9582-9588 (2007); g) 
Kapeller, D. C. & Hammerschmidt, F. Enantiopure chiral (2,4,6-triisopropylbenzoyl)oxy-[D1]methyllithium: 
configurational stability, reactions, and mechanistic studies. J. Org. Chem. 74, 2380-2388 (2009); h) Schlosser, 
M. & Limat, D. Sparteine-mediated α-lithiation of N-BOC-N-methylbenzylamine: rapid racemization and 
subsequent deracemization. J. Am. Chem. Soc. 117, 12342-12343 (1995); i) Serino, C., Stehle, N., Park, Y. S., 
Florio, S. & Beak, P. Asymmetric syntheses of N-Boc 2-substituted pyrrolidines and piperidines by 
intramolecular cyclization. J. Org. Chem. 64, 1160-1165 (1999); j) Gawley, R. E. & Zhang, Q. 2-Lithio-N-
methylpiperidine and 2-lithio-N-methylpyrrolidine: configurationally and chemically stable unchelated α-
aminoorganolithiums. J. Am. Chem. Soc. 115, 7515-7516 (1993); k) Coldham, I., Dufour, S., Haxell, T. F. N., 
Patel, J. J. & Sanchez-Jimenez, G. Dynamic thermodynamic and dynamic kinetic resolution of 2-
lithiopyrrolidines. J. Am. Chem. Soc. 128, 10943-10951 (2006); l) Kapeller, D. C. & Hammerschmidt, F. 
Preparation of enantiopure chiral amino-[D1]methyllithium compounds and determination of their micro- and 
macroscopic configurational stabilities. Chem. Eur. J. 15, 5729-5739 (2009); m) Hoffmann, R. W., Dress, R. K., 
Ruhland, T. & Wenzel, A. Enantiomerization of α-thio-, α-seleno-, and α-telluro-substituted alkyllithium 
compounds; kinetic and mechanistic studies. Chem. Ber. 128, 861- 870 (1995); n) O’Brien, P. & Warren, S. 
Investigation of the configurational stability of lithiated phosphine oxides using diastereomerically pure and 
enantiomerically enriched phosphine oxides. J. Chem. Soc., Perkin Trans. 1, 2567- 2573 (1996); o) Hoffmann, 
R. W., Ruhland, T. & Bewersdorf, M. On the configurational stability of α-bromo-alkyllithium compounds. J. 
Chem. Soc., Chem. Commun., 195-196 (1991); p) Kapeller, D. C. & Hammerschmidt, F. Preparation and 
configurational stability of chiral chloro-[D1]methyllithiums of 98% enantiomeric excess. J. Am. Chem. Soc. 
130, 2329- 2335 (2008). 
6
 a) Lefranc, J., Fournier, A. M., Mingat, G., Herbert, S., Marcelli, T. & Clayden, J. Intramolecular vinylation of 
secondary and tertiary organolithiums. J. Am. Chem. Soc. 134, 7286-7289 (2012); b) Clayden, J., Helliwell, M., 
Pink, J. H. & Westlund, N. Stereospecificity and stereoselectivity in electrophilic substitution reactions of  non-
α-heterosubstituted organolithiums and stannanes: a rotationally restricted amide as an internal stereochemical 
marker. J. Am. Chem. Soc. 123, 12449-12457 (2001); c) Hoffmann, R. W., Rühl, T., Chemla, F. & Zahneisen, T. 
On the configurational stability of  α-methylbenzyllithium. Liebigs. Ann. Chem., 719-724 (1992); d) Peoples, P. 
R. & Grutzner, J. B. Structure of the 7-phenylnorbornyl carbanion. A pyramidal organolithium and planar 
organopotassium. J. Am. Chem. Soc. 102, 4709-4715 (1980); e) Prat, L., Mojovic, L., Levacher, V., Dupas, G., 
Quéguiner, G. & Bourguignon, J. Deracemization of diarylmethanes via lateral lithiation-protonation sequences 
by means of sparteine. Tetrahedron: Asymmetry 9, 2509-2516 (1998); f) Hoppe, I., Marsch, M., Harms, K., 
Boche, G. & Hoppe, D. Generation of enantiomerically enriched lithium indenides by means of (-)-sparteine: 
structure, stereoselective substitution and solvent effects. Angew. Chem. Int. Ed. Engl. 34, 2158-2160 (1995); g) 
Curtis, M. D. & Beak, P. Asymmetric carbon-carbon bond formation in Michael reactions: conjugate addition 
reactions of configurationally stable benzylic and allylic organolithium species J. Org. Chem. 64, 2996-2997 
(1999). 
7
 a) Hoppe, D. & Hense, T. Enantioselective synthesis with lithium/(-)-sparteine carbanion pairs. Angew. Chem. 
Int. Ed. Engl. 36, 2282-2316 (1997); b) Hoppe, D. α-Metallated O-2-alkenyl carbamates: synthetic equivalents 
of chiral homoenolates and materials for asymmetric homoaldol reaction. Synthesis, 43-55 (2009); c) Hoppe, I., 
Marsch, M., Harms, K., Boche, G. & Hoppe, D. Generation of enantiomerically enriched lithium indenides by 
means of (-)-sparteine: structure, stereoselective substitution and solvent effects. Angew. Chem. Int. Ed. Engl. 34, 
2158-2160 (1995); d) Curtis, M. D. & Beak, P. Asymmetric carbon-carbon bond formation in Michael reactions: 
conjugate addition reactions of configurationally stable benzylic and allylic organolithium species J. Org. Chem. 
64, 2996-2997 (1999). 
8
 Curtis, M. D. & Beak, P. Asymmetric carbon-carbon bond formation in Michael reactions: conjugate addition 
reactions of configurationally stable benzylic and allylic organolithium species. J. Org. Chem. 64, 2996-2997 
(1999). 
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Scheme 1: Generation of chiral allylic and benzylic organolithium species via (-)-sparteine-mediated 
enantioselective deprotonation. 
 
Their conjugate addition to benzylideneacetylacetone (4) provided the adducts (S,S)-5 and 
(S,R)-6 with superior regio-, diastereo- and enantioselectivities. Hoppe et al. also showed that 
(-)-sparteine (1) can be used to selectively stabilize the non-heteroatom α-substituted chiral 
lithium indenide 7 by crystallization leading after quenching with electrophiles to the 
respective enantioenriched products of type 8 (Scheme 2).7c 
 
 
Scheme 2: Generation of chiral α-substituted lithium indenide 7 by crystallization with (-)-sparteine (1). 
 
Cohen and Lin observed an interesting phenomenon based on both the configurational 
instability of the highly anionic C-Li bond and the stereochemical bias in substituted 
lithiopyrans.5a Thus, reductive lithiation of the conformationally locked thioether 9 
(axial:equatorial= 3.4:1) using lithium 1-(dimethylamino)napthalenide (LDMAN) 
exclusively furnished axially substituted organolithium compound ax-10 (Scheme 3). 
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Scheme 3: Stereospecific generation of lithiofurans via reductive lithiation of thioethers and the different 
stereochemical stabilities of the conformationally locked lithium reagent ax-10 and flexible 12. 
 
Quenching with benzaldehyde (PhCHO), D2O or CD3CO2D furnished products of type ax-11 
with extraordinarily high selectivity. Remarkably, when ax-10 was warmed to -30 °C in the 
presence of chelating TMEDA and cooled back to -78 °C, the equatorially substituted 
products of type eq-11 were obtained preferentially. This showed that ax-10 had equilibrated 
into the more stable eq-10 via inversion of the C-Li bond. This thermodynamic control could, 
however, not be applied to the 3-methyl-substituted 2-lithiopyran 12. The authors suggested 
that the flexibility of 12 is responsible for the lacking epimerization of the C-Li bond. Thus, 
ax-12a in which the Li occupies the axial position can easily undergo a ring flip placing the Li 
moiety in the more stable equatorial position (ax-12b) thus rendering an epimerization 
(formation of eq-12) as observed in the conformationally locked lithiopyran 10 unnecessary 
for the C-Li bond to occupy its thermodynamically preferred position. Coldham et al. also 
made use of the configurational instability of organolithium compounds. They showed that N-
Boc-2-lithiopyrrolidine (13) can be subjected to a dynamic kinetic resolution (DKR) process 
in the presence of the diastereomeric chiral aminoalcohol-ligands 14 and epi-14 (Scheme 4).5k 
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Scheme 4: Dynamic kinetic resolution (DKR) in N-Boc-2-lithiopyrrolidine (13 and ent-13) using the chiral 
aminoalcohol-ligands 14 and epi-14. 
 
Thus, deprotonation of N-Boc-pyrrolidine (15) using sBuLi in the presence of a chiral ligand 
led to the respective complexes between 13 and enantiomeric ent-13 with 14 or epi-14. The 
complex 13•14 reacted faster with Me3SiCl as electrophile than the diastereomeric complex 
ent-13•14 leading to the chiral silane 16 with high enantioselectivity. When epi-14 was 
employed as ligand the ensuing complex ent-13•epi-14 reacted preferably giving a highly 
selective access to the opposite enantiomer of 16 (ent-16) upon quenching with Me3SiCl. 
Another interesting dynamic resolution process based on thermodynamic control (compare 
Scheme 3) was observed by Coldham et al. for the N-iso-butyl-substituted lithiopyrrolidines 
17 and ent-17 in conjunction with the chiral aminoalcohol ligand 14 (Scheme 5). 
 
 
Scheme 5: Dynamic thermodynamic resolution (DTR) in N-iso-butyl-substituted 2-lithiopyrrolidine (17 and ent-
17) using the chiral amino alcohol ligands 14. 
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Sn-Li exchange on stannane 18 led to the lithium species 17 and ent-17. At -78 °C addition of 
the chiral ligand 14 leading to the formation of the complexes 17•14 and ent-17•14 and 
subsequent quenching with Me3SiCl gave only racemic product (19). When the Sn-Li 
exchange and addition of the chiral ligand 14 was performed at ambient temperature 
quenching with Me3SiCl furnished 19 with high enantioselectivity (94% ee). Interestingly, 
quenching with a substoichiometric amount of Me3SiCl at -78 °C gave the product with low 
selectivity and a preference for the opposite enantiomer (ent-19). This hints at a dynamic 
thermodynamic resolution process in which the less stable complex ent-17•14 equilibrates 
into the diastereomeric complex 17•14. The energy diagrams for the dynamic thermodynamic 
(Scheme 5) and the dynamic kinetic resolution processes (Scheme 4) are depicted in 
Scheme 6. 
 
∆Gǂinv∆GǂSE2retdia1
∆GǂSE2retdia2
∆G0/products
∆G0/start
Dynamic thermodynamic resolution (DTR)
∆Gǂinv
∆GǂSE2retdia1
∆GǂSE2retdia2
∆G0/products
∆G0/start
∆∆GǂSE2retdia1-dia2
Dynamic kinetic resolution (DKR)
 
Scheme 6: Representative energy schemes for the dynamic thermodynamic resolution (DTR) and the dynamic 
kinetic resolution of lithiopyrrolidines with chiral ligands. 
 
In the latter, the difference in activation energies (∆∆G≠) for the quenching reactions 
determines the overall stereoselectivity of the process with a low activation energy barrier for 
equilibration between 13•14 and ent-13•14. In the former, the difference in ground state 
energies (∆G0) between the diastereomeric complexes 17•14 and ent-17•14 is responsible for 
the stereochemical outcome. A relatively high activation barrier for equilibration between 
17•14 and ent-17•14 leads to a stable equilibrium between those complexes at lower 
temperatures (quenching temperature: -20 °C). Interestingly, the stereochemical paths of SE2 
reactions of chiral organolithium compounds are not uniform for all electrophiles. Thus, 
Hoppe and Hammerschmidt could show that the nature of the respective electrophiles 
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determined the stereochemical outcome of the quenching of the tertiary benzylic Li-reagent 
20, which was derived from 21 via deprotonation using sBuLi and TMEDA (Scheme 7).9 
 
 
Scheme 7: Electrophile-dependent stereochemical outcome in the quenching of the chiral benzylic lithium 
reagent 20. 
 
Thus, electrophiles like MeOD, HOAc and (MeO)2CO furnish the respective products of type 
22 with retention of stereoconfiguration, whereas invertive substitution is observed with 
Me3SnCl, CO2, alkyl bromides and iodides leading to products of type ent-23.  
 
∆Gǂinv∆GǂSE2retdia1
∆G0/products
∆∆GǂSE2dia1ret-inv
∆GǂSE2invdia1
∆∆GǂSE2dia1inv-ret
∆GǂSE2retdia2
∆GǂSE2invdia2
 
Scheme 8: Hypothetical scenario with different activation barriers for invertive and retentive quenching for two 
distinct diastereomeric organozinc reagents (in this simplified scheme same ground state energies are assumed 
for the organometallic diastereomeric reagents and diastereomeric quenching products; this does not necessarily 
need to be the case). 
 
                                                 
9
 a) Hoppe, D., Carstens, A. & Krämer, T. Generation of a configurationally stable chiral benzyllithium 
derivative, and the capricious stereochemistry of its electrophilic substitution. Angew. Chem. Int. Ed. Engl. 29, 
1424-1425 (1990); b) Carstens, A. & Hoppe D. Generation of a configurationally stable, enantioenriched α-oxy-
α-methylbenzyIlithium: stereodivergence of its electrophilic substitution. Tetrahedron 50, 6097-6108 (1994); c) 
Hammerschmidt, F., Hanninger, A. & Völlenkle, H. Proof of inversion of configuration on stannylation of a 
configurationally stable, tertiary benzyllithium compound from a single-crystal X-ray structure analysis. Chem. 
Eur. J. 3, 1728-1732 (1997). 
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Therefore, a scenario in which distinct kinetic preferences in the quenching reactions for 
diastereomeric organometallics in which one reacts with retention and the other with 
inversion of the C-metal bond is also conceivable but has not yet been reported in the 
literature so far. Scheme 8 shows an energy diagram for such a hypothetical scenario in which 
distinct activation energy barriers for the retentive and invertive substitution processes lead to 
different stereochemical outcomes. The stereoselective generation of unstabilized secondary 
alkyllithium reagents has been far less studied. An early report by Letsinger featured an I-Li 
exchange on (-)-2-iodooctane (24) at -70 °C leading to stereodefined 1-methylheptyllithium 
(25) which was quenched with CO2 to give the carbonic acid 26 with 80% racemization 
(Scheme 9).10 
 
 
Scheme 9: I-Li exchange on enantiopure (-)-2-iodooctane and quenching with CO2 at -70 °C goes along with 
80% racemization. 
 
Reich et al. reported on the stereoselective generation of the diastereomeric cyclohexyllithium 
compounds ax-27 and eq-27 via Te-Li exchange on tellurides ax-28 and eq-28 (Scheme 10).11 
The influence of chelators such as TMEDA and PMDTA and lithium iodide salt on the 
configurational stability of ax-27 which tends to equilibrate into the more stable eq-27 was 
examined. 
 
 
Scheme 10: Te-Li exchange on stereodefined cyclohexyl tellurides ax-28 and eq-28 proceeds with retention of 
stereoconfiguration. 
 
                                                 
10
 Letsinger, R. L. Formation of optically active 1-methylheptyllithium. J. Am. Chem. Soc. 72, 4842 (1950). 
11
 Reich, H. J., Medina, M. A. & Bowe, M. D. Stereochemistry of a cyclohexyllithium reagent. A case of higher 
configurational stability in strongly coordinating media. J. Am. Chem Soc. 114, 11003-11004 (1992). 
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2.2. Preparation of Stereodefined Carbon-Magnesium Bonds 
 
Stereodefined Grignard reagents have been much less studied than their organolithium 
counterparts. Jensen and Nakamaye reported on the stereoselective generation of endo-
norbornylmagnesium bromide (endo-29) via a kinetic resolution process already as early as 
1966.12 They used the greater reactivity of exo-29 towards the reduction of benzophenone to 
selectively remove it (Scheme 11).  
 
 
Scheme 11: Kinetic resolution of the diastereomeric norbornylmagnesium reagents exo-29 and endo-29. 
 
The remaining endo-29 was studied by NMR and trapping experiments with HgBr2 and CO2 
gave the respective endo-products endo-30 and endo-31 stereospecifically with retention of 
configuration. In accordance with the results of Whitesides and Roberts13 only a very slow 
interconversion from endo-29 to exo-29 was observed showing the relatively high 
configurational stability of these bicyclic secondary alkyl Grignard reagents. The (-)-menthyl-
/neomenthyl Grignard reagents 32 and 33 represent the most extensively studied chiral 
organomagnesium reagents (Scheme 12).14 
 
                                                 
12
 Jensen, F. R. & Nakamaye, K. L. Preparation of geometrically isomeric Grignard reagents and the 
stereochemical courses of their reactions. J. Am. Chem. Soc. 88, 3437-3438 (1966). 
13
 Whitesides, G. M. & Roberts, J. D. Nuclear magnetic resonance spectroscopy. The configurational stability of 
primary Grignard reagents. J. Am. Chem. Soc. 87, 4878-4888 (1965). 
14
 Beckmann, J., Dakternieks, D., Dräger, M. & Duthie, A. New insights into the classic chiral Grignard reagent 
(1R,2S,5R)-menthylmagnesium chloride. Angew. Chem. Int. Ed. Engl. 45, 6509-6512 (2006). 
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Scheme 12: Mg-insertion in either menthyl chloride (eq-34) or neomenthyl chloride (ax-34) results in a 1:1-
mixture of the diastereomeric Grignard reagents 32 and 33; 32 can be selectively trapped using Ph2PCl. 
 
Originally, it was believed that the insertion of Mg metal into (-)-menthyl chloride (eq-34) 
would exclusively lead to the stereodefined 33, since quenching of the resulting Grignard 
reagent(s) with Ph2PCl only gave equatorially substituted diastereomeric phosphine 35.15 A 
more recent investigation by Beckmann, Dakternieks and Duthie showed that, after Mg-
insertion into 34, a 1:1-mixture of diastereomeric 32 and 33 ensues, which was proven by 
quenching the mixture with D2O.15 The same ratio was found when Mg-insertion was 
performed on the diastereomeric neomenthyl chloride (ax-34) The reaction of this mixture 
with 0.5 equiv. of Ph2PCl was reported to result in a kinetic resolution similar to the one 
shown in Scheme 11 where the more reactive and more Lewis-acidic 32 was selectively 
quenched and 33 remained in solution, as proven by quenching with D2O. Interestingly, the 
stereochemical outcome of the quenching reactions of the 32/33 mixture is highly dependent 
on the nature of the electrophile. Thus, Dakternieks et al. observed a 3:2-mixture of the 
diastereomeric stannanes 36 and 37 upon quenching with Ph3SnCl,16 whereas the reaction 
with Me3SnCl was reported by Schumann et al. to give exclusively the equatorially 
substituted stannane 38 (Scheme 13).17 
 
                                                 
15
 Tanaka, M. & Ogata, I. A novel route to menthyldiphenylphosphine. Bull. Chem. Soc. Jpn. 48, 1094 (1975). 
16
 Dakternieks, D., Dunn, K. & Henry, D. J. Organostannanes derived from (-)-menthol: controlling 
stereochemistry during the preparation of (1R,2S,5R)-menthyldiphenyltin hydride an bis((1R,2S,5R)-
menthyl)phenyltin hydride. Organometallics 18, 3342-3347 (1999). 
17
 Schumann, H., Wassermann, B. C. & Hahn, F. E. Synthesis and characterization of chiral (-)-menthyltin (4) 
compounds. X-ray structure of tert-butyl-8-(dimethylamino)naphthyl-(-)-menthyltin hydride. Organometallics 
11, 2803-2811 (1992). 
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Scheme 13: Quenching of the diastereomeric Grignard reagents 32 and 33 with different organotin chlorides 
leading to distinct stereochemical outcomes. 
 
The addition of Lewis-bases, such as Ph3P, to Ph3SnCl prior to the addition of the 32/33 
mixture restored selectivity presumably due to a decreased Lewis-acidity of the Ph3SnCl-PPh3 
complex. At that time, the 32/33-mixture was still considered to consist of only 32 and an 
electrophile-triggered radical epimerization of 32 was proposed.17 Hoffmann et al. developed 
a general and straightforward access to chiral organomagnesium reagents via a sulfoxide-
magnesium exchange/ carbenoid homologation sequence using excess EtMgCl and α-chloro-
substituted chiral secondary alkylsulfoxides of type 39.18 The resulting chiral 
organomagnesium reagent 40 was shown to undergo racemization at -10 °C in a first order 
process with a half-life of only 5 h.19 40 was subjected to trapping and transmetalation 
reactions with different electrophiles (Scheme 14).19  
 
                                                 
18
 a) Hoffmann, R. The quest for chiral Grignard reagents. Chem. Soc. Rev. 32, 225-230 (2003); b) Hoffmann, R. 
W., Hölzer, B., Knopff, O. & Harms, K. Asymmetric synthesis of a chiral secondary Grignard reagent. Angew. 
Chem. Int. Ed. 39, 3072-3074 (2000). 
19
 a) Hoffmann, R. W., Hölzer, B. & Knopff, O. Amination of Grignard reagents with retention of configuration. 
Org. Lett. 3, 1945-1948 (2001); b) Hoffmann, R. W. & Hölzer, B. Concerted and stepwise Grignard additions, 
probed with a chiral Grignard reagent. Chem. Commun., 491-492 (2001); c) Hoffmann, R. W. & Hölzer, B. 
Stereochemistry of the transmetalation of Grignard reagents to copper (I) and manganese (II). J. Am. Chem. Soc. 
124, 4204-4205 (2002); d) Hoffmann, R. W. & Hölzer, B. Kumada–Corriu coupling of Grignard reagents, 
probed with a chiral Grignard reagent. Chem. Commun., 732-733 (2003). 
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Scheme 14: Enantioselective generation of secondary alkylmagnesium reagents via sulfoxide magnesium 
exchange and electrophile-dependent stereochemical outcomes. 
 
These experiments showed that the stereochemical outcome highly depends on the nature of 
the respective electrophile. Whereas retention of the stereoinformation hinted toward polar 
addition processes, losses in enantiopurity were interpreted to indicate radical single electron 
transfer (SET) processes. 
 
2.3. Preparation of Stereodefined Carbon-Zinc Bonds 
 
Reports on the generation and configurational behaviour of stereodefined organozinc reagents 
are scarce in the literature. Despite their usefulness for organic synthesis due to their high 
tolerance towards functional groups and their decreased reactivity relative to the 
corresponding organo-lithium and -magnesium species, their stereochemical behaviour has 
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not yet been studied in detail. This may be due to the fact that stereodefined C-Zn bonds are 
not easy to generate. A first seminal investigation on the stereochemical behaviour of 
secondary diastereomeric organozinc reagents was published by Knochel et al. in 1994.20 In 
this article, Zn-insertion was performed on the endo- and exo-norbornyl iodides exo-41 and 
endo-41 and the resulting zinc reagents (42 and 43) were subjected to quenching with 
different electrophiles (Scheme 15).  
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Scheme 15: Stereoselective generation of secondary alkylzinc reagents. A phenomenon of stereoconvergent 
quenching or of an amide-directed Zn-insertion? 
 
Interestingly, iodolysis of 42 gave the iodide exo-44 with high diastereoselectivity (exo:endo= 
95:5), whereas quenching of 43 with I2 led to a 67:33-mixture in favour of exo-44. From these 
results it was concluded that the Zn-insertion into exo-41 proceeded stereoselectively to give 
the stereodefined Zn-reagent 42, while Zn-insertion into the diastereomeric endo-41 furnished 
a mixture of exo-/endo-configured Zn-reagents. Further quenching reactions using Me3SnCl 
and 2-(bromomethyl)hexane confirmed the observed trend. Still, when 43 was trapped, after 
transmetalation to copper, with Me3SnCl the stereochemical outcome depended highly on the 
                                                 
20
 Duddu, R., Eckhardt, M., Furlong, M., Knoess, H. P., Berger, S. & Knochel, P. Preparation and reactivity of 
chiral β-amido-alkylzinc iodides and related configurationally stable zinc organometallics. Tetrahedron 50, 
2415-2432 (1994). 
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amount of equivalents used. Thus, a 85:15 d.r. in favour of exo-45 was obtained with 1.2 
equiv. Me3SnCl which could be increased to 94:6 with only 0.5 equiv. of Me3SnCl. Another 
interesting observation was made, when exo- and endo-7-iodonorcarane (exo-46 and endo-46) 
were subjected to Zn-insertion using Rieke-zinc (Scheme 16).  
 
 
Scheme 16: Stereoselective generation of secondary alkylzinc reagents. A phenomenon of stereoconvergent 
quenching? Zinc-insertion into exo- and endo-7-iodonorcarane (exo-46 and endo-46). 
 
In both cases, after iodolysis an exo/endo ratio of the resulting iodide (46) of 95:5 was 
obtained. Thus, the stereoselective formation of exo-zinc reagent 48 was concluded. When 
Zn-insertion was performed on cis-4-tert-butylcyclohexyl iodide 49 using Rieke-zinc and the 
resulting organozinc species 50 was quenched with I2 the respective organic iodide products 
(cis-51 and trans-51) were obtained in a 35:65 cis:trans-ratio at -78 °C and in a 60:40-ratio at 
25 °C (Scheme 17). 
 
 
Scheme 17: Stereoselective generation of secondary alkylzinc reagents? A phenomenon of stereoconvergent 
quenching? Dependence of the stereoselectivity on reaction conditions and electrophiles. 
 
Trapping of 50 with AcOD resulted in a 60:40-ratio of deuterated products (cis-51 and trans-
51). Quenching with D2O, however, gave almost exlusively trans-51. These results 
underlined the influence of reaction conditions on the stereochemical outcome of the 
quenching reactions. The conclusion that only one Zn-species is formed in the case of 42 and 
47 has still to be verified, since the zinc reagent was not directly analyzed spectroscopically. 
Further insights into the stereochemical behaviour of C-Zn reagents were given by the 
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enantioselective cross-coupling of the benzylic zinc reagents 52a-c using a chiral ferrocene-
based Pd-catalyst (53) by Hayashi and Kumada (Scheme 18).21 
 
 
Scheme 18: Enantioselective Pd-catalyzed cross-coupling of secondary alkylzinc reagents 52a-c. 
 
The racemic zinc reagents 52a-c were proposed to undergo a dynamic kinetic resolution 
process in the presence of chiral 53 thus leading to the cross-coupling product 54 with high 
enantioselectivities.2a Thus, the organozinc reagents 52b-c, which were obtained via 
transmetalation from the Grignard reagent 55, reacted much faster and gave higher yields than 
52a which was prepared via Zn-insertion into the benzylic bromide 56. Such a dynamic 
kinetic resolution process has also been proposed for the remotely controlled 
diastereoselective cross-coupling of 3- and 4-substituted cyclohexylzinc reagents (Scheme 
19).22  
 
                                                 
21
 Hayashi, T., Hagihara, T., Katsuro, Y. & Kumada, M. Asymmetric cross-coupling of organozinc reagents with 
alkenyl bromides catalyzed by a chiral ferrocenylphosphine-palladium complex. Bull. Chem. Soc. Jpn. 56, 363-
364 (1983). 
22
 Thaler, T., Haag, B., Gavryushin, A., Schober, K., Hartmann, E., Gschwind, R., Zipse, H., Mayer, P. & 
Knochel, P. Highly diastereoselective Csp3-Csp2 Negishi cross-coupling with 1,2-, 1,3- and 1,4-substituted 
cycloalkylzinc compounds. Nature Chem. 2, 125-130 (2010). 
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Scheme 19: A DKR mechanism proposed for the stereoconvergent Negishi cross-couplings of diastereomeric 
cyclohexylzinc reagents. 
 
Here, the equatorially substituted cyclohexylzinc reagent eq-57 was assumed to react much 
faster with the arylpalladium complex 58 than ax-57 thus selectively leading to the 
thermodynamically favoured all-equatorially substituted products of type eq-59 
(transmetalation and reductive elimination were assumed to proceed with rentention of 
stereoconfiguration). An efficient way for the stereoselective generation of C-Zn bonds was 
disclosed by Knochel et al.: A hydroboration/B-Zn exchange sequence on trisubstituted 
double-bonds (60) leads to the regio- and stereodefined trans-configured organozinc reagents 
of type 61 (Scheme 20).23 
 
 
Scheme 20: Hydroboration/B-Zn exchange sequence for the generation of diastereomerically defined organozinc 
reagents. 
 
Thereby, the hydroboration proceeds with anti-Markovnikov- and syn-addition-selectivity and 
the B-Zn exchange with retention of stereoconfiguration. The configurational behaviour of 
these trans-configured organozinc reagents was examined using indanyl derivative trans-62 
(Scheme 21).24 
                                                 
23
 Boudier, A., Hupe, E. & Knochel, P. Highly diastereoselective synthesis of monocyclic and bicyclic secondary 
diorganozinc reagents with defined configuration. Angew. Chem. Int. Ed. Engl. 39, 2294-2297 (2000). 
24
 Boudier, A., Darcel, C., Flachsmann, F., Micouin, L., Oestreich, M. & Knochel, P. Stereoselective preparation 
and reactions of configurationally defined dialkylzinc compounds. Chem. Eur. J. 6, 2748-2761 (2000). 
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Scheme 21: Deterioration of the diastereoselectivity in the quenching of trans-62 with D2O in the presence of 
ZnBr2. 
 
When trans-62 was quenched at -78 °C with D2O almost exclusively, as expected, the trans-
deuterated product trans-63 was formed. Prior addition of ZnBr2 to trans-62 at -78 °C for 20 
min and subsequent quenching with D2O, however, led to an erosion of the trans/cis ratio to 
92:8. This method was extended to an enantioselective hydroboration/B-ligand exchange/B-
Zn transmetalation sequence which allowed the preparation of the enantioenriched organozinc 
reagent 65 which was trapped with allylic, alkynyl and propargylic bromides to furnish the 
products 66-68 (Scheme 22).25 
 
 
Scheme 22: Enantioselective conjugate functionalizations by an asymmetric hydroboration and B-Zn exchange 
sequence. 
                                                 
25
 Hupe, E. & Knochel, P. Formal enantioselective Michael addition with umpolung of reactivity. Angew. Chem. 
Int. Ed. Engl. 40, 3022-3025 (2001). 
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Next to Cu-mediated trapping reactions with allyl bromides, also Pd-catalyzed acylations and 
cross-couplings with iodoalkenes has been described (Scheme 23).26 
 
 
Scheme 23: Enantio- and diastereoselective preparation of cyclic and acyclic organozinc reagents and 
subsequent Pd-catalyzed cross-coupling and acylation. 
 
The respective products were received with high diastereomeric ratios favouring the trans-
configuration. Interestingly, a 1H-NMR-investigation by Rieke and Guijarro on the 
configurational stability of secondary alkylzinc reagents, in which the racemic Zn-species 69 
was complexed with a chiral bisoxazoline ligand (70) to give the distinguishable 
diastereomeric complexes 71 and 72, showed that the C-Zn bond is configurationally 
extremely stable (Scheme 24).27 
 
Scheme 24: High configurational stabilities for bisoxazoline-complexed diastereomeric secondary alkylzinc 
reagents 71 and 72. 
 
With no mentionable coalescence between these species being observed on an NMR-time 
scale, the authors calculated the lifetime of the inversion process to be 4130 h at 25 °C 
assuming a mononuclear transition state for inversion. 
                                                 
26
 Boudier, A. & Knochel, P. Palladium catalyzed stereoselective cross-couplings and acylations of chiral 
secondary diorganozincs. Tetrahedron Lett. 40, 687-690 (1999). 
27
 Guijarro, A. & Rieke, R. D. Study of the configuration stability of the carbon-zinc bond, direct measurement 
of enantiomeric ratios, and tentative assignment of the absolute configuration in secondary organozinc halides. 
Angew. Chem. Int. Ed 39, 1475-1479 (2000).  
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3. Objectives 
One of the aims of this thesis was to develop a practical method for the preparation of 
stereodefined non-stabilized diastereomeric cyclohexyllithium reagents of type 73 so that 
their reactivities towards various electrophiles as well as their stereochemical behaviours 
could be investigated (Scheme 25). 
 
 
Scheme 25: A stereoselective method for the generation of stereodefined cyclohexyllithium reagents – studies 
and explanations of their stereochemical behaviours. 
 
Also, the stereochemical behaviour of diastereomeric cyclic zinc reagents should be examined 
in order to elucidate the true mechanism of their remotely controlled Pd-catalyzed 
diastereoselective Negishi-cross-coupling with aryl halides (Scheme 26). 
 
 
Scheme 26: Two plausible mechanistic scenarios for the stereoconvergent cross-coupling of substituted 
diastereomeric cyclohexylzinc reagents. 
 
Although a dynamic kinetic resolution (DKR) mechanism had already been proposed (see 
Schemes 6 and 19), distinct kinetic preferences of the diastereomeric cyclohexylzinc 
complexes in the reaction with the arylpalladium complex cannot be ruled out (see Scheme 8) 
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especially since a high configurational stability of the C-Zn bond has been reported (see 
Scheme 24).27 
Furthermore, the highly diastereoselective cross-coupling methodology should be extended to 
functionalized organozinc reagents, such as substituted piperidinylzinc reagents of types 74 
and 75 and cyclohexylzinc reagents bearing functionalities, such as 76 and 77 (Scheme 27). 
Moreover, a method for a simultaneous enantio- and diastereoselective cross-coupling should 
be established. 
 
 
Scheme 27: Diastereoselective cross-couplings of substituted piperidinylzinc and functionalized cycloalkylzinc 
reagents. 
 
 
 
B. Results and Discussion  22  
 
 
B. Results and Discussion 
 
B. Results and Discussion  23  
 
1. Stereoselective Preparation, Configurational Stability and Reactivity 
of Substituted Cyclohexyllithium Derivatives 
1.1. Introduction 
 
Although the stereoselective generation and stereochemistry of α-heteroatom-substituted 
alkyl-, benzylic and allylic organolithium reagents are well studied, the stereoselective 
preparation of non-stabilized secondary alkyllithiums remains a major synthetic challenge. In 
this work, a practical stereoretentive synthesis to unstabilized stereodefined cyclohexyllithium 
reagents from the readily available organic iodides via I-Li exchange is presented. Using this 
approach a detailed study on the configurational stabilities, stereochemical behaviour and 
reactivities of various axially and equatorially substituted cyclohexyllithium reagents was 
performed. Thus, the stereochemical paths (SE2 vs. Si2) of the quenching reactions were 
shown to depend on the respective cyclohexyllithium diastereomer and the electrophile. In all 
cases, the axial cyclohexyllithium was found to almost completely equilibrate into the 
configurationally stable, equatorial diastereomer. This inversion process was followed for 
differently substituted cyclohexyllithiums over time showing distinct behaviour. DFT-
calculations demonstrated that the formation of oligomeric cyclohexyllithium structures is the 
key determinant for the observed stereochemical preference. 
 
1.2. Results and Discussion 
 
Initial experiments showed that the addition of tert-butyllithium (tBuLi) to a solution of 4-
tert-butylcyclohexyl iodide (78) in hexane/ether (3:2)28 at -100 °C gave mainly the 
protonation and elimination products 79 and 80 (Scheme 28a). This is due to a very similar 
reactivity of tBuLi and the newly formed secondary cyclohexyllithium 81. Moreover, the 
mode of addition implies the presence of excess amounts of organic iodide 78 relative to 
                                                 
28
 a) Bailey, W. F. & Patricia, J. J. The mechanism of the lithium-halogen interchange reaction: a review of the 
literature. J. Organomet. Chem. 352, 1-46 (1988); b) Bailey, W. F. & Punzalan, E. R. Convenient general 
method for the preparation of primary alkyllithiums by lithium-iodine exchange. J. Org. Chem. 55, 5404-5406 
(1990); c) Negishi, E.-I., Swanson, D. R. & Rousset, C. J. Clean and convenient procedure for converting 
primary alkyl iodides and  α,ω-diiodoalkanes into the corresponding alkyllithium derivatives by treatment with 
tert-butyllithium. J. Org. Chem. 55, 5406-5409 (1990); d) Bailey, W. F., Nurmi, T. T., Patricia, J. J. & Wang, W. 
Preparation and regiospecific cyclization of alkenyllithiums. J. Am. Chem. Soc. 109, 2442-2448 (1987); e) 
Ashby, E. C. & Pham, T. N. Single electron transfer in metal-halogen exchange. The reaction of organolithium 
compounds with alkyl halides. J. Org. Chem. 52, 1291-1300 (1987); f) Bailey, W. F., Brubaker, J. D. & Jordan, 
K. P. Effect of solvent and temperature on the lithium-iodine exchange of primary alkyl iodides: reaction of t-
butyllithium with 1-iodooctane in heptane-ether mixtures. J. Organomet. Chem. 681, 210-214 (2003). 
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organolithium species favouring elimination side-reactions. This results in a low yield of 81 
(<7%; determined by quenching experiments, see below). However, inversion of the addition 
order28 led to an efficient suppression of unwanted protonation and elimination pathways and 
the desired secondary cyclohexyllithium 81 was obtained in 70-90% yield. Using these 
optimized conditions, we were able to stereoselectively access various new non-stabilized 
secondary cyclohexyllithiums and, consequently, to probe their stereochemical behaviours. 
 
 
Scheme 28: Optimization of the I-Li exchange conditions for 4-t-butyl-cyclohexyl iodide 78 and stereoselective 
generation of the corresponding lithium reagents trans-(eq)-81 and cis-(ax)-81. 
 
Thus, we have prepared the stereodefined cis- and trans-4-tert-butylcyclohexyl iodides cis-
(ax)-7829 (cis/trans= 98:2) and trans-(eq)-78 (cis/trans= 10:90) from the respective cyclic 
alcohols30 and subjected them to the I-Li exchange conditions described above. Addition of 
the stereodefined cyclohexyl iodide trans-(eq)-78 (1.0 equiv., 1.0 M in 3:2 hexane/ether) to a 
solution of tBuLi (2.2 equiv., 0.2 M) cooled to -100 °C instantaneously produced the trans-
                                                 
29
 CCDC/890872 (for β-(eq)-94a), CCDC/890873 (for cis-(ax)-78), CCDC/890874 (for neomen-(ax)-91b) and 
CCDC/890875 (for trans-(eq)-82f) contain supplementary crystallographic data. These data can be obtained free 
of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
30
 Lange, G. L. & Gottardo, C. Facile conversion of primary and secondary alcohols to alkyl iodides. Synth. 
Commun. 20, 1473–1479 (1990). 
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cyclohexyllithium reagent trans-(eq)-81. Quenching with Me2S2 (dimethyl disulfide; 4 equiv., 
-100 oC, 5 min) led to the expected trans-thioether trans-(eq)-82a with retention of 
configuration (cis:trans= 9:91) in a 90% yield (Scheme 28c). Notably, this trans-lithium 
reagent (trans-(eq)-81) with the Li-atom occupying an equatorial position was stable at 
-100 °C for several hours (probed for a period of 7 h). Subjecting cis-(ax)-78 to the same 
exchange reaction conditions produced the axially substituted cis-cyclohexyllithium cis-(ax)-
81 (-100 °C; 5 s). Quenching with Me2S2 (4 equiv., -100 °C, 5 min) mainly gave the 
corresponding cis-thioether cis-(ax)-82a (cis:trans= 90:10) in a 73% yield. The lithium 
species cis-(ax)-81 bearing the Li-atom in an axial position displayed a much lower 
configurational stability and fully equilibrated into the stable all-equatorially substituted 
cyclohexyllithium trans-(eq)-81 within 7 h at -100 °C (cis:trans <3:97; see also the detailed 
kinetic and theoretical studies on the configurational stability below). The lower stability of 
cis-(ax)-81 compared to its diastereomer trans-(eq)-81 is also likely to account for the slightly 
decreased yield. 
Next, the reactivity of trans-(eq)-81 and cis-(ax)-81 towards a variety of electrophiles was 
examined (Table 1). While the reactions of trans-(eq)-81 with a range of electrophiles 
proceeded with retention of configuration leading to the expected trans-substituted products 
in 85-92% yield and with excellent stereoselectivities (up to d.r. >99:1; entries 1-4; Table 1), 
 
Table 1: Reactivities of trans- and cis-81 with different electrophiles. 
Entry Li-Reagent Electrophile Product d.r. (cis:trans)a Yield [%]b 
 
 
1 
 
 
trans-(eq)-81 
 
 
Bu2S2 
 
 
trans-(eq)-82b 
 
 
<1:99 
 
 
85 
 
 
 
 
2 
 
 
 
 
trans-(eq)-81 
 
 
 
 
Ph-NCO 
 
 
 
trans-(eq)-82c 
 
 
 
 
<1:99 
 
 
 
 
87 
 
 
 
3 
 
 
 
trans-(eq)-81 
 
 
 
F3CCO2D 
 
 
 
trans-(eq)-82d 
 
 
 
4:96c 
 
 
 
85d 
 
 
4 
 
 
trans-(eq)-81 
 
 
Me3SnCl 
 
 
 
trans-(eq)-82e 
 
 
 
<1:99 
 
 
92 
 
 
 
5 
 
 
cis-(ax)-81 
 
 
 
Bu2S2 
 
 
cis-(ax)-82b 
 
 
 
90:10 
 
 
 
59 
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6 
 
 
 
 
cis-(ax)-81 
 
 
 
 
Ph-NCO 
 
 
cis-(ax)-82c 
 
 
 
 
90:10 
 
 
 
 
60 
 
 
 
7 
 
 
 
cis-(ax)-81 
 
 
 
F3CCO2D 
 
 
cis-(ax)-82d 
 
 
 
92:8c 
 
 
 
75d 
 
 
 
8 
 
 
 
cis-(ax)-81 
 
 
 
Me3SnCl 
 
 
 
trans-(eq)-82e 
 
 
 
7:93 
 
 
 
55 
 
 
9 
 
 
cis-(ax)-81 
 
 
Ph3SnCl 
 
 
 
trans-(eq)-82f 
 
 
 
8:92e, f 
 
 
51 
[a] Determined via capillary GC analysis and 1H-NMR. [b] Isolated yields. [c] Determined via 2H-NMR. [d] 
Determined via capillary GC analysis. [e] The relative configuration was determined by X-ray analysis.29 [f] 
Determined via 119Sn-NMR. 
 
quenching of the configurationally labile cis-(ax)-81 was not as predictable. Trapping of cis-
(ax)-81 with Bu2S2 (dibutyl disulfide), d-TFA and phenyl isocyanate (PhNCO) 
stereoselectively provided the expected cis-products (cis-(ax)-82b-d; entries 5-7; Table 1). 
However, quenching of cis-(ax)-81 with Me3SnCl and Ph3SnCl proceeded with inversion 
resulting mainly in the trans-substituted stannanes (trans-(eq)-82e-f; entries 8 and 9; Table 
1).31 Due to the greater lability of cis-(ax)-81 lower yields (51-75%) are generally obtained 
than in the reactions of trans-(eq)-81. The configurational instability of cis-(ax)-81 also 
accounts for the lower observed stereoselectivities in the retentive quenching reactions 
(entries 5-7; Table 1). 
Intrigued by these results, we became interested in the scope of substrates suitable for the I-Li 
exchange reaction. Therefore, we chose a variety of differently substituted cyclohexyl iodides 
and subjected them to the I-Li exchange conditions. First, the reactions of equatorially 
substituted cyclohexyl iodides, which lead to the configurationally more stable organolithium 
reagents, were examined (Table 2). 
 
 
 
                                                 
31
 a) Hoppe, D., Carstens, A. & Krämer, T. Generation of a configurationally stable chiral benzyllithium 
derivative, and the capricious stereochemistry of its electrophilic substitution. Angew. Chem. Int. Ed. Engl. 29, 
1424-1425 (1990); b) Hammerschmidt, F., Hanninger, A & Völlenkle, H. Proof of inversion of configuration on 
stannylation of a configurationally stable, tertiary benzyllithium compound from a single-crystal X-ray structure 
analysis. Chem. Eur. J. 3, 1728-1732 (1997). 
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R
eq
tBuLi
(2.2 equiv.)
hexane/ether (3:2)
-100 oC, 5 s
E+ (4 equiv.)
-100 oC, 5 min
I
R
eq
Li R
eq
E
 
Table 2: Scope study of the I-Li exchange using equatorially substituted cyclohexyl iodides and quenching of 
the ensuing Li-species with electrophiles. 
Entry Cyclohexyl Iodide Cyclohexyllithium E
+ Product d.r.
 
ax:eqa 
Yield 
[%]b 
 
 
1 
 
 
trans-(eq)-83a 
 
 
trans-(eq)-84a 
 
 
Bu2S2 
 
 
trans-(eq)-85a 
 
 
<1:99 
 
 
91 
 
 
2 
 
 
trans-(eq)-83b 
 
 
trans-(eq)-84b 
 
 
Bu2S2 
 
 
trans-(eq)-85b 
 
 
<1:99 
 
 
83 
 
 
3 
 
 
trans-(eq)-83c 
 
 
trans-(eq)-84c 
 
 
Bu2S2 
 
 
trans-(eq)-85c 
 
 
1:99 
 
 
90 
 
 
4 
 
 
trans-(eq)-83c 
 
 
trans-(eq)-84c 
 
 
Ph2PCl, S8 
 
 
trans-(eq)-85d 
 
 
2:98 
 
 
69 
 
 
5 
 
 
 
trans-(eq)-83c 
 
 
 
trans-(eq)-84c 
 
 
 
EtSO2Cl 
 
 
 
trans-(eq)-85e 
 
 
 
1:99 
 
 
 
61 
 
 
 
6 
 
 
cis-(eq)-86a 
 
 
cis-(eq)-87a 
 
 
Bu2S2 
 
 
cis-(eq)-88a 
 
 
1:99 
 
 
81 
 
 
7 
 
 
 
cis-(eq)-86b 
 
 
 
cis-(eq)-87b 
 
 
 
Bu2S2 
 
 
 
cis-(eq)-88b 
 
 
 
2:98 
 
 
 
63 
 
 
 
 
8 
 
 
men-(eq)-89 
 
 
men-(eq)-90 
 
 
 
Me2S2 
 
 
men-(eq)-91a 
 
 
 
13:87 
 
 
 
54 
 
 
 
9 
 
 
 
 
men-(eq)-89 
 
 
 
 
men-(eq)-90 
 
 
 
 
Ph2PCl, S8 
 
 
 
men-(eq)-91b 
 
 
 
 
10:90d 
 
 
 
 
59 
 
 
 
 
 
 
 
 
10 
 
β-(eq)-92 
 
β-(eq)-93 
 
 
 
 
 
 
 
Me2S2 
 
 
β-(eq)-94a 
 
 
 
 
 
 
1:99c 
 
 
 
 
 
 
71 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
β-(eq)-92 
 
 
 
 
 
 
 
β-(eq)-93 
 
 
 
 
 
 
 
Ph2PCl, S8 
 
β-(eq)-94b 
 
 
 
 
 
 
6:94e 
 
 
 
 
 
 
 
80 
 
B. Results and Discussion  28  
 
 
 
 
 
 
 
 
12 
 
β-(eq)-95 
 β-(eq)-96 
 
 
 
 
 
 
 
Me2S2 
 
 β-(eq)-97 
 
 
 
 
 
 
2:98 
 
 
 
 
 
 
74 
[a] Determined via capillary GC analysis and 1H-NMR. [b] Isolated yields. [c] The relative configuration was 
determined by X-ray analysis.29 [d] Determined via 31P-NMR. [e] Determined via 1H-NMR. 
 
Thus, the 4-methyl-substituted cyclohexyl iodide (trans-(eq)-83a) was stereoselectively 
converted to the organolithium reagent trans-(eq)-84a which upon trapping with Bu2S2 
exclusively provided the trans-configured thioether trans-(eq)-85a in 91% yield (entry 1; 
Table 2). Replacing the methyl group with coordinating (MeO; trans-(eq)-84b) and non-
coordinating (TIPSO; TIPS= i-Pr3Si; trans-(eq)-84c) oxygen functionalities led, after 
quenching, to the expected trans-substituted products with equally high yields and 
diastereoselectivities (83-90%; d.r.: >99:1; entries 2-3; Table 2). Trapping of the 
functionalised organolithium reagent trans-(eq)-84c with Ph2PCl and subsequent protection 
with S8 gave the trans-substituted thiophosphane trans-(eq)-85d in 69% overall yield with a 
d.r. of 98:2 (entry 4; Table 2). The reaction of trans-(eq)-84c with EtSO2Cl exclusively led to 
the all-equatorially substituted cyclohexyl chloride trans-(eq)-85e (entry 5; Table 2). The cis-
1,3-disubstituted cyclohexyl iodides cis-(eq)-86a-b smoothly underwent the I-Li exchange 
reaction. The resulting equatorially substituted Li-reagents cis-(eq)-87a-b were trapped with 
Bu2S2 leading to the cis-configured products cis-(eq)-88a-b with 63-81% yield and high 
diastereoselectivities (entries 6 and 7; Table 2). Subjection of menthyl iodide (men-(eq)-89) 
with a diastereomeric purity of 75:25 (menthyl(eq)/neomenthyl(ax)) to the I-Li exchange 
reaction resulted in the formation of mainly menthyllithium (men-(eq)-90) whose immediate 
quenching with Me2S2 or Ph2PCl gave the menthyl derivatives men-(eq)-91a-b with improved 
diastereoselectivities relative to the starting material reaching from 87:13 to 90:10 (entries 8-
9; Table 2). The comparatively low yields (54-59%) can be attributed to the increased basicity 
of men-(eq)-90 which competes more readily with tBuLi for deprotonation of the tert-butyl 
iodide (tBuI) side-product (compare Scheme 28) and to the presence of 25% neomenthyl 
iodide (neomen-(ax)-89) in the starting material which leads to an unstable axial 
organolithium (neomen-(ax)-90; see Table 3). I-Li exchange on cholesteryl iodide β-(eq)-92 
led to the configurationally stable Li-reagent β-(eq)-93 which underwent quenching with 
Me2S2 and Ph2PCl with retention of stereoconfiguration furnishing the products β-(eq)-94a29 
and β-(eq)-94b with 71-80% yield and high stereoselectivities (d.r. 94:6 to 99:1; entries 10-
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11, Table 2). Subjection of cholestanyl iodide β-(eq)-95 with a diastereomeric purity of 85:15 
(β/α) to the I-Li exchange and subsequent trapping of the resulting lithium compound β-(eq)-
96 with Me2S2 gave the thioether β-(eq)-97 in 74% yield with a significantly increased 
diastereomeric ratio of 98:2 in favour of the β-isomer (entry 12, Table 2). Next, we examined 
the substrate scope of the corresponding axially substituted cyclohexyllithium reagents (cis-
(ax)-84a-c, trans-(ax)-87, neomen-(ax)-90) by subjecting the respective stereochemically 
pure cyclohexyl iodides (cis-(ax)-83a-c, trans-(ax)-86, neomen-(ax)-89) to the I-Li exchange 
conditions (Table 3). 
 
 
Table 3: Scope study of the I-Li exchange using axially substituted cyclohexyl iodides and quenching of the 
ensuing Li-species with electrophiles. 
Entry Cyclohexyl Iodide Cyclohexyllithium E+ Product d.r.
 
ax:eqa 
Yield 
[%]b 
 
 
 
1 
 
 
cis-(ax)-83a 
 
 
cis-(ax)-84a 
 
 
 
Bu2S2 
 
 
cis-(ax)-85a 
 
 
 
91:9 
 
 
 
74 
 
 
 
2 
 
 
cis-(ax)-83b 
 
 
cis-(ax)-84b 
 
 
 
Bu2S2 
 
 
85b 
 
 
 
52:48 
 
 
 
67 
 
 
 
3 
 
 
cis-(ax)-83c 
 
 
cis-(ax)-84c 
 
 
 
Bu2S2 
 
 
cis-(ax)-85c 
 
 
 
96:4 
 
 
 
79 
 
 
 
4 
 
 
 
cis-(ax)-83c 
 
 
 
cis-(ax)-84c 
 
 
 
Ph2PCl, S8 
 
 
cis-(ax)-85d 
 
 
 
92:8 
 
 
 
51 
 
 
 
5 
 
 
 
cis-(ax)-83c 
 
 
 
cis-(ax)-84c 
 
 
 
EtSO2Cl 
 
 
cis-(ax)-85e 
 
 
 
94:6 
 
 
 
56 
 
 
 
6 
 
 
 
trans-(ax)-86 
 
 
 
trans-(ax)-87 
 
 
 
 
Bu2S2 
 
 
 
trans-(ax)-88 
 
 
 
 
89:11 
 
 
 
 
56 
 
 
 
 
 
7 
 
 
neomen-(ax)-89 
 
 
neomen-(ax)-90 
 
 
 
 
Me2S2 
 
 
neomen-(ax)-91a 
 
 
 
 
93:7 
 
 
 
 
23 
 
 
 
 
8 
 
 
 
 
neomen-(ax)-89 
 
 
 
 
neomen-(ax)-90 
 
 
 
 
Ph2PCl, S8 
 
 
neomen-(ax)-91b 
 
 
 
 
91:9c,d 
 
 
 
 
28 
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9 
 
 
 
cis-(ax)-98 
 
 
 
cis-(ax)-99 
 
 
 
 
Bu2S2 
 
 
 
cis-(ax)-100 
 
 
 
 
88:12 
 
 
 
 
34 
 
 
 
 
 
 
 
 
10 
 
 
α-(ax)-95 
 
 
α-(ax)-96 
 
 
 
 
 
 
 
 
Me2S2 
 
 
α-(ax)-97 
 
 
 
 
 
 
 
 
77:23 
 
 
 
 
 
 
 
 
18 
 
[a] Determined via capillary GC analysis and 1H-NMR. [b] Isolated yields. [c] Determined via 31P-NMR. [d] The 
relative configuration was determined by X-ray analysis.29 
 
Thus, the 4-methyl-substituted cis-configured cyclohexyllithium cis-(ax)-84a generated from 
the corresponding axial iodide cis-(ax)-83a gave the expected product cis-(ax)-85a after 
immediate trapping (5 s) with Bu2S2 with predominant retention of configuration (d.r.: 91:9, 
74%; entry 1 of Table 3). Remarkably, when the I-Li exchange was performed on the 4-
methoxy-substituted cyclohexyl iodide cis-(ax)-83b, immediate quenching with Bu2S2 led to a 
52:48 cis:trans-mixture of the thioether 85b (entry 2, Table 3). We reasoned that this decay in 
stereoselectivity could be attributed to the coordinative properties of the 4-MeO-group which 
may intramolecularly break the unstable C-Li bond and facilitate its isomerization to the 
configurationally more stable equatorially substituted organolithium trans-(eq)-84b. Indeed, 
complete isomerisation from cis-(ax)-84b to trans-(eq)-84b takes place within only 2.5 min at 
-100 °C in a hexane:ether 3:2-mixture (cis:trans 2:98; see also the detailed kinetic studies on 
the configurational stability below; Scheme 29b), whereas the corresponding 4-tert-butyl-
substituted axial cyclohexyllithium cis-(ax)-81 requires 7 h under the same conditions to 
isomerise to the stable equatorial cyclohexyllithium compound trans-(eq)-81 (see also 
Scheme 29a). Interestingly, accelerated isomerization was not observed with an OTIPS-
substituent and the desired cis-configured products cis-(ax)-85c-e were obtained upon 
quenching in 51-79% yield with stereoselectivities up to 96:4 (entries 3-5, Table 3). The 
bulky silyl group prevents the neighbouring oxygen atom from coordinating to the Li+-ion. I-
Li exchange on the 3-methyl-substituted trans-configured cyclohexyl iodide trans-(ax)-86 led 
to formation of configurationally unstable trans-(ax)-87 which upon immediate quenching 
with Bu2S2 gave the expected product trans-(ax)-88 with 56% yield and a slightly decreased 
d.r. of 89:11 (entry 6, Table 3). Immediate trapping of neomenthyllithium (neomen-(ax)-90), 
generated from neomenthyl iodide (neomen-(ax)-89), with Me2S2 and Ph2PCl furnished the 
axially substituted products with good stereoselectivities (d.r. 91:9 to 93:7), however, in low 
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yields (23-28%; entries 7-8, Table 3). The decreased yields are due to a highly reactive 
neomenthyllithium species (neomen-(ax)-90) whose C-Li bond is weakened by the 
neighbouring isopropyl-group. Thus, the higher reactivity of this C-Li bond makes it a better 
competitor for tBuLi in the deprotonation of tBuI explaining the lower yields (compare 
Scheme 28a). Similar results were obtained in the quenching of the cis-2-methyl-substituted 
cyclohexyllithium cis-(ax)-99 which was generated from iodide cis-(ax)-98. Trapping of cis-
(ax)-99 with Bu2S2 led to the product cis-(ax)-100 with a good diastereomeric ratio of 88:12 
in 34% yield (entry 9, Table 3) underlining the higher reactivity and greater instability of 2-
substituted cyclohexyllithium species with an axial C-Li bond. We have also prepared the 
more complex epicholestanyl iodide α-(ax)-95 and subjected it to an I-Li exchange. The 
resulting organolithium species α-(ax)-96 was immediately quenched with Me2S2. The axially 
substituted product α-(ax)-97 was predominantly obtained (α/β: 77:23) albeit in a low yield 
(18%; entry 10, Table 3). Presumably, the large cholestanyl moiety in α-(ax)-96 hampers the 
formation of stabilizing oligomeric organolithium-clusters (see also DFT-analysis below). 
Next, we followed the kinetics of the invertive equilibration processes under standard 
conditions at -100 °C for the 4-substituted cyclohexyllithium reagents cis-(ax)-81, cis-(ax)-
84a and cis-(ax)-84b (Scheme 29a-b). The ratio of axial to equatorial Li-species, determined 
via retentive quenching with Me2S2 or Bu2S2, was recorded during a time course of 7 h. 
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Scheme 29: Kinetic investigation on the equilibration of the configurationally unstable axially substituted 
cyclohexyllithium reagents into their stable equatorially substituted diastereomers. 
 
Plotting of the percentage of the respective axial 4-substituted cyclohexyllithium species 
versus time resulted in near-exponential curves for cis-(ax)-81 and cis-(ax)-84a showing that 
invertive equilibration proceeds with first-order rate kinetics. Interestingly, the inversion 
process was faster for cis-(ax)-84a bearing the less bulky methyl group in position 4. Thus, 
after 2 h, an ax/eq-ratio of 9:91 was reached for 84a, whereas the 4-tert-butyl-substituted 
cyclohexyllithium 81 had only equilibrated to a ratio of 32:68 in the same time period. After 
7 h, cis-(ax)-81 and cis-(ax)-84a had almost completely been converted to the diastereomeric 
configurationally stable Li-species trans-(eq)-81 (ax/eq: 3:97) and trans-(eq)-84a (ax/eq: 
2:98). Equilibration towards the more stable equatorially substituted cyclohexyllithium trans-
(eq)-84b proceeded much faster for cis-(ax)-84b due to facilitated C-Li bond breakage via 
intramolecular coordination of the Li-atom to the methoxy-moiety. Here, after already 5 s, an 
ax/eq-ratio of 52:48 is reached. After 2.5 min cis-(ax)-84b has almost completely equilibrated 
to the diastereomeric isomer trans-(eq)-84b (ax/eq: 2:98). Thus, we wondered whether 
addition of THF, which is known to be a strongly coordinating solvent for organolithium 
species,32 to cis-(ax)-81 would similarly accelerate its equilibration to the stable trans-(eq)-
81. Indeed, when 25 vol% THF were added to cis-(ax)-81 at -100 °C immediate quenching 
                                                 
32
 a) Gronert, S. & Streitwieser, Jr., A. Carbon acidity. 71. The indicator scale of lithium ion pairs in 
tetrahydrofuran. J. Am. Chem. Soc. 108, 7016-7022 (1986); b) Carbone, G., O’Brien, P. & Hilmersson, G. 
Asymmetric deprotonation using sBuLi or iPrLi and chiral diamines in THF: the diamine matters. J. Am. Chem. 
Soc. 132, 15445-15450 (2010); c) Reich, H. J. & Borst, J. P. Direct nuclear magnetic resonance spectroscopic 
determination of organolithium ion pair structures in THF/HMPA solution. J. Am. Chem. Soc. 113, 1835-1837 
(1991); d) Bauer, W., Winchester, W. R. & von Ragué Schleyer, P. Monomeric organolithium compounds in 
tetrahydrofuran: tert-butyllithium, sec-butyllithium, “supermesityllithium”, mesityllithium, and phenyllithium. 
Carbon-lithium coupling constants and the nature of carbon-lithium bonding. Organometallics 6, 2371-2379 
(1987); e) Kwon, O., Sevin, F. & McKee, M. L. Density functional calculations of methyllithium, t-butyllithium, 
and phenyllithium oligomers: effect of hyperconjugation on conformation. J. Phys. Chem. A 105, 913-922 
(2001). 
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with Me2S2 already displayed an ax/eq-ratio of 9:91. Quenching after 10 min gave the product 
trans-(eq)-82a in 63% isolated yield with a d.r. of 4:96. 
When we turned our attention to the kinetics of C-Li bond inversion with neomenthyllithium 
neomen-(ax)-90 bearing a large isopropyl group in the neighbouring position, we were 
surprised to find a completely different behaviour. Its equilibration followed a sigmoidal 
curve. Thus, inversion was very slow during the first 4 h reaching only an ax/eq-ratio of 
71:29. After 4 h, the curve’s slope got steeper showing an accelerated inversion resulting in an 
ax/eq-ratio of 29:71 after 7 h. This hints towards an auto-mediated process in which 
menthyllithium men-(eq)-90 promotes its own formation. With enough menthyllithium men-
(eq)-90 (ca. 30%) formed, inversion accelerates. However, the overall inversion proceeds 
much slower than for the 4-substituted cyclohexyllithiums. Almost complete inversion from 
neomen-(ax)-90 to men-(eq)-90 could be achieved when the reaction mixture was warmed, 
directly after I-Li exchange on neomen-(ax)-89, from -100 °C to -60 °C within 50 min. 
Quenching of the lithium reagent with Me2S2 gave men-(eq)-91a with a high stereoselectivity 
(ax/eq= 2:98) and 32% yield. Notably, addition of 25 vol% of THF did not speed up the 
equilibration from neomen-(ax)-90 to men-(eq)-90 at -100 °C. Instead, the ax/eq-ratio 
changed much more slowly over time. In this case, the kinetic behaviour was best described 
by a straight line. After 7 h, the ax/eq-ratio had only dropped to 84:16. 
In order to explore the preference of lithium for the equatorial over the axial positions in 
cyclohexane ring systems, theoretical studies have been performed for 4-tert-
butylcyclohexyllithium 81 in its equatorial (trans-(eq)-81) and axial (cis-(ax)-81) 
configurations. Following earlier theoretical work on organolithium species32,33 geometry 
optimizations have been performed at the B3LYP/6-31+G(d) level of theory. Thermal 
corrections to free energies at 298.15 K have been calculated at the same level using the rigid 
rotor/harmonic oscillator model. Single point energies have then been added at MP2(FC)/6-
311+G(2d,p) level and combined with thermal corrections obtained at B3LYP/6-31+G(d) 
level in order to calculate free energies at 298.15 K. Interestingly, comparison of the gas 
phase stabilities of monomeric trans-(eq)-81 and cis-(ax)-81 indicated a small 
thermodynamic preference for the axially substituted cis-(ax)-81 (Table 4) by 3.8 kJ/mol. 
This energy difference remains essentially unchanged at even higher levels of theory such as 
G3+(MP2)B3. This, however, is in clear contrast to the trapping experiments performed at 
                                                 
33
 a) Hæffner, F. & Brinck, T. How does methyllithium invert? A density functional study. Organometallics 20, 
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-100 °C in Et2O/hydrocarbon solvents demonstrating a large or exclusive preference for 
equatorial isomers. Since the experimentally observed strong stereochemical preference for 
the equatorially substituted trans-(eq)-81 may be due to aggregates formed at low 
temperatures in weakly coordinating solvents, calculations have been additionally performed 
on the respective cyclohexyllithium aggregates. Comparison of the gas phase stabilities of the 
dimeric lithium species trans-(eq)-101 and cis-(ax)-101 shows only a small preference of 
4.72 kJ/mol for the equatorial isomer (Table 4). The hexameric structures found for nBuLi34 
(from hexane) and cyclohexyllithium35 (from benzene) indicate that higher aggregates can 
easily be formed in less polar solvents. The equatorial/axial preference was therefore also 
explored for the hexameric form of cyclohexyllithium. 
 
Table 4: Relative gas phase stabilities of monomeric, dimeric and hexameric cyclohexyllithiums. 
Entry Structuresa, ∆G298/ax-eq [kJ/mol]b 
 
 
 
trans-(eq)-81 
 
 
 
cis-(ax)-81 
 
1 -3.8 
 
 
 
 
trans-(eq)-101 
 
 
tBu
Li
H
tBu
Li
H
 
cis-(ax)-101 
 
2 +4.7 
 
 
Li
Li Li
Li
Li Li
H
H
H
H
H
H
 
trans-(eq)-102 
 
 
 
 
Li
Li Li
Li
Li Li
H
H
H
H
H
H
 
cis-(ax)-102 
 
3 +71.3 
[a] Geometries have been optimized at the B3LYP/6-31+G(d) level in all cases. [b] Energies were determined at 
the MP2(FC)/6-311+G(2d,p) level. 
 
                                                 
34
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Despite the fact that this system now lacks the tbutyl anchor at position 4 of the cyclohexane 
ring, the results are nevertheless expected to be also relevant for the substituted system. The 
results obtained at B3LYP or MP2 level of theory are quite clear about the strong preference 
for the all-equatorial isomer trans-(eq)-102 over the all axial isomer cis-(ax)-102, in 
agreement with the conformation found in the hexameric X-ray crystal structure.35 The large 
energy difference of 71.3 kJ/mol in favour of trans-(eq)-102 implies a preference of 11.9 
kJ/mol for the equatorial orientation in each of the six monomers. Compared to the 
equatorial/axial energy differences found for the respective tbutyl cyclohexyllithium 
monomers (trans-(eq)-81 and cis-(ax)-81) and dimers (trans-(eq)-101 and cis-(ax)-101), this 
implies that the state of aggregation is the key determinant for the stereochemical preferences 
in substituted cyclohexyllithiums. 
 
In summary, we have described a practical preparation of stereodefined cyclohexyllithium 
reagents from the corresponding organic iodides. This stereoretentive method allowed a 
detailed study of the configurational stabilities, stereochemical behaviours and reactivities of 
a wide range of axially and equatorially substituted cyclohexyllithium reagents. Thus, it was 
possible to stereoselectively synthesize various cis- and trans-cyclohexane derivatives by 
quenching with several classes of electrophiles. We have also found a clear tendency of 
equilibration towards the equatorially substituted lithium compounds. This thermodynamic 
phenomenon was explained by the formation of hexameric organolithium species which 
display a large difference in energy for the all-equatorial and all-axial species as proven by 
DFT-calculations. Polar solvents, such as THF, speed up the equilibration process for axial 4-
substituted cyclohexyllithium reagents, while they display a stabilization effect on 2-
substituted neomenthyllithium neomen-(ax)-90. An invertive reactivity pathway was found 
for the reaction of configurationally labile axially substituted cyclohexyllithium cis-(ax)-81 
with organotin halides. 
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2. Novel Insights into the Stereochemical Behaviour of Diastereomeric 
Cyclohexylzinc Reagents – Stereoconvergence through Distinct 
Stereochemical Pathways 
2.1. Introduction 
 
Whereas the reactivities and configurational stabilities of diverse stereodefined alkyllithium36 
and -magnesium species37 have been subject to extensive studies, the stereochemical 
behaviour of organozinc species has only been sporadically investigated. The C-Zn bond 
plays an exceptional role in organometallic chemistry, as it has a significantly more covalent 
character than C-Li and C-Mg bonds which results in a broad compatibility towards sensitive 
functional groups.38 Still, the reactivity of organozinc reagents is considerably increased 
compared to the corresponding organoboron reagents making them highly useful reagents for 
organic synthesis.38 A stereoselective preparation of secondary alkylzinc reagents, however, 
proved difficult and the B-Zn exchange reaction so far represents the only general method for 
generating stereodefined C-Zn bonds.39 Only a few more examples for the stereoselective 
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preparations of secondary alkylzinc reagents have been reported. Thus, Zn-insertion using the 
highly active Rieke-Zn into diastereomerically pure endo-2-acetamido-7-
iodobicyclo[2.2.1]heptane was stated to proceed with retention of configuration. 
Stereoconvergence leading to the exo-configured organozinc species was observed with exo- 
and endo-7-iodonorcaranes using the same conditions.40 However, the respective organozinc 
compounds have not been directly analyzed and all conclusions on their stereoconfiguration 
have been deduced from quenching experiments with I2 and Me3SnCl. Recently, a 
stereoconvergent remotely stereocontrolled cross-coupling between substituted 
cyclohexylzinc reagents and (hetero)aryl halides41 and alkynyl bromides was disclosed.42 In a 
preliminary mechanistic proposal, a relatively fast equilibration between the diastereomeric 
cyclohexylzinc reagents was assumed and the observed high diastereoselectivities in the 
coupling reactions were ascribed to a dynamic kinetic resolution process43 in which the 
equatorially substituted cyclohexylzinc reagent eq-103 would react faster than the axially 
substituted conformer ax-103 leading selectively to the Pd-intermediate eq-104 and after 
reductive elimination to the all equatorially substituted arylated product eq-105 (Scheme 
30).41,42 
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Scheme 30: Initial mechanistic proposal showing a dynamic kinetic resolution (DKR) process for the 
stereoconvergence observed in the Pd-catalyzed cross-couplings of substituted cyclohexylzinc reagents with aryl 
halides (a). A relatively fast equilibrium between the diastereomeric cyclohexylzinc reagents was postulated due 
to the results of a modified Hoffmann-test (b). NMR studies indicated that only one cyclohexylpalladium 
intermediate was formed with the palladium occupying the equatorial position, whereas signals for several 
organozinc species were found (c). The DKR proposal is based on these experimental observations. 
 
This model suited best, at that time, the experimental results and theoretical calculations. 
Thus, a modified Hoffmann-test44 on the configurational stability of 3-methylcyclohexylzinc 
chloride (106) using a five-fold excess of aryl iodide (electrophile) or zinc reagent 
(nucleophile) was performed. Since in both cases, the same d.r. had been achieved, it was 
concluded that the C-Zn bond was configurationally unstable and a DKR process would be 
the reason for the observed stereoconvergence. In combination with the fact that only one 
cyclohexylpalladium intermediate was observed using 1H31P-NMR, in which the Pd-moiety 
occupied the equatorial position, and with the DFT-calculations that showed significant 
energetic differences only for the cyclohexylpalladium intermediates, however, not for the 
corresponding cyclohexylzinc compounds, this seemed a judicious approach.  
The results of the modified Hoffmann-test, still, are ambiguous due to two reasons: 1) It was 
performed on a Pd-catalyzed reaction. Thus, reaction with excess or substoichiometric 
amounts of nucleophile would always have to pass through the bottleneck of a catalytic 
amount of Pd-intermediate. 2) Diastereomeric organozinc compounds were examined. For 
two diastereomeric reagents the stereochemical course (retention vs. inversion) of substitution 
with electrophiles does not have to be identical, since, in contrast to the isoenergetic reaction 
pathways of enantiomers, the pathways for diastereomers can differ in energy. Although not 
yet experimentally proven, Basu and Thayumanavan had anticipated such a scenario in a 
seminal review on the configurational stability of organolithium compounds.36d Thus, with 
our preliminary mechanistic investigations, we could not exclude the possibility of distinct 
stereochemical pathways for the two diastereomeric cyclohexylzinc derivatives in the 
transmetalation with Ar-PdLnX. Importantly, the configurational stability of secondary 
organozinc reagents has been contradictorily discussed in the literature: Guijarro and Rieke 
have published a comprehensive NMR-study on the configurational stability of (R)-and (S)-
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sec-butylzinc bromide using a chiral bisoxazoline-ligand.45 The resulting diastereomeric 
complexes displayed distinct proton signals for the methine group and could thus be probed 
for equilibration. An extremely slow inversion process was observed (t1/2= 4.0 months!). 
Early experiments from our laboratories with stereodefined secondary alkylzinc reagents, 
however, suggested that the presence of salts considerably decreased the stability of the C-Zn 
bond by deteriorating the observed diastereoselectivities in quenching reactions with D2O.39b 
A DKR process and thus configurational lability were also hypothesized by Hayashi and 
Kumada for the enantioselective coupling of (1-phenylethyl)zinc halides with vinyl bromide 
using a chiral Pd-ferrocene catalyst.46 
 
2.2. Results and Discussion 
 
Intrigued by these contradictory reports, we decided to get more deeply involved in the study 
of the stereochemical behaviour of diastereomeric cyclohexylzinc systems in order to disclose 
the true reasons for the observed stereoconvergence in their diastereoselective Negishi-
couplings. 
 
 
Scheme 31: Negishi-cross-coupling on the structurally identical substituted cyclohexylzinc reagents trans-(eq)-
107 and 108 displaying different stereochemical purities. 
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In preliminary experiments, we prepared the 2-substituted cyclohexylzinc reagents trans-(eq)-
107 and 108 which are structurally identical but differ in stereochemical purity and subjected 
them to our Negishi-cross-coupling conditions (Scheme 31). While trans-(eq)-107 (trans:cis= 
98:2) was stereoselectively prepared using hydroboration on 109 followed by a stereoretentive 
B-Zn exchange,39 108 was obtained as a mixture of diastereomers (trans:cis= 69:31) from 
LiCl-promoted Zn-insertion into the corresponding organic iodide 110.47,48 The 
stereochemical purity of these compounds was checked by deuterolysis with d-TFA (10 
equiv.) at RT. All equatorially substituted trans-(eq)-107 was then subjected to Negishi-cross-
couplings using Pd(dba)2 (2 mol%; dba: dibenzylideneacetone) and SPhos (2 mol%; 
dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine)49 as catalyst system with 
several aryl iodides at RT. The respective arylated products 111a-b were obtained after 12-
24 h in 90-93% yield (64-68% overall yield). Their diastereomeric purity (trans:cis= 98:2) 
completely reflected the stereochemical content of the starting organozinc trans-(eq)-107. 
Thus, the cross-couplings had proceeded with complete retention of stereoconfiguration. 
When the diastereomerically undefined 108 underwent the identical cross-coupling conditions 
with the same aryl iodides, 111a-b were obtained with 65-83% yield and diastereomeric ratios 
reaching from trans:cis 74:26 to 88:12. The diastereomeric purity had increased compared to 
the starting zinc reagent 108. In addition, however, the formation of regioisomers was 
observed (6-14%). Strikingly, when the cross-couplings were performed at lower 
temperatures (-25 °C to -10 °C), solely the all equatorially substituted, thermodynamically 
favourable trans-configured products were obtained (57-83% yield; trans:cis >99:1). The 
formation of regioisomers was thereby not observed. These results made us question our 
previous hypothesis of a DKR-driven stereoconvergence for two main reasons: 1) The 
configurationally defined, equatorially substituted trans-(eq)-107 reacted smoothly to give the 
products 111a-b with the same diastereomeric ratio, which does not corroborate the 
presumption of a fast equilibration between two thermodynamically almost equally favoured 
cyclohexylzinc diastereomers. 2) The observation of regioisomers in the cross-coupling 
reactions of stereochemically undefined 108 suggests that the axially substituted cis-(ax)-108 
diastereomer may undergo distinct reaction pathways from trans-(eq)-108. 
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In order to determine whether C-Zn bonds can invert on a relatively fast time scale (hours or 
minutes) and whether a fast equilibration was therefore possible, we decided to probe the 
configurational stability of trans-(eq)-d-112 and cis-(ax)-d-112 (Scheme 32). 
 
 
Scheme 32: Test on the configurational stability of the C-Zn bond in substituted diastereomeric cis-(ax)-d-113 
and trans-(eq)-d-113. 
 
The remotely substituted cyclohexylzinc reagent d-112 (trans-(eq)-d-112 & cis-(ax)-d-112) 
which bears a tert-butyl-substituent in position 4 and a deuterium on carbon 1 geminal to the 
zinc enabled us to directly observe the stereochemical purity of the organozinc via 2H-NMR. 
The bulky tert-butyl-group also functions as an anchor for the cyclohexyl ring ensuring that 
the diastereomeric zinc reagents differ only in the configuration of the C-Zn bond (axial (cis) 
vs. equatorial (trans)). Zn-insertion into the stereodefined 4-tert-butylcyclohexyl iodides cis-
d-113 and trans-d-113 resulted both in a cis:trans-mixture of d-112 (53:47). No change in the 
ratio was observed after 2 d at RT. EXSY-experiments showed no cross-signal for neither the 
deuterium in 2H- nor the deuterated carbon in 13C-NMR analysis over a period of 12 h. When 
the EXSY experiments were applied to 112, bearing a proton instead of the deuterium, cross-
signals could be found for neither the methine proton nor carbon. A significant coalescence-
shift was not observed in the 2H-NMR analysis of d-112 even upon heating to 50 °C. 
Subjection of d-112 to quenching with TFA immediately and even after standing for 2 d at 
room temperature further confirmed the observed configurational stability of the 
cyclohexylzinc reagents. 
It was now clear to us that due to the high configurational stability of the C-Zn bond a DKR 
mechanism which implies an equilibration between the diastereomeric zinc reagents and thus 
flipping of the C-Zn bond cannot be the cause of the observed stereoconvergence in the 
Negishi cross-coupling (Scheme 30). The mechanistic possibilities were now limited to either 
an equilibration on the stage of the Pd-intermediate (eq-104; Scheme 30), a Pd-salt induced 
equilibration or different stereochemical pathways for the diastereomeric cyclohexylzinc 
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reagents in which the equatorial C-Zn bond would react with retention and the axial C-Zn 
bond with inversion of stereoconfiguration in the transmetalation step selectively forming eq-
104. Thus, aware of the pivotal influence of temperature on the diastereoselectivity in the 
Negishi-cross-coupling (Scheme 31), we decided to probe the stereochemistry of several 
diastereomeric cyclohexylzinc reagents in the deuterolysis with d-TFA and MeOD at different 
temperatures (Table 5).  
 
 
 
 
Table 5: Deuterolysis of diastereomeric cyclohexylzinc reagents. 
Entry Cyclohexylzinc Reagent  D
+/H+-
Source 
Reaction 
Temp. 
[°C] 
Products d.r.
 
(eq:ax)a 
1 
 
108 
d-TFA 25 
 
trans-(eq)-114 + 
 cis-(ax)-114 
69:31 
2 d-TFA -78 99:1 
3 MeOD 25 99:1 
 
 
    
4 
 
115 
d-TFA 25 
 
trans-(eq)-116 + 
 cis-(ax)-116 
48:52 
5 d-TFA -78 96:4 
6 MeOD 25 87:13 
7 MeOD 0 97:3 
 
 
    
8 
 
112 
d-TFA 25 
 
trans-(eq)-117 +  
cis-(ax)-117 
67:33 
9 d-TFA -78 >99:1 
10 MeOD 25 >99:1 
 
 
    
11 
 
118
 
trans-(eq)-118 + cis-(ax1)-118 + 
cis-(ax2)-118 
d-TFA 25 
 
trans-(eq)-119 + 
 cis-(ax)-119 
66:34 
12 d-TFA -78 76:24 
13 MeOD 25 76:24 
14 MeOD 0 90:10 
 
 
    
15 
 
120 
d-TFA 25 
 
cis-(eq)-121 + 
 trans-(ax)-121 
65:35 
16 d-TFA -78 80:20 
17 MeOD 25 76:24 
18 MeOD 0 90:10 
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19 
 
122 
d-TFA 25 
 
cis-(eq)-123 + 
 trans-(ax)-123 
58:42 
20 d-TFA -78 79:21 
21 MeOD 25 66:44 
22 MeOD 0 84:16 
 
 
    
23 
 
124 
d-TFA 25 
 
men-(eq)-125 + 
 neomen-(ax)-125 
65:35 
24 d-TFA -78 >99:1 
25 MeOD 25 >99:1 
 
 
    
26 
 
126 
d-TFA 25 
 β-(eq)-127 + α-(ax)-127 
82:18 
27 d-TFA -78 >99:1 
28 MeOD 25 >99:1 
 
 
    
29 
 
128 
d-TFA 25 
 β-(eq)-129 + α-(ax)-129 
79:21 
30 d-TFA -78 99:1 
31 MeOD 25 90:10 
32 MeOD 0 >99:1 
 
 
    
33 
 
d-126 
TFA 25 
 
α-(ax)-127 + β-(eq)-127 
88:12 
 
 
    
34 
 
d-112 
TFA 25 
 
cis-(ax)-117 + 
 trans-(eq)-117 
64:36 
35 TFA -78 63:37 
36 MeOH 25 87:13 
37 MeOH 0 91:9 
 [a] Determined via 2H-NMR. 
 
Thus, quenching of 108 with d-TFA, which had resulted in a cis:trans-ratio of 31:69 at RT, 
led almost exclusively to the trans-configured deuterated product trans-(eq)-114 
(cis(ax):trans(eq)= 1:99) when performed at -78 °C (entries 1-2). Remarkably, replacing the 
strong acid d-TFA with the weak D+-source MeOD furnished trans-(eq)-114 
(cis(ax):trans(eq)= 1:99) upon quenching at RT (entry 3). A similar behaviour was found for 
115 bearing a less sterically demanding methyl-group in position 2 (entries 4-7). Interestingly, 
a cis(ax)/trans(eq)-ratio of deuterated product 116 of 13:87 was obtained when quenched with 
MeOD at RT (entry 6). This d.r. could be further improved to 3:97 when the reaction 
temperature was decreased to 0 °C (entry 7). For 112 bearing the tert-butyl anchor in position 
4, the identical clear trend was observed: While quenching with d-TFA revealed the true 
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diastereomeric ratio of 112 (cis:trans= 33:67), exclusively trans-(eq)-117 was obtained when 
the reaction was performed at -78 °C (entries 8-9). Quenching with MeOD at RT gave trans-
(eq)-117 with a diastereomeric purity of >99:1 (entry 10). Using 118 in which the tert-butyl 
anchor is replaced by a smaller methyl-group which allows the presence of an additional 
conformer for the axial cis-configured diastereomer cis-(ax2)-118 in which the methyl-group 
occupies an axial position while the C-Zn bond is oriented equatorially. Thus, the trend 
towards the all equatorially substituted, deuterated trans-product trans-(eq)-119 upon 
quenching at low temperature and with the weaker acid MeOD is less pronounced (entries 11-
14). Upon quenching with MeOD at 0 °C a cis:trans-ratio of only 10:90 was achieved (entry 
14). Almost identical ratios were obtained for the deuterolysis products cis-(eq)-121 and 
trans-(ax)-121 of the 3-methyl-substituted cyclohexylzinc reagent 120 (entries 15-18). The 3-
OTBS-substituted 122, in accordance with the lower a-value of oxygen-groups on cyclohexyl 
rings,50 displayed a smaller bias towards equatorial deuteration, as reflected by the ratio of 
cis-(eq)-123 and trans-(ax)-123 (entries 19-22). With MeOD-quenching at 0 °C, however, a 
trans(ax):cis(eq)-ratio of 84:16 was achieved (entry 19). The rigid menthyl- (124), 
cholesteryl- (126) and cholestanylzinc (128) reagents showed a very strong tendency towards 
equatorial deuteration with both d-TFA and MeOD (entries 23-32). Thus, for menthylzinc 
reagent 124, which gave a 65:35 mixture of men-(eq)-125 to neomen-(ax)-125 upon trapping 
with d-TFA at RT, only the menthyl-diastereomer men-(eq)-125 was obtained, when the 
temperature was decreased to -78 °C (entry 24). Also, quenching with MeOD at RT resulted 
only in the formation of men-(eq)-125 (entry 25). For rigid cholesteryl- (126) and 
cholestanylzinc iodide (128) quenching with d-TFA at RT resulted already in α(ax): β(eq)-
ratios of 18:82 and 21:79 (entries 26 and 29). Quenching with d-TFA at -78 °C and MeOD 
resulted in a strong preference for the equatorially deuterated products β-(eq)-127 and β-(eq)-
129 (entries 27-28, 30-32). In order to test whether these trends hold also true for protolysis, 
we performed analogous quenching reactions with the deuterated cyclohexylzinc iodides d-
126 and d-112 using TFA and MeOH as proton sources (entries 33-37).51 Quenching d-126 
with TFA at room temperature resulted already in a d.r. of 88:12 for the equatorially 
protonated product, thus corroborating the tendencies which were observed with the 
deuterolysis of 126 before (compare entries 26 and 33). The results for protolysis of d-112 
were more remarkable: While trapping of d-112 with TFA at -78 °C and at RT both resulted 
in the same diastereomeric ratio (cis:trans= 36:64; 37:63; entries 34-35), quenching with 
                                                 
50
 Eliel, E. L. Stereochemistry of carbon compounds (McGraw-Hill, New York, 1962). 
51
 Giagou, T. & Meyer, M. P. Kinetic isotope effects in asymmetric reactions. Chem. Eur. J. 16, 10616-10628 
(2010).  
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MeOH, however, resulted in preferential equatorial protonation with cis:trans-ratios of 13:87 
at RT and 9:91 at 0 °C (entries 36-37). This unequivocally proves the tendency of the axial C-
Zn bond in the cis-configured diastereomer cis-(ax)-d-112 to undergo invertive quenching. 
We also observed a dependence of the diastereoselectivity in the quenching reactions on the 
mode of addition (Scheme 33). While direct quenching of 112 with d-TFA at RT resulted in a 
cis:trans-ratio of 33:67, slow addition of d-TFA over 2 h gave almost exclusively trans-(eq)-
117. (A test experiment showed that this result was a function of the time used for addition, 
not of the lower concentration of d-TFA.) The same trend was observed in the protolysis of d-
112 with TFA. 
 
 
Scheme 33: Comparison of direct and slow addition of d-TFA addition to 112.  
 
Thereby, addition of TFA over 2 h led preferentially to cis-(ax)-d-112 (cis:trans= 89:11). The 
distinct chemical shifts of the deuterium atoms on d-112 (prepared without LiCl) and on the 
protonated products allowed us to follow the protolysis reaction of d-112 via 2H-NMR. Thus, 
TFA was added slowly via syringe pump and the d.r. of d-112 and the protonation product 
117 was checked after several periods of time. Remarkably, the starting d.r. of d-112 (cis(ax-
Zn):trans(eq-Zn)= 37:63) remained constant during addition of TFA. More strikingly even, 
the d.r. of the protonated compound did not alter considerably. Thus, when 5 mol% TFA were 
added after 2 min, already a cis(ax-H):trans(ax-H)-ratio of 83:17 was observed for 117. This 
ratio remained more or less the same after the addition of 20 mol% TFA after 20 min (85:15) 
and after 1 h, when quenching of d-112 was finished after 1 h upon a total 110 mol% TFA 
(87:13). Accompanying 2H-EXSY-NMR experiments showed no observable cross-peak, thus 
excluding an equilibration of the C-Zn bond on NMR timescale. These results along with the 
fact that only one Pd-intermediate could be observed in the cross-coupling show that the 
equatorial C-Zn bond must react with retention and the axial C-Zn bond with inversion of the 
stereoconfiguration in the transmetalation step to ArPdLnX thus leading to stereoconvergence 
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in the reaction. Therefore, we replace the DKR scenario with a mechanistic view in which the 
two diastereomeric cyclohexylzinc reagents react via distinct stereochemical (retentive vs. 
invertive) pathways. 
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3. Diastereo- and Enantioselective Cross-Coupling with Functionalized 
Cyclohexylzinc Reagents 
3.1. Synthesis of Chiral Protected Cyclohexyl Derivatives for the Enantio- and 
Diastereoselective Synthesis of 1-, 2-, 3-trisubstituted Cyclohexanes 
 
The diastereoselective cross-coupling of substituted cyclohexylzinc derivatives should be 
applied to chiral functionalized building blocks. For this purpose, the chiral 131 was 
synthesized from 2-iodocyclohex-2-enone52 (130) via CBS-catalysis53 using diethylaniline 
borane in 98% yield and 96% ee. Subsequent protection with tert-butyldimethylsilylchloride 
(TBSCl) and cross-coupling with Me2Zn-2LiCl furnished the chiral functionalized cyclohex-
2enol derivative 132 in 63% yield (Scheme 34). 
 
 
Scheme 34: Synthesis of chiral precursor molecule 132 via CBS reduction of iodocyclohex-2-enone (130), TBS 
protection of the resulting alcohol 131 and cross-coupling with Me2Zn-2LiCl. 
 
Consequently, 132 was subjected to hydroboration with different boranes at 25 °C. In order to 
determine both the diastereoselectivity and conversion, an oxidated aliquot was checked by 
GC analysis. Thereby, di-(S)-isopinocampheylborane afforded the highest diastereoselectivity 
(d.r.= 77:23) (Table 6). 
 
Me
OTBS OTBS
Me
OH
OTBS
Me
OH
133 134
+
1) R2BH, 40 °C
2) NaBO3-4H2O
MeOH/ H2O (4:1),
25 °C
132
 
Table 6: Hydroboration of 132 with different boranes; optimization of the diastereoselectivity. 
                                                 
52
 Krafft, M. E. & Cran, J. W. A convenient protocol for the α-iodination of α,β-unsaturated carbonyl 
compounds with I2 in an aqueous medium. Synlett 8, 1263-1266 (2005). 
53
 overview article: Corey, E. J. & Helal, C. J. Reduction of carbonyl compounds with chiral oxazaborolidine 
catalysts: a new paradigm for enantioselective catalysis and a powerful new synthetic method. Angew. Chem. Int. 
Ed. 37, 1986-2012 (1998). 
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Entry Boran  Conversion [%] Diastereoselectivity  (133 : 134) 
1 
 
 
9-BBN 
 
0 -:- 
2 
 
di-(R)-isopino-campheylborane 
 
58 37:63 
3 
 
di-(S)-isopino-campheylborane 
 
60 77:23 
 
For further increasing the diastereoselectivity, substrates with sterically more challenging 
protecting groups (PG) and moieties (R) at the double bond were employed (135, 136, 137 in 
Scheme 35). 
 
 
Scheme 35: Sterically hindered substrate for hydroboration with sterically hindered substituents and silyl 
protecting groups. 
 
The bulkier triphenylsilyl- as well as the tert-butyldiphenylsilyl- (TBDPS-)) protecting group 
and equally the large phenyl- and cyclohexyl moieties were supposed to increase the steric 
interaction between substrate and hydroborating agent and thus improve the 
diastereoselectivity. However, 135, 136 and 137 did not react at all with 9-BBN, with di-(S)-
isopinocampheylborane or (S)-isopinocampheylborane, even at higher temperatures (60 °C) 
no hydroboration was observed. Since high diastereoselectivity during the hydroboration step 
is essential for controlling all three stereo centers, this synthetic approach was no longer 
pursued. 
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3.2. Investigations with [2-(1,3-Dioxolane-2-yl)cyclohexyl]- and [2-(5,5-
Dimethyl-1,3-dioxane-2-yl)cyclohexyl]zinc Compounds 
 
Further investigations should determine whether the stereochemical purity of the 
cyclohexylzinc reagents has an influence on the diastereoselectivity of the cross-coupling 
reactions. Therefore, the protected cyclohexenyl derivatives 138 and 139 were transformed 
via hydroboration followed by boron-zinc exchange using Et2Zn into the stereodefined 
ethylzinc compounds 140 and 141 (Scheme 36). 
 
 
Scheme 36: Hydroboration of 138 and 139 with subsequent boron-zinc exchange and cross-coupling of the 
freshly generated ethylzinc compounds 140 and 141. 
 
Subsequently, 140 and 141 were reacted using Pd-catalysis (Pd(dba)2 (2 mol%) and SPhos54 
(2 mol%)) with various aryl iodides (3 equiv.). Cross-couplings of 141 resulted already at 
room temperature in high diastereoselectivities (d.r.= 98:2; entries 2, 4, 5 and 6 of Table 7). 
Thereby, it did not make a difference whether an electron-poor or -rich aryl iodide was used 
(compare entry 2 with entries 5 und 6 of Table 7). However, cross-couplings with 140 as a 
nucleophile proceeded with significantly lower diastereoselectivities (entries 1 and 3 of 
Table 7). 
 
Table 7: Pd-catalyzed cross-couplings of the ethylzinc compounds 140 and 141. 
Entry Zinc Reagent  Aryl Iodide Temperature [°C] / Time [h] Yield [%]
a
 , d.r.b 
 
1 
 
140 
 
 
 
25 / 12 
 
71, 87:13 
 
2 
 
141 
 
 
 
25 / 12 
 
56, 98:2 
                                                 
54
 Walker, S. D., Barder, T. E., Martinelli, J. R. & Buchwald, S. L. A rationally designed universal catalyst for 
Suzuki-Miyaura coupling processes. Angew. Chem. Int. Ed. 43, 1871-1876 (2004). 
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3 
 
140 
 
 
 
-10 to 0 / 24 
 
40, 80:20 
 
4 
 
141 
 
I CO2Me
 
 
-10 to 25 / 24 
 
64, 98:2 
 
5 
 
141 
 
 
 
25 / 12 
 
68, 98:2 
 
6 
 
141 
 
 
 
 
25 / 12 
 
67, 98:2 
 [a] Isolated yield of analytically pure product. [b] Diastereoselectivity determined by capillary GC analysis 
before and after purification. 
 
In the following part, the preparation and the cross-couplings of the respective non-
stereodefined organozinc iodides (142, 143) will be discussed. 1-Cyclohexen-1-carbaldehyde 
144 was therefore protected with the respective diols. The resulting products 138 und 139 
were then converted with BH3-THF and the hydroborated intermediates subsequently 
oxidized with NaBO3-4H2O at 0 °C furnishing the corresponding alcohols 145 and 146. 
Reaction with dicyclohexylcarbodiimide-iodomethane-complex (DCC-MeI)55 in THF at 
50 °C led to the cyclohexyl iodides 147 und 148.56 Subsequent zinc insertion57 in the presence 
of LiCl furnished the cyclohexyl iodides 142 and 143 in 72% and 74% yield (Scheme 37). 
 
                                                 
55
 Scheffold, R. & Saladin, E. Carbodiimidium compounds as reagents in organic chemistry. Angew. Chem. Int. 
Ed. 11, 229-231 (1972). 
56
 H. Stadtmüller, Dissertation, Marburg/Lahn 1995. 
57
 Krasovskiy, A., Malakhov, V., Gavryushin, A. & Knochel, P. Efficient synthesis of functionalized organozinc 
compounds by the direct insertion of zinc into organic iodides and bromides. Angew. Chem. Int. Ed. 45, 1871-
6044 (2006). 
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Scheme 37: Synthesis of [2-(1,3-dioxolan-2-yl)cyclohexyl]- (142) und [2-(5,5-dimethyl-1,3-dioxan-2-
yl)cyclohexyl]zinc iodide (143). 
 
Hydroboration of the ketals 149 and 150 followed by oxidation into the respective alcohols 
151 and 152 was successful, whereas the transformation into the corresponding cyclohexyl 
iodides (153, 154) even with an excess of DCC-MeI and longer reaction times as well as 
higher reaction temperatures (65 °C) had failed (Scheme 38). 
 
Me
OO
149
150
Me
OO
Me
OO
151; 46%
152; 51%
Me
OO
Me
OO
Me
OO
OH
OH I
I
1) BH3-THF,
-10 °C
2) NaBO3-4H2O,
MeOH/H2O (4:1)
25 °C
1) BH3-THF,
-10 °C
2) NaBO3-4H2O,
MeOH/H2O (4:1)
25 °C
DCC-MeI
DCC-MeI
153
154
 
Scheme 38: Attempt to synthesize the cyclohexyl iodides 153 and 154 for subsequent zinc insertion. 
 
142 and 143 were then subjected to Pd-catalyzed cross-coupling reactions with various aryl 
iodides at different temperatures (Table 8). It showed that the diastereoselectivity depends 
strongly on the reaction temperature and the nature of the applied aryl iodide. Cross-coupling 
of 142 and 143 with electron-rich 4-iodoanisole proceeded already at room temperature with 
relatively high diastereoselectivities (d.r.= 93:7 and 98:2; entry 1 und 2 of Table 8) but lower 
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yields, whereas cross-coupling with electron-poor aryl iodides (methyl-4-iodobenzoate and 1-
iodo-2-(trifluoromethyl)benzene; entries 3, 4, 5 und 6 of Table 8) led to a significantly 
decreased diastereoselectivity (d.r.= 74:26 to 90:1). Even at -10 °C, cross-couplings of 142 
with methyl-4-iodobenzoate und 1-iodo-2-(trifluormethyl)benzene furnished only 
diastereomeric ratios of 81:19 (entry 3 of Table 8) and 90:10 (entry 5 of Table 8). In contrast, 
very high diastereoselectivities combined with good yields were obtained when the cross-
coupling reactions were carried out at -25 °C (entries 7 to 9 of Table 8). 
 
 
Table 8: Cross-coupling of organozinc iodides 142 und 143 with different aryl iodides. 
Entry Zinc Reagent  Aryl Iodide Temperature [°C] / Time [h] Yield [%]
a
 , d.r.b Regio- isomer 
 
1 
 
142 
 
 
 
25 / 12 
 
44, 93:7 
 
6% 
 
2 
 
143 
 
 
 
25 / 12 
 
47, 98:2 
 
0% 
 
3 
 
142 
 
 
 
-10 / 12 
 
60, 81:19 
 
7% 
 
4 
 
143 
 
 
 
25 / 12 
 
83, 74:26 
 
6% 
 
5 
 
142 
 
 
 
-10 / 12 
 
79, 90:10 
 
17%c 
 
6 
 
143 
 
 
 
25 / 12 
 
65, 88:12 
 
14% 
 
7 
 
143 
 
 
 
-25 to -10 / 24 
 
73, >99:1 
 
0% 
 
8 
 
143 
 
 
 
-25 to -10 / 24 
 
57, >99:1 
 
0% 
 
9 
 
143 
 
 
 
 
-25 to -10 / 24 
 
83, >99:1 
 
0% 
 [a] Isolated yield of analytically pure product. [b] Determined by capillary GC analysis before and after 
purification. [c] This regioisomer was isolated by column chromatography and analysed. 
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The observed divergence of diastereoselectivity in the cross-coupling reactions of the 
organozinc iodides 142 and 143 with electron-poor aryl iodides at higher temperatures is due 
to a negligible difference in reactivity between the axial and equatorial C-Zn bonds. The 
formation of regioisomers is due to β-hydride elimination58 which may occur on the stage of 
the Pd-intermediate after stereoselective transmetalation (Scheme 39).59 The fact that 
regioisomers are not observed with the stereodefined all equatorially substituted organozinc 
reagents 140 and 141, which were produced via hydroboration/B-Zn-exchange sequences, 
suggests that this pathway is restricted to the axially substituted cis-configured diastereomer 
(Probably due to an unstable axial C-Pd bond). β-Hydride elimination may additionally be 
responsible for the low observed diastereoselectivities (Scheme 39). These results also 
corroborate the hypothesis presented in Chapter 2. The results of the cross-coupling reactions 
with the cyclohexylzinc reagents 142 and 143 compared to those with the analogous ethylzinc 
compounds 140 and 141 showed that the latter proceeded already at higher temperatures with 
excellent diastereoselectivities. This can be attributed to the distinct stereochemistry of the 
zinc reagents (ZnI vs. ZnEt). While the ethylzinc compounds (140 and 141) are 
stereochemically defined, the organozinc iodides 142 and 143 were employed as 
diastereomeric mixtures (see Chapter 2 on the diverse stereochemical behaviour of 
diastereomeric cyclohexylzinc reagents). 
                                                 
58
 overview article on β-hydride elimination: Lu, X. Control of β-hydride elimination making palladium-
catalyzed coupling reactions more diversified. Topics in Catalysis 35, 73-86 (2005). 
59
 Thaler, T., Haag, B., Gavryushin, A., Schober, K., Hartmann, E., Gschwind, R., Zipse, H., Mayer, P. & 
Knochel, P. Highly diastereoselective Csp3-Csp2 Negishi cross-coupling with 1,2-, 1,3- and 1,4-substituted 
cycloalkylzinc compounds. Nature Chem. 2, 125-130 (2010). 
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Scheme 39: Formation of regioisomers and diastereomers in the cross-coupling reactions by β-hydride 
elimination on step of the palladium intermediate 160. 
 
After β-hydride elimination has taken place the resulting aryl palladium hydride complex 156 
has various opportunities for rearrangement to generate cyclohexenes 139 and 157. The 
formation of regioisomeric cross-coupling products and their diastereomers could also be 
observed at temperatures >-25 °C (Table 8). 
 
3.3. Development of an Enantioselective Version of the Diastereoselective 
Cross-Coupling 
 
In order to develop an asymmetric version of the diastereoselective cross-coupling reaction of 
substituted cyclohexylzinc derivatives,59 a sequence of enantioselective hydroboration 
followed by B-Zn exchange and eventually Pd-catalyzed cross-coupling was envisioned. 
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Therefore, a method established by E. Hupe and P. Knochel60 was applied. They reacted 
cyclohexene 138 with (-)-isopinocampheylborane ((-)-IpcBH2) at -10 °C in THF, treated it 
with an excess of HBEt2 and performed a subsequent boron-zinc exchange with iPr2Zn. The 
chiral organozinc reagent 158 was trapped via Cu(I) mediated alkinylation with high 
diastereoselectivity (Scheme 40). 
 
 
Scheme 40: Enantioselective hydroboration, boron-zinc exchange with subsequent Cu mediated alkinylation of 
the chiral cyclohexylzinc compound 158. 
 
The chiral cyclohexylzinc compounds 159 and 160 were performed using this method via 
enantioselective hydroboration with subsequent boron-zinc exchange and then subjected to 
cross-coupling reactions with different aryl iodides (Scheme 41). 
 
 
Scheme 41: Synthesis of the chiral cyclohexylzinc reagents 159 und 160 and Palladium catalyzed cross-coupling 
with aryl iodides. 
 
The respective cross-coupling products were obtained with diastereoselectivities of >99:1 and 
enantioselectivities of 68 to 81% ee (Table 9). This method allows the direct and 
stereoselective approach to functionalized 1,2-disubstituted cyclohexanes. 
 
 
                                                 
60
 Hupe, E. & Knochel, P. Formal enantioselective Michael addition with umpolung of reactivity. Angew. Chem. 
Int. Ed. 40, 3022-3025 (2001). 
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Table 9: Cross-coupling of the chiral ethylzinc reagents 159 und 160. 
Entry Zinc Reagent  Aryl Iodide Temperature [°C] / Time [h] Yield [%]
a
 , d.r.b ee [%]c 
 
1 
 
159 
 
 
 
25 / 12 
 
39, >99:1 
 
n. d. 
 
2 
 
160 
 
 
 
25 / 12 
 
82, >99:1 
 
73 
 
3 
 
159 
 
 
 
-5/ 12 
 
32, >99:1 
 
n. d. 
 
4 
 
160 
 
 
 
-10 to 0 / 24 
 
82, >99:1 
 
81 
 
5 
 
160 
 
 
 
-10 to 0 / 24 
 
54, >99:1 
 
77 
 
6 
 
160 
 
 
 
 
-10 to 0 / 24 
 
52, >99:1 
 
68 
 [a] Isolated yield of analytically pure product. [b] Diastereoselectivity determined by capillary GC analysis 
before and after purification. [c] Enantioselectivity. 
 
3.4. Cross-Coupling with [8-(Ethoxymethoxy)decahydronaphthalen-1-
yl](ethyl)zinc 
 
E. Hupe und P. Knochel showed that decahydro-1-naphthalenol 166 can be highly 
diastereoselectively functionalized via hydroboration, boron-zinc exchange and subsequent 
allylation (Scheme 42).61 Thus, two stereocentres (2 and 3) can be introduced into the 
molecule at the same time. Via hydroboration it is possible to determine the relative 
configuration between the two stereocentres 1 and 2. In his thesis, E. Hupe points out that the 
choice of alcohol-protecting groups as well as the choice of solvent during the hydroboration 
step are crucial for achieving high diastereoselectivities.62 The Cu-mediated allylation of the 
organozinc compound 162, which is generated via boron-zinc exchange, is highly 
stereoselective and forms the stereocentre 3 with a d.r. (rel. conf. of  positions 2,3) >98:2. In 
the final product 163, all substituents of the cyclohexyl ring of the trans-configured 
decahydro-1-naphthalenol occupy equatorial positions. Thus, the thermodynamically most 
stable product is formed. 
                                                 
61
 a) Boudier, A., Hupe, E. & Knochel, P. Highly diastereoselective synthesis of monocyclic and bicyclic 
secondary diorganozinc reagents with defined configuration. Angew. Chem. Int. Ed. Engl. 39, 2294-2297 (2000); 
b) Hupe, E., Calaza, M. I. & Knochel, P. Substrate-controlled highly diastereoselective synthesis of primary and 
secondary diorganozinc reagents by a hydroboration/boron-zinc exchange sequence. Chem. Eur. J. 9, 2789-2796 
(2003). 
62
 E. Hupe, Dissertation, München 2002. 
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Scheme 42: Synthesis of decahydronaphthalenylzinc reagent 162 and stereoselective functionalization via Cu-
mediated allylation; selective synthesis of the thermodynamically most stable products. 
 
We were then wondering if it was possible to achieve similar high diastereoselectivities by 
cross-coupling the decahydronaphthalenylzinc compound 162 with aryl iodides. Therefore, 
hexahydronaphthalenone (164) was synthesized starting from the chiral alcohol 131 which 
was transformed in the first step with diethylchlorophosphate to the phosphate 165. A 
subsequent SN2’ reaction with the functionalized organozinc compound 166 led to the ester 
167, which was cyclized after iodine-lithium exchange to give compound 164 (Scheme 43).63 
 
 
Scheme 43: Synthesis of EOM-protected decahydronaphthalenol derivative 169. 
 
Following, 164 was diastereoselective reduced via Luche-reduction64 to the alcohol 168 and 
protected with ethoxymethyl chloride (EOMCl). Then, according to the procedure described 
by E. Hupe et al., 169 was subjected to hydroboration with Et2BH-SMe2 complex in CH2Cl2 
followed by a boron-zinc exchange with Et2Zn.61 The resulting organozinc compound 170 
                                                 
63
 Calaza, M. I., Hupe, E. & Knochel, P. Highly anti-selective SN2’ substitutions of chiral cyclic 2-iodo-allylic 
alcohol derivatives with mixed zinc-copper reagents. Org. Lett. 5, 1059-1061 (2003). 
64
 Gemal, A. L. & Luche, J.-L. Lanthanoids in organic synthesis. 6. The reduction of α-enones by sodium 
borohydride in the presence of Lanthanoid chlorides: synthetic and mechanistic aspects. J. Am. Chem. Soc. 103, 
5454-5459 (1981). 
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was used in Pd-catalyzed cross-coupling with 4-iodoanisole and methyl-4-iodobenzoate 
(Scheme 44). 
 
 
Scheme 44: Synthesis of [8-(ethoxymethoxy)decahydronaphthalen-1-yl](ethyl)zinc (170) and subsequent cross-
coupling. 
 
The results are summarized in Table 10. The conversion of the reaction was low and the 
diastereoselectivity moderate. Hydroboration provided a diastereoselectivity of 90:10, 
whereas in the cross-coupling reactions significantly lower selectivities (d.r.= 67:33 and 
85:15) were achieved. In order to check whether the correct reaction conditions were used, the 
allylation of Scheme 42 was repeated. The allylation product 163 was isolated with a yield of 
57% (lit.: 65%) and diastereoselectivities of d.r.(1,2) 97:3 and d.r.(1,3) >98:2 (lit.: 97:3 and 
>98:2). Thus, reproduction of the reaction was successful.  
 
Table 10: Pd-catalyzed cross-coupling with [8-(ethoxymethoxy)decahydronaphthalen-1-yl](ethyl)zinc (170). 
Entry Zinc Reagent  Aryl Iodide Temperature [°C] d.r.(1,2); d.r.(1,3)
a Yield[%]b 
 
1 
 
170 
 
 
 
25 
 
90:10; 67:33 
 
n. i. 
 
2 
 
170 
 
 
 
 
-10 
 
91:9; 85:15 
 
31 
 [a] Diastereoselectivity determined by capillary GC analysis before and after purification. [b] Isolated yield of 
analytically pure product. 
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4. Highly Diastereoselective Arylations of Substituted Piperidines  
4.1. Introduction 
 
Substituted piperidines are ubiquitous structural motifs present in numerous bioactive 
alkaloids.65 In order to ensure appropriate biological activity, many of them have to be 
prepared in a stereodefined manner.65 Therefore, the development of efficient methods for the 
diastereoselective construction of piperidines bearing more than one stereocenter represents 
an important synthetic task.66 Still, procedures for the direct stereoselective arylation of the 
                                                 
65
 (a) de Risi, C., Fanton, G., Pollini, G. P., Trapella, C., Valente, F. & Zanirato, V. Recent advances in the 
stereoselective synthesis of trans-3,4-disubstituted-piperidines: applications to (-)-paroxetine. Tetrahedron: 
Asymmetry 19, 131-155 (2008); (b) Escolano, C., Amat, M. & Bosch, J. Chiral oxazolopiperidone lactams: 
versatile intermediates for the enantioselective synthesis of piperidine-containing natural products. Chem. Eur. J. 
12, 8198-8207 (2006); c) Buffat, M. G. P. Synthesis of piperidines. Tetrahedron 60, 1701-1729 (2004); (d) 
Felpin, F.-X. & Lebreton, J. Recent advances in the total synthesis of piperidine and pyrrolidine natural alkaloids 
with ring-closing metathesis as a key step. Eur. J. Org. Chem., 3693-3712 (2003); (e) Laschat, S. & Dickner, T. 
Stereoselective synthesis of piperidines. Synthesis 13, 1781-1813 (2000); (f) Bailey, P. D., Millwood, P. A. & 
Smith, P. D. Asymmetric routes to substituted piperidines. Chem. Commun., 633-640 (1998). 
66
 (a) Larivée, A. & Charette, A. B. New methodology towards chiral, non-racemic 2,5-cis-substituted 
piperidines via Suzuki cross-coupling. Org. Lett. 8, 3955-3957 (2006); b) Legaut, C. Y. & Charette, A. B. 
Catalytic asymmetric hydrogenation of N-iminopyridinium ylides: expedient approach to enantioenriched 
substituted piperidine derivatives. J. Am. Chem. Soc. 127, 8966-8967 (2005); (c) Johnson, T. A., Jang, D. O., 
Slafer, B. W., Curtis, M. D. & Beak, P. Asymmetric carbon-carbon bond formations in conjugate additions of 
lithiated N-Boc allylic and benzylic amines to nitroalkenes: enantioselective synthesis of substituted piperidines, 
pyrrolidines, and pyrimidinones. J. Am. Chem. Soc. 124, 11689-11698 (2002); d) Vink, M. K. S., Schortinghuis, 
C. A., Luten, J., Van Maarseveen, J. H., Schoemaker, H. E., Hiemstra, H. & Rutjes, F. P. J. T. A stereodivergent 
approach to substituted 4-hydroxypiperidines. J. Org. Chem. 67, 7869-7871 (2002); e) Watson, P. S., Jiang, B. & 
Scott, B. A diastereoselective synthesis of 2,4-disubstituted piperidines: scaffolds for drug discovery. Org. Lett. 
2, 3679-3681 (2000); (f) Wijdeven, M. A., van Delft, F. L. & Rutjes, F. P. J. T. Synthesis of functionalized 3-
hydroxypiperidines. Tetrahedron 66, 5623-5636 (2010); (g) Ragoussi, M.-E., Walker, S. M., Piccanello, A., 
Kariuki, B. M., Horton, P. N., Spencer, N. & Snaith, J. S. Stereoselective synthesis of 2,4,5-trisubstituted 
piperidines via radical cyclization. J. Org. Chem. 75, 7347-7347 (2010); (h) Moustafa, M. M. A. R. & 
Pagenkopf, B. L. Ytterbium triflate catalyzed synthesis of alkoxy-substituted donor-acceptor cyclobutanes and 
their formal [4+2] cycloaddition with imines: stereoselective synthesis of piperidines. Org. Lett. 12, 4732-4735 
(2010); (i) Guérinot, A., Serra-Muns, A., Gnamm, C., Bensoussan, C., Reymond, S. & Cossy, J. FeCl3-catalyzed 
highly diastereoselective synthesis of substituted piperidines and tetrahydropyrans. Org. Lett. 12, 1808-1811 
(2010); (j) Urushima, T., Sakamoto, D., Ishikawa, H. & Hayashi, Y. Enantio- and diastereoselective synthesis of 
piperidines by coupling of four components in a “one-pot” sequence involving diphenylprolinol silyl ether 
mediated Michael reaction. Org. Lett. 12, 4588-4591 (2010); k) Andersson, H., Gustafsson, M., Boström, D., 
Olsson, R. & Almqvist, F. The regio- and stereoselective synthesis of trans-2,3-dihydropyridine N-oxides and 
piperidines. Angew. Chem. Int. Ed. 48, 3288-3291 (2009); (l) Chen, M. Z. & Micalizio, G. C. Convergent 
synthesis of piperidines by the union of conjugated alkynes with imines: a unique regioselective bond 
construction for heterocycle synthesis. Org. Lett. 11, 4982-4985 (2009); (m) Humphrey, J. M., Arnold, E. P., 
Chappie, T. A., Feltenberger, J. B., Nagel, A., Simon, W., Suarez-Contreras, M., Tom, N. J. & O’Neill, B. T. 
Diastereoselctive synthesis of 2,3,6-trisubstituted piperidines. J. Org. Chem. 74, 4525-4536 (2009); (n) Chen, Y., 
Zhong, C., Petersen, J. L., Akhmedov, N. G. & Shi, X. One-pot asymmetric synthesis of substituted piperidines 
by exocyclic chirality induction. Org. Lett. 11, 2333-2336 (2009); (o) Bilke, J. L., Moore, S. P., O’Brien, P. & 
Gilday, J. Catalytic asymmetric synthesis of piperidines from pyrrolidine: concise synthesis of L-773,060§. Org. 
Lett. 11, 1935-1938 (2009); (p) Barbe, G., St-Onge, M. & Charette, A. B. Silver ion-induced grob fragmentation 
of χ-amino iodides: highly stereoselective synthesis of polysubstituted piperidines. Org. Lett. 10, 5497-5499 
(2008); (q) Mix, S. & Blechert, S. Diastereoselective synthesis of 2,6-trans-disubstituted piperidines via 
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piperidine ring are scarce.67 Only one isolated example of the diastereoselective coupling of a 
6-methylpiperidin-2-yl organometallic with 4-bromoveratrole furnishing the trans-2,6-
disubstituted product has been reported.67c So far the direct stereoselective synthesis of 2,4- 
and 2,5-disubstituted arylated piperidines via Csp3-Csp2 cross-coupling remains a challenging 
problem. Recently, a highly diastereoselective couplings of several substituted cycloalkyl 
derivatives mediated by Pd was reported.68 Herein, we show that Pd-catalyzed cross-
couplings can be efficiently used for a highly diastereoselective preparation of various 
disubstituted or annulated piperidines. 
 
4.2. Results and Discussion 
 
It was previously demonstrated that cross-couplings of substituted cyclohexylzinc reagents 
with diverse aryl halides result in the stereoconvergent formation of the thermodynamically 
                                                                                                                                                        
sequential cross-metathesis-cationic cyclisation. Adv. Synth. Catal. 349, 157-160 (2007); (r) Cortez, G. A., 
Schrock, R. R. & Hoveyda, A. H. Efficient enantioselective synthesis of piperidines through catalytic 
asymmetric ring-opening/cross-metathesis reactions. Angew. Chem. Int. Ed. 46, 4534-4538 (2007); (s) Amat, M., 
Bassas, O., Llor, N., Cantó, M., Pérez, M., Molins, E. & Bosch, J. Dynamic kinetic resolution and 
desymmetrization processes: a straightforward methodology for the enantioselective synthesis of piperidines. 
Chem. Eur. J. 12, 7872-7881 (2006); (t) Kauffman, G. S., Watson, P. S. & Nugent, W. A. Strategy for the 
enantioselective synthesis of trans-2,4-disubstituted piperidines: application to the CCR3 Antagonist IS811. J. 
Org. Chem. 71, 8975-8977 (2006); (u) Takemiya, A. & Hartwig, J. F. Rhodium-catalyzed intramolecular, anti-
Markovnikov hydroamination. Synthesis of 3-arylpiperidines. J. Am. Chem. Soc. 128, 6042-6043 (2006); (v) 
Peltier, H. M. & Ellman, J. A. N-Sulfinyl metalloenamine conjugate additions: asymmetric synthesis of 
piperidines. J. Org. Chem. 70, 7342-7345 (2005); (w) Poerwono, H., Higashiyama, K., Yamauchi, T., Kubo, H., 
Ohmiya, S. & Takahashi, H. Stereocontrolled preparation of cis- and trans-2,6-dialkylpiperidines via 
diastereoselective reaction of 1-aza-4-oxabicyclo[4.3.0]nonane derivatives with Grignard reagents. Tetrahedron 
54, 13955-13970 (1998). 
67
 (a) Prokopcová, H., Bergman, S. D., Aelvoet, K., Smout, V., Herrebout, W., Van der Veken, B., Meerpoel, L. 
& Maes, B. U. W. C-2 arylation of piperidines through directed transition-metal-catalyzed sp3 C-H activation. 
Chem. Eur. J. 16, 13063-13067 (2010); (b) Pastine, S. J., Gribkov, D. V. & Sames, D. sp3 C-H bond arylation 
directed by amidine protecting group: α-arylation of pyrrolidines and piperidines. J. Am. Chem. Soc. 128, 14220-
14221 (2006); (c) Coldham, I. & Leonori, D. Synthesis of 2-arylpiperidines by palladium couplings of aryl 
bromides with organozinc species derived from deprotonation of N-Boc-piperidines. Org. Lett. 10, 3923-3925 
(2008); (d) (d) Amat, M., Bosch, J., Hidalgo, J., Cantó, M., Pérez, M., Llor, N., Molins, E., Miravitlles, C., 
Orozco, M. & Luque, J. Synthesis of enantiopure trans-3,4-disubstituted piperidines. An enantiodivergent 
synthesis of (+)- and (-)-paroxetine. J. Org. Chem. 65, 3074-3084 (2000); (e) Amat, M., Pérez, M., Minaglia, A. 
T. & Bosch, J. An enantioselective synthetic route to cis-2,4-disubstituted and 2,4-bridged piperidines. J. Org. 
Chem. 73, 6920-6923 (2008). For enantioselective arylations of N-Boc piperidine, see: (f) Beng, T. K. & 
Gawley, R. E. Application of catalytic dynamic resolution of N-Boc-2-lithiopiperidine to the asymmetric 
synthesis of 2-aryl and 2-vinyl piperidines. Org. Lett. 13, 394-397 (2011). For enantioselective arylations of N-
Boc pyrrolidines , see: (g) Klapars, A., Campos, K. R., Waldman, J. H., Zewge, D., Dormer, P. G. & Chen, C. 
Enantioselective Pd-catalyzed α-arylation of N-Boc-pyrrolidine: the key to an efficient and practical synthesis of 
a glucokinase activator. J. Org. Chem. 73, 4986-4993 (2008); (h) Campos, K. R., Klapars, A., Waldman, J. H., 
Dormer, P. G. & Chen, C. Enantioselective, Palladium-catalyzed α-arylation of N-Boc-pyrrolidine. J. Am. Chem. 
Soc. 128, 3538-3539 (2006). 
68
 Thaler, T., Haag, B., Gavryushin, A., Schober, K.; Hartmann, E., Gschwind, R. M., Zipse, H., Mayer, P. & 
Knochel, P. Highly diastereoselective Csp3-Csp2 Negishi cross-coupling with 1,2-, 1,3- and 1,4-substituted 
cycloalkylzinc compounds. Nature Chem. 2, 125-130 (2010). 
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favoured arylpalladium intermediates which after reductive elimination afford the desired 
arylated products with retention of configuration (d.r. up to >99:1).68 Due to the structural 
importance of piperidines, we have envisioned the performance of diastereoselective cross-
couplings with the related substituted piperidinylzinc compounds. By exploiting the pseudo-
allylic strain induced by the protecting group at the N,69 we were able to prepare both the cis- 
and trans-2,4-disubstituted piperidine derivatives with excellent levels of diastereoselectivity. 
First, we have generated various piperidin-2-ylzinc reagents of type 1 starting from the 
respective piperidines 172a-e according to the procedures of Beak and Lee70 and Coldham 
and Leonori.67c To our delight, the Pd-catalyzed cross-coupling of 171a-e with various aryl 
and heteroaryl iodides using 2% SPhos71 or 5% RuPhos72 and 2-5% Pd(dba)2 as catalyst 
system furnished the desired α-arylated products 173 in 54-84% yield and with an exceptional 
level of diastereoselectivity (d.r. of 95:5 to >99:1; Table 11). Thus, cross-coupling of the 4-
methyl-substituted piperidinylzinc reagent 171a with electron-rich 4-iodoanisole using 2% 
Pd(dba)2 and 2% SPhos at 55 °C furnished exclusively the cis-configured product 173a in 
78% yield (entry 1of Table 11).73 
 
 
 
 
 
 
                                                 
69
 (a) Paulsen, H. & Todt, K. Magnetic anisotropy of the amide group. Angew. Chem. Int. Ed. Engl. 5, 899-900 
(1966); (b) Johnson, R. A. Conformations of alkylpiperidine amides. J. Org. Chem. 33, 3627-3632 (1967). 
70
 (a) Beak, P. & Lee, W. K. α-Lithioamine synthetic equivalents: syntheses of diastereoisomers from Boc 
derivatives of cyclic amines. J. Org. Chem. 58, 1109-1117 (1993); (b) Beak, P. & Lee, W. K. α-Lithioamine 
synthetic equivalents: syntheses of diastereoisomers from the Boc piperidines. J. Org. Chem. 55, 2578-2580 
(1990). 
71
 Walker, S. D., Barder, T. E., Martinelli, J. R. & Buchwald, S. L. A rationally designed universal catalyst for 
Suzuki-Miyaura coupling processes. Angew. Chem. Int. Ed. 43, 1871-1876 (2004). 
72
 Charles, M. D., Schultz, P. & Buchwald, S. L. Efficient Pd-catalyzed amination of heteroaryl halides. Org. 
Lett. 7, 3965-3968 (2005). 
73
 The relative configurations of 173d and 173h were directly determined via X-ray analysis. The relative 
configurations of 173n and 173q were determined via acidic removal of the Boc-protective group and 
subsequent tosylation. The crystals of the tosylates (173na and 173qa) proved suitable for X-ray analysis. See 
supporting information for details. 
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Table 11: Diastereoselective cross-coupling of substituted piperidin-2-ylzinc reagents. 
Entry  Product Yield [%]a d.r.b 
1 
 
173a: Ar: 4-MeO-C6H4 78 >99:1c 
2 173b: Ar: 4-F3C-C6H4 81 95:5c 
3 173c: Ar: 3-Cl-C6H4 76 96:4c 
4 173d: Ar: 3-NC-C6H4 64 97:3c 
5 173e: Ar: 4-EtO2C-C6H4 67 98:2c 
6 173f: Ar: 4-pyridinyl 73 95:5c 
 
  
  
7 
 
173g: Ar: 4-F3C-C6H4 64 97:3d 
8 173h: Ar: 4-NC-C6H4 79 >99:1d 
9 173i: Ar: 4-MeO2C-C6H4 67 99:1d 
 
 
   
10 
 
173j: Ar: 4-EtO2C-C6H4 84 97:3e 
11 173k: Ar: 4-F-C6H4 83 95:5e 
12 173l: Ar: 4-F3C-C6H4 81 95:5e 
13 173m: Ar: 4-NC-C6H4 81 97:3e 
 
 
   
14 
 
173n: Ar: 4-F3C-C6H4 69 >99:1d 
15 173o: Ar: 4-NC-C6H4 54 >99:1d 
16 173p: Ar: 4-MeO-C6H4 60 97:3d 
 
 
   
17 
 
173q: Ar: 4-NC-C6H4 62 96:4d 
18 173r: Ar: 4-EtO2C-C6H4 59 95:5d 
 
 
   
 [a] Isolated yield. [b] Determined by GC and/or 1H/13C NMR analysis. [c] 2% Pd(dba)2, 2% SPhos, THF, 55 °C, 
12 h. [d] 5% Pd(dba)2, 5% RuPhos, THF, 55 °C, 12 h. [e] 5% Pd(dba)2, 5% RuPhos, THF, 55 °C, 60 h. [f] 5% 
Pd(dba)2, 5% RuPhos, THF, 0 °C (6 h), then rt (12 h), then 40 °C (12 h). 
 
Coupling of 171a with electron-poor aryl iodides and 4-iodopyridine under the same 
conditions gave the products 173b-f with d.r. from 95:5 to 98:2 (entries 2-6). The 
piperidinylzinc reagent 171b bearing a large phenyl ring instead of the smaller methyl 
substituent provided, under slightly altered conditions (5% Pd(dba)2 and 5% RuPhos at 55 
°C), the cis-products 173g-i with comparable yields (64-79%) and equally high 
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diastereoselectivities (97:3 to >99:1; entries 7-9). Even the functionalized piperidinylzinc 
reagent 171c bearing an OTIPS (OSi(i-Pr)3) group in position 4 reacted smoothly furnishing 
the cis-α-arylated products 173j-m with high yields (81-84%) and d.r. between 95:5 and 97:3 
(entries 10-13). The method also proved applicable to the trans-decahydroisoquinolinyl 
scaffold. By using the method of Beak and Lee70  we were able for the first time to 
regioselectively metalate this heterocycle at position 3. Cross-coupling of the resulting 
organozinc species 171d led to the stereodefined 2,4,5-trisubstituted products 173n-p in 54-
69% yield with excellent d.r. (97:3 to >99:1; entries 14-16). In the case of the 5-methyl-
substituted reagent 171e, lower temperatures were necessary for achieving high 
diastereoselectivities (Table 11). Thus, the trans-2,5-disubstituted products 173q-r were 
obtained in moderate yields of 59-62% with a high d.r. of 95:5 (entries 17-18). 
Complementary to the diastereoselective preparation of the cis-2,4-disubstituted piperidines, 
we also report the synthesis of the corresponding trans-isomers by switching the positions of 
the substituent and the C-Zn bond. Thus, in preliminary experiments, we have prepared the 2-
substituted piperidin-4-ylzinc reagent 174a via LiCl-promoted Zn-insertion into the iodide 
175a74 and subjected it to cross-coupling with 4-iodobenzonitrile and iodobenzene using 5% 
TMPP2PdCl275 as catalyst (Table 12).68 The trans-coupling products 176a-b were obtained in 
50-74% yield with diastereoselectivities of d.r.: 91:9 and 92:8 (entries 1 and 2 of Table 12).76 
By examining the NMR spectra of the N-Boc protected products 176a and 176b, we found 
that both revealed the presence of two Boc-conformers at room temperature. These findings 
are supported by DFT-analysis.77 The calculations also confirmed the presence of two 
energetically close chair and twist-boat conformers whose existence may be responsible for 
the observed non-perfect diastereoselectivity. Furthermore, X-ray structures of the already 
prepared N-Boc protected piperidines 173d and 173h73 (entries 4 and 8 of Table 11) showed a 
twisted ring conformation, whereas the structures of the N-Ts protected piperidines 173na and 
173qa73 displayed an almost perfect chair-like structure. We, therefore, prepared the 
corresponding N-tosylated zinc reagent 174b. Cross-coupling of 174b with 4-iodobenzonitrile 
                                                 
74
 Krasovskiy, A., Malakhov, V., Gavryushin, A. & Knochel, P. Efficient synthesis of functionalized organozinc 
compounds by the direct insertion of zinc into organic iodides and bromides. Angew. Chem. Int. Ed. 45, 6040-
6044 (2006). 
75
 Dunbar, K. R. & Sun, J.-S. Synthesis and structure of the distorted octahedral Palladium(ΙΙ) complex 
[Pd(tmpp)2][BF4]2 [tmpp= tris(2,4,6-trimethoxyphenyl)phophine]. J. Chem. Soc. Chem. Commun., 2387-2388 
(1994). 
76
 The relative configuration of 176a was determined via acidic removal of the Boc-protective group and 
subsequent tosylation. The crystals of the tosylate proved suitable for X-ray analysis. The relative configurations 
of 176c and 176e were directly determined via X-ray analysis. See supporting information for details. 
77
 
1H and 13C NMR analyses of 176a and 176b at 70 °C showed an average spectrum of the two conformers. 
This finding is supported by a conformational analysis of product 176b at the B3LYP / 6-31 G (d,p) level. See 
the Supporting Information for details. 
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under the same reaction conditions led to the exclusive formation of the trans-isomer 176c in 
70% yield (entry 3). Remarkably, the couplings of the zinc reagent 174c bearing only a small 
methyl group in position 2 also gave the respective trans-isomers 176e-f with an excellent 
diastereoselectivity of d.r.: 97:3 (entries 5 and 6). 
 
 
Table 12: Diastereoselective cross-coupling of 2-substituted piperidin-4-ylzinc reagents. 
Entry  Product Yield [%]a d.r.b 
 
1 
2 
 
 
 
176a: Ar: 4-NC-C6H4 
176b: Ar: Ph 
 
74 
50 
 
91:9 
92:8 
 
3 
4 
 
 
 
176c: Ar: 4-NC-C6H4 
176d: Ar: 4-MeO2C-C6H4 
 
70 
69 
 
>99:1 
96:4 
 
5 
6 
 
 
 
 
176e: Ar: 4-NC-C6H4 
176f: Ar: 4-MeO2C-C6H4 
 
84 
89 
 
97:3 
97:3 
 [a] Isolated yield. [b] Determined by GC and/or 1H/13C NMR analysis.  
 
In order to explain the distinct stereochemical outcome of these couplings, the cis/trans 
stability differences between 173g and 176b together with the respective data for the Zn- and 
Pd-intermediates were analyzed at the B3LYP/631SVP level (Scheme 44 and Table 13).78 
From our former studies,68 it was clear that the relative stabilities of the Pd-intermediates 
represent the crucial factor for the determination of the final diastereoselectivity of the cross-
coupling. 
 
                                                 
78
 The theoretical methods used herein are identical to those in ref 68 and involved the combination of the 
B3LYP hybrid functional with the def2-SVP all-electron basis set for Zn, the ECP-based def2-SVP basis set for 
Pd,21 and the 6-31G(d,p) basis set for all other elements. 
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Scheme 44: DFT-conformational analysis of cis-isomer 173g and trans-isomer 176b. 
 
The stabilities of the products (173g and 176b) and of the corresponding zinc intermediates 
have been calculated in order to refine our mechanistic picture. In contrast to the 
corresponding cyclohexanes, in which an overall equatorial substitution pattern is 
thermodynamically preferred,68 the pseudo-allylic strain in N-Boc piperidines caused by the 
partial double-bond character of the amide bond forces the substituent vicinal to the nitrogen 
into an axial orientation.69 Therefore, cis-isomer 173g was found to be significantly less stable 
(by 13.4 kJ/mol) than trans-isomer 176b. Detailed DFT conformational analysis (chair vs. 
twist boat) shows that the energy difference between the chair and twist-boat conformation is 
negligible for 173g, whereas it is large for 176b thus confirming our observations on 176a 
and 176b by 1H and 13C NMR spectroscopy. 
 
Table 13: DFT calculation-based conformational analysis on the diastereomeric Zinc and Palladium complexes. 
Entry Zn- and Pd-Intermediates
a
, ∆H298ax-eq (kJ/mol)b 
 
 
 
eq-171b (C) 
 
 
 
ax-171b (C) 
 
1 +15.4 
 
 
 
eq-174a (TB) 
 
 
 
 
ax-174a (C) 
 
2 -8.4 
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eq-177 (C) 
 
 
N
O
Ot-Bu
Ph
PdL2 Ar
 
ax-177 (C) 
 
3 +15.0 
 
 
 
eq-178 (TB) 
 
 
 
 
ax-178 (C) 
 
4 -8.6 
 [a] Ar: 4-F3C-C6H4. Preferred conformations are indicated as twist-boat (TB) or chair (C). [b] Calculated 
energetic differences (B3LYP/631SVP) between the thermodynamically lowest conformers of the two 
diastereomers; L: PMe3. 
 
The stabilities of the respective Pd- and Zn-intermediates involved in the formation of the 
cross-coupling products 173g and 176b have been calculated using the same model as in our 
recent study of the analogous cyclohexyl systems.68 Whereas the diastereomeric substituted 
cyclohexylzinc complexes possessed very similar energies, large differences in the stabilities 
of the corresponding piperidinylzinc species were found. In the case of piperidin-2-ylzinc 
reagent 171b, the equatorial orientation of the C-Zn bond is stabilized by its coordination to 
the carbonyl oxygen atom of the Boc group leading to a pentacoordinated Zn-center. This 
results in an energetic preference for eq-171b by 15.4 kJ/mol (entry 1 of Table 13). Since 
pseudo-allylic strain in the 4-zincated piperidinyl species 174a dictates an axial position of the 
substituent at C2, axial orientation of the C-Zn bond is hampered by 1,3-diaxial repulsions 
resulting in ax-174a as the most stable conformer (entry 2). This underlines the “Janus-like” 
nature of the Boc-group showing its sterically demanding, repulsive character towards vicinal 
substituents, yet turning into an electrostatically attractive neighbor with Lewis-acidic metal 
centers present at the same position. Analogously to the cyclohexyl systems, the Pd moiety 
shows a preference for the equatorial position in all cases. In the piperidin-2-ylpalladium 
intermediates (eq-177 and ax-177; entry 1), in which the square-planar coordination sphere of 
Pd is not perturbed, this natural preference is magnified by a close contact between the Pd-
center and the carbonyl oxygen atom of the Boc group. If, however, C2 is occupied by an 
aryl/alkyl substituent, 1,3-allylic strain69 takes effect and causes axial orientation (ax-178 vs. 
eq-178; entry 2). Without this interaction, diaxial repulsions dictate equatorial orientation of 
the aryl/alkyl substituent (eq-177 vs. ax-177; entry 1).68 Considering the energetic differences 
of the organometallic intermediates, the diastereoselectivity in the couplings of the 
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piperidinylzinc reagents (171 and 174) may be determined both on the stage of the respective 
Zn- as well as Pd-complexes. In the case of the couplings of the piperidin-2-ylzinc chlorides 
(171), there is strong evidence that the diastereoselectivity may already be introduced into the 
molecule via the lithiation step.67c,f,g,70 For the piperidin-4-ylzinc iodides (174), the 
stereoselectivity is most likely introduced via a selective transmetalation step between the Zn-
reagent and the aryl-Pd complex leading to the thermodynamically most stable intermediate, 
as proposed in Chapter 2. 
In continuation of our study, we found that arylations with the 6-methyl-substituted piperidin-
2-ylzinc reagent 179 in the presence of Pd(dba)2/RuPhos72 as catalyst system consistently 
resulted in the highly stereoselective formation of the 5-arylated trans-configured products of 
type 181 (d.r.: 93:7 to 96:4),79 whereas the expected trans-2,6-disubstituted products (180)67c 
were not obtained (Scheme 45). It is noteworthy that the coupling proceeded equally well 
with electron-rich (181b) and electron-poor aryl iodides (181c-e). We assume that this 
reaction proceeds via β−hydride elimination of the Pd moiety.80 The resulting ArPdL2H81 
complex stays bound to the same side of the tetrahydropyridinyl ring and its subsequent syn-
addition82 places the Pd in the sterically less hindered position 5. Rapid reductive elimination 
furnishes the observed δ-arylated 2,5-disubstituted coupling products (181). This Pd 1,2-
migration/ cross-coupling sequence seems to be a function of the nature and stoichiometry of 
the phosphine ligand. In our case, a Pd/ RuPhos ratio of 1:1 was used. Coldham and 
Leonori67c reported the use of Pd(OAc)2/ tBu3P with a ratio of 1:2 as the catalyst system, 
which may lead to a better stabilization of Pd(0) and thus prevent β-hydride elimination. 
 
                                                 
79
 The relative configuration of 181c was determined via acidic removal of the Boc protecting group and 
subsequent tosylation. The crystals of the tosylate proved suitable for X-ray analysis. 
80
 (a) Ogawa, R., Shigemori, Y., Uehara, K., Sano, J., Nakajima, T. & Shimizu, I. Enantioselective elimination of 
Pd-H from η3-allylpalladium-Tol BINAP complexes. evidence of syn elimination pathway. Chem. Lett. 36, 
1338-1339 (2007); (b) Lloyd-Jones, G. C. & Slatford, P. A. Unusually large 2H/1H kinetic isotope effects 
accompanying a syn-β-H elimination reaction in a σ-alkyl-palladium complex. J. Am. Chem. Soc. 126, 2690-
2691 (2004) and references therein. 
81
 (a) Hills, I. D. & Fu, G. C. Elucidating reactivity differences in palladium-catalyzed coupling processes: The 
chemistry of palladium hydrides. J. Am. Chem. Soc. 126 13178-13179 (2004); (b) Grushin, V. V. Hydrido 
complexes of palladium. Chem. Rev. 96, 2011-2033 (1996); (c) Heck, R. F. Palladium-catalyzed reactions of 
organic halides with olefins. Acc. Chem. Res. 12, 146-151 (1979). 
82
 (a) Schmidt, A. F. & Smirnov, V. V. The mechanism of the palladium hydride β-elimination step in the Heck 
reaction. Kinet. Catal. 44, 518-523 (2003); (b) Henry, P. M. & Ward, G. A. Stereochemistry of 
phenylpalladation of cyclohexene. J. Am. Chem. Soc. 94, 673-674 (1972). 
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Scheme 45: Pd-1,2-migration in the diastereoselective cross-coupling of N-Boc 6-methylpiperidin-2-ylzinc 
chloride. 
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5. Summary and Outlook 
This work dealt with both the investigation and applications of the distinct stereochemical 
behaviours of carbon-metal bonds. Therefore, a novel practical access to stereodefined C-Li 
bonds was established via a stereoretentive I-Li exchange on cyclohexyl iodides which 
allowed a thorough examination of their configurational stabilities and the stereochemistry of 
their quenching with various electrophiles. Mechanistic studies on the configurational stability 
of the C-Zn bond in substituted cyclohexylzinc reagents showed that distinct stereochemical 
pathways are responsible for the observed stereoconvergence in the diastereoselective Pd-
catalyzed cross-couplings. Thereby, the equatorial C-Zn bond reacts with retention and the 
axial C-Zn bond with inversion of its stereoconfiguration under suitable reaction conditions. 
The highly diastereoselective Pd-catalyzed cross-coupling methodology was extended to 
functionalized cyclohexyl derivatives and an enantio- and diastereoselective method for the 
preparation of chiral arylated functionalized cyclohexanes was developed. Highly 
diastereoselective cross-coupling was also established for piperidinylzinc derivatives. 
Selective access to both the cis- and trans-2,4-disubstituted piperidine derivatives was 
enabled. 
 
5.1. Stereoselective Preparation, Configurational Stability and Reactivity of 
Substituted Cyclohexyllithium Derivatives 
 
Although the stereoselective generation and stereochemistry of α-heteroatom-substituted 
alkyl-, benzylic and allylic organolithium reagents are well studied, the stereoselective 
preparation of non-stabilized secondary alkyllithiums has remained a major synthetic 
challenge. A practical stereoretentive synthesis to unstabilized stereodefined 
cyclohexyllithium reagents from the readily available organic iodides via I-Li exchange has 
been presented in this work. Using this approach a detailed study on the configurational 
stabilities, stereochemical behaviour and reactivities of various axially and equatorially 
substituted cyclohexyllithium reagents was performed. Thus, the stereochemical paths (SE2 
vs. Si2) of the quenching reactions were shown to depend on the respective cyclohexyllithium 
diastereomer and the electrophile. In all cases, the axial cyclohexyllithium was found to 
almost completely equilibrate into the configurationally stable, equatorial diastereomer. This 
inversion process was followed for differently substituted cyclohexyllithiums over time 
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showing distinct behaviour. DFT-calculations demonstrated that the formation of oligomeric 
cyclohexyllithium structures is the key determinant for the observed stereochemical 
preference. 
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Scheme 46: A new practical stereoretentive I-Li exchange reaction for the stereoselective preparation of 
cyclohexyllithiums. The behaviours of the resulting diastereomeric substituted cyclohexyllithium reagents were 
studied. 
 
5.2. Novel Insights into the Stereochemical Behaviour of Diastereomeric 
Cyclohexylzinc Reagents – Stereoconvergence through Distinct 
Stereochemical Pathways 
 
A novel revised mechanistic view of the stereoconvergent Negishi-cross-coupling of 
substituted cyclohexylzinc reagents has been established through our investigations. The 
observed high configurational stability of the C-Zn bond excludes a mechanism based on a 
dynamic kinetic resolution process, since flipping of the C-Zn bond takes place too slowly. 
Via deuterolysis and protolysis experiments, we were able to show that high 
stereoselectivities can be achieved in quenching diastereomeric cyclohexylzinc reagents with 
preference of the all equatorially substituted products, excluding an equilibration on the stage 
of the cyclohexyl-palladium intermediates as key factor for the stereoconvergence. Moreover, 
both diastereomers were observed to react with the same observable rate at the NMR time 
scale in slow addition/protolysis. In combination, these crucial results along with the fact that 
only one Pd-intermediate could be observed in the cross-coupling68 show that the equatorial 
C-Zn bond must react with retention and the axial C-Zn bond with inversion of the 
stereoconfiguration in the transmetalation step to ArPdLnX thus leading to stereoconvergence 
in the reaction (Scheme 47). 
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Scheme 47: Substituted diastereomeric cyclohexylzinc complexes eq-103 and ax-103 which differ in the 
configuration of their C-Zn bond undergo distinct stereochemical pathways in the transmetallation to ArPdLnX 
thus leading to overall stereoconvergence in the cross-coupling reaction. The energy diagram sums up the 
experimental observations. The high energetic barrier between the diastereomeric zinc reagents prevents their 
equilibration. The fact that reaction pathways for diastereomers do not need to be isoenergetic, as is the case for 
enantiomers, allows distinct stereochemical reactivities. Thus, the axially configured cyclohexylzinc 
diastereomer reacts with inversion and the equatorially substituted one with retention of the stereoconfiguration 
resulting in overall stereoconvergence of the reaction. 
 
To the best of our knowledge, this work represents the first experimental proof that 
diastereomeric organometallics can undergo distinct stereochemical pathways which result in 
the stereoselective formation of one diastereomerically defined product. We anticipate that in 
addition to the dynamic resolution processes which have been well established for 
configurationally unstable organolithiums, these observations will lead to the further 
understanding and development of stereoconvergent reactions for configurationally stable 
alkyl organometallics. 
 
5.3. Diastereo- and Enantioselective Cross-Coupling with Functionalized 
Cyclohexylzinc Reagents 
 
Cross-couplings of functionalized cyclohexylzinc reagents such as [2-(1,3-dioxolan-2-
yl)cyclohexyl]- and [2-(5,5-dimethyl-1,3-dioxan-2-yl)cyclohexyl]zinc reagents (142, 143 und 
140, 141) lead to high diastereoselectivities. β-Hydride eliminations which were observed in 
cross-coupling reactions of the organizinc iodides 142 and 143 could be avoided by 
decreasing the temperature to -25 °C. Moreover, it was illustrated that cross-coupling of 
diorganozinc complexes 140 and 141 can be successfully performed even at higher 
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temperatures up to 25 °C without loss in diastereoselectivity. Hereby, β-hydride elimination 
processes did not occur which can be probably explained by the stereochemically pure nature 
featuring only an equatorial C-Zn bond. Cross-coupling of the chiral organozinc reagents 159 
and 160 synthesized via enantioselective hydroboration, proceeded diastereoselectively and 
furnished the respective arylated 1,2-disubstituted cyclohexanes in moderate enantiomeric 
excess. Cross-coupling of [8-(ethoxymethoxy)decahydronaphthalen-1-yl](ethyl)zinc (170) 
was performed with moderate diastereoselectivity. Since the arylation of 170 proceeds with 
high stereoselectivity, β-hydride elimination processes on the step of the palladium 
intermediate can be responsible for the observed low diastereoselectivity. 
 
 
Scheme 48: Enantio- and diastereoselective arylation via a hydroboration/B-Zn-exchange/cross-coupling 
sequence. 
 
5.4. Highly Diastereoselective Arylations of Substituted Piperidines  
 
A highly diastereoselective methodology for the preparation of various substituted piperidines 
via Negishi cross-couplings with (hetero)aryl iodides was developed. Depending on the 
position of the C-Zn bond relative to the nitrogen (position 2 vs. position 4), the 
stereoselectivity of the coupling can be directed either towards the trans- or the cis-2,4-
disubstituted products. DFT-calculations on the relative stabilities of the Zn- and Pd-
intermediates were performed to explain the high diastereoselectivities obtained. A novel Pd-
1,2-migration further expands this method to the stereoselective preparation of 5-arylated 2,5-
disubstituted piperidines. 
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Scheme 49: Switchable stereoselectivity in the cross-couplings of piperidinylzinc reagents and a novel 
diastereoselective Pd-1,2-migration. 
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1. General Considerations 
All reactions were carried out with magnetic stirring and, if the reagents were air or moisture 
sensitive, in flame-dried glassware under argon. Syringes which were used to transfer 
reagents and solvents were purged with argon prior to use.  
 
1.1. Solvents 
 
Solvents were dried according to standard procedures by distillation over drying agents and 
stored under argon. 
CH2Cl2 was predried over CaCl2 and distilled from CaH2. 
DMF was heated to reflux for 14 h over CaH2 and distilled from CaH2.  
1,4-Dioxane  was heated to reflux for 14 h over CaH2 and distilled from CaH2. 
Et2O was predried over calcium hydride and dried with the solvent purification system SPS-
400-2 from INNOVATIVE TECHNOLOGIES INC. 
NEP was heated to reflux for 14 h over CaH2 and distilled from CaH2. 
Pyridine was dried over KOH and distilled. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. 
Toluene was predried over CaCl2 and distilled from CaH2. 
Triethylamine was dried over KOH and distilled. 
Solvents for column chromatography were distilled prior to use.  
 
1.2. Reagents 
 
All reagents were obtained from commercial sources and used without further purification 
unless otherwise stated. Liquid aldehydes and acid chlorides were distilled prior to use. 
iPrMgCl·LiCl solution in THF was purchased from Rockwood Lithium (Chemetall). 
iPrMgCl solution in THF was purchased from Rockwood Lithium (Chemetall). 
PhMgCl solution in THF was purchased from Rockwood Lithium (Chemetall). 
nBuLi solution in n-hexane was purchased from Rockwood Lithium (Chemetall). 
sBuLi solution in cyclohexane was purchased from Rockwood Lithium (Chemetall). 
tBuLi solution in n-pentane was purchased from Rockwood Lithium (Chemetall). 
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Content determination of organometallic reagents 
The respective organometallic reagents were titrated using either the method reported by 
Paquette83 or Knochel84 prior to their use. 
 
ZnCl2 solution (1.00 M) was prepared by drying ZnCl2 (100 mmol, 136 g) in a Schlenk-flask 
under vacuum at 140 °C for 5 h. After cooling to room temperature, 100 mL dry THF were 
added and stirring was continued until the salt was dissolved. The reagent was stirred under a 
nitrogen atmosphere. 
 
MgCl2 solution (0.5 M) was prepared by drying magnesium turnings (30 mmol, 0.73 g) in a 
Schlenk-flask under high vacuum at 140 °C for 15 min. After cooling to room temperature, 60 
mL dry THF was filled in. The mixture was vigorously stirred and 1,2-dichloroethane (30 
mmol, 2.38 mL) was carefully added dropwise until all magnesium filings had been 
consumed. The reagent was stirred under a nitrogen atmosphere. 
 
CuCN.2LiCl solution (1.00 m) was prepared by drying LiCl (8.48 g, 200 mmol) and CuCN 
(8.96 g, 100 mmol) for 5 h at 140 oC under high vacuum. After cooling to room temperature, 
100 mL dry THF were added and stirring was continued until the salt was dissolved. The 
Schlenk-tube was wrapped in an aluminium-foil to protect from light. The reagent appears as 
a slightly greenish solution and has to be stored under argon. 
 
Preparation of a 0.7 M solution of cHexMgBr in THF 
In a dry and Ar-flushed 250 mL 3-necked flask, equipped with a reflux condenser, a dropping 
funnel and a magnetic stirring bar, LiCl (2.33 g, 55.0 mmol) was placed and dried over 10 
min at 500 °C in high vacuum (1 mbar). After cooling to room temperature Mg turnings (1.34 
g, 55.0 mmol) and 1,2-dibromoethane (0.52 g, 0.24 mL, 2.75 mmol) were added. The 
heterogeneous mixture was vigorously stirred before THF (38.5 mL) was added and then 
gently heated in order to activate the Mg surface. A solution of cyclohexyl bromide (8.15 g, 
6.13 mL, 50.0 mmol) in THF (15 mL) was added dropwise and the resulting reaction mixture 
was stirred for 45 min at room temperature. 
 
                                                 
83
 Lin, H.-S. & Paquette, L. A. A convenient method for determining the concentration of Grignard reagents. 
Synth. Commun. 24, 2503-2506 (1994). 
84
 Krasovskiy, A. & Knochel, P. Convenient titration method for organometallic zinc, magnesium, and 
lanthanide reagents. Synthesis 5, 890-891 (2006). 
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Preparation of a 7.3 M solution of Et2BH in SMe2 
In a dry and Ar-flushed 50 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
septum, BH3.SMe2 (3.80 g, 4.74 mL, 50.0 mmol) was placed and neat BEt3 (9.80 g, 14.5 mL, 
100 mmol) was added dropwise. The resulting solution was stirred at room temperature for 48 
h. It was stored in a freezer (–28 °C). 
 
Preparation of a 1.0 M solution of (–)-IpcBH2 in THF 
In a dry and Ar-flushed 100 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
septum, [(–)-IpcBH2]2.TMEDA-complex (5.00 g, 12.0 mmol) was dissolved in THF (24 mL) 
at room temperature and freshly distilled BF3.Et2O-complex (3.40 g, 3.00 mL, 24.0 mmol) 
was added dropwise. The reaction mixture was stirred for 2 h and then filtrated through a 
Schlenk-frit into an Ar-flushed Schlenk-tube. The precipitate was washed with a small amount 
of THF. The solution was concentrated (0.1 mm Hg, 25 °C, 2 h) and the residue redissolved 
in THF (24 mL). 
 
1.3. Chromatography 
 
Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm) from 
Merck.  
Thin layer chromatography was performed using SiO2 pre-coated aluminium plates (Merck 
60, F-254). The chromatograms were examined under UV light at 254 nm and/or by staining 
of the TLC plate with one of the solutions given below followed by heating with a heat gun: 
- KMnO4 (3.0 g), 5 drops of conc. H2SO4 in water (300 mL). 
- Phosphomolybdic acid (5.0 g), Ce(SO4)2 (2.0 g) and conc. H2SO4 (12 mL) in water 
(230 mL). 
1.4. Analytical Data 
 
NMR spectra were recorded on VARIAN Mercury 200, BRUKER AXR 300, VARIAN VXR 
400 S and BRUKER AMX 600 instruments. Chemical shifts are reported as δ-values in ppm 
relative to the residual solvent peak of CHCl3 (δH : 7.25, δC : 77.0). For the characterization of 
the observed signal multiplicities the following appreviations were used: s (singlet), d 
(doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet) as well as br 
(broad). 
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Mass spectroscopy: High resolution (HRMS) and low resolution (MS) spectra were recorded 
on a FINNIGAN MAT 95Q instrument. Electron impact ionization (EI) was conducted with 
an electron energy of 70 eV.  
For the combination of gas chromatography with mass spectroscopic detection, a GC/MS 
from Hewlett-Packard HP 6890 / MSD 5973 was used.  
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER 
Spectrum BX-59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II 
Diamond ATR sensor was used. The absorption bands are reported in wavenumbers (cm-1). 
Melting points (M.p.) were determined on a BÜCHI B-540 apparatus and are uncorrected. 
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2. Stereoselective Preparation, Configurational Stability and Reactivity 
of Substituted Cyclohexyllithium Derivatives 
2.1. Preparation of Starting Materials 
2.1.1. Typical Procedure 1: Iodination of alcohols (TP1) 
 
A 1.0 M solution of I2 in CH2Cl2 was prepared in a flame-dried, Ar-flushed Schlenk-flask 
equipped with a stirring bar and cooled to 0 oC using a Huber T100 cryostat. PPh3 (1.2 equiv.) 
was added portionwise. The resulting suspension was stirred for 1 h, before N-methyl-
imidazole (NMI; 1.2 equiv.) was added. The reaction mixture became a bright yellow 
suspension and the respective alcohol was added portionwise. The resulting mixture was 
stirred for 15 h at 0 oC, then quenched with NaHSO3 sat. solution. The phases were separated 
and the aqueous phase was extracted with 3 x CH2Cl2. The combined organic layers were 
dried over Na2SO4 and the solvents evaporated (35 oC, rotavap, 8 mbar, <30 min). Column 
chromatographic purification (flash silica) was performed. The solvents were evaporated 
(35 oC, rotavap, 8 mbar, <30 min) and, if necessary, the product was subjected to high 
vacuum (10-3 mbar) at 30 oC in order to remove cyclohexene/elimination byproducts. The 
neat corresponding cyclohexyl iodides were thus obtained. 
 
trans-1-(tert-butyl)-4-iodocyclohexane (trans-(eq)-78) 
 
column chromatography: SiO2; i-hexane 
yield: 3.0 g (20%), colourless oil 
d.r.: 10:90. 
1H-NMR (300 MHz, CDCl3) δ: 4.10 (tt, J1=12.3 Hz, J2=4.0 Hz, 1 H), 2.48 (d, J=11.9 Hz, 2 
H), 2.05–1.90 (m, 2 H), 1.72–1.61 (m, 2 H), 1.17–1.02 (m, 3 H), 0.83 (s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 46.7, 41.1, 32.6, 30.9, 30.3, 27.4. 
MS (70 eV, EI) m/z (%): 266 (12) [M+], 140 (14), 139 (100), 128 (12), 123 (18), 97 (15), 95 
(10), 83 (45), 81 (20), 69 (20), 67 (18), 57 (65), 55 (20), 40 (16). 
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IR (ATR) ν~  (cm-1): 2943 (vs), 2859 (m), 1478 (m), 1469 (m), 1448 (m), 1394 (w), 1366 
(m), 1265 (w), 1258 (w), 1249 (w), 1228 (w), 1196 (w), 1188 (w), 1147 (s), 1079 (m), 996 
(s), 897 (w), 810 (w), 663 (s). 
HRMS (EI) for C10H19I (266.0531): 266.0518. 
 
trans-1-iodo-4-methoxycyclohexane (trans-(eq)-83b) 
 
column chromatography: SiO2; i-hexane 
yield: 0.91 g (30%), colourless oil 
d.r.: 5:95. 
1H-NMR (400 MHz, CDCl3) δ: 4.29–4.23 (m, 1 H), 3.28 (s, 3 H), 3.22 (tt, J1=8.8 Hz, J2=3.2 
Hz, 1 H), 2.22–2.18 (m, 2 H), 1.92–1.83 (m, 4 H), 1.43–1.35 (m, 2 H). 
13C-NMR (100 MHz, CDCl3) δ: 76.6, 55.9, 36.4, 31.9, 30.7. 
MS (70 eV, EI) m/z (%): 240 (6) [M+], 191 (28), 175 (65), 128 (21), 113 (38), 85 (40), 83 
(54), 81 (100), 58 (19), 43 (14). 
IR (ATR) ν~  (cm-1): 2942, 2863, 1454, 1369, 1230, 1159, 1102, 1089, 1010, 898, 800, 678. 
HRMS (EI) for C7H13IO (240.0011): 239.9995.  
 
tert-butyl((cis-3-iodocyclohexyl)oxy)dimethylsilane (cis-(eq)-86b) 
 
column chromatography: SiO2; i-hexane 
yield: 6.75 g (27%), colourless oil 
d.r.: 97:3. 
1H-NMR (400 MHz, C6D6) δ: 4.51–4.35 (m, 1 H), 3.78 (br. s., 1 H), 2.02–1.85 (m, 2 H), 
1.73–1.64 (m, 2 H), 1.57–1.47 (m, 1 H), 1.33 (br. s., 3 H), 0.92 (s, 9 H), -0.02 (s, 3 H), -0.01 
(s, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 69.5, 47.4, 39.0, 34.1, 28.9, 26.4, 22.9, 18.6, 4.4. 
MS (70 eV, EI) m/z (%): 340 (8) [M+], 284 (10), 213 (12), 155 (16), 81 (100), 75 (49), 73 
(17). 
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IR (ATR) ν~  (cm-1): 2929 (m), 2857 (m), 1252 (m), 1240 (m), 1152 (m), 1099 (s), 1068 (m), 
1053 (s), 1032 (s), 1006 (m), 902 (m), 871 (m), 852 (m), 834 (vs), 824 (s), 799 (m), 773 (vs), 
688 (m). 
HRMS (EI) for C12H25IOSi (340.0719): 340.0714. 
 
cis-1-(tert-butyl)-4-iodocyclohexane (cis-(ax)-78) 
 
column chromatography: SiO2; i-hexane 
yield: 7.5 g (57%), white solid 
d.r.: 98:2. 
m.p.: 32.8 – 34.9 °C. 
1H-NMR (599 MHz, CDCl3) δ: 4.89 (br. s., 1 H), 2.13 (d, J=14.0 Hz, 2 H), 1.68–1.62 (m, 2 
H), 1.60–1.47 (m, 4 H), 1.08 (tt, J1=11.5 Hz, J2=3.3 Hz, 1 H), 0.90 (s, 9 H). 
13C-NMR (151 MHz, CDCl3) δ: 47.8, 37.9, 36.9, 32.6, 27.4, 23.3. 
MS (70 eV, EI) m/z (%): 266 (8) [M+], 140 (11), 139 (100), 123 (15), 83 (47), 81 (21), 69 
(17), 67 (18), 57 (69), 55 (17), 41 (14). 
IR (ATR) ν~  (cm-1): 2956 (s), 2939 (vs), 2921 (m), 2885 (m), 2863 (m), 2845 (m), 2832 (m), 
1482 (w), 1472 (w), 1444 (w), 1430 (m), 1418 (m), 1390 (w), 1366 (m), 1350 (w), 1308 (m), 
1243 (m), 1232 (m), 1186 (s), 1016 (m), 996 (m), 851 (m), 764 (w), 652 (m). 
HRMS (EI) for C10H19I (266.0531): 266.0530. 
 
cis-1-iodo-4-methoxycyclohexane (cis-(ax)-83b) 
 
column chromatography: SiO2; i-hexane 
yield: 0.64 g (30%), colourless oil 
d.r.: 99:1. 
1H-NMR (400 MHz, CDCl3) δ: 4.42–4.38 (m, 1 H), 3.37–3.31 (m, 1 H), 3.30 (s, 3 H), 2.23–
2.14 (m, 2 H), 1.87–1.80 (m, 2 H), 1.79–1.73 (m, 2 H), 1.67–1.61 (m, 2 H). 
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13C-NMR (100 MHz, CDCl3) δ: 75.6, 55.8, 34.9, 31.5, 30.3. 
MS (70 eV, EI) m/z (%): 240 (6) [M+], 113 (25), 81 (100), 71 (13), 58 (13), 45 (11), 43 (14), 
41 (15). 
IR (ATR) ν~  (cm-1): 2939, 2859, 2820, 1446, 1371, 1229, 1163, 1101, 1089, 1001, 933, 898, 
806, 675. 
HRMS (EI) for C7H13IO (240.0011): 240.0003. 
 
cis-1-iodo-2-methylcyclohexane (cis-(ax)-98) 
 
column chromatography: SiO2; i-hexane 
yield: 4.7 g (48%), colourless oil 
d.r.: 98:2. 
1H-NMR (300 MHz, C6D6) δ: 4.26 (d, J=2.5 Hz, 1 H), 2.02–1.92 (m, 1 H), 1.80–1.64 (m, 1 
H), 1.45 (dddd, J1=12.9 Hz, J2=3.7 Hz, J3=3.6 Hz, J4=1.4 Hz, 1 H), 1.37–1.20 (m, 3 H), 1.17–
1.08 (m, 1 H), 1.08–0.89 (m, 1 H), 0.80 (d, J=6.6 Hz, 3 H), 0.23–0.10 (m, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 49.7, 38.0, 37.1, 31.2, 25.7, 24.6, 23.3. 
MS (70 eV, EI) m/z (%): 224 (72) [M+], 98 (13), 97 (100). 
IR (ATR) ν~  (cm-1): 2956 (m), 2925 (vs), 2853 (m), 2834 (m), 1452 (m), 1442 (m), 1377 
(w), 1335 (w), 1318 (w), 1290 (w), 1256 (m), 1246 (m), 1211 (m), 1162 (s), 964 (w), 955 (m), 
872 (w), 815 (w), 760 (w). 
HRMS (EI) for C7H13I (224.0062): 224.0053. 
 
(1R,2R,4R)-2-iodo-1-isopropyl-4-methylcyclohexane (men-(eq)-89) 
 
Lepore, S. D., Mondal, D., Li, S. Y. & Bhunia, A. K., Angew. Chem. Int. Ed. 47, 7511-7514 
(2008). 
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β-cholesteryl iodide (β-(eq)-92) 
 
Sun, Q., Cai, S. & Peterson, B. R., Org. Lett. 11, 567-570 (2009). 
 
β-cholestanyl iodide (β-(eq)-95) 
HH
H
I
H
 
Bayless, A. V. & Zimmer, H., Tetrahedron Lett. 35, 3811-3812 (1968). 
 
(1R,2S,4R)-2-iodo-1-isopropyl-4-methylcyclohexane (neomen-(ax)-89) 
 
Lange, G. L. & Gottardo, C. Synth. Commun. 20, 1473–1479 (1990). 
 
α-cholestanyl iodide (α-(ax)-95) 
HH
H
I
H
 
Lange, G. L. & Gottardo, C. Synth. Commun. 20, 1473–1479 (1990). 
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2.2. I-Li Exchange and Subsequent Quenching with Electrophiles  
2.2.1. Typical Procedure 2: I-Li exchange and subsequent quenching with electrophiles 
(TP2) 
           (Compounds of Scheme 23, Table 1, Table 2, Table 3 and Scheme 24) 
 
A solution of n-hexane/ether (3:2; 5.5 mL) was placed into a flame-dried and Ar-flushed 
Schlenk-tube equipped with a stirring bar and cooled to -100 oC using a Huber T100 cryostat. 
A tBuLi solution (2.2 equiv.; 1.3 M in n-hexane; 0.84 mL; 1.1 mmol) was added via syringe. 
After 5 min, a 1.0 M solution (0.5 M for the cholesteryl and cholestanyl derivatives 92 and 
95) of the respective cyclohexyl iodide (1.0 equiv.; 0.5 mmol) in n-hexane/ether (3:2) was 
added. The reaction was directly quenched after 4-5 s with the corresponding electrophile
 
(4 
equiv.; 0.18 mL; 2 mmol; solid Ph3SnCl was added as a 1 M solution in Et2O). The reaction 
mixture was stirred for 5 min at -100 oC before NH4Cl sat. aq solution (2 mL) was added. 
After warming to room temperature the phases were separated and the aqueous phase was 
extracted with Et2O (3 x 5 mL). The combined organic phases were dried over Na2SO4 and 
the solvents were evaporated. Column chromatographic purification of the crude material 
(flash silica) provided the respective products. 
 
(trans-4-(tert-butyl)cyclohexyl)(methyl)sulfane (trans-(eq)-82a) (Scheme 28) 
 
 
column chromatography: SiO2; i-hexane 
yield: 84 mg (90%), colourless oil 
d.r.: 9:91. 
1H-NMR (300 MHz, CDCl3) δ: 2.43 (tt, J1=12.0 Hz, J2=3.6 Hz, 1 H), 2.09 (s, 3 H), 2.06 (br. 
s., 1 H), 1.84 (d, J=10.0 Hz, 2 H), 1.36–1.15 (m, 3 H), 1.13–0.96 (m, 3 H), 0.85 (s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 47.5, 44.9, 33.7, 32.4, 27.6, 27.5, 13.1. 
MS (70 eV, EI) m/z (%): 186 (100) [M+], 175 (89), 138 (49), 129 (55), 123 (48), 95 (54), 83 
(55), 82 (40), 81 (87), 69 (32), 67 (31), 57 (92), 55 (35), 41 (32). 
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IR (ATR) ν~  (cm-1): 2936 (vs), 2856 (s), 1478 (m), 1467 (m), 1448 (m), 1394 (w), 1365 (s), 
1275 (w), 1235 (w), 1230 (w), 1211 (w), 1174 (w), 1038 (w), 1013 (m), 1006 (m), 970 (w), 
954 (w), 897 (w). 
HRMS (EI) for C11H22S (186.1442): 186.1432. 
 
(cis-4-(tert-butyl)cyclohexyl)(methyl)sulfane (cis-(ax)-82a) (Scheme 23) 
 
 
column chromatography: SiO2; i-hexane 
yield: 68 mg (73%), colourless oil 
d.r.: 90:10. 
1H-NMR (300 MHz, CDCl3) δ: 3.03 (br. s., 1 H), 2.06 (s, 3 H), 1.95 (d, J=14.1 Hz, 2 H), 
1.66 (tt, J1=13.4 Hz, J2=3.7 Hz, 2 H), 1.59–1.49 (m, 2 H), 1.49–1.34 (m, 2 H), 1.07–0.96 (m, 
1 H), 0.86 (s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 48.4, 44.3, 32.6, 31.1, 27.5, 21.9, 14.8. 
MS (70 eV, EI) m/z (%): 186 (8) [M+], 175 (28), 147 (25), 83 (10), 57 (22). 
IR (ATR) ν~  (cm-1): 2938 (vs), 2930 (vs), 2864 (m), 2846 (m), 1478 (m), 1467 (m), 1440 
(m), 1393 (w), 1365 (s), 1312 (m), 1263 (m), 1237 (w), 1227 (w), 1214 (m), 1024 (w), 865 
(w), 770 (w). 
HRMS (EI) for C11H22S (186.1442): 186.1443. 
 
trans-tert-butyl(4-2H1)cyclohexane (trans-(eq)-82d) (Table 1) 
 
yield: (85%) 
d.r.: 4:96. 
2H-NMR (61 MHz, THF) δ: 1.53 (s, 1 D). 
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cis-tert-butyl(4-2H1)cyclohexane (cis-(ax)-82d) (Table 1) 
 
yield: 75% (GC) 
d.r.: 92:8. 
2H NMR (61 MHz, THF) δ: 0.99 (s, 1 D). 
 
(trans-4-(tert-butyl)cyclohexyl)triphenylstannane (trans-(eq)-82f) (Table 1) 
 
column chromatography: SiO2; i-hexane/Et2O 40:1 
yield: 127 mg (52 %), white solid 
d.r.:8:92. 
m.p.: 99.1 – 101.9 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.65–7.55 (m, 5 H), 7.51–7.36 (m, 10 H), 2.22 (dd, J1=12.0 
Hz, J2=1.2 Hz, 2 H), 2.03–1.80 (m, 3 H), 1.79–1.63 (m, 2 H), 1.12–1.00 (m, 3 H), 0.84 (s, 9 
H). 
13C-NMR (75 MHz, CDCl3) δ: 138.8, 137.4, 128.7, 128.4, 48.2, 32.5, 32.2, 29.9, 28.5, 27.4. 
119Sn-NMR (149 MHz, CDCl3) δ: 116.34 (major) -107.77 (minor). 
MS (70 eV, EI) m/z (%): 490 (3) [M+], 355 (17), 353 (16), 352 (20), 351 (100), 350 (39), 349 
(76), 348 (33), 347 (45), 196 (11). 
IR (ATR) ν~  (cm-1): 3061 (w), 2956 (m), 2917 (m), 2849 (m), 1480 (w), 1467 (w), 1444 (w), 
1427 (m), 1390 (w), 1362 (w), 1300 (w), 1231 (w), 1190 (w), 1148 (w), 1073 (m), 1060 (w), 
1023 (w), 997 (w), 874 (w), 724 (s), 697 (vs), 666 (w), 657 (w). 
HRMS (EI) for C28H34Sn (490.1682): 490.1690. 
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butyl(trans-4-methoxycyclohexyl)sulfane (trans-(eq)-85b) (Table 2) 
 
column chromatography: SiO2; i-hexane/Et2O 25:1 
yield: 84 mg (83%), colourless oil 
d.r.: <1:99. 
1H-NMR (300 MHz, CDCl3) δ: 3.33–3.28 (m, 1 H), 3.27 (s, 3 H), 2.69 (quint, J=6.4 Hz, 1 
H), 2.49 (t, J=7.5 Hz, 2 H), 1.90–1.81 (m, 2 H), 1.72–1.66 (m, 4 H), 1.55–1.48 (m, 4 H), 
1.41–1.33 (m, 2 H), 0.88 (t, J=7.2 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 75.7, 55.7, 42.7, 32.3, 30.3, 29.1, 28.6, 22.3, 13.9. 
MS (70 eV, EI) m/z (%): 202 (64) [M+], 170 (15), 116 (23), 113 (10), 81 (70), 80 (100), 79 
(14), 71 (11), 58 (14), 43 (12), 41 (10). 
IR (ATR) ν~  (cm-1): 2931, 2856, 1451, 1374, 1187, 1145, 1099, 933, 746. 
HRMS (EI) for C11H22OS (202.1391): 202.1392.  
 
tert-butyl((cis-3-(butylthio)cyclohexyl)oxy)dimethylsilane (cis-(eq)-88b) (Table 2) 
 
column chromatography: SiO2; i-hexane/Et2O 40:1 
yield: 95 mg (63%), colourless oil 
d.r.: 2:98. 
1H-NMR (400 MHz, C6D6) δ: 3.55–3.43 (m, 1 H), 2.37–2.31 (m, 1 H) 2.47–2.37 (m, 3 H), 
1.81 (t, J=15.4 Hz, 2 H), 1.56–1.45 (m, 4 H), 1.30 (dq, J1=15.0 Hz, J2=7.5 Hz, 3 H), 1.17–
1.01 (m, 2 H), 0.98 (s, 9 H), 0.81 (t, J=7.4 Hz, 3 H), 0.06 (s, 6 H). 
13C-NMR (101 MHz, C6D6) δ: 71.7, 44.3, 41.9, 36.3, 33.7, 32.8, 30.3, 26.4, 24.6, 22.7, 18.6, 
14.2, 4.0. 
29Si-NMR (80 MHz, C6D6) δ: 16.4. 
MS (70 eV, EI) m/z (%): 302 (1) [M+], 246 (16), 245 (100), 155 (24), 147 (15), 81 (1), 75 
(19). 
IR (ATR) ν~  (cm-1): 2930 (m), 2857 (m), 1462 (w), 1372 (w), 1255 (m), 1250 (m), 1124 (m), 
1086 (s), 1006 (w), 976 (m), 878 (m), 860 (m), 846 (s), 834 (vs), 803 (m), 773 (vs), 666 (m). 
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HRMS (EI) for C16H34OSSi (302.2100): 302.2094. 
 
((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)(methyl)sulfane (men-(eq)-91a) (Table 2) 
 
 
column chromatography: SiO2; i-hexane 
yield: 50 mg (54%), colourless oil 
d.r.: 13:87. 
1H-NMR (400 MHz, C6D6) δ: 2.68–2.53 (m, 1 H), 2.25 (td, J1=11.2 Hz, J2=3.71 Hz, 1 H), 
2.09–1.98 (m, 1 H), 1.80 (s, 3 H), 1.62–1.52 (m, 2 H), 1.23–1.03 (m, 3 H), 0.96–0.86 (m, 4 
H), 0.84 (d, J=6.3 Hz, 3 H), 0.80 (d, J=6.9 Hz, 3 H), 0.77–0.69 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 48.0, 46.9, 43.6, 35.4, 33.8, 27.9, 25.3, 22.8, 21.9, 15.9, 12.3. 
MS (70 eV, EI) m/z (%): 186 (86) [M+], 138 (93), 123 (51), 97 (35), 95 (100), 85 (33), 83 
(69), 82 (32), 81 (57), 71 (31), 69 (50), 57 (51), 55 (39). 
IR (ATR) ν~  (cm-1): 2954 (vs), 2918 (vs), 2869 (m), 2848 (m), 1454 (m), 1446 (m), 1385 
(w), 1368 (w), 1300 (w), 1198 (w), 955 (w), 934 (w). 
HRMS (EI) for C11H22S (186.1442): 186.1440. 
 
((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)diphenylphosphine sulfide (men-(eq)-91b) 
(Table 2) 
 
 
column chromatography: SiO2; i-hexane/Et2O 30:1 
yield: 105 mg (59 %), white solid 
d.r.: 10:90. 
m.p.: 163.0 – 166.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.16–8.06 (m, 2 H), 8.06–7.95 (m, 2 H), 7.05–6.93 (m, 6 H), 
2.63–2.55 (m, 1 H), 2.29–2.20 (m, 1 H), 1.99 (quin, J=6.7 Hz, 1 H), 1.66 (ddd, J1=13.0 Hz, 
J2=6.2 Hz, J3=3.2 Hz, 1 H), 1.57 (d, J=11.9 Hz, 1 H), 1.50–1.36 (m, 2 H), 1.33–1.23 (m, 1 H), 
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1.05 (qd, J1=12.8 Hz, J2=3.1 Hz, 1 H), 0.87 (d, J=6.6 Hz, 3 H), 0.85–0.75 (m, 1 H), 0.64 (d, 
J=6.4 Hz, 3 H), 0.39 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 135.5 (d, J=72.8 Hz), 134.0 (d, J=76.3 Hz), 131.5 (d, J=9.0 
Hz), 131.0 (d, J=9.6 Hz), 130.5 (d, J=3.0 Hz), 130.4 (d, J=2.9 Hz), 128.2 (d, J=9.8 Hz), 128.0 
(d, J=9.5 Hz), 44.1 (d, J=1.7 Hz), 39.5 (d, J=53.7 Hz), 35.7 (d, J=1.1 Hz), 34.4 (d, J=1.7 Hz), 
33.3 (d, J=14.2 Hz), 27.5 (d, J=4.1 Hz), 24.8 (d, J=13.1 Hz), 22.3 (d, J=0.7 Hz), 21.5, 15.8. 
31P-NMR (162 MHz, C6D6) δ: 49.5, 43.6. 
MS (70 eV, EI) m/z (%): 356 (8) [M+], 219 (26), 218 (100), 185 (11), 183 (12). 
IR (ATR) ν~  (cm-1): 2961 (m), 2953 (m), 2942 (w), 2921 (m), 2869 (w), 2844 (w), 1479 (w), 
1454 (w), 1436 (m), 1308 (w), 1092 (s), 1068 (w), 1026 (w), 997 (w), 855 (w), 760 (m), 744 
(s), 732 (m), 717 (m), 704 (s), 697 (vs), 688 (vs), 660 (s). 
HRMS (EI) for C22H29PS (356.1728): 356.1727. 
 
(β-cholesteryl)(methyl)sulfane (β-(eq)-94a) (Table 2) 
 
 
column chromatography: SiO2; i-hexane/CH2Cl2 1:1 
yield: 147 mg (71%), white solid 
d.r.: 1:99. 
m.p.: 127.8 – 129.6 °C. 
1H-NMR (400 MHz, C6D6) δ: 5.34 (d, J=4.8 Hz, 1 H), 2.50–2.35 (m, 3 H), 2.04 (dt, J1=12.5 
Hz, J2=3.2 Hz, 1 H), 1.99–1.91 (m, 1 H), 1.91–1.81 (m, 5 H), 1.75 (dt, J1=13.0 Hz, J2=3.2 Hz, 
1 H), 1.61–1.51 (m, 4 H), 1.47–1.37 (m, 6 H), 1.31–1.05 (m, 8 H), 1.03 (d, J=6.6 Hz, 3 H), 
0.99–0.92 (m, 12 H), 0.68 (s, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 142.4, 121.4, 57.4, 57.0, 51.1, 46.6, 43.0, 40.6, 40.5, 40.3, 
37.5, 37.0, 36.6, 32.6, 32.5, 30.1, 29.0, 28.8, 25.0, 24.7, 23.4, 23.1, 21.7, 19.8, 19.4, 13.5, 
12.5. 
MS (70 eV, EI) m/z (%): 416 (28) [M+], 401 (11), 370 (11), 368 (100). 
IR (ATR) ν~  (cm-1): 2952 (s), 2928 (vs), 2911 (vs), 2899 (s), 2870 (s), 2852 (s), 1463 (s), 
1444 (m), 1431 (m), 1381 (m), 1374 (m), 1366 (m), 960 (m), 825 (m), 800 (m). 
HRMS (EI) for C28H48S (416.3477): 416.3473. 
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(β-cholesteryl)diphenylphosphine sulphide (β-(eq)-94b) (Table 2) 
 
 
column chromatography: SiO2; i-hexane/Et2O 30:1 
yield: 236 mg (80%), white solid 
d.r.: 6:94. 
m.p.: 184.3 – 186.1 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.01–7.94 (m, 4 H), 7.07–7.02 (m, 6 H), 5.20–5.14 (m, 1 H), 
3.12–3.00 (m, 1 H), 2.62–2.53 (m, 1 H), 2.28–2.15 (m, 1 H), 1.99 (d, J=12.5 Hz, 2 H), 1.92–
1.72 (m, 3 H), 1.58–1.48 (m, 3 H), 1.47–1.33 (m, 8 H), 1.32–1.16 (m, 5 H), 1.16–1.03 (m, 5 
H), 1.02–1.00 (m, 6 H), 0.92 (d, J=6.6 Hz, 6 H), 0.63 (s, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 141.4 (d, J=14.2 Hz), 132.7 (d, J=76.1 Hz), 132.5 (d, J=76.1 
Hz), 131.6 (d, J=9.4 Hz), 131.5 (d, J=9.4 Hz), 130.9 (d, J=3.0 Hz), 130.8 (d, J=2.9 Hz), 128.4 
(d, J=11.5 Hz), 128.3 (d, J=11.5 Hz), 121.0, 56.9, 56.3, 50.9 (d, J=1.4 Hz), 42.3, 40.0, 39.7, 
39.3 (d, J=14.6 Hz), 39.0 (d, J=55.7 Hz), 37.2 (d, J=1.4 Hz), 36.4, 35.9, 32.2 (d, J=0.4 Hz), 
31.8, 31.5, 28.4, 28.2, 24.3, 24.1, 22.8, 22.5, 21.6 (d, J=1.3 Hz), 21.0, 19.2, 18.8, 11.8. 
31P-NMR (162 MHz, C6D6) δ: 49.0. 
MS (70 eV, EI) m/z (%): 586 (12) [M+], 369 (16), 368 (27), 220 (15), 219 (73), 218 (100), 
186 (16), 185 (17), 183 (17), 140 (10), 108 (11. 
IR (ATR) ν~  (cm-1): 2948 (m), 2930 (s), 2888 (m), 2866 (m), 2847 (m), 1463 (m), 1436 (s), 
1375 (w), 1101 (s), 827 (w), 778 (m), 751 (m), 742 (m), 732 (m), 709 (vs), 691 (vs). 
HRMS (EI) for C39H55PS (586.3762): 586.3752. 
 
(β-cholestanyl)(methyl)sulfane (β-(eq)-97) (Table 2) 
H
H H
MeS
H
 
column chromatography: SiO2; i-hexane/CH2Cl2 20:1 
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yield: 153 mg (74%), white solid 
d.r.: 2:98. 
m.p.: 79.4 – 81.5 °C. 
1H-NMR (400 MHz, C6D6) δ: 2.45–2.37 (m, 1 H), 2.04–1.98 (m, 1 H), 1.91 (s, 3 H), 1.89–
1.80 (m, 2 H), 1.68–1.48 (m, 6 H), 1.48–1.28 (m, 6 H), 1.27–1.07 (m, 10 H), 1.03 (d, J=6.4 
Hz, 3 H), 0.94 (d, J=6.6 Hz, 6 H), 0.90–0.77 (m, 2 H), 0.69 (d, J=11.4 Hz, 6 H), 0.56 (td, 
J1=11.2 Hz, J2=4.0 Hz, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 57.2, 57.1, 55.1, 47.5, 45.5, 43.3, 40.8, 40.3, 39.5, 37.0, 36.6, 
36.4, 36.3, 36.1, 32.8, 29.8, 29.4, 29.0, 28.8, 24.9, 24.7, 23.4, 23.1, 21.8, 19.4, 13.4, 12.7. 
MS (70 eV, EI) m/z (%): 418 (100) [M+], 404 (11), 372 (10), 371 (11), 278 (10), 264 (11), 
263 (18), 215 (10), 107 (14), 95 (15), 93 (11), 81 (14), 69 (10), 57 (14), 55 (14), 43 (15). 
IR (ATR) ν~  (cm-1): 2954 (s), 2928 (vs), 2863 (s), 2850 (s), 2360 (w), 1739 (m), 1467 (s), 
1458 (s), 1443 (m), 1424 (w), 1383 (m), 1379 (m), 1365 (m), 1350 (w), 1232 (w), 1216 (m), 
1163 (w), 1155 (w), 961 (w), 954 (w). 
HRMS (EI) for C28H50S (418.3633): 418.3626. 
 
butyl (4-methoxycyclohexyl)sulfane (85b) (Table 3) 
 
column chromatography: SiO2; i-hexane/Et2O 25:1 
yield: 68 mg (67%), colourless oil 
d.r.: 52:48. 
1H-NMR (300 MHz, CDCl3) δ: 3.30 (s, 3 H), 3.16–3.07 (m, 1 H), 2.60–2.55 (m, 1 H), 2.50 
(t, J=7.5 Hz, 2 H), 2.07–2.01 (m, 4 H), 1.58–1.48 (m, 2 H), 1.41–1.33 (m, 2 H), 1.32–1.21 (m, 
4 H), 0.88 (t, J=7.2 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 78.6, 55.9, 42.6, 32.3, 31.6, 30.4, 22.3, 13.9. 
MS (70 eV, EI) m/z (%): 202 (90) [M+], 170 (20), 145 (23), 114 (28), 113 (48), 112 (100), 
111 (28), 97 (27), 81 (65), 79 (17), 41 (13). 
IR (ATR) ν~  (cm-1): 2931, 2858, 1451, 1374, 1187, 1099, 1024, 933, 746. 
HRMS (EI) for C11H22OS (202.1391): 202.1386.  
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((1S,2S,5R)-2-isopropyl-5-methylcyclohexyl)(methyl)sulfane (neomen-(ax)-91a) (Table 3) 
SMe
 
column chromatography: SiO2; i-hexane 
yield: 21 mg (23%), colourless oil 
d.r.: 93:7. 
1H-NMR (400 MHz, C6D6) δ: 2.86 (d, J=1.9 Hz, 1 H), 2.18–2.03 (m, 1 H), 1.93–1.86 (m, 1 
H), 1.86–1.81 (m, 1 H), 1.80 (s, 3 H), 1.71–1.62 (m, 2 H), 1.38–1.27 (m, 2 H), 1.05–1.00 (m, 
1 H), 0.98 (d, J=6.3 Hz, 3 H), 0.90 (d, J=6.6 Hz, 3 H), 0.89 (d, J=6.6 Hz, 3 H), 0.87–0.74 (m, 
2 H). 
13C-NMR (101 MHz, C6D6) δ: 49.6, 49.2, 40.4, 36.1, 30.8, 27.0, 26.8, 22.9, 21.7, 21.3, 15.4. 
MS (70 eV, EI) m/z (%): 186 (52) [M+], 139 (26), 138 (73), 123 (27), 101 (16), 97 (32), 96 
(22), 95 (100), 94 (10), 83 (69), 82 (21), 81 (50), 79 (11), 69 (38), 68 (12), 67 (27), 61 (10), 
57 (37), 55 (53), 53 (14), 43 (24), 41 (46), 39 (12), 29 (11), 27 (10). 
IR (ATR) ν~  (cm-1): 2946 (s), 2913 (vs), 2868 (m), 2840 (m), 2360 (w), 1474 (m), 1455 (m), 
1444 (m), 1383 (w), 1366 (w), 1297 (w), 1281 (w), 1264 (w), 1241 (w), 863 (w), 859 (w). 
HRMS (EI) for C11H22S (186.1442): 186.1437. 
 
((1S,2S,5R)-2-isopropyl-5-methylcyclohexyl)diphenylphosphine sulfide (neomen-(ax)-
91b) (Table 3) 
 
column chromatography: SiO2; i-hexane/Et2O 30:1 
yield: 50 mg (28%), white solid 
d.r.: 91:9. 
m.p.: 139.3 – 141.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.18–8.11 (m, 2 H), 8.11–8.05 (m, 2 H), 7.06–6.96 (m, 6 H), 
3.17–3.09 (m, 1 H), 3.09–2.96 (m, 1 H), 2.68–2.52 (m, 1 H), 2.09 (sxt, J=6.6 Hz, 1 H), 2.02–
1.87 (m, 2 H), 1.66–1.42 (m, 2 H), 1.25–1.07 (m, 1 H), 0.97–0.89 (m, 1 H), 0.87 (d, J=6.8 Hz, 
3 H), 0.67 (d, J=6.6 Hz, 3 H), 0.58 (d, J=6.4 Hz, 3 H). 
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13C-NMR (101 MHz, C6D6) δ: 134.8 (d, J=72.9 Hz), 134.7 (d, J=75.1 Hz), 131.9 (d, J=9.4 
Hz), 131.6 (d, J=9.0 Hz), 130.5 (d, J=3.0 Hz), 130.4 (d, J=2.9 Hz), 128.0 (d, J=11.3 Hz), 
127.9 (d, J=11.4 Hz), 48.5 (br), 37.3 (br), 36.8 (d, J=52.1 Hz), 34.8 (br), 29.1 (d, J=3.4 Hz), 
27.0 (d, J=3.7 Hz), 23.4 (d, J=2.9 Hz), 23.2, 21.9 (s, br), 20.9. 
31P-NMR (162 MHz, C6D6) δ: 49.5, 43.5. 
MS (70 eV, EI) m/z (%): 356 (6) [M+], 219 (25), 218 (100), 183 (10). 
IR (ATR) ν~  (cm-1): 2950 (w), 2943 (m), 2936 (m), 2916 (w), 2894 (w), 2842 (w), 1476 (w), 
1454 (w), 1438 (m), 1367 (w), 1090 (s), 998 (w), 756 (m), 743 (m), 716 (s), 700 (vs), 690 
(vs), 680 (s). 
HRMS (EI) for C22H29PS (356.1728): 356.1722. 
 
butyl (cis-2-methylcyclohexyl)sulfane (cis-(ax)-100) (Table 3) 
 
column chromatography: SiO2; i-hexane 
yield: 32 mg (34%), colourless oil 
d.r.: 88:12. 
1H-NMR (400 MHz, C6D6) δ: 2.71–2.65 (m, 1 H), 2.35 (t, J=7.4 Hz, 2 H), 1.83–1.69 (m, 3 
H), 1.59–1.42 (m, 5 H), 1.36–1.27 (m, 4 H), 1.27–1.14 (m, 1 H), 1.08 (d, J=6.8 Hz, 3 H), 0.81 
(t, J=7.4 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 50.6, 36.0, 32.9, 32.4, 32.1, 31.8, 24.8, 23.6, 22.7, 18.6, 14.2. 
MS (70 eV, EI) m/z (%): 186 (9) [M+], 146 (10), 145 (100), 103 (19), 97 (20), 96 (16), 87 
(13), 81 (12), 61 (24), 57 (12), 55 (41), 41 (16), 29 (12). 
IR (ATR) ν~  (cm-1): 2957 (s), 2927 (vs), 2870 (m), 2854 (m), 1739 (m), 1454 (m), 1445 (m), 
1377 (m), 1366 (w), 1353 (w), 1228 (w), 1217 (m). 
HRMS (EI) for C11H22S (186.1442):186.1440. 
 
(α-cholestanyl)(methyl)sulfane (α-(ax)-97) (Table 3) 
H
H H
MeS
H
 
column chromatography: SiO2; i-hexane 
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yield: 38 mg (18%), colourless oil 
d.r.: 77:23. 
1H-NMR (400 MHz, C6D6) δ: 2.85 (br. s., 1 H), 1.99 (dt, J1=12.3 Hz, J2=3.1 Hz, 1 H), 1.89–
1.83 (m, 1 H), 1.83 (s, 3 H), 1.81–1.72 (m, 1 H), 1.72–1.68 (m, 1 H), 1.66–1.49 (m, 7 H), 
1.49–1.36 (m, 6 H), 1.29–1.15 (m, 9 H), 1.13–1.05 (m, 4 H), 1.01 (d, J=6.4 Hz, 3 H), 0.92 (d, 
J=6.4 Hz, 6 H), 0.75 (s, 3 H), 0.70–0.66 (m, 4 H). 
13C-NMR (101 MHz, C6D6) δ: 57.1, 57.0, 54.7, 47.5, 45.5, 43.3, 41.2, 40.7, 40.3, 37.0, 36.7, 
36.2, 34.1, 33.9, 32.6, 29.4, 29.0, 28.8, 27.0, 24.9, 24.8, 23.4, 23.2, 21.6, 19.4, 15.4, 12.8, 
12.4. 
MS (70 eV, EI) m/z (%): 418 (51) [M+], 371 (38), 370 (100), 355 (23), 263 (11), 257 (12), 
217 (13), 216 (11), 215 (20), 109 (11), 107 (13), 95 (15), 81 (11). 
IR (ATR) ν~  (cm-1): 2926 (vs), 2868 (s), 2851 (s), 1467 (m), 1462 (m), 1452 (m), 1442 (m), 
1434 (m), 1379 (m), 1366 (m), 1278 (w), 1258 (w), 1167 (w), 968 (w), 952 (m). 
HRMS (EI) for C28H50S (418.3633): 418.3632. 
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3. Novel Insights into the Stereochemical Behaviour of Diastereomeric 
Cyclohexylzinc Reagents – Stereoconvergence through Distinct 
Stereochemical Pathways 
3.1. Deuterolysis and Protolysis Experiments 
3.1.1. Typical Procedure 3: Deuterolysis of organozinc reagents (TP 3) 
            (Compounds of Scheme 31 and Table 5) 
 
An in vacuo dried, Ar-flushed 10 mL Schlenk- flask, equipped with a magnetic stirring bar 
was charged with the respective cyclohexylzinc compound (0.25 mmol, 1.0 equiv.). The flask 
was then cooled to the corresponding temperature, stirred for 10 min at that temperature 
before d-TFA (10 equiv.) or MeOD (10 equiv.) were added neat. After 20 min, the reaction 
was quenched with NH4Cl sat. solution (2 mL). It was neutralized with NaHCO3 sat. solution. 
Phases were separated followed by extracting the aqueous phase with 1 mL Et2O (2 x). The 
org. phases were combined, dried over Na2SO4. The solution was concentrated at the rotary 
evaporator (careful! Products are volatile!) to 0.6 mL. These were transferred into an NMR 
tube and analyzed. 
 
2-[trans-(2-2H1)cyclohexyl]-5,5-dimethyl-1,3-dioxane (trans-(eq)-114) 
& 
2-[cis-(2-2H1)cyclohexyl]-5,5-dimethyl-1,3-dioxane (cis-(eq)-114) 
 
 
from trans-(eq)-107 (deuterolysis at rt with d-TFA): 
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d.r.: 98:2. 
2H-NMR (61 MHz, THF) δ: 2.18 (s, 1 D) (major), 1.50 (s, 1 D) (minor). 
 
from 108 (deuterolysis at rt with d-TFA): 
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d.r.: 69:31. 
2H-NMR (61 MHz, THF) δ: 2.34 (s, 1 D) (major), 1.58 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
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d.r.: 99:1. 
2H-NMR (61 MHz, THF) δ: 2.34 (s, 1 D) (major), 1.68 (s, 1 D) (minor). 
 
(deuterolysis at rt with MeOD) 
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d.r.: 99:1. 
2H-NMR (61 MHz, THF) δ: 2.30 (s, 1 D) (major), 1.62 (s, 1 D) (minor). 
 
trans-methyl(2-2H1)cyclohexane (trans-(eq)-116) 
& cis-methyl(2-2H1)cyclohexane (cis-(eq)-116) 
 
(deuterolysis at rt with d-TFA) 
 
 
d.r.: 48:52. 
2H-NMR (61 MHz, THF) δ: 2.11 (s, 1 D) (major), 1.33 (s, 1 D) (minor). 
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(deuterolysis at -78 oC with d-TFA) 
 
 
d.r.: 96:4. 
2H-NMR (61 MHz, THF) δ: 2.11 (s, 1 D) (major), 1.37 (s, 1 D) (minor). 
 
(deuterolysis at rt with MeOD) 
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d.r.: 87:13. 
2H-NMR (61 MHz, THF) δ: 2.10 (s, 1 D) (major), 1.32 (s, 1 D) (minor). 
 
(deuterolysis at 0oC with MeOD) 
 
 
d.r.: 97:3. 
2H-NMR (61 MHz, THF) δ: 2.18 (s, 1 D) (major), 1.45 (s, 1 D) (minor). 
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trans-tert-butyl(4-2H1)cyclohexane (trans-(eq)-117) 
& cis-1-(tert-butyl)-4-deuterocyclohexane (cis-(eq)-117) 
 
(deuterolysis at rt with d-TFA) 
 
d.r.: 67:33. 
2H-NMR (61 MHz, THF) δ: 2.07 (s, 1 D) (major), 1.54 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
 
d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 2.05 (s, 1 D) (major), 1.30 (s, 1 D) (minor). 
 
(deuterolysis at rt with MeOD) 
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d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 1.90 (s, 1 D) (major), 1.30 (s, 1 D) (minor). 
 
trans-methyl(4-2H1)cyclohexane (trans-(eq)-119) 
& cis-methyl(4-2H1)cyclohexane (cis-(eq)-119) 
 
(deuterolysis at rt with d-TFA) 
 
 
d.r.: 66:34. 
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2H-NMR (61 MHz, THF) δ: 2.27 (s, 1 D) (major), 1.67 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
 
 
d.r.: 76:24. 
2H-NMR (61 MHz, THF) δ: 2.23 (s, 1 D) (major), 1.74 (s, 1 D) (minor). 
 
(deuterolysis at rt with MeOD) 
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d.r.: 76:24. 
2H-NMR (61 MHz, THF) δ: 2.25 (s, 1 D) (major), 1.75 (s, 1 D) (minor). 
 
(deuterolysis at 0oC with MeOD) 
 
 
d.r.: 90:10. 
2H-NMR (61 MHz, THF) δ: 1.69 (s, 1 D) (major), 1.13 (s, 1 D) (minor). 
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trans-methyl(3-2H1)cyclohexane (cis-(eq)-121) 
& cis- methyl(3-2H1)cyclohexane (trans-(eq)-121) 
 
(deuterolysis at rt with d-TFA) 
 
 
d.r.: 65:35. 
2H-NMR (61 MHz, THF) δ: 1.54 (s, 1 D) (major), 1.12 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
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d.r.: 80:20. 
2H-NMR (61 MHz, THF) δ: 1.63 (s, 1 D) (major), 1.21 (s, 1 D) (minor). 
 
(deuterolysis at rt with MeOD) 
 
 
d.r.: 76:24. 
2H-NMR (61 MHz, THF) δ: 1.62 (s, 1 D) (major), 1.19 (s, 1 D) (minor). 
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(deuterolysis at 0 oC with MeOD) 
 
 
d.r.: 90:10. 
2H-NMR (61 MHz, THF) δ: 1.54 (s, 1 D) (major), 1.12 (s, 1 D) (minor). 
 
trans-tert-butyldimethyl(((3-2H1)cyclohexyl)oxy)silane (cis-(eq)-123) 
& cis- tert-butyldimethyl(((3-2H1)cyclohexyl)oxy)silane (trans-(eq)-123) 
 
(deuterolysis at rt with d-TFA) 
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d.r.: 58:42. 
2H-NMR (61 MHz, THF) δ: 2.07 (s, 1 D) (major), 1.63 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
 
 
d.r.: 79:21. 
2H-NMR (61 MHz, THF) δ: 2.13 (s, 1 D) (major), 1.68 (s, 1 D) (minor). 
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(deuterolysis at rt with MeOD) 
 
 
d.r.: 66:44. 
2H-NMR (61 MHz, THF) δ: 2.22 (s, 1 D) (major), 1.79 (s, 1 D) (minor). 
 
(deuterolysis at 0 oC with MeOD) 
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d.r.: 84:16. 
2H-NMR (61 MHz, THF) δ: 2.17 (s, 1 D) (major), 1.73 (s, 1 D) (minor). 
 
(1R,2R,4R)-4-methyl-1-(1-methylethyl)(2-2H1)cyclohexane (men-(eq)-125) 
& (1R,2S,4R)-4-methyl-1-(1-methylethyl)(2-2H1)cyclohexane (neomen-(ax)-125) 
 
(deuterolysis at rt with d-TFA) 
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d.r.: 65:35. 
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2H-NMR (61 MHz, THF) δ: 2.13 (s, 1 D) (major), 1.43 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
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d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 2.10 (s, 1 D) (major), 1.39 (s, 1 D) (minor). 
 
(deuterolysis at rt with MeOD) 
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d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 2.13 (s, 1 D) (major), 1.56 (s, 1 D) (minor). 
 
β-cholesteryl deuteride (β-(eq)-127) 
& α-cholesteryl deuteride (α-(ax)-127) 
 
(deuterolysis at rt with d-TFA) 
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d.r.: 82:18. 
2H-NMR (61 MHz, THF) δ: 2.13 (s, 1 D) (major), 1.56 (s, 1 D) (minor). 
 
(deuterolysis at -78 oC with d-TFA) 
 
 
d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 2.13 (s, 1 D). 
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(deuterolysis at rt with MeOD) 
 
 
d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 2.14 (s, 1 D) (major). 
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β-cholestanyl deuteride (β-(eq)-129) 
& α-cholestanyl deuteride (α-(ax)-129) 
 
(deuterolysis at rt with d-TFA) 
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d.r.: 79:21. 
2H-NMR (61 MHz, THF) δ: 1.95 (s, 1 D) (major), 1.52 (s, 1 D) (minor). 
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(deuterolysis at -78 oC with d-TFA) 
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d.r.: 99:1. 
2H-NMR (61 MHz, THF) δ: 1.96 (s, 1 D). 
 
(deuterolysis at rt with MeOD) 
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d.r.: 90:10. 
2H-NMR (61 MHz, THF) δ: 1.94 (s, 1 D) (major), 1.54 (s, 1 D) (minor). 
 
(deuterolysis at 0 oC with d-TFA) 
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d.r.: >99:1. 
2H-NMR (61 MHz, THF) δ: 1.94 (s, 1 D). 
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3.1.2. Typical Procedure 4: Protolysis of deuteron-organozinc reagents (TP 4) 
            (Compounds of Table 5) 
 
An in vacuo dried, Ar-flushed 10 mL Schlenk- flask, equipped with a magnetic stirring bar 
was charged with the respective α-deutero-cyclohexylzinc compound (0.25 mmol, 
1.0 equiv.). The flask was then cooled to the corresponding temperature, stirred for 10 min at 
that temperature before TFA (10 equiv.) or MeOH (10 equiv.) were added neat. After 20 min, 
the reaction was quenched with NH4Cl sat. solution (2 mL). It was neutralized with NaHCO3 
sat. solution. Phases were separated followed by extracting the aqueous phase with 1 mL Et2O 
(2 x). The org. phases were combined, dried over Na2SO4. The solution was concentrated at 
the rotary evaporator (careful! Products are volatile!) to 0.6 mL. These were transferred into 
an NMR tube and analyzed. 
 
 
β-cholesteryl deuteride (β-(eq)-127) 
& α-cholesteryl deuteride (α-(ax)-127) 
from α-deuterated cholesterylzinc iodide d-126 
 
 
(protolysis at rt with TFA) 
 
 C. Experimental Section  119 
 
 
d.r.: 12:88. 
2H-NMR (61 MHz, THF) δ: 1.83 (s, 1 D) (minor), 1.29 (s, 1 D) (major). 
 
trans-tert-butyl(4-2H1)cyclohexane (trans-(eq)-117) 
& cis-1-(tert-butyl)-4-deuterocyclohexane (cis-(eq)-117) 
from α-deuterated 4-tert-butylcyclohexylzinc iodide d-112 
 
 
(protolysis at rt with TFA) 
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d.r.: 36:64. 
2H-NMR (61 MHz, THF) δ: 2.08 (s, 1 D) (minor), 1.54 (s, 1 D) (major). 
 
(protolysis at -78 oC with TFA) 
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d.r.: 37:63. 
2H-NMR (61 MHz, THF) δ: 2.16 (s, 1 D) (minor), 1.63 (s, 1 D) (major). 
 
(protolysis at rt with MeOH) 
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d.r.: 13:87. 
2H-NMR (61 MHz, THF) δ: 2.12 (s, 1 D) (minor), 1.52 (s, 1 D) (major). 
 
(protolysis at 0oC with MeOH) 
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d.r.: 9:91. 
2H-NMR (61 MHz, THF) δ: 2.13 (s, 1 D) (minor), 1.52 (s, 1 D) (major). 
 
3.2. Cross-Coupling Experiments 
3.2.1. Typical Procedure 5: Diastereoselective cross-coupling with stereodefined 
cyclohexylzinc reagents produced via hydroboration and subsequent boron-zinc 
exchange (TP5) 
           (Compounds of Scheme 31 and Table 7) 
 
A dry and argon-flushed 25 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
septum was charged with the respective cyclohexenyl derivative (1.00 mmol, 1.0 equiv.) in 
THF (1 mL) and cooled to 0 °C. Et2BH (0.41 mL, 7.3 M in Me2S, 3.00 mmol, 3.0 equiv.) was 
added dropwise, the reaction mixture was allowed to warm up to room temperature and stirred 
for 48 h at that temperature. After complete hydroboration, the mixture was concentrated 
(0.1 mm Hg, 25 °C, 2 h) and Et2Zn (0.31 mL, 3.00 mmol, 3.0 equiv.) was added. After 3 h of 
stirring, a boron-zinc exchange ˃ 85 % was determined by GC-analysis of an oxidated aliqot 
(3 M NaOH, 30 % H2O2). The reaction mixture was again concentrated (0.1 mm Hg, 25 °C, 
1 h), the grey-black residue redissolved in THF (2 mL) and then added dropwise to a mixture 
of the respective electrophile (3.00 mmol, 3.0 equiv.) Pd(dba)2 (11.5 mg, 0.02 mmol, 
2.0 mol%) und S-Phos (8.20 mg, 0.02 mmol, 2.0 mol%) in THF (3 mL) at given temperature. 
After stirring for the given time and temperature the reaction mixture was quenched with sat. 
aq. NH4Cl solution (10 mL), extracted with Et2O (3 x 20 mL) and the combined organic 
layers were dried over MgSO4. The solvents were removed in vacuo and the crude product 
was purified by column chromatography (SiO2). 
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methyl-4-(trans-2-(5,5-dimethyl-1,3-dioxane-2-yl)cyclohexyl)benzoate (111a) 
 
According to TP5, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via hydroboration with Et2BH, followed by a boron-zinc exchange and 
subsequent cross-coupling (–10 °C, 12 h; then 25 °C 12 h) with methyl-4-iodobenzoate 
(786 mg, 3.00 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 20 
then 1 : 10) furnished the title compound (213 mg, 0.64 mmol, 64 %) as a colourless solid.  
d.r.: 98 : 2. 
m.p.: 81.4 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.14 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 3.93 (d, J = 
2.1 Hz, 1H), 3.47 (s, 3H), 3.32 (dd, J1 = 10.8 Hz, J2 = 2.8 Hz, 1H), 3.25 (dd, J1 = 10.8 Hz, J2 
= 2.8 Hz, 1H), 2.83 (d, J = 2.3 Hz, 1H), 2.80 (d, J = 2.3 Hz, 1H), 2.67 (td, J1 = 11.5 Hz, J2 = 
3.5 Hz, 1H), 2.32-2.36 (m, 1H), 1.83 (tt, J1 = 11.5 Hz, J2 = 2.7 Hz, 1H), 1.68-1.78 (m, 2H), 
1.57-1.61 (m, 1H), 1.20-1.31 (m, 4H), 1.05 (s, 3H), 0.14 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 166.7, 151.7, 130.1, 128.9, 101.5, 76.8, 76.8, 51.5, 47.5, 46.0, 
35.2, 29.9, 26.9, 26.1, 24.7, 22.9, 21.3. 
MS (70 eV, EI) m/z (%): 196 (29), 115 (100), 97 (11), 83 (11), 71 (11), 70 (10), 69 (52), 57 
(22), 56 (9), 55 (22), 45 (10), 44 (36), 43 (26), 41 (25). 
IR (ATR) ν~  (cm-1): 2929 (m), 2852 (m), 1717 (s), 1608 (w), 1438 (m), 1393 (m), 1270 (s), 
1184 (m), 1153 (m), 1110 (vs), 1098 (s), 1030 (m), 1017 (m), 987 (m), 973 (m), 932 (m), 852 
(w), 770 (s), 710 (s). 
HRMS (EI) for C20H28O4 (332.1988): 332.1977. 
 
2-(trans-2-(3-(trifluoromethyl)phenyl)cyclohexyl)–5,5-dimethyl-1,3-dioxane (111b) 
O
O
CF3
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According to TP5, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via hydroboration with Et2BH, followed by a boron-zinc exchange and 
subsequent cross-coupling (25 °C, 12 h) with 1-iodo-3-(trifluoromethyl)benzene (816 mg, 
3.00 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 30) furnished 
the title compound (232 mg, 0.68 mmol, 68 %) as a colourless oil.  
d.r.: 98 : 2. 
1H-NMR (400 MHz, C6D6) δ: 7.53 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 
6.95 (t, J = 7.7 Hz, 1H), 3.86 (d, J = 2.2 Hz, 1H), 3.29 (dd, J1 = 10.8 Hz, J2 = 2.9 Hz, 1H), 
3.21 (dd, J1 = 10.9 Hz, J2 = 2.8 Hz, 1H), 2.80 (d, J = 10.8 Hz, 1H), 2.74 (d, J = 11.0 Hz, 1H), 
2.62 (td, J1 = 11.5 Hz, J2 = 3.1 Hz, 1H), 2.27-2.30 (m, 1H), 1.76 (tt, J1 = 11.5 Hz, J2 = 2.8 Hz, 
1H), 1.59-1.66 (m, 1H), 1.52-1.57 (m, 2H), 1.11-1.21 (m, 4H), 1.00 (s, 3H), 0.11 (s, 3H). 
13C-NMR (75 MHz, C6D6) δ: 147.4, 131.1, 130.8 (q, J = 31.7 Hz), 129.0, 125.1 (d, J = 3.4 
Hz), 123.1 (q, J = 3.9 Hz) 101.5, 76.8, 76.8, 47.6, 45.7, 35.1, 29.9, 26.9, 26.1, 24.9, 22.9, 
21.3. 
MS (70 eV, EI) m/z (%): 207 (13), 196 (24), 159 (21), 115 (100), 81 (10), 69 (56), 57 (15), 56 
(10), 55 (22), 45 (12), 44 (48), 43 (18), 41 (28). 
IR (ATR) ν~  (cm-1): 2930 (w), 2853 (w), 1451 (w), 1394 (w), 1328 (s), 1160 (s), 1116 (vs), 
1091 (s), 1074 (s), 1042 (m), 1027 (m), 993 (m), 969 (m), 932 (w), 919 (w), 903 (w), 799 (m), 
703 (m), 664 (m). 
HRMS (EI) for C19H25F3O2 (342.1807): 342.1791. 
 
3.2.2. Typical Procedure 6: Diastereoselective cross-coupling with non-stereodefined 
cyclohexylzinc iodides produced via zinc insertion into the respective cyclohexyl 
iodide (TP6) 
           (Compounds of Scheme 31 and Table 7) 
 
In a dry and argon-flushed 25 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
septum, first LiCl (63.6 mg, 1.50 mmol, 1.5 equiv.) then Zn (196 mg, 3.00 mmol, 3.0 equiv.) 
were dried under high vacuum at 500 °C for 20 min using a heat gun. After activation with 
1,2-dibromoethane (5.0 mol%), THF (2 mL) was added and the reaction was initiated by 
carefully heating to a gentle reflux with a heat gun. Once the gas development had stopped, a 
solution of the respective iodide (1.00 mmol, 1.0 equiv.) in THF (1 mL) was added dropwise 
and the reaction mixture was stirred for 4 h at room temperature. After completion of the zinc 
 C. Experimental Section  125 
 
insertion, the reaction mixture was added dropwise to a mixture of the respective electrophile 
(0.70 mmol, 0.7 equiv.), Pd(dba)2 (11.5 mg, 0.02 mmol, 2.0 mol%) und S-Phos (8.20 mg, 
0.02 mmol, 2.0 mol%) in THF (1 mL) at the given temperature. The reaction was stirred for 
the given time and temperature, then quenched with sat. aq. NH4Cl solution (10 mL), 
extracted with Et2O (3 x 20 mL) and the combined organic layers were dried over MgSO4. 
The solvents were removed in vacuo and the crude product was purified by column 
chromatography (SiO2). 
 
methyl-4-(trans-2-(5,5-dimethyl-1,3-dioxan-2-yl)cyclohexyl)benzoate 
 
According to TP6, 2-(cis-2-iodocyclohexyl)-5,5-dimethyl-1,3-dioxane (148) (324 mg, 
1.00 mmol) was transformed via zinc insertion to the corresponding organozinc reagent 
followed by subsequent cross-coupling (–25 °C, 12 h; then –10 °C, 12 h) with methyl-4-
iodobenzoate (183 mg, 0.70 mmol). Purification by column chromatography (SiO2; Et2O/n-
pentane 1 : 10) furnished the title compound (171 mg, 0.51 mmol, 73 %) as a colourless solid.  
d.r.: > 99 : 1. 
m.p.: 80.4 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.14 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 3.93 (d, J = 
2.1 Hz, 1H), 3.47 (s, 3H), 3.32 (dd, J1 = 10.8 Hz, J2 = 2.8 Hz, 1H), 3.25 (dd, J1 = 10.8 Hz, J2 
= 2.8 Hz, 1H), 2.83 (d, J = 2.3 Hz, 1H), 2.80 (d, J = 2.3 Hz, 1H), 2.67 (td, J1 = 11.5 Hz, J2 = 
3.5 Hz, 1H), 2.32-2.36 (m, 1H), 1.83 (tt, J1 = 11.5 Hz, J2 = 2.7 Hz, 1H), 1.68-1.78 (m, 2H), 
1.57-1.61 (m, 1H), 1.20-1.31 (m, 4H), 1.05 (s, 3H), 0.14 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 166.7, 151.7, 130.1, 128.9, 101.5, 76.8, 76.8, 51.5, 47.5, 46.0, 
35.2, 29.9, 26.9, 26.1, 24.7, 22.9, 21.3. 
MS (70 eV, EI) m/z (%): 196 (29), 115 (100), 97 (11), 83 (11), 71 (11), 70 (10), 69 (52), 57 
(22), 56 (9), 55 (22), 45 (10), 44 (36), 43 (26), 41 (25). 
IR (ATR) ν~  (cm-1): 2929 (m), 2852 (m), 1717 (s), 1608 (w), 1438 (m), 1393 (m), 1270 (s), 
1184 (m), 1153 (m), 1110 (vs), 1098 (s), 1030 (m), 1017 (m), 987 (m), 973 (m), 932 (m), 852 
(w), 770 (s), 710 (s). 
HRMS (EI) for C20H28O4 (332.1988): 332.1982. 
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2-(trans-2-(3-(trifluoromethyl)phenyl)cyclohexyl)–5,5-dimethyl-1,3-dioxane 
O
O
CF3
 
According to TP6, 2-(cis-2-iodocyclohexyl)-5,5-dimethyl-1,3-dioxane (148) (324 mg, 
1.00 mmol) was transformed via zinc insertion to the corresponding organozinc reagent 
followed by subsequent cross-coupling (–25 °C, 12 h; then –10 °C, 12 h) with 1-iodo-3-
(trifluoromethyl)benzene (190 mg, 0.70 mmol). Purification by column chromatography 
(SiO2; Et2O/n-pentane 1 : 30) furnished the title compound (136 mg, 0.40 mmol, 57 %) as a 
colourless oil.  
d.r.: > 99 : 1. 
1H-NMR (400 MHz, C6D6) δ: 7.53 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 
6.95 (t, J = 7.7 Hz, 1H), 3.86 (d, J = 2.2 Hz, 1H), 3.29 (dd, J1 = 10.8 Hz, J2 = 2.9 Hz, 1H), 
3.21 (dd, J1 = 10.9 Hz, J2 = 2.8 Hz, 1H), 2.80 (d, J = 10.8 Hz, 1H), 2.74 (d, J = 11.0 Hz, 1H), 
2.62 (td, J1 = 11.5 Hz, J2 = 3.1 Hz, 1H), 2.27-2.30 (m, 1H), 1.76 (tt, J1 = 11.5 Hz, J2 = 2.8 Hz, 
1H), 1.59-1.66 (m, 1H), 1.52-1.57 (m, 2H), 1.11-1.21 (m, 4H), 1.00 (s, 3H), 0.11 (s, 3H). 
13C-NMR (75 MHz, C6D6) δ: 147.4, 131.1, 130.8 (q, J = 31.7 Hz), 129.0, 125.1 (d, J = 3.4 
Hz), 123.1 (q, J = 3.9 Hz) 101.5, 76.8, 76.8, 47.6, 45.7, 35.1, 29.9, 26.9, 26.1, 24.9, 22.9, 
21.3. 
MS (70 eV, EI) m/z (%): 207 (13), 196 (24), 159 (21), 115 (100), 81 (10), 69 (56), 57 (15), 56 
(10), 55 (22), 45 (12), 44 (48), 43 (18), 41 (28). 
IR (ATR) ν~  (cm-1): 2930 (w), 2853 (w), 1451 (w), 1394 (w), 1328 (s), 1160 (s), 1116 (vs), 
1091 (s), 1074 (s), 1042 (m), 1027 (m), 993 (m), 969 (m), 932 (w), 919 (w), 903 (w), 799 (m), 
703 (m), 664 (m). 
HRMS (EI) for C19H25F3O2 (342.1807): 342.1809. 
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4. Diastereo- and Enantioselective Cross-Coupling with Functionalized 
Cyclohexylzinc Reagents 
4.2. Diastereoselective Cross-Coupling with Functionalized Cyclohexylzinc 
Derivatives 
4.2.1. Preparation of starting materials (Scheme 34) 
 
2-iodocyclohex-2-enone (130) 
O
I
 
To a solution of cyclohex-2-enone (50.4 mL, 520 mmol) dissolved in 1.0 L THF/H2O (1 : 1) 
was added K2CO3 (86.2 g, 624 mmol), I2 (198 g, 780 mmol) und 4-(dimethylamino)pyridine 
(DMAP) (12.7 g, 104 mmol). After 2 h of stirring at 25 °C, the reaction mixture was diluted 
with 250 mL of EtOAc and then cooled to 0 °C. The reaction mixture was then slowly 
quenched with sat. aq. NaHSO3 solution (400 mL), the organic phase was extracted with 
0.1 M HCl solution (2 x 500 mL) and the combined aqueous layers were extracted with 
EtOAc (3 x 200 mL). The solvent was partly evaporated in vacuo (100 mbar, 30 °C) and the 
residue dissolved in heptane. Crystallisation at -28 °C furnished the title compound (80.1 g, 
361 mmol, 69 %) as yellow cristalls.  
m.p.: 48.4 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.00 (t, J = 4.4 Hz, 1H), 2.03-2.07 (m, 2H), 138-1.43 (m, 2H), 
1.15-1.22 (m, 2 H). 
13C-NMR (101 MHz, C6D6) δ: 190.6, 158.6, 104.5, 37.1, 29.4, 22.6. 
IR (ATR) ν~  (cm-1): 2936 (w), 1671 (vs), 1583 (s), 1422 (m), 1408 (m), 1328 (m), 1310 (s), 
1155 (m), 1119 (s), 979 (m), 966 (vs), 914 (s), 873 (m), 802 (s), 702 (s). 
 
(R)-2-iodocyclohex-2-enol (131) 
I
OH
 
A dry and argon-flushed 500 mL 2-necked Schlenk-flask, equipped with a dropping funnel, a 
magnetic stirring bar and a septum, was charged with a solution of B(OMe)3 (312 mg, 
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3.00 mmol) and (R)-diphenylprolinol (760 mg, 3.00 mmol) in THF (100 mL) and stirred for 
1 h at room temperature. After addition of 2-iodocyclohex-2-enone (130) (22.2 g, 100 mmol) 
the reaction mixture was cooled to 0 °C and borane N,N-diethylaniline complex (17.9 g, 
110 mmol) was added dropwise. The reaction mixture was then warmed to room temperature 
and stirred for additional 12 h. After addition of sat. aq. KHSO4 solution (200 mL), phases 
were separated and the aqueous phase was extracted with Et2O (2 x 200 mL). The combined 
organic layers were washed with sat. aq. KHSO4 solution, 2 M NaOH solution and sat. aq. 
NaCl solution and dried over MgSO4. Evaporation of the solvents in vacuo (˃ 200 mbar, 
30 °C) furnished the crude product (21.2 g, 94.6 mmol, 95 %), as a pale yellow oil, which was 
used in the next step without further purification.  
1H-NMR (400 MHz, C6D6) δ: 6.13 (t, J = 3.9 Hz, 1H), 3.90 (s, 1H), 1.95 (s, 1H), 1.36-1.62 
(m, 6H). 
13C-NMR (101 MHz, C6D6) δ: 140.5, 104.6, 72.0, 32.3, 29.3, 17.7. 
IR (ATR) ν~  (cm-1): 2936 (m), 2861 (w), 1626 (w), 1426 (m), 1328 (m), 1249 (m), 1161 (m), 
1077 (m), 1049 (s), 988 (s), 969 (vs), 931 (m), 903 (m), 869 (m), 827 (m), 803 (s), 773 (m), 
738 (s), 690 (m). 
 
4.2.2. Typical Procedure 7: Protection with organosilyl chlorides (TP7) 
 
A dry and Ar-flushed 250 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
septum, was charged with a solution of alcohol (R)-2-iodocyclohex-2-enol (131) (8.96 g, 
40.0 mmol, 1.0 equiv.) and imidazole (6.80 g, 100 mmol, 2.5 equiv.) in DMF (20 mL) at 
room temperature and the respective organosilyl chloride (50.0 mmol, 1.25 equiv.) was added. 
After 1 h at 25 °C, the reaction mixture was diluted with Et2O (150 mL), the organic phase 
was washed with water (100 mL), 0.5 M HCl solution (120 mL) and sat. aq. NaCl solution 
(50 mL). The solvents were evaporated in vacuo (˃ 200 mbar, 40 °C) and the crude product 
was purified via column chromatography to give the respective title compound. 
 
(R)-tert-butyl-(2-iodocyclohex-2-enyloxy)dimethylsilane 
I
OTBS
 
According to TP7, (R)-2-iodocyclohex-2-enol (131) (8.96 g, 40.0 mmol) was protected with 
tert-butyldimethylsilylchloride (TBSCl) (7.5 g, 50 mmol). Purification by column 
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chromatography (SiO2; Et2O/n-pentane 1 : 50) furnished the title compound (10.4 g, 30.8 
mmol, 77 %) as a slightly yellow oil.  
1H-NMR (400 MHz, C6D6) δ: 6.20 (d, J = 3.7 Hz, 1H), 4.08 (s, 1H), 1.57 (d, J = 6.0 Hz, 5H), 
1.19-1.24 (m, 1H), 1.03 (s, 9H), 0.27 (s, 3H), 0.06 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 140.3, 103.8, 73.0, 33.7, 29.3, 26.2, 25.9, 18.4, 17.5, -4.0, 
-4.2. 
MS (70 eV, EI) m/z (%): 283 (11), 282 (40), 281 (30), 185 (81), 153 (41), 79 (22), 75 (100), 
73 (13). 
IR (ATR) ν~  (cm-1): 2948 (m), 2928 (m), 2856 (w), 1472 (w), 1360 (w), 1250 (m), 1163 (w), 
1088 (s), 1060 (m), 1019 (s), 989 (m), 936 (w), 911 (m), 891 (m), 826 (s), 812 (s), 772 (vs), 
712 (m), 695 (w), 667 (m). 
HRMS (EI) for C12H23IOSi (338.0563): 338.0454. 
 
(R)-(2-iodocyclohex-2-enyloxy)triphenylsilane 
I
O
SiPh3
 
According to TP7, (R)-2-iodocyclohex-2-enol (131) (8.96 g, 40.0 mmol) was protected with 
triphenylsilylchloride (14.7 g, 50 mmol). Purification by column chromatography (SiO2; 
Et2O/n-pentane 1 : 100) furnished the title compound (11.8 g, 24.5 mmol, 61 %) as a 
colourless solid.  
m.p.: 77.9 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.71-7.75 (m, 6H), 7.36-7.49 (m, 9H), 6.52 (t, J = 3.9 Hz, 
1H), 4.33 (t, J = 4.5 Hz, 1H), 2.10-2.20 (m, 1H), 1.72-2.04 (m, 4H), 1.53-1.61 (m, 1H). 
13C-NMR (75 MHz, CDCl3) δ: 141.0, 135.8, 135.6, 135.4, 135.4, 135.2, 134.3, 130.0, 129.8, 
127.9, 127.7, 102.2, 73.8, 33.2, 29.4, 17.4. 
MS (70 eV, EI) m/z (%): 405 (14), 404 (25), 403 (23), 355 (15), 309 (18), 277 (27), 276 (12), 
260 (25), 259 (100), 217 (22), 200 (11), 199 (58), 197 (13), 182 (11), 181 (40), 180 (10), 155 
(10), 105 (13), 91 (10), 77 (17). 
IR (ATR) ν~  (cm-1): 3066 (vw), 2945 (w), 2923 (w), 1589 (vw), 1484 (vw), 1428 (m), 1176 
(vw), 1160 (w), 1115 (s), 1094 (s), 1056 (m), 1019 (m), 998 (m), 936 (w), 910 (w), 897 (w), 
844 (w), 811 (w), 797 (w), , 739 (m), 705 (s), 697 (vs). 
HRMS (EI) for C24H23IOSi (482.0563): 482.0553. 
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(R)-tert-butyl-(2-iodocyclohex-2-enyloxy)diphenylsilane 
I
OTBDPS
 
According to TP7, (R)-2-iodocyclohex-2-enol (131) (8.96 g, 40.0 mmol) was protected with 
tert-butyldiphenylsilylchloride (TBDPSCl) (13.7 g, 50.0 mmol). Purification by column 
chromatography (SiO2; Et2O/n-pentane 1 : 50) furnished the title compound (16.1 g, 
34.8 mmol, 87 %) as a colourless solid.  
m.p.: ˂ 30 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.94-7.96 (m, 2H), 7.84-7.86 (m, 2H), 7.22-7.28 (m, 6H), 6.23 
(t, J = 3.7 Hz, 1H), 4.28 (d, J = 4.4 Hz, 1H), 1.50-1.64 (m, 3H), 1.35-1.43 (m, 2H), 1.28 (s, 
9H), 1.02-1.09 (m, 1H). 
13C-NMR (101 MHz, C6D6) δ: 140.8, 136.8, 136.4, 136.2, 135.9, 135.2, 134.9, 133.6, 130.1, 
129.9, 127.9, 127.8, 102.8, 74.1, 33.1, 29.3, 27.5, 19.9, 17.5, 1.4. 
MS (70 eV, EI) m/z (%): 406 (24), 405 (100), 309 (86), 277 (10), 249 (31), 200 (15), 199 
(78), 181 (22), 157 (14), 77 (12). 
IR (ATR) ν~  (cm-1): 2929 (m), 2856 (m), 1106 (s), 1080 (s), 1056 (s), 1013 (s), 1005 (s), 821 
(m), 794.00 (m), 740 (m), 720 (m), 699 (vs), 612(s). 
HRMS (EI) for C22H27IOSi (462.0876): 462.0871. 
 
4.2.3. Typical Procedure 8: Cross-coupling of silyl-protected (R)-2-iodocyclohex-2-enol 
derivatives (TP8) (Schemes 34 and 35) 
 
In a dry and Ar-flushed 25 mL Schlenk-flask LiCl (5.0 equiv.) und ZnCl2 (2.5 equiv.) were 
dried under high vacuum at 500 °C using a heat gun for 20 min. After cooling to room 
temperature, anhydrous NEP (N-ethyl-2-pyrrolidone) (5.5 equiv.) was added and stirring was 
continued until the salts were dissolved. The solution was cooled to 0 °C, anhydrous THF (0.6 
M) was added followed by dropwise addition of the freshly titrated organomagnesium 
solution (5.0 equiv.). After warming up to room temperature, the aryl iodide (1.0 equiv.) and 
bis[4-(di-tert-butylphosphine)-N,N-dimethylphenylamino]palladium-dichloride (0.5 mol%) 
were added and the mixture was heated to 60 °C and left to stir overnight at that temperature. 
The reaction mixture was then quenched with sat. aq. NH4Cl solution, extracted with Et2O 
and dried over MgSO4. The solvents were removed in vacuo and the crude product was 
subjected to column chromatography. 
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(R)-tert-butyldimethyl-(2-methylcyclohex-2-enyloxy)silane (132) 
 
According to TP8, LiCl (1.70 g, 40 mmol) und ZnCl2 (2.73 g, 20 mmol) were dried, dissolved 
in NEP (5.3 mL) and THF (13.3 mL) was added at 0 °C. After complete addition of MeMgCl 
(20.3 mL, 1.97 M in THF, 40 mmol) at 0 °C the reaction mixture was warmed to room 
temperature, (R)-tert-butyl-(2-iodocyclohex-2-enyloxy)dimethyl-silane (2.71 g, 8.00 mmol) 
and Bis[4-(di-tert-butylphosphine)-N,N-dimethylphenylamino]palladium-dichloride (28.3 mg, 
0.04 mmol) were added and the mixture was heated to 60 °C and left to stir overnight at that 
temperature. Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 50) furnished 
the title compound (1.48 g, 6.56 mmol, 82 %) as a colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 5.42 (s, 1H), 3.96-3.97 (m, 1H), 1.88-1.92 (m, 1H), 1.77-1.80 
(m, 4H), 1.65-1.72 (m, 3H), 1.37-1.44 (m, 1H), 1.00 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 136.4, 124.4, 69.6, 33.4, 26.1, 25.9, 25.8, 21.3, 19.4, 18.3, -
4.2, -4.7. 
MS (70 eV, EI) m/z (%): 226 (12), 169 (49), 93 (37), 77 (10), 75 (100), 73 (11), 41 (11). 
IR (ATR) ν~  (cm-1): 2930 (m), 2857 (m), 1472 (w), 1462 (w), 1439 (w), 1361 (w), 1250 (m), 
1152 (w), 1083 (s), 1072 (s), 1038 (m), 1019 (m), 1003 (s), 963 (w), 939 (w), 893 (s), 832 
(vs), 807 (m), 771 (vs), 669 (m). 
HRMS (EI) for C13H26OSi (226.1753): 226.1754. 
 
(R)-triphenyl-(2-phenylcyclohex-2-enyloxy)silane  
 
According to TP8, LiCl (233 mg, 5.50 mmol) und ZnCl2 (375 mg, 2.75 mmol) were dried, 
dissolved in NEP (0.7 mL) and THF (1.8 mL) was added at 0 °C. After complete addition of 
PhMgCl (3.14 mL, 1.75 M in THF, 5.50 mmol) at 0 °C the reaction mixture was warmed to 
room temperature, (R)-(2-iodocyclohex-2-enyloxy)triphenylsilane (531 mg, 1.10 mmol) and 
Bis[4-(di-tert-butylphosphin)-N,N-dimethylphenylamino]palladium-dichloride (3.54 mg, 
0.005 mmol) were added and the mixture was heated to 60 °C and left to stir overnight at that 
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temperature. Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 100) 
furnished the title compound (0.39 mg, 0.90 mmol, 82 %) as a colourless solid.  
m.p.: 64.6 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.52-7.54 (m, 7H), 7.07-7.20 (m, 13H), 5.89-5.91 (m, 1H), 
4.90 (d, J = 4.0 Hz, 1H), 1.85-2.05 (m, 3H), 1.75-1.82 (m, 1H), 1.45-1.53 (m, 1H), 1.32-1.38 
(m, 1H). 
13C-NMR (101 MHz, C6D6) δ: 142.0, 140.7, 136.3, 136.0, 135.8, 135.6, 135.5, 135.3, 130.3, 
130.3, 130.0, 128.5, 128.4, 127.3, 126.9, 67.9, 32.8, 26.3, 17.9, 1.4. 
MS (70 eV, EI) m/z (%): 432 (12), 354 (11), 326 (20), 289 (12), 260 (24), 259 (100), 217 
(15), 199 (45), 181 (20), 156 (57). 
IR (ATR) ν~  (cm-1): 3060 (vw), 2933 (w), 1428 (w), 1260 (m), 1114 (s), 1106 (s), 1064 (s), 
1013 (s), 800 (s), 739 (m), 705 (s), 695 (vs). 
HRMS (EI) for C30H28OSi (432.1909): 432.1913. 
 
(R)-(2-cyclohexylcyclohex-2-enyloxy)triphenylsilane (136) 
 
According to TP8, LiCl (1.70 g, 40.0 mmol) und ZnCl2 (2.73 g, 20.0 mmol) were dried, 
dissolved in NEP (5.3 mL) and THF (13.3 mL) was added at 0 °C. After complete addition of 
c-HexMgBr (60.6 mL, 0.66 M in THF, 40.0 mmol) at 0 °C the reaction mixture was warmed 
to room temperature, (R)-(2-iodocyclohex-2-enyloxy)triphenylsilane (3.86 g, 8.00 mmol) and 
Bis[4-(di-tert-butylphosphine)-N,N-dimethylphenylamino]palladium-dichloride (28.3 mg, 
0.04 mmol) were added and the mixture was heated to 60 °C and left to stir for 6 h at that 
temperature. Purification by column chromatography (SiO2; EtOAc/n-pentane 1 : 300 then 1 : 
200) furnished the title compound (1.66 g, 3.78 mmol, 47 %) as a colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 7.78-7.84 (m, 6H), 7.20-7.21 (m, 9H), 5.54 (t, J = 3.5 Hz, 1H), 
4.50 (d, J = 4.4 Hz, 1H), 2.22 (t, J = 11.2 Hz, 1H), 1.87-2.06 (m, 4H), 1.74-1.84 (m, 2H), 
1.54-1.66 (m, 4H), 1.33-1.39 (m, 1H), 1.05-1.27 (m, 4H), 0.85-0.94 (m, 1H). 
13C-NMR (101 MHz, C6D6) δ: 145.2, 136.0, 135.9, 135.8, 135.6, 135.1, 131.0, 130.2, 129.5, 
128.1, 127.9, 122.3, 68.6, 40.6, 34.2, 33.1, 32.2, 27.3, 26.9, 25.8, 18.6. 
MS (70 eV, EI) m/z (%): 438 (12), 356 (20), 355 (68), 260 (20), 259 (100), 199 (39), 181 
(10). 
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IR (ATR) ν~  (cm-1): 2923 (m), 2850 (w), 1428 (m), 1114 (s), 1058 (m), 1029 (m), 1012 (m), 
997 (m), 928 (w), 801 (w), 739 (m), 708 (s), 696 (vs). 
HRMS (EI) for C30H34OSi (438.2379): 438.2372. 
 
(R)-tert-butyl(2-cyclohexylcyclohex-2-enyloxy)diphenylsilane (137) 
 
According to TP8, LiCl (1.70 g, 40.0 mmol) und ZnCl2 (2.73 g, 20.0 mmol) were dried, 
dissolved in NEP (5.3 mL) and THF (13.3 mL) was added at 0 °C. After complete addition of 
c-HexMgBr (60.6 mL, 0.66 M in THF, 40.0 mmol) at 0 °C the reaction mixture was warmed 
to room temperature, ((R)-tert-butyl-(2-iodocyclohex-2-enyloxy)diphenylsilane (3.70 g, 
8.00 mmol)  and Bis[4-(di-tert-butylphosphine)-N,N-dimethylphenylamino]palladium-
dichloride (28.3 mg, 0.04 mmol) were added and the mixture was heated to 60 °C and left to 
stir for 6 h at that temperature. Purification by column chromatography (SiO2; EtOAc/n-
pentane 1 : 300 then 1 : 200) furnished the title compound (1.27 g, 3.04 mmol, 38 %) as a 
colourless solid.  
m.p.: ˂ 30 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.82-7.85 (m, 4H), 7.22-7.24 (m, 6H), 5.50 (t, J = 3.5 Hz, 1H), 
4.31 (t, J = 4.2 Hz, 1H), 2.15 (t, J = 11.2 Hz, 1H), 2.02 (dd, J1 = 16.7 Hz, J2 = 4.4 Hz, 1H), 
1.75-1.95 (m, 5H), 1.59 (d, J = 12.7 Hz, 3H), 1.29-1.51 (m, 4H), 1.21 (s, 9H), 1.08-1.12 (m, 
2H), 0.77-0.88 (m, 1H). 
13C-NMR (101 MHz, C6D6) δ: 145.4, 136.4, 135.1, 134.7, 129.8, 127.8, 122.0, 68.2, 40.3, 
34.3, 32.9, 31.9, 27.4, 27.3, 26.9, 25.8, 19.7, 18.5. 
MS (70 eV, EI) m/z (%): 362 (31), 361 (100), 201 (12), 200 (42), 199 (55). 
IR (ATR) ν~  (cm-1): 2924 (m), 2852 (m), 1427 (w), 1109 (m), 1060 (s), 1021 (s), 822 (m), 
738 (m), 699 (vs), 606 (m). 
HRMS (EI) for C28H38OSi (418.2692): 418.2682. 
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4.2.4. Typical Procedure 9: Protection of cyclohex-2-encarboxaldehyde and 
acetylcycloalk-2-ene (TP9) (Schemes 37 and 38) 
 
A 250 mL 2-neck flask, equipped with a magnetic stirring bar, a reflux condenser, a Dean-
Stark-condenser and a drying tube, was charged with the respective α,β-unsaturated carbonyl 
compound (45.4 mmol, 1.0 equiv.), MgSO4 (5.46 g, 45.4 mmol, 1.0 equiv.), L-tartaric acid 
(41.5 mg, 0.27 mmol, 0.6 mol%) and benzene (60 mL). The respective diol (123 mmol, 
2.7 equiv.) was added portionwise at room temperature and the reaction mixture was heated to 
reflux at 115 °C for 12 h. After cooling to 0 °C, NaHCO3 (45.3 mg, 0.54 mmol, 1.2 mol%) 
was added as a solid and the reaction mixture was stirred for additional 30 min. The reaction 
mixture was then filtrated over NaHCO3 and washed with CH2Cl2. The solvents were 
removed in vacuo and the crude product was subjected to column chromatography. 
 
2-cyclohex-1-enyl-1,3-dioxolane (138) 
 
According to TP9, 1-cyclohexen-1-carboxaldehyde (5.00 g, 45.4 mmol) was protected with 
1,2-ethane diole (7.63 g, 6.87 mL, 123 mmol). Purification by column chromatography (SiO2; 
Et2O/n-pentane 1 : 20) furnished the title compound (6.65 g, 43.1 mmol, 95 %) as a colourless 
oil.  
1H-NMR (300 MHz, C6D6) δ: 5.88 (m, 1H), 5.15 (s, 1H), 3.39-3.63 (m, 4H), 2.18-2.23 (m, 
2H), 1.87 (qd, J1 = 6.0 Hz, J2 = 2.5 Hz, 2H), 1.39-1.57 (m, 4H). 
13C-NMR (75 MHz, C6D6) δ: 135.9, 127.4, 106.9, 65.2, 25.1, 22.8, 22.6, 22.4. 
MS (70 eV, EI) m/z (%): 154 (92), 153 (95), 126 (18), 125 (100), 99 (11), 43 (19). 
IR (ATR) ν~  (cm-1): 2928 (m), 2860 (m), 1684 (w), 1438 (w), 1394 (w), 1372 (w), 1300 (w), 
1190 (m), 1137 (w), 1093 (s), 1071 (vs), 1042 (s), 943 (s), 837 (s), 801 (m), 690 (m). 
HRMS (EI) for C9H14O2 (154.0994): 154.0986. 
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2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) 
 
According to TP9, 1-cyclohexen-1-carboxaldehyde (5.00 g, 45.4 mmol) was protected with 
2,2-dimethylpropane-1,3-diole (12.8 g, 123 mmol). Purification by column chromatography 
(SiO2; Et2O/n-pentane 1 : 10) furnished the title compound (8.36 g, 42.6 mmol, 94 %) as a 
colourless oil.  
1H-NMR (300 MHz, C6D6) δ: 5.99 (s, 1H), 4.67 (s, 1H), 3.49 (d, J = 10.8 Hz, 2H), 3.21 (d, J 
= 10.5 Hz, 2H), 2.35-2.40 (m, 2H), 1.92-1.97 (m, 2H), 1.42-1.61 (m, 4H), 1.18 (s, 3H), 0.34 
(s, 3H). 
13C-NMR (75 MHz, C6D6) δ: 136.5, 125.3, 104.4, 77.2, 30.0, 25.1, 23.6, 23.1, 22.8, 22.7, 
21.7. 
MS (70 eV, EI) m/z (%): 196 (94), 195 (29), 167 (68), 111 (65), 110 (44), 109 (37), 81 (48), 
69 (100), 67 (52), 56 (22), 55 (22), 41 (35). 
IR (ATR) ν~  (cm-1): 2929 (m), 2839 (m), 1470 (w), 1390 (m), 1362 (w), 1184 (m), 1100 (vs), 
1015 (m), 979 (s), 911 (m), 838 (m), 801 (w), 644 (w). 
HRMS (EI) for C12H20O2 (196.1463): 196.1461. 
 
2-cyclohex-1-enyl-2-methyl-1,3-dioxolane (149) 
 
According to TP9, 1-cyclohexenylethanone (12.4 g, 100 mmol) was protected with 1,2-ethane 
diol (16.8 g, 15.1 mL, 270 mmol) Purification by column chromatography (SiO2; Et2O/n-
pentane 1 : 30) furnished the title compound (10.4 g, 61.8 mmol, 62 %) as a colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 6.02 (dt, J1 = 3.6 Hz, J2 = 1.9 Hz, 1H), 3.46-3.61 (m, 4H), 2.09 
(qd, J1 = 4.0, J2 = 2.0 Hz, 2H), 1.92-1.96 (m, 2H), 1.51-1.57 (m, 5H), 1.41-1.47 (m, 2H). 
13C-NMR (101 MHz, C6D6) δ: 138.6, 122.0, 109,6, 64.3, 25.0, 24.3, 23.1, 22.7. 
MS (70 eV, EI) m/z (%): 154 (10), 153 (43), 109 (16), 87 (100), 81 (23), 43 (28). 
IR (ATR) ν~  (cm-1): 2930 (m), 2882 (m), 1668 (w), 1439 (w), 1371 (m), 1273 (w), 1194 (s), 
1112 (m), 1076 (m), 1042 (vs), 947 (m), 924 (w), 863 (s), 805 (m). 
HRMS (EI) for C10H16O2 (168.1150): 168.1156. 
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2-cyclopent-1-enyl-2-methyl-1,3-dioxolane (150) 
 
According to TP9, 1-cyclopentenylethanone (5.00 g, 45.4 mmol) was protected with 1,2-
ethane diol (7.63 g, 6.87 mL, 123 mmol). Purification by column chromatography (SiO2; 
Et2O/n-pentane 1 : 20) furnished the title compound (5.63 g, 36.5 mmol, 80 %) as a colourless 
oil.  
1H-NMR (400 MHz, C6D6) δ: 5.77-5.79 (m, 1H), 3.52-3.62 (m, 4H), 2.37-2.42 (m, 2H), 2.23 
(tq, J1 = 7.4, J2 = 2.3 Hz, 2H), 1.74-1.82 (m, 2H), 1.57 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 146.1, 126.4, 107.7, 64.7, 32.6, 31.9, 24.4, 24.0. 
MS (70 eV, EI) m/z (%): 140 (25), 139 (61), 96 (13), 95 (100), 87 (25), 67 (12). 
IR (ATR) ν~  (cm-1): 2950 (w), 2886 (w), 2850 (w), 1444 (w), 1371 (m), 1296 (w), 1248 (w), 
1184 (s), 1105 (m), 1034 (vs), 947 (m), 863 (s), 811 (m). 
HRMS (EI) for C9H14O2 (154.0994): 154.1004. 
4.2.5. Typical Procedure 10: Preparation of alcohols via hydroboration and oxidation 
(TP10) (Schemes 37 and 38) 
 
A 1.0 M solution of the respective olefin (1.0 equiv.) in THF was placed in a dry and argon-
flushed 250 mL Schlenk-flask, equipped with a magnetic stirring bar and a septum. It was 
cooled to –10 °C and a 1.0 M solution of BH3.THF-complex (1.1 equiv.) was slowly added. 
The reaction mixture was then allowed to warm to 0 °C and stirred for 12 h. After completion 
of the hydroboration a suspension of NaBO3.4 H2O (13 equiv.) in MeOH/ H2O (2 : 1) was 
carefully added. The resulting reaction mixture was stirred for 24 h at room temperature. 
After filtration, the filtrate was dried over Na2SO4 and washed with EtOAc. The solvents were 
removed in vacuo and the crude product was subjected to column chromatography. 
 
trans-(1,3-dioxolane-2-yl)cyclohexan-1-ol (145) 
 
According to TP10, 2-cyclohex-1-enyl-1,3-dioxolane (138) (2.47 g, 16.0 mmol), dissolved in 
THF (16 mL) was reacted with BH3.THF (17.6 mL, 1.0 M in THF, 17.6 mmol). The resulting 
mixture was then oxidatively quenched with a suspension of NaBO3.4H2O (32.0 g, 208 mmol) 
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in MeOH/ H2O (2 : 1) (96 mL). Purification by column chromatography (SiO2; Et2O/n-
pentane 2 : 1 then 3 : 1) furnished the title compound (2.31 g, 13.4 mmol, 67 %) as a 
colourless oil.  
1H-NMR (400 MHz, C6D6) δ: = 4.63 (d, J = 5.2 Hz, 1H), 3.73 (s, 1H), 3.67 (td, J1 = 10.2, J2 
=  4.6 Hz, 1H), 3.33-3.40 (m, 2H), 3.17-3.25 (m, 2H), 2.09-2.16 (m, 1H), 1.81-1.85 (m, 1H), 
1.46-1.66 (m, 3H), 1.30-1.40 (m, 1H), 0.95-1.13 (m, 3H). 
13C-NMR (101 MHz, C6D6) δ: 107.6, 70.7, 64.8, 64.2, 48.1, 34.9, 26.4, 25.3, 24.7. 
MS (70 eV, EI) m/z (%): 171 (2), 154 (2), 125 (2), 91 (7), 82 (6), 81 (3), 74 (4), 73 (100), 67 
(4), 57 (2), 45 (6). 
IR (ATR) ν~  (cm-1): 2930 (m), 2857 (m), 1450 (m), 1402 (m), 1159 (m), 1120 (s), 1063 (vs), 
1030 (vs), 981 (s), 944 (s), 847 (m). 
HRMS (EI) for C9H16O3 (172.1099): 171.1031 (–H). 
 
trans-2-(5,5-dimethyl-1,3-dioxane-2-yl)cyclohexan-1-ol (146)  
 
According to TP10, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (3.93 g, 20.0 mmol), 
dissolved in THF (20 mL) was reacted with BH3.THF (22.0 mL, 1.0 M in THF, 22.0 mmol) 
The resulting mixture was then oxidatively quenched with a suspension of NaBO3.4H2O 
(40.0 g, 260 mmol) in 120 mL MeOH/ H2O (2 : 1). Purification by column chromatography 
(SiO2; Et2O/n-pentane 1 : 1 then 2 : 1) furnished the title compound (3.06 g, 14.3 mmol, 
72 %) as a colourless oil.  
1H-NMR (300 MHz, C6D6) δ: 4.31 (d, J = 4.1 Hz, 1H), 3.85 (td, J1 = 10.1 Hz, J2 = 4.6 Hz, 
2H), 3.32 (ddd, J1 = 11.1 Hz, J2 = 6.5 Hz, J3 = 2.8 Hz, 2H), 3.25 (d, J = 6.3 Hz, 1H), 3.02 (dd, 
J1 = 11.1 Hz, J2 = 2.8 Hz, 2H), 2.12-2.18 (m, 1H), 1.81.1.87 (m, 1H), 1.50-1.73 (m, 5H), 
1.31-1.45 (m, 1H), 1.06 (s, 3H), 0.25 (s, 3H). 
13C-NMR (75 MHz, C6D6) δ: 105.3, 77.2, 77.0, 70.8, 48.9, 35.3, 29.9, 26.2, 25.5, 24.8, 22.8, 
21.4. 
MS (70 eV, EI) m/z (%): 127 (29), 115 (100), 83 (33), 81 (35), 71 (20), 69 (80), 67 (21), 57 
(47), 56 (23), 55 (56), 44 (23), 43 (49), 41 (51). 
IR (ATR) ν~  (cm-1): 2924 (s), 2853 (m), 1450 (m), 1394 (m), 1161 (m), 1116 (vs), 1089 (s), 
1042 (s), 1020 (vs), 985 (s), 969 (s), 927 (m), 850 (w). 
HRMS (EI) for C12H22O3 (214.1569): could not be determined via EI-MS. 
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trans-2-(2-methyl-1,3-dioxolane-2-yl)cyclohexan-1-ol (151) 
 
According to TP10, 2-cyclohex-1-enyl-2-methyl-1,3-dioxolane (149) (5.05 g, 30.0 mmol) 
dissolved in THF (30 mL) was reacted with BH3.THF (33.0 mL, 1.0 M in THF, 33.0 mmol) 
The resulting mixture was then oxidatively quenched with a suspension of NaBO3.4H2O 
(60.0 g, 390 mmol) in 180 mL MeOH/ H2O (2 : 1). Purification by column chromatography 
(SiO2; Et2O/n-pentane 2 : 1) furnished the title compound (2.57 g, 13.8 mmol, 46 %) as a 
colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 4.50 (s, 1H), 3.62 (td, J1 = 10.2 Hz, J2 = 4.6 Hz, 1H), 3.31-
3.39 (m, 4H), 2.20-2.26 (m, 1H), 1.86-1.90 (m, 1H), 1.49-1.59 (m, 3H), 1.36-1.46 (m, 1H), 
1.20 (s, 3H), 0.90-1.12 (m, 3H). 
13C-NMR (101 MHz, C6D6) δ: 112.9, 71.3, 64.4, 63.7, 51.8, 35.6, 27.2, 26.0, 25.0, 20.1. 
MS (70 eV, EI) m/z (%): 171 (23), 88 (35), 87 (67), 81 (16), 71 (13), 43 (100), 41 (10). 
IR (ATR) ν~  (cm-1): 3508 (w), 2930 (m), 2883 (m), 2858 (m), 1450 (m), 1381 (m), 1220 (m), 
1163 (s), 1132 (s), 1101 (s), 1068 (s), 1046 (vs), 1029 (vs), 984 (m), 949 (s), 899 (m), 855 (s). 
HRMS (EI) for C10H18O3 (186.1256): could not be determined via EI-MS. 
 
trans-2-(2-methyl-1,3-dioxolane-2-yl)cyclopentan-1-ol (152) 
Me
O
O
OH
 
According to TP10, 2-cyclopent-1-enyl-2-methyl-1,3-dioxolane (150) (1.54 g, 10.0 mmol) 
dissolved in THF (10 mL) was reacted with BH3.THF (11.0 mL, 1.0 M in THF, 11.0 mmol) 
The resulting mixture was then oxidatively quenched with a suspension of NaBO3.4H2O 
(20.0 g, 130 mmol) in 60 mL MeOH/ H2O (2 : 1). Purification by column chromatography 
(SiO2; Et2O/n-pentane 2 : 1 then 3 : 1) furnished the title compound (871 mg, 5.06 mmol, 
51 %) as a colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 4.20 (q, J = 7.0 Hz, 1H), 3.43-3.44 (m, 4H), 2.62 (s, 1H), 2.07-
2.13 (m, 1H), 1.95 (td, J1 = 13.0 Hz, J2 = 7.0 Hz, 1H), 1.66-1.77 (m, 2H), 1.42-1.63 (m, 3H), 
1.2 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 111.8, 74.5, 64.7, 64.4, 56.0, 34.8, 26.6, 22.5, 22.3. 
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MS (70 eV, EI) m/z (%): 157 (13), 87 (100), 71 (10), 67 (10), 57 (13), 55 (13), 43 (46), 41 
(12). 
IR (ATR) ν~  (cm-1): 2955 (m), 2875 (m), 1448 (w), 1376 (m), 1250 (m), 1222 (m), 1156 (m), 
1073 (s), 1030 (vs), 986 (m), 948 (m), 866 (s). 
HRMS (EI) for C9H16O3 (172.1099): could not be determined via EI-MS. 
 
4.2.6. Typical Procedure 11: Preparation of functionalized cyclohexyl iodides (TP11)  
 
In a dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, 
the respective alcohol (0.26 M in THF, 1.0 equiv.) was charged and freshly prepared 
DCC.MeI (2.0 equiv.) was added at room temperature. The reaction mixture was heated to 
50 °C for 24 h. After completion of iodination the reaction mixture was diluted with Et2O. 
The layers were separated, the organic phase was extracted with water and the combined 
aqueous layers were extracted with Et2O. Then the combined organic layers were washed 
with sat. aq. NaHSO3 solution and dried over MgSO4. After removal of the solvents in vacuo 
the crude product was subjected to column chromatography. 
 
2-(cis-2-iodocyclohexyl)-1,3-dioxolane (147) 
 
According to TP11, trans-(1,3-dioxolane-2-yl)cyclohexan-1-ol (145) (1.03 g, 6.00 mmol) in 
THF (23 mL) was reacted with DCC.MeI (4.18 g, 12.0 mmol). The reaction mixture was 
heated to 50 °C for 24 h. Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 
30) furnished the title compound (1.06 g, 3.76 mmol, 63 %) as a colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 4.85 (s, 1H), 4.66 (d, J = 7.0 Hz, 1H), 3.39-3.46 (m, 2H), 3.25-
3.34 (m, 2H), 1.86-1.94 (m, 2H), 1.69-1.80 (m, 1H), 1.49-1.61 (m, 2H), 1.19-1.27 (m, 2H), 
0.96-1.08 (m, 1H), 0.52-0.58 (m, 1H). 
13C-NMR (101 MHz, C6D6) δ: 108.9, 64.8, 64.7, 46.9, 39.6, 36.4, 25.2, 24.3, 22.6. 
MS (70 eV, EI) m/z (%): 154 (100), 93 (13), 83 (11), 73 (63), 45 (13). 
IR (ATR) ν~  (cm-1): 2931 (m), 2860 (m), 1446 (m), 1254 (m), 1156 (s), 1130 (m), 1078 (vs), 
1059 (s), 1031 (s), 979 (s), 938 (s), 891 (s), 860 (m), 829 (m), 644 (m). 
HRMS (EI) for C9H15IO2 (282.0117): 282.0092. 
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2-(cis-2-iodocyclohexyl)-5,5-dimethyl-1,3-dioxane (148)  
 
According to TP11, trans-2-(5,5-dimethyl-1,3-dioxane-2-yl)cyclohexan-1-ol (146) (2.57 g, 
12.0 mmol) in THF (46 mL) was reacted with DCC.MeI (8.36 g, 24.0 mmol). The reaction 
mixture was heated to 50 °C for 24 h. Purification by column chromatography (SiO2; Et2O/n-
pentane 1 : 30) furnished the title compound (2.31 g, 7.13 mmol, 59 %) as a colourless oil.  
1H-NMR (300 MHz, C6D6) δ: 4.95 (s, 1H), 4.22 (d, J = 7.5 Hz, 1H), 3.42 (ddd, J1 = 18.0 Hz, 
J2 = 10.9 Hz, J3 = 2.9 Hz, 2H), 3.23 (d, J = 10.9 Hz, 1H), 3.08 (d, J = 10.9 Hz, 1H), 1.93-1.98 
(m, 2H), 1.69-1.84 (m, 1H), 1.48-1.58 (m, 2H), 1.22-1.36 (m, 2H), 1.13 (s, 2H), 1.05 (tt, J1 = 
13.2 Hz, J2 = 3.7 Hz, 2H), 0.78-0.86 (m, 1H), 0.29 (s, 3H). 
13C-NMR (75 MHz, C6D6) δ: 106.7, 77.2, 77.1, 46.7, 40.9, 36.4, 30.2, 25.3, 24.0, 23.2, 22.8, 
21.5. 
MS (70 eV, EI) m/z (%): 197 (46), 115 (64), 111 (25), 97 (34), 83 (100), 71 (26), 69 (96), 67 
(36), 57 (54), 56 (31), 55 (86), 41 (35), 39 (50). 
IR (ATR) ν~  (cm-1): 2928 (s), 2851 (m), 2116 (vs), 1713 (w), 1450 (m), 1391 (m), 1360 (m), 
1300 (m), 1257 (w), 1233 (w), 1166 (m), 1150 (m), 1099 (s), 1038 (s), 1022 (s), 993 (m), 976 
(s), 948 (m), 892 (m), 864 (m), 834 (w), 786 (m), 645 (m). 
HRMS (EI) for C12H21IO2 (324.0586): 323.0482 [M-H-]. 
 
4.3. Synthesis of EOM-Protected Decahydro-1-naphthalinol  
 
(R)-diethyl(2-iodocyclohex-2-en-1-yl)phosphate (165) (Scheme 43) 
I
O
P(OEt)2
O
 
A dry and argon-flushed 500 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
septum was charged with a solution of (R)-2-iodocyclohex-2-enole (131) (18.7 g, 83.5 mmol) 
in CH2Cl2 (170 mL) and cooled 0 °C. N-Methylimidazole (NMI) (13.7 g, 13.3 mL, 
167 mmol) was slowly added via syringe. After complete addition, the reaction mixture was 
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stirred for 1 h at that temperature before a solution of diethylchlorophosphate (14.4 g, 
12.1 mL, 83.5 mmol) was added dropwise. The reaction mixture was allowed to warm to 
room temperature and stirred for additional 7 h. The reaction mixture was then quenched with 
H2O (150 mL), phases were separated and the aqueous phase was extracted with CH2Cl2 (3 x 
80 mL). The combined organic layers were washed with sat. aq. NaCl solution (100 mL) and 
dried over MgSO4. The solvents were evaporated in vacuo and the residue was subjected to 
column chromatography (SiO2; Et2O) furnishing the title compound (21.3 g, 59.2 mmol, 
71 %) as a colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 6.16 (t, J = 3.7 Hz, 1H), 4.91-4.95 (m, 1H), 4.05-4.14 (m, 2H), 
3.84-3.93 (m, 2H), 1.28-1.57 (m, 6H), 1.06-1.11 (m, 3H), 0.96-1.01 (m, 3H). 
13C-NMR (101 MHz, C6D6) δ: 143.7, 96.2 (d, J = 10.4 Hz), 78.0 (d, J = 4.2 Hz), 64.0 (d, J = 
5.4 Hz), 63.5 (d, J = 6.2 Hz), 31.3, 29.0, 16.5, 16.3 (d, J = 6.5 Hz), 16.2 (d, J = 6.9 Hz). 
MS (70 eV, EI) m/z (%):  
IR (ATR) ν~  (cm-1): 2982 (w), 2935 (w), 1442 (w), 1393 (w), 1368 (w), 1334 (w), 1260 (m), 
1164 (w), 1024 (s), 975 (vs), 919 (s), 908 (s), 852 (m), 803 (m), 761 (m), 719 (w), 703 (w). 
MS (EI, 70 eV): m/z (%) = 234 (10), 233 (100), 205 (35), 177 (40), 155 (18), 127 (25), 99 
(78), 97 (24), 81 (13), 80 (14), 79 (69), 78 (14), 77 (25). 
HRMS (EI) for C10H18IO4P (359.9987): 359.9973. 
 
(S)-ethyl-4-(2-iodocyclohex-2-en-1-yl)butanoate (167) 
 
In a dry and argon-flushed 500 mL Schlenk-flask LiCl (10.2 g, 240 mmol) was dried under 
high vacuum at 500 °C for 20 min. After addition of Zn (39.2 g, 600 mmol) the mixture was 
dried for additional 30 min at 170 °C under high vacuum and then cooled to room 
temperature. Anhydrous THF (200 mL) was filled in followed by 1,2-dibromo ethane (1.88 g, 
0.87 mL, 10.0 mmol) and trimethylsilylchloride (TMSCl) (4.35 g, 5.06 mL, 40.0 mmol). The 
reaction was initiated by carefully heating to a gentle reflux using a heat gun and a solution of 
dry ethyl-4-bromobutyrate (39.0 g, 28.7 mL, 200 mmol) was added dropwise. The reaction 
mixture was heated to 50 °C and stirred for 12 h. After completion of the zinc insertion the 
resulting organozinc reagent (106 mL, 0.66 M in THF, 70.0 mmol) was slowly dropped via a 
cannula to a cooled solution of CuCN.2LiCl (70.0 mL, 1.0 M in THF, 70.0 mmol) at –30 °C. 
After 30 min of stirring a solution of (R)-diethyl(2-iodocyclohex-2-en-1-yl)phosphate (165) 
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(12.6 g, 35.0 mmol) in N-methylpyrrolidone (63 mL) was added dropwise and the reaction 
mixture was allowed to warm to room temperature and stirred for additional 12 h. The 
reaction mixture was then quenched with sat. aq. NH4Cl solution (500 mL, mixed with 60 mL 
30 % NH3 solution) and further stirred until all copper salts were dissolved. The phases were 
separated, the aqueous phase was extracted with Et2O (3 x 250 mL), the combined organic 
layers were washed with sat. aq. NaCl solution (250 mL) and dried over MgSO4. The solvents 
were evaporated in vacuo and the residue was subjected to column chromatography (SiO2; 
Et2O/n-pentane 1 : 20) furnishing the title compound (10.2 g, 31.7 mmol, 91 %) as colourless 
oil.  
1H-NMR (400 MHz, C6D6) δ: 6.18 (dt, J1 = 4.1 Hz, J2 = 1.5 Hz, 1H), 3.95 (q, J = 7.2 Hz, 
2H), 2.07 (t, J = 7.5 Hz, 2H), 1.53-1.79 (m, 4H), 1.12-1.46 (m, 7H), 0.97 (t, J = 7.1 Hz, 3H). 
13C-NMR (75 MHz, C6D6) δ: 172.7, 138.8, 106.5, 60.0, 45.0, 34.4, 34.3, 29.5, 28.0, 22.5, 
18.5, 14.3. 
MS (70 eV, EI) m/z (%): 195 (65), 150 (25), 149 (77), 132 (10), 131 (57), 121 (33), 107 
(100), 105 (12), 93 (19), 91 (24), 81 (12), 80 (18), 79 (63), 77 (21), 67 (18), 41 (16). 
IR (ATR) ν~  (cm-1): 2934 (m), 2860 (w), 1731 (vs), 1445 (w), 1373 (m), 1300 (w), 1243 (m), 
1176 (s), 1138 (m), 1094 (m), 1034 (m), 963 (m), 927 (w), 863 (w), 802 (w), 724 (m). 
HRMS (EI) for C12H19IO2 (322.0430): 322.0448. 
 
3,4,4a,5,6,7-hexahydro-1(2H)-naphthalinone (164) 
O
H
 
A dry and argon-flushed 1 L Schlenk-flask, equipped with a dropping funnel and a magnetic 
stirring bar was charged with a solution of (S)-ethyl-4-(2-iodocyclohex-2-en-1-yl)butanoate 
(167) (8.05 g, 25.0 mmol) in THF (500 mL) and cooled to –100 °C. Trimethylsilylchloride 
(TMSCl) (8.15 g, 9.49 mL, 75.0 mmol) was slowly added via syringe. After complete 
addition the reaction mixture was stirred for 30 min at that temperature before a solution of 
tBuLi (34.2 mL, 1.68 M in THF, 57.5 mmol) was added dropwise. After stirring for 12 h at –
70 °C, the reaction mixture was allowed to warm to 0 °C and stirred for additional 12 h. The 
reaction mixture was then quenched with sat. aq. NH4Cl solution (330 mL), extracted with 
Et2O (3 x 250 mL) and the combined organic layers were dried over MgSO4. The solvents 
were partly evaporated in vacuo (˃ 500 mbar, 40 °C) and the remainder were removed under 
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high vacuum at 0 °C. Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 6) 
furnished the title compound (3.40 g, 22.6 mmol, 90 %) as a pale yellow oil.  
1H-NMR (300 MHz, C6D6) δ: 6.78-6.82 (m, 1H), 2.37-2.46 (m, 1H), 1.77-2.02 (m, 4H), 
1.36-1.55 (m, 4H), 1.09-1.34 (m, 2H), 0.80-0.96 (m, 2H). 
13C-NMR (75 MHz, C6D6) δ: 198.2, 139.9, 134.7, 40.2, 37.9, 31.7, 30.6, 26.1, 22.7, 21.8. 
MS (70 eV, EI) m/z (%): 150 (68), 135 (11), 132 (21), 122 (34), 104 (17), 94 (67), 93 (22), 91 
(21), 81 (10), 80 (16), 79 (100), 77 (20), 42 (10). 
IR (ATR) ν~  (cm-1): 2925 (m), 2859 (m), 1684 (vs), 1614 (vs), 1452 (m), 1412 (w), 1352 
(w), 1320 (w), 1262 (s), 1214 (s), 1180 (m), 1154 (w), 1123 (m), 1082 (w), 1036 (w), 1012 
(w), 998 (w), 970 (w), 926 (m), 903 (w), 885 (m), 862 (w), 835 (m), 798 (m), 720 (w), 643 
(m). 
HRMS (EI) for C10H14O (150.1045): 150.1036. 
 
1,2,3,4,4a,5,6,7-Octahydro-1-naphthalinol (168) 
H
OH
 
3,4,4a,5,6,7-hexahydro-1(2H)-naphthalinone (164) (3.15 g, 21.0 mmol) was added to a 
solution of CeCl3.7H2O (52.5 mL, 0.4 M in MeOH, 21.0 mmol) at 25 °C, followed by 
portionswise addition of NaBH4 (794 mg, 21.0 mmol). The reaction mixture was stirred for 30 
min and then quenched with sat. aq. NH4Cl solution (100 mL). Phases were separated, the 
aqueous phase was extracted with Et2O (3 x 180 mL) and the combined organic layers were 
dried over MgSO4. Evaporation of the solvents in vacuo (˃ 200 mbar, 40 °C) furnished the 
title compound (2.88 g, 18.9 mmol, 90 %) as a colourless oil, which was used in the next step 
without further purification.  
1H-NMR (300 MHz, C6D6) δ: 5.77-5.81 (m, 1H), 3.71-3.77 (m, 1H), 1.88-1.98 (m, 3H), 
1.63-1.77 (m, 2H), 1.31-1.58 (m, 4H), 1.06-1.22 (m, 2H), 0.85-0.98 (m, 2H). 
13C-NMR (75 MHz, C6D6) δ: 143.1, 116.1, 72.4, 37.6, 36.6, 35.1, 30.9, 25.6, 24.2, 21.6. 
IR (ATR) ν~  (cm-1): 2920 (vs), 2853 (s), 1447 (m), 1354 (m), 1330 (m), 1262 (w), 1138 (m), 
1102 (s), 1074 (m), 1058 (s), 1024 (m), 958 (m), 923 (w), 851 (m), 816 (m), 767 (m), 651 (s). 
MS (EI, 70 eV): m/z (%) = 152 (82), 134 (31), 124 (46), 123 (100), 119 (21), 110 (87), 109 
(51), 97 (25), 95 (21), 93 (33), 92 (25), 91 (49), 81 (52), 79 (60), 77 (22), 67 (36), 41 (20). 
HRMS (EI) for C10H16O (152.1201): 152.1199. 
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1-(ethoxymethoxy)-1,2,3,4,4a,5,6,7-octahydronaphthaline (169)  
 
In a dry and argon-flushed 250 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
septum 1,2,3,4,4a,5,6,7-octahydro-1-naphthalinole (168) (2.28 g, 15.0 mmol) was dissolved in 
CH2Cl2 (30 mL) and cooled to 0 °C. After addition of diisopropylethylamine (DIPEA) 
(3.88 g, 4.96 mL, 30.0 mmol) the reaction mixture was stirred for 30 min at 0 °C before 
ethoxymethylchlorid (EOMCl) (2.84 g, 2.79 mL, 30.0 mmol) was dropped. The resulting 
solution was allowed to reach room temperature and stirred for further 12 h. After completion 
of the reaction sat. aq. NaCl solution (150 mL) was added, the aqueous phase was extracted 
with Et2O (3 x 150 mL) and the combined organic layers were dried over MgSO4. The 
solvents were evaporated in vacuo and the residue was subjected to column chromatography 
(SiO2; Et2O/n-pentane 1 : 25) furnishing the title compound (3.03 g, 14.4 mmol, 96 %) as a 
colourless oil.  
1H-NMR (400 MHz, C6D6) δ: 5.94-5.97 (m, 1H), 4.69 (q, J = 7.1 Hz, 2H), 3.90-3.94 (m, 
1H), 3.55-3.63 (m, 1H), 3.41-3.49 (m, 1H), 2.02-2.08 (m, 1H), 1.92-1.98 (m, 2H), 1.62-1.75 
(m, 2H), 1.46-1.58 (m, 2H), 1.29-1.45 (m, 3H), 1.11-1.24 (m, 3H), 1.07 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, C6D6) δ: 140.7, 116.9, 94.0, 77.4, 63.3, 36.8, 35.2, 35.1, 30.8, 25.6, 
24.3, 21.4, 15.4. 
IR (ATR) ν~  (cm-1): 2974 (w), 2924 (m), 2856 (m), 1447 (w), 1391 (w), 1182 (w), 1134 (m), 
1113 (m), 1098 (s), 1037 (vs), 1014 (s), 947 (w), 867 (w), 847 (w), 818 (w), 629 (w). 
MS (EI, 70 eV): m/z (%) = 210 (63), 181 (50), 164 (100), 151 (55), 136 (84), 136 (65), 135 
(99), 134 (58), 133 (49), 123 (93), 121 (57), 110 (75), 107 (43), 105 (30), 93 (38), 91 (64), 79 
(39), 59 (30).  
HRMS (EI) for C13H22O2 (210.1620): 210.1615. 
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4.4. Diastereoselective Cross-Coupling with Cyclohexylzinc Reagents Produced 
via Hydroboration and Subsequent Boron-Zinc Exchange (Table 7) 
 
2-(trans-2-(4-methoxyphenyl)cyclohexyl)-1,3-dioxolane  
 
According to TP5, 2-cyclohex-1-enyl-1,3-dioxolane (138) (154 mg, 1.00 mmol) was reacted 
via hydroboration with Et2BH, followed by a boron-zinc exchange and subsequent cross-
coupling (25 °C, 12 h) with 4-iodoanisole (702 mg, 3.00 mmol). Purification by column 
chromatography (SiO2; Et2O/n-pentane 1 : 10) furnished the title compound (187 mg, 
0.71 mmol, 71 %) as a colourless solid.  
d.r.: 87 : 13. 
m.p.: 52.1 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.07 (d, J = 9.7 Hz, 2H), 6.75 (d, J = 11.0 Hz, 2H), 4.62 (d, J = 
5.2 Hz, 1H), 3.37-3.42 (m, 2H), 3.29 (s, 3H), 3.14-3.20 (m, 2H), 2.66 (td, J1 = 11.7 Hz, J2 = 
3.5 Hz, 1H), 2.09-2.15 (m, 1H), 1.98 (ddt, J1 = 11.5 Hz, J2 = 3.5 Hz, J3 = 1.9 Hz, 1H), 1.62-
1.66 (m, 1H), 1.40-1.52 (m, 2H), 1.23-1.32 (m, 4H). 
13C-NMR (101 MHz, C6D6) δ: 158.6, 137.9, 128.8, 114.2, 104.4, 65.1, 65.0, 54.7, 46.3, 45.9, 
36.5, 27.2, 26.1, 24.2. 
MS (70 eV, EI) m/z (%): 262 [M+] (25), 201 (13), 200 (48), 154 (69), 125 (12), 121 (24), 73 
(100). 
IR (ATR) ν~  (cm-1): 2927 (m), 2872 (m), 1609 (m), 1511 (s), 1448 (m), 1306 (w), 1282 (m), 
1245 (s), 1177 (s), 1157 (s), 1115 (s), 1097 (m), 1034 (vs), 989 (m), 946 (s), 885 (m), 824 (s), 
814 (s), 756 (m), 690 (m). 
HRMS (EI) for C16H22O3 (262.1569): 262.1570. 
 
2-(trans-2-(4-methoxyphenyl)cyclohexyl)–5,5-dimethyl-1,3-dioxane  
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According to TP5, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via hydroboration with Et2BH, followed by a boron-zinc exchange and 
subsequent cross-coupling (25 °C, 12 h) with 4-iodoanisole (702 mg, 3.00 mmol). Purification 
by column chromatography (SiO2; Et2O/n-pentane 1 : 20) furnished the title compound 
(171 mg, 0.56 mmol, 56 %) as a colourless solid.  
d.r.: 98 : 2. 
m.p.: 60.7 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.09 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 4.11 (d, J = 
2.1 Hz, 1H), 3.38 (dd, J1 = 10.7 Hz, J2 = 2.9 Hz, 1H), 3.31 (s, 3H), 3.28 (dd, J1 = 10.8 Hz, J2 
= 2.8 Hz, 1H), 2.92 (d, J = 10.7 Hz, 1H), 2.85 (d, J = 10.7 Hz, 1H), 2.70 (td, J1 = 11.7 Hz, J2 
= 3.5 Hz, 1H), 2.38-2.42 (m, 1H), 1.89 (tt, J1 = 11.5 Hz, J2 = 2.6 Hz, 1H), 1.73-1.81 (m, 2H), 
1.64-1.67 (m, 1H), 1.22-1.45 (m, 4H), 1.09 (s, 3H), 0.15 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 158.6, 138.3, 128.8, 114.2, 101.8, 76.9, 54.7, 48.1, 45.1, 36.0, 
30.0, 27.3, 26.4, 24.9, 23.0, 21.4. 
MS (70 eV, EI) m/z (%): 304 (13), 200 (41), 196 (47), 147 (10), 121 (26), 115 (100), 69 (48). 
IR (ATR) ν~  (cm-1): 2923 (s), 2851 (m), 1609 (w), 1512 (s), 1460 (m), 1394 (m), 1284 (m), 
1247 (vs), 1176 (m), 1156 (s), 1114 (vs), 1077 (s), 1039 (s), 1026 (s), 989 (s), 967 (s), 822 (s), 
814 (s). 
HRMS (EI) for C19H28O3 (304.2038): 304.2041. 
 
ethyl-4-(trans-2-(1,3-dioxolane-2-yl)cyclohexyl)benzoate 
O
O
CO2Et
 
According to TP5, 2-cyclohex-1-enyl-1,3-dioxolane (138) (154 mg, 1.00 mmol) was reacted 
via hydroboration with Et2BH, followed by a boron-zinc exchange and subsequent cross-
coupling (–10 °C, 12 h; then 0 °C, 12 h) with ethyl-4-iodobenzoate (828 mg, 3.00 mmol). 
Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 10 then 1 : 1) furnished the 
title compound (123 mg, 0.71 mmol, 40 %) as a colourless solid.  
d.r.: 80 : 20. 
m.p.: 69.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.13 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.2 Hz, 2H), 4.11 (q, J = 
7.0 Hz, 2H), 3.33-3.36 (m, 2H), 2.86-2.99 (m, 3H), 2.74-2.78 (m, 1H), 2.23 (td, J1 = 11.4 Hz, 
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J2 = 3.1 Hz, 1H), 1.82-1.87 (m, 1H), 1.64-1.67 (m, 1H), 1.40-1.52 (m, 2H), 1.12-1.26 (m, 
4H), 0.99 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, C6D6) δ: 166.3, 151.5, 130.2, 129.8, 129.3, 74.1, 72.3, 61.8, 60.7, 47.1, 
43.4, 35.3, 30.5, 26.8, 26.4, 14.3. 
MS (70 eV, EI) m/z (%): 259 (8), 155 (3), 154 (27), 129 (4), 125 (4), 115 (4), 99 (4), 91 (3), 
74 (3), 73 (100), 45 (8). 
IR (ATR) ν~  (cm-1): 2930 (m), 2856 (m), 1709 (vs), 1608 (m), 1444 (w), 1419 (w), 1366 (w), 
1269 (vs), 1182 (m), 1156 (m), 1107 (s), 1094 (vs), 1052 (s), 1040 (m), 1019 (s), 990 (m), 
972 (m), 949 (m), 920 (w), 873 (w), 854 (m), 769 (s), 708 (s), 670 (w). 
HRMS (EI) for C18H24O4 (304.1675): 304.1666. 
 
2-(trans-2-phenylcyclohexyl)–5,5-dimethyl-1,3-dioxane  
O
O
 
According to TP5, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via hydroboration with Et2BH, followed by a boron-zinc exchange and 
subsequent cross-coupling (25 °C, 12 h) with iodobenzene (612 mg, 3.00 mmol). Purification 
by column chromatography (SiO2; Et2O/n-pentane 1 : 20 then 1 : 10) furnished the title 
compound (185 mg, 0.67 mmol, 67 %) as a colourless oil.  
d.r.: 98 : 2. 
1H-NMR (400 MHz, C6D6) δ: 7.16-7.21 (m, 4H), 7.04-7.09 (m, 1H), 4.06 (d, J = 2.1 Hz, 
1H), 3.35 (dd, J1 = 10.7 Hz, J2 = 2.9 Hz, 1H), 3.25 (dd, J1 = 10.8 Hz, J2 = 2.8 Hz, 1H), 2.86 
(d, J = 10.9 Hz, 1H), 2.79 (d, J = 10.7 Hz, 1H), 2.72 (td, J1 = 11.8 Hz, J2 = 3.4 Hz, 1H), 2.37-
2.40 (m, 1H), 1.92 (tt, J1 = 11.4 Hz, J2 = 2.7 Hz, 1H), 1.72-1.79 (m, 2H), 1.59-1.64 (m, 1H), 
1.23-1.44 (m, 4H), 1.00 (s, 3H), 0.11 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 146.4, 128.7, 126.4, 101.6, 76.8, 47.7, 46.0, 35.8, 29.9, 27.2, 
26.3, 24.8, 23.0, 21.3. 
MS (70 eV, EI) m/z (%): 273 (13), 196 (72), 170 (13), 167 (15), 159 (10), 117 (15), 116 (21), 
115 (100), 91 (51), 69 (90). 
IR (ATR) ν~  (cm-1): 2926 (m), 2851 (m), 1451 (m), 1393 (m), 1153 (m), 1115 (vs), 1088 
(m), 1078 (m), 1043 (m), 1025 (m), 1017 (m), 991 (m), 967 (m), 931 (m), 756 (s), 699 (vs), 
644 (w). 
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HRMS (EI) for C18H26O2 (274.1933): 274.1940. 
4.5. Diastereoselective Csp3-Csp2 Cross-Coupling with Cyclohexylzinc Iodides 
(Table 8) 
 
2-(trans-2-(4-methoxyphenyl)cyclohexyl)-1,3-dioxolane  
 
According to TP6, 2-(cis-2-iodocyclohexyl)-1,3-dioxolane (147) (282 mg, 1.00 mmol) was 
transformed via zinc insertion to the corresponding organozinc reagent followed by 
subsequent cross-coupling (25 °C, 12 h) with 4-iodoanisole (164 mg, 0.70 mmol). Purification 
by column chromatography (SiO2; Et2O/n-pentane 1 : 10) furnished the title compound 
(81 mg, 0.31 mmol, 44 %) as a colourless solid.  
d.r.: 93 : 7. 
m.p.: 51.6 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.07 (d, J = 9.7 Hz, 2H), 6.75 (d, J = 11.0 Hz, 2H), 4.62 (d, J = 
5.2 Hz, 1H), 3.37-3.42 (m, 2H), 3.29 (s, 3H), 3.14-3.20 (m, 2H), 2.66 (td, J1 = 11.7 Hz, J2 = 
3.5 Hz, 1H), 2.09-2.15 (m, 1H), 1.98 (ddt, J1 = 11.5 Hz, J2 = 3.5 Hz, J3 = 1.9 Hz, 1H), 1.62-
1.66 (m, 1H), 1.40-1.52 (m, 2H), 1.23-1.32 (m, 4H). 
13C-NMR (101 MHz, C6D6) δ: 158.6, 137.9, 128.8, 114.2, 104.4, 65.1, 65.0, 54.7, 46.3, 45.9, 
36.5, 27.2, 26.1, 24.2. 
MS (70 eV, EI) m/z (%) :262 [M+] (25), 201 (13), 200 (48), 154 (69), 125 (12), 121 (24), 73 
(100). 
IR (ATR) ν~  (cm-1): 2927 (m), 2872 (m), 1609 (m), 1511 (s), 1448 (m), 1306 (w), 1282 (m), 
1245 (s), 1177 (s), 1157 (s), 1115 (s), 1097 (m), 1034 (vs), 989 (m), 946 (s), 885 (m), 824 (s), 
814 (s), 756 (m), 690 (m). 
HRMS (EI) for C16H22O3 (262.1569): 262.1573. 
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2-(trans-2-(4-methoxyphenyl)cyclohexyl)–5,5-dimethyl-1,3-dioxane  
 
According to TP6, 2-(cis-2-iodocyclohexyl)-5,5-dimethyl-1,3-dioxane (148) (324 mg, 
1.00 mmol) was transformed via zinc insertion to the corresponding organozinc reagent 
followed by subsequent cross-coupling (25 °C, 12 h) with 4-iodoanisole (164 mg, 
0.70 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 20) furnished 
the title compound (100 mg, 0.33 mmol, 47 %) as a colourless solid.  
d.r.: 98 : 2. 
m.p.: 56.1 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.09 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 4.11 (d, J = 
2.1 Hz, 1H), 3.38 (dd, J1 = 10.7 Hz, J2 = 2.9 Hz, 1H), 3.31 (s, 3H), 3.28 (dd, J1 = 10.8 Hz, J2 
= 2.8 Hz, 1H), 2.92 (d, J = 10.7 Hz, 1H), 2.85 (d, J = 10.7 Hz, 1H), 2.70 (td, J1 = 11.7 Hz, J2 
= 3.5 Hz, 1H), 2.38-2.42 (m, 1H), 1.89 (tt, J1 = 11.5 Hz, J2 = 2.6 Hz, 1H), 1.73-1.81 (m, 2H), 
1.64-1.67 (m, 1H), 1.22-1.45 (m, 4H), 1.09 (s, 3H), 0.15 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 158.6, 138.3, 128.8, 114.2, 101.8, 76.9, 54.7, 48.1, 45.1, 36.0, 
30.0, 27.3, 26.4, 24.9, 23.0, 21.4. 
MS (70 eV, EI) m/z (%): 304 (9), 200 (29), 196 (37), 121 (19), 115 (100), 69 (39). 
IR (ATR) ν~  (cm-1): 2927 (m), 2850 (m), 1609 (w), 1511 (s), 1456 (m), 1394 (m), 1363 (w), 
1303 (w), 1284 (m), 1246 (vs), 1175 (m), 1154 (s), 1114 (vs), 1076 (m), 1037 (s), 1026 (s), 
990 (s), 967 (s), 932 (m), 910 (m), 885 (w), 822 (s), 798 (m), 754 (m), 646 (m). 
HRMS (EI) for C19H28O3 (304.2038): 304.2044. 
 
methyl-4-(trans-2-(1,3-dioxolan-2-yl)cyclohexyl)benzoate  
 
According to TP6, 2-(cis-2-iodocyclohexyl)-1,3-dioxolane (147) (282 mg, 1.00 mmol) was 
transformed via zinc insertion to the corresponding organozinc reagent followed by 
subsequent cross-coupling (–10 °C, 12 h) with methyl-4-iodobenzoate (183 mg, 0.70 mmol). 
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Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 10 then 1 : 1) furnished the 
title compound (122 mg, 0.42 mmol, 60 %) as a colourless solid.  
d.r.: 81 : 19. 
m.p.: 56.9 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.11 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 4.46 (d, J = 
1.7 Hz, 1H), 3.49 (s, 3H), 3.27-3.42 (m, 2H), 3.05-3.19 (m, 2H), 2.63 (dt, J1 = 11.5 Hz, J2 = 
3.6 Hz, 1H), 2.03-2.15 (m, 1H), 1.94 (ddt, J1 = 11.5 Hz, J2 = 3.5 Hz, J3 = 1.9 Hz, 1H), 1.52-
1.67 (m, 2H), 1.34-1.47 (m, 1H), 1.12-1.31 (m, 4H). 
13C-NMR (175 MHz, C6D6) δ: 166.7, 151.4, 130.1, 129.7, 128.8, 128.7, 104.4, 64.9, 51.4, 
46.6, 45.7, 35.7, 26.9, 25.9, 24.3. 
MS (70 eV, EI) m/z (%): 259 (3), 154 (22), 149 (3), 129 (3), 115 (3), 99 (3), 74 (3), 73 (100), 
45 (7). 
IR (ATR) ν~  (cm-1): 2931 (m), 2853 (m), 1712 (vs), 1608 (m), 1573 (w), 1432 (m), 1314 (w), 
1272 (vs), 1184 (m), 1155 (m), 1110 (s), 1096 (s), 1053 (m), 1040 (m), 1018 (m), 990 (m), 
948 (s), 885 (w), 852 (w), 838 (w), 806 (w), 769 (s), 709 (s), 670 (w). 
HRMS (EI) for C17H22O4 (290.1518): 290.1493. 
 
2-(trans-2-(3-(trifluoromethyl)phenyl)cyclohexyl)–1,3-dioxolane 
 
According to TP6, 2-(cis-2-iodocyclohexyl)-1,3-dioxolane (147) (282 mg, 1.00 mmol) was 
transformed via zinc insertion to the corresponding organozinc reagent followed by 
subsequent cross-coupling (–10 °C, 12 h) with 1-iodo-3-(trifluormethyl)benzene (190 mg, 
0.70 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 10) furnished 
the title compound (166 mg, 0.55 mmol, 79 %) as a colourless oil.  
d.r.: 90 : 10. 
1H-NMR (400 MHz, C6D6) δ: 7.52 (s, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.06 (d, J = 8.2 Hz, 1H), 
6.90 (t, J = 7.7 Hz, 1H), 4.35 (d, J = 2.2 Hz, 1H), 3.18-3.36 (m, 2H), 2.97-3.09 (m, 2H), 2.54 
(td, J1 = 11.5 Hz, J2 = 2.8 Hz, 1H), 1.97-2.02 (m, 1H), 1.83 (ddt, J1 = 11.5 Hz, J2 = 3.3 Hz, J3 
= 2.2 Hz, 1H), 1.66-1.70 (m, 1H), 1.48-1.54 (m, 2H), 1.23-1.32 (m, 4H). 
13C-NMR (101 MHz, C6D6) δ: 147.2, 131.3, 130.8 (q, J = 31.5 Hz), 129.0, 124.8 (d, J = 3.1 
Hz), 123.1 (q, J = 3.9 Hz), 104.3, 65,0, 64.9, 46.4, 45.8, 35.8, 26.8, 25.8, 24.5. 
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MS (70 eV, EI) m/z (%): 300 (17), 299 (28), 281 (37), 185 (10), 165 (10), 159 (35), 154 (26), 
129 (10), 73 (100). 
IR (ATR) ν~  (cm-1): 2926 (m), 2855 (w), 1450 (w), 1328 (s), 1191 (w), 1159 (s), 1119 (vs), 
1089 (m), 1074 (s), 1040 (m), 992 (w), 949 (m), 889 (w), 799 (m), 703 (m), 664 (m). 
HRMS (EI) for C16H19F3O2 (300.1337): 300.1328. 
 
2-(trans-2-phenylcyclohexyl)–5,5-dimethyl-1,3-dioxane 
O
O
 
According to TP6, 2-(cis-2-iodocyclohexyl)-5,5-dimethyl-1,3-dioxane (148) (324 mg, 
1.00 mmol) was transformed via zinc insertion to the corresponding organozinc reagent 
followed by subsequent cross-coupling (–25 °C, 12 h; then –10 °C, 12 h) with iodobenzene 
(143 mg, 0.70 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 20) 
furnished the title compound (158 mg, 0.58 mmol, 83 %) as a colourless oil.  
d.r.: > 99 : 1. 
1H-NMR (400 MHz, C6D6) δ: 7.16-7.21 (m, 4H), 7.04-7.09 (m, 1H), 4.06 (d, J = 2.1 Hz, 
1H), 3.35 (dd, J1 = 10.7 Hz, J2 = 2.9 Hz, 1H), 3.25 (dd, J1 = 10.8 Hz, J2 = 2.8 Hz, 1H), 2.86 
(d, J = 10.9 Hz, 1H), 2.79 (d, J = 10.7 Hz, 1H), 2.72 (td, J1 = 11.8 Hz, J2 = 3.4 Hz, 1H), 2.37-
2.40 (m, 1H), 1.92 (tt, J1 = 11.4 Hz, J2 = 2.7 Hz, 1H), 1.72-1.79 (m, 2H), 1.59-1.64 (m, 1H), 
1.23-1.44 (m, 4H), 1.00 (s, 3H), 0.11 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 146.4, 128.7, 126.4, 101.6, 76.8, 47.7, 46.0, 35.8, 29.9, 27.2, 
26.3, 24.8, 23.0, 21.3. 
MS (70 eV, EI) m/z (%): 273 (13), 196 (72), 170 (13), 167 (15), 159 (10), 117 (15), 116 (21), 
115 (100), 91 (51), 69 (90). 
IR (ATR) ν~  (cm-1): 2926 (m), 2851 (m), 1451 (m), 1393 (m), 1153 (m), 1115 (vs), 1088 
(m), 1078 (m), 1043 (m), 1025 (m), 1017 (m), 991 (m), 967 (m), 931 (m), 756 (s), 699 (vs), 
644 (w). 
HRMS (EI) for C18H26O2 (274.1933): 274.1926. 
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4.6. Typical Procedure 12: Enantioselective Hydroboration/ Boron-Zinc 
Exchange with Subsequent Cross-Coupling (TP12) (Table 9) 
 
In a dry and argon-flushed 25 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
septum was placed freshly prepared (–)-IpcBH2 (1.20 mL, 1.0 M in THF, 1.20 mmol, 
1.2 equiv.) and cooled to -25 °C. A 1.0 M solution of the respective cyclohexenyl derivative 
(1.00 mmol, 1.0 equiv.) in THF was added dropwise within 1 h and the resulting mixture was 
stirred for additional 48 h at that temperature. After complete hydroboration it was allowed to 
warm to room temperature and concentrated in vacuo (0.1 mm Hg, 25 °C, 2 h). Et2BH 
(0.69 mL, 7.3 M in Me2S, 5.00 mmol, 5.0 equiv.) was added and the mixture was heated to 50 
°C for 12 h. The reaction mixture was then concentrated (0.1 mm Hg, 25 °C, 2 h), Et2Zn 
(0.51 mL 5.00 mmol , 5.0 equiv.) was added dropwise via syringe and stirring was continued 
for 12 h at room temperature. After determination of a boron-zinc exchange ˃ 85 % by GC-
analysis of an oxidated aliqot (3 M NaOH, 30 % H2O2) the reaction mixture was again 
concentrated (0.1 mm Hg, 25 °C, 1 h), the grey-black residue redissolved in THF (2 mL) and 
then added dropwise to a mixture of the respective electrophile (3.00 mmol, 3.0 equiv.) 
Pd(dba)2 (11.5 mg, 0.02 mmol, 2.0 mol%) und S-Phos (8.20 mg, 0.02 mmol, 2.0 mol%) in 
THF (3 mL) at the indicated temperature. After stirring for the indicated time and at the 
indicated temperature, the mixture was quenched with sat. aq. NH4Cl solution (10 mL), 
extracted with Et2O (3 x 20 mL) and the combined organic layers were dried over MgSO4. 
The solvents were removed in vacuo and the crude product was purified by column 
chromatography (SiO2). 
 
chiral 2-(trans-2-(4-methoxyphenyl)cyclohexyl)-1,3-dioxolane  
 
According to TP12, 2-cyclohex-1-enyl-1,3-dioxolane (138) (154 mg, 1.00 mmol) was reacted 
via asymmetric hydroboration with (–)-IpcBH2, followed by a boron-zinc exchange and 
subsequent cross-coupling (25 °C, 12 h) with 4-iodoanisole (702 mg, 3.00 mmol). Purification 
by column chromatography (SiO2; Et2O/n-pentane 1 : 10 then 1 : 1) furnished the title 
compound (103 mg, 0.39 mmol, 39 %) as a colourless solid.  
d.r.: > 99 : 1. 
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m.p.: 52.0 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.07 (d, J = 9.7 Hz, 2H), 6.75 (d, J = 11.0 Hz, 2H), 4.62 (d, J = 
5.2 Hz, 1H), 3.37-3.42 (m, 2H), 3.29 (s, 3H), 3.14-3.20 (m, 2H), 2.66 (td, J1 = 11.7 Hz, J2 = 
3.5 Hz, 1H), 2.09-2.15 (m, 1H), 1.98 (ddt, J1 = 11.5 Hz, J2 = 3.5 Hz, J3 = 1.9 Hz, 1H), 1.62-
1.66 (m, 1H), 1.40-1.52 (m, 2H), 1.23-1.32 (m, 4H). 
13C-NMR (101 MHz, C6D6) δ: 158.6, 137.9, 128.8, 114.2, 104.4, 65.1, 65.0, 54.7, 46.3, 45.9, 
36.5, 27.2, 26.1, 24.2. 
MS (70 eV, EI) m/z (%): 262 [M+] (25), 201 (13), 200 (48), 154 (69), 125 (12), 121 (24), 73 
(100). 
IR (ATR) ν~  (cm-1): 2927 (m), 2872 (m), 1609 (m), 1511 (s), 1448 (m), 1306 (w), 1282 (m), 
1245 (s), 1177 (s), 1157 (s), 1115 (s), 1097 (m), 1034 (vs), 989 (m), 946 (s), 885 (m), 824 (s), 
814 (s), 756 (m), 690 (m). 
HRMS (EI) for C16H22O3 (262.1569): 262.1553. 
 
chiral 2-(trans-2-(4-methoxyphenyl)cyclohexyl)–5,5-dimethyl-1,3-dioxane  
 
According to TP12, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via asymmetric hydroboration with (–)-IpcBH2, followed by a boron-zinc 
exchange and subsequent cross-coupling (25 °C, 12 h) with 4-iodoanisole (702 mg, 
3.00 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 20) furnished 
the title compound (251 mg, 0.82 mmol, 82 %) as a colourless solid.  
d.r.: > 99 : 1. 
m.p.: 56.0 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.09 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 4.11 (d, J = 
2.1 Hz, 1H), 3.38 (dd, J1 = 10.7 Hz, J2 = 2.9 Hz, 1H), 3.31 (s, 3H), 3.28 (dd, J1 = 10.8 Hz, J2 
= 2.8 Hz, 1H), 2.92 (d, J = 10.7 Hz, 1H), 2.85 (d, J = 10.7 Hz, 1H), 2.70 (td, J1 = 11.7 Hz, J2 
= 3.5 Hz, 1H), 2.38-2.42 (m, 1H), 1.89 (tt, J1 = 11.5 Hz, J2 = 2.6 Hz, 1H), 1.73-1.81 (m, 2H), 
1.64-1.67 (m, 1H), 1.22-1.45 (m, 4H), 1.09 (s, 3H), 0.15 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 158.6, 138.3, 128.8, 114.2, 101.8, 76.9, 54.7, 48.1, 45.1, 36.0, 
30.0, 27.3, 26.4, 24.9, 23.0, 21.4. 
MS (70 eV, EI) m/z (%): 304 (13), 200 (41), 196 (47), 147 (10), 121 (26), 115 (100), 69 (48). 
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IR (ATR) ν~  (cm-1): 2923 (s), 2851 (m), 1609 (w), 1512 (s), 1460 (m), 1394 (m), 1284 (m), 
1247 (vs), 1176 (m), 1156 (s), 1114 (vs), 1077 (s), 1039 (s), 1026 (s), 989 (s), 967 (s), 822 (s), 
814 (s). 
HRMS (EI) for C19H28O3 (304.2038): 304.2035. 
Enantiomeric purity: 73 % ee. 
HPLC: Column: AD; n-Heptan : iPrOH: 100 : 0; flux: 0.2 mL/ min. 
 
chiral ethyl-4-(trans-2-(1,3-dioxolan-2-yl)cyclohexyl)benzoate  
O
O
CO2Et
 
According to TP12, 2-cyclohex-1-enyl-1,3-dioxolane (138) (154 mg, 1.00 mmol) was reacted 
via asymmetric hydroboration with (–)-IpcBH2, followed by a boron-zinc exchange and 
subsequent cross-coupling (–5 °C, 12 h) with ethyl-4-iodobenzoate (828 mg, 3.00 mmol). 
Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 10 then 1 : 1) furnished the 
title compound (96.0 mg, 0.32 mmol, 32 %) as a colourless oil.  
d.r.: > 99 : 1. 
1H-NMR (400 MHz, C6D6) δ: 8.13 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.2 Hz, 2H), 4.11 (q, J = 
7.0 Hz, 2H), 3.33-3.36 (m, 2H), 2.86-2.99 (m, 3H), 2.74-2.78 (m, 1H), 2.23 (td, J1 = 11.4 Hz, 
J2 = 3.1 Hz, 1H), 1.82-1.87 (m, 1H), 1.64-1.67 (m, 1H), 1.40-1.52 (m, 2H), 1.12-1.26 (m, 
4H), 0.99 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, C6D6) δ: 166.3, 151.5, 130.2, 129.8, 129.3, 74.1, 72.3, 61.8, 60.7, 47.1, 
43.4, 35.3, 30.5, 26.8, 26.4, 14.3. 
MS (70 eV, EI) m/z (%):261 (25), 260 (30), 245 (15), 244 (79), 216 (41), 215 (27), 203 (13), 
190 (13), 185 (15), 176 (11), 172 (15), 171 (100), 163 (22), 148 (10), 143 (13), 135 (15), 131 
(14), 129 (28), 119 (10), 117 (11), 115 (11), 91 (20), 81 (11), 45 (15). 
IR (ATR) ν~  (cm-1): 2924 (m), 2854 (m), 1714 (s), 1609 (w), 1448 (w), 1418 (w), 1367 (m), 
1311 (w), 1273 (vs), 1179 (m), 1108 (s), 1060 (m), 1020 (m), 848 (w), 708 (m), 771 (m). 
HRMS (EI) for C18H24O4 (304.1675): 305.1753 [M+H+]. 
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chiral methyl-4-(trans--2-(5,5-dimethyl-1,3-dioxan-2-yl)cyclohexyl)-benzoate  
 
According to TP12, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via asymmetric hydroboration with (–)-IpcBH2, followed by a boron-zinc 
exchange and subsequent cross-coupling (–10 °C, 12 h; then 0 °C, 12 h) with methyl-4-
iodobenzoate (786 mg, 3.00 mmol). Purification by column chromatography (SiO2; Et2O/n-
pentane 1 : 20) furnished the title compound (251 mg, 0.82 mmol, 82 %) as a colourless solid.  
d.r.: > 99 : 1. 
m.p.: 78.6 °C. 
1H-NMR (400 MHz, C6D6) δ: 8.14 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 3.93 (d, J = 
2.1 Hz, 1H), 3.47 (s, 3H), 3.32 (dd, J1 = 10.8 Hz, J2 = 2.8 Hz, 1H), 3.25 (dd, J1 = 10.8 Hz, J2 
= 2.8 Hz, 1H), 2.83 (d, J = 2.3 Hz, 1H), 2.80 (d, J = 2.3 Hz, 1H), 2.67 (td, J1 = 11.5 Hz, J2 = 
3.5 Hz, 1H), 2.32-2.36 (m, 1H), 1.83 (tt, J1 = 11.5 Hz, J2 = 2.7 Hz, 1H), 1.68-1.78 (m, 2H), 
1.57-1.61 (m, 1H), 1.20-1.31 (m, 4H), 1.05 (s, 3H), 0.14 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 166.7, 151.7, 130.1, 128.9, 101.5, 76.8, 76.8, 51.5, 47.5, 46.0, 
35.2, 29.9, 26.9, 26.1, 24.7, 22.9, 21.3. 
MS (70 eV, EI) m/z (%):196 (29), 115 (100), 97 (11), 83 (11), 71 (11), 70 (10), 69 (52), 57 
(22), 56 (9), 55 (22), 45 (10), 44 (36), 43 (26), 41 (25). 
IR (ATR) ν~  (cm-1): 2929 (m), 2852 (m), 1717 (s), 1608 (w), 1438 (m), 1393 (m), 1270 (s), 
1184 (m), 1153 (m), 1110 (vs), 1098 (s), 1030 (m), 1017 (m), 987 (m), 973 (m), 932 (m), 852 
(w), 770 (s), 710 (s). 
HRMS (EI) for C20H28O4 (332.1988): 332.1980. 
Enantiomeric purity: 81 %ee. 
HPLC: Column: OD; n-Heptan : iPrOH: 98 : 2; flux: 0.3 mL/min. 
 
chiral 2-(trans-2-(3-(trifluormethyl)phenyl)cyclohexyl)–5,5-dimethyl-1,3-dioxane  
O
O
CF3
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According to TP12, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via asymmetric hydroboration with (–)-IpcBH2, followed by a boron-zinc 
exchange and subsequent cross-coupling (–10 °C, 12 h; then 0 °C, 12 h) with 1-iodo-3-
(trifluormethyl)benzene (816 mg, 3.00 mmol). Purification by column chromatography (SiO2; 
Et2O/n-pentane 1 : 30) furnished the title compound (186 mg, 0.54 mmol, 54 %) as a 
colourless oil.  
d.r.: > 99 : 1. 
1H-NMR (400 MHz, C6D6) δ: 7.53 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 
6.95 (t, J = 7.7 Hz, 1H), 3.86 (d, J = 2.2 Hz, 1H), 3.29 (dd, J1 = 10.8 Hz, J2 = 2.9 Hz, 1H), 
3.21 (dd, J1 = 10.9 Hz, J2 = 2.8 Hz, 1H), 2.80 (d, J = 10.8 Hz, 1H), 2.74 (d, J = 11.0 Hz, 1H), 
2.62 (td, J1 = 11.5 Hz, J2 = 3.1 Hz, 1H), 2.27-2.30 (m, 1H), 1.76 (tt, J1 = 11.5 Hz, J2 = 2.8 Hz, 
1H), 1.59-1.66 (m, 1H), 1.52-1.57 (m, 2H), 1.11-1.21 (m, 4H), 1.00 (s, 3H), 0.11 (s, 3H). 
13C-NMR (75 MHz, C6D6) δ: 147.4, 131.1, 130.8 (q, J = 31.7 Hz), 129.0, 125.1 (d, J = 3.4 
Hz), 123.1 (q, J = 3.9 Hz) 101.5, 76.8, 76.8, 47.6, 45.7, 35.1, 29.9, 26.9, 26.1, 24.9, 22.9, 
21.3. 
MS (70 eV, EI) m/z (%):207 (13), 196 (24), 159 (21), 115 (100), 81 (10), 69 (56), 57 (15), 56 
(10), 55 (22), 45 (12), 44 (48), 43 (18), 41 (28). 
IR (ATR) ν~  (cm-1): 2930 (w), 2853 (w), 1451 (w), 1394 (w), 1328 (s), 1160 (s), 1116 (vs), 
1091 (s), 1074 (s), 1042 (m), 1027 (m), 993 (m), 969 (m), 932 (w), 919 (w), 903 (w), 799 (m), 
703 (m), 664 (m). 
HRMS (EI) for C19H25F3O2 (342.1807): 342.1786. 
Enantiomeric purity: 77 % ee. 
HPLC: Column: OD; n-Heptan : iPrOH: 100 : 0; flux: 0.2 mL/ min. 
 
chiral 2-(trans-2-phenylcyclohexyl)–5,5-dimethyl-1,3-dioxane 
O
O
 
According to TP12, 2-cyclohex-1-enyl-5,5-dimethyl-1,3-dioxane (139) (196 mg, 1.00 mmol) 
was reacted via asymmetric hydroboration with (–)-IpcBH2, followed by a boron-zinc 
exchange and subsequent cross-coupling (–10 °C, 12 h; then 0 °C, 12 h) with iodobenzene 
(612 mg, 3.00 mmol). Purification by column chromatography (SiO2; Et2O/n-pentane 1 : 20) 
furnished the title compound (143 mg, 0.52 mmol, 52 %) as a colourless oil.  
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d.r.: >99:1. 
1H-NMR (400 MHz, C6D6) δ: 7.16-7.21 (m, 4H), 7.04-7.09 (m, 1H), 4.06 (d, J = 2.1 Hz, 
1H), 3.35 (dd, J1 = 10.7 Hz, J2 = 2.9 Hz, 1H), 3.25 (dd, J1 = 10.8 Hz, J2 = 2.8 Hz, 1H), 2.86 
(d, J = 10.9 Hz, 1H), 2.79 (d, J = 10.7 Hz, 1H), 2.72 (td, J1 = 11.8 Hz, J2 = 3.4 Hz, 1H), 2.37-
2.40 (m, 1H), 1.92 (tt, J1 = 11.4 Hz, J2 = 2.7 Hz, 1H), 1.72-1.79 (m, 2H), 1.59-1.64 (m, 1H), 
1.23-1.44 (m, 4H), 1.00 (s, 3H), 0.11 (s, 3H). 
13C-NMR (101 MHz, C6D6) δ: 146.4, 128.7, 126.4, 101.6, 76.8, 47.7, 46.0, 35.8, 29.9, 27.2, 
26.3, 24.8, 23.0, 21.3. 
MS (70 eV, EI) m/z (%): 273 (13), 196 (72), 170 (13), 167 (15), 159 (10), 117 (15), 116 (21), 
115 (100), 91 (51), 69 (90). 
IR (ATR) ν~  (cm-1): 2926 (m), 2851 (m), 1451 (m), 1393 (m), 1153 (m), 1115 (vs), 1088 
(m), 1078 (m), 1043 (m), 1025 (m), 1017 (m), 991 (m), 967 (m), 931 (m), 756 (s), 699 (vs), 
644 (w). 
HRMS (EI) for C18H26O2 (274.1933): 274.1933. 
Enantiomeric purity: 68 % ee. 
HPLC: Column: OD; n-Heptan : iPrOH: 100 : 0; flux: 0.2 mL/ min. 
 
4.7. Cross-Couplings with [8-(Ethoxymethoxy)decahydronaphthalin-1-
yl](ethyl)zinc 
4.7.1. Diastereoselective preparation of methyl-4-(8-
(ethoxymethoxy)decahydronaphthalin-1-yl)benzoate (Table 10) 
H
EOMO
H
CO2Me
 
A dry and argon-flushed 25 mL Schlenk-flask, equipped with a magnetic stirring bar and a 
septum was charged with a solution of 1-(ethoxymethoxy)-1,2,3,4,4a,5,6,7-
octahydronaphthaline (169) (210 mg, 1.00 mmol) in CH2Cl2 (2 mL) and freshly prepared 
Et2BH (0.41 mL, 7.3 M in Me2S, 3.00 mmol) was added dropwise at room temperature. The 
reaction mixture was stirred for 48 h at that temperature. After complete hydroboration the 
solution was concentrated in vacuo (0.1 mm Hg, 25 °C, 2 h), Et2Zn (371 mg, 0.31 mL, 
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3.00 mmol) was added and stirring was continued for additional 5 h at room temperature. The 
reaction mixture was again concentrated (0.1 mm Hg, 25 °C, 1 h), the grey-black residue 
redissolved in THF (2.5 mL) and then added dropwise to a mixture of methyl-4-iodobenzoate 
(1.31 g, 5.00 mmol), Pd(dba)2 (11.5 mg, 0.02 mmol) und S-Phos (8.20 mg, 0.02 mmol) in 
THF (5 mL) at –10 °C. The resulting reaction mixture was left to stir overnight at this 
temperature before it was quenched with sat. aq. NH4Cl solution (10 mL). The phases were 
separated, the aqueous phase was extracted with Et2O (3 x 20 mL) and the combined organic 
layers were dried over MgSO4. The solvents were evaporated in vacuo and the residue was 
subjected to column chromatography (SiO2; Et2O/n-pentane 1 : 7) furnishing the title 
compound (113 mg, 0.31 mmol, 31 %) as a colourless oil.  
d.r. (1,2); d.r. (1,3): 91:9; 85:15. 
1H-NMR (400 MHz, C6D6) δ: 8.13 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 3.99 (d, J = 
7.2 Hz, 1H), 3.60 (d, J = 7.2 Hz, 1H) 3.49 (s, 3H), 3.31 (q, J = 7.1 Hz, 2H), 1.48-1.60 (m, 4H), 
1.08-1.47 (m, 12H), 0.89 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, C6D6) δ: 167.0, 154.8, 129.4, 127.7, 95.9, 83.7, 62.9, 52.1, 51.4, 50.3, 
42.0, 38.3, 35.1, 34.1, 34.0, 26.5, 24.3, 15.2. 
MS (70 eV, EI) m/z (%): 300 (39), 272 (100), 271 (27), 270 (39), 269 (26), 255 (51), 240 
(36), 239 (52), 177 (26), 162 (58), 150 (24), 149 (29), 131 (23), 59 (70). 
IR (ATR) ν~  (cm-1): 2924 (m), 2857 (m), 1721 (s), 1609 (m), 1434 (m), 1277 (vs), 1179 (m), 
1109 (s), 1099 (s), 1044 (vs), 1017 (s), 847 (m), 771 (m), 708 (m). 
HRMS (EI) for C21H30O4 (346.2144): 346.2135. 
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5. Highly Diastereoselective Arylations of Substituted Piperidines 
5.1. Preparation of Starting Materials 
 
t-butyl 4-((triisopropylsilyl)oxy)-piperidine-1-carboxylate (172c) 
N
OTIPS
Boc
 
To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (100 mmol; 20.1 g) and 
imidazole (250 mmol; 17.0 g) in DMF (250 mL) was slowly added TIPSCl (120 mmol; 23.1 
g; 25.7 mL) via syringe. The reaction mixture was stirred for further 6 h at room temperature. 
NaHCO3 sat. aq. solution (500 mL) was added, phases were separated and the aqueous phase 
was extracted with Et2O (4 x 300 mL). The combined organic layers were washed with brine 
(300 mL) and dried over Na2SO4. The solvents were evaporated and the residue was subjected 
to column chromatography (SiO2; n-pentane/Et2O 15:1) yielding 34.1 g (95%) of the title 
compound. 
1H-NMR (400 MHz, C6D6) δ: 3.68 (ddd, J1=10.2 Hz, J2=6.8 Hz, J3=3.3 Hz, 4 H), 3.27 (br. s., 
1 H), 1.57 - 1.50 (m, 2 H), 1.48 (s, 9 H), 1.45 - 1.37 (m, 2 H), 1.12 - 1.01 (m, 18 H), 0.99 - 
0.92 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 79.2, 67.9, 35.1, 28.9, 18.6, 18.4, 13.2, 12.9, 12.6. 
MS (70 eV) m/z (%): 259 (15), 258 (77), 215 (18), 214 (100), 131 (13), 56 (12). 
IR (ATR) ν~  (cm-1): 2944 (m), 2866 (m), 1698 (vs), 1464 (m), 1420 (s), 1366 (m), 1274 (m), 
1230 (s), 1172 (s), 1110 (s), 1086 (s), 1068 (s), 1044 (vs), 1012 (m), 994 (m), 882 (s), 870 (s), 
850 (m), 802 (m), 678 (s), 658 (s), 632 (m). 
HRMS (ESI) for C19H39NO3SiNa+ (380.2591) [M+Na+]: 380.2592.  
 
t- butyl 2-methyl-4-((triisopropylsilyl)oxy)piperidine-1-carboxylate 
N
Boc
OTIPS
Me
 
A solution of t-butyl 4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (17 mmol; 6.08 g) and 
TMEDA (17 mmol; 1.97 g; 2.53 mL) in anhydrous Et2O (60 mL) was cooled to -78 °C. 
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s-BuLi (1.07 M in hexanes) (20.4 mmol; 19.07 mL) was slowly added via syringe. The 
reaction mixture was stirred for 4 h at this temperature before MgCl2 (0.5 M in THF) (8.5 
mmol; 17 mL) was added. After the addition was complete, CuCN·2 LiCl (1 M in THF) (17 
mmol; 17 mL) was dropped to the reaction mixture. The reaction mixture was stirred for 15 
min at -78 °C before methyl iodide (17 mmol; 2.41 g; 1.06 mL) was added. The reaction 
mixture was kept for 4 h at -78 °C and was then allowed to warm to room temperature. NH4Cl 
sat. aq. solution (100 mL) was added, the phases were separated and the aqueous phase was 
extracted with Et2O (4 x 30 mL). The combined organic layers were washed with brine (50 
mL) and dried over Na2SO4. The solvents were evaporated and the residue was subjected to 
column chromatography (SiO2; i-hexane/Et2O 10:1) yielding 4.87 g (77%) of the title 
compound as a colorless oil. 
1H-NMR (400 MHz, C6D6) δ: 4.48 (br. s., 1 H), 4.02 (br. s., 1 H), 3.91 - 3.75 (m, 1 H), 3.39 - 
3.23 (m, 1 H), 1.53 - 1.35 (m, 13 H), 1.23 - 0.69 (m, 24 H). 
13C-NMR (75 MHz, C6D6) δ: 155.2, 79.1, 66.1, 46.6, 37.4, 34.2, 33.9, 29.0, 19.7, 18.7, 18.4, 
13.2, 12.8. 
MS (70 eV) m/z (%): 371 (1) [M+], 273 (16), 272 (79), 230 (13), 229 (19), 228 (100), 184 
(12), 142 (16), 131 (42). 
IR (ATR) ν~  (cm-1): 2942 (m), 2892 (w), 2866 (m), 1694 (s), 1464 (m), 1412 (m), 1390 (m), 
1378 (m), 1364 (m), 1342 (m), 1290 (w), 1272 (w), 1250 (w), 1212 (w), 1174 (s), 1134 (m), 
1112 (m), 1090 (s), 1072 (s), 1054 (vs), 1028 (m), 1004 (m), 934 (w), 918 (w), 882 (s), 864 
(m), 800 (w), 768 (w), 674 (s), 656 (s). 
HRMS (ESI) for C20H42NO3Si+ (372.2934) [M+H+]: 372.2927.  
 
5.2. Typical Procedure 13: Cross-Coupling of (1-(t-Butoxycarbonyl)-4-
methylpiperidin-2-yl)zinc Chloride (TP 13) (Table 11) 
 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t-butyl 4-methylpiperidine-1-carboxylate (1 mmol; 0.20 g) and TMEDA (1 mmol; 
0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and s-BuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred 
for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The 
reaction mixture was stirred for 15 min at -78 °C and was then warmed to room temperature. 
Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the respective aryl 
iodide (0.7 mmol), Pd(dba)2 (11.5 mg; 0.02 mmol) and S-Phos (8.2 mg; 0.02 mmol) was 
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prepared and stirred for 10 min. The piperidinylzinc reagent was added to this mixture at 
room temperature. The reaction mixture was then heated to 55 °C for 15 h. NH4Cl sat. aq. 
solution (20 mL) was added, the phases were separated and the aqueous phase was extracted 
with Et2O (4 x 10 mL). The combined organic layers were washed with brine (10 mL) and 
dried over Na2SO4. The solvents were evaporated and the residue was subjected to column 
chromatography yielding the respective title compound. 
 
cis-t-butyl 2-(4-methoxyphenyl)-4-methylpiperidine-1-carboxylate (173a) 
 
Cross-coupling was performed according to TP13. 
column chromatography: SiO2; n-pentane/Et2O 4:1 
yield: 167 mg (78 %) 
d.r.: 99:1. 
1H-NMR (400 MHz, C6D6) δ: 7.10 (d, J=8.4 Hz, 2 H), 6.81 (d, J=8.6 Hz, 2 H), 4.91 (dd, 
J1=9.4 Hz, J2=6.4 Hz, 1 H), 4.11 (ddd, J1=13.6 Hz, J2=7.0 Hz, J3=2.9 Hz, 1 H), 3.33 (s, 3 H), 
3.14 (ddd, J1=13.7 Hz, J2=10.7 Hz, J3=5.6 Hz, 1 H), 1.83 - 1.73 (m, 1 H), 1.66 (ddd, J1=13.3 
Hz, J2=6.2 Hz, J3=3.6 Hz, 1 H), 1.54 - 1.44 (m, 1 H), 1.38 (s, 9 H), 1.36 - 1.27 (m, 1 H), 0.93 
- 0.84 (m, 1 H), 0.67 (d, J=6.8 Hz, 3 H).  
13C-NMR (101 MHz, C6D6) δ: 159.1, 156.1, 137.5, 127.2, 114.3, 79.2, 56.7, 55.1, 38.8, 38.6, 
31.7, 28.8, 27.0, 21.8. 
MS (70 eV, EI) m/z (%): 305 (2) [M+], 250 (10), 249 (67), 248 (23), 205 (14), 204 (100), 162 
(10), 134 (10), 121 (15), 96 (14), 57 (28). 
IR (ATR) ν~  (cm-1): 2951 (w), 2929 (w), 1686 (vs), 1612(w), 1512 (s), 1477 (w), 1455 (m), 
1403 (s), 1364 (s), 1328 (m), 1292 (m), 1279 (m), 1243 (vs), 1173 (s), 1148 (vs), 1126 (m), 
1112 (m), 1090 (m), 1066 (m), 1035(s), 1000 (w),864 (m), 827 (s), 775 (m), 758 (m). 
HRMS (EI) for C18H27NO3 (305.1991): 305.1977. 
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cis-t-butyl 4-methyl-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (173b) 
 
Cross-coupling was performed according to TP13. 
column chromatography: SiO2; n-pentane/Et2O 5:1 
yield: 195 mg (81 %) 
d.r.: 95:5. 
1H-NMR (400 MHz, C6D6) δ: 7.39 (d, J=8.0 Hz, 2 H), 7.00 (d, J=8.2 Hz, 2 H), 4.68 (dd, 
J1=9.8 Hz, J2=6.3 Hz, 1 H), 3.90 (ddd, J1=13.7, J2=6.6 Hz, J3=3.9 Hz, 1 H), 3.08 (ddd, 
J1=13.9 Hz, J2=10.0 Hz, J3=5.5 Hz, 1 H), 1.69 (dddd, J1=13.3 Hz, J2=10.0 Hz, J3=6.9 Hz, 
J4=6.7 Hz, 1 H), 1.55 - 1.49 (m, 1 H), 1.42 - 1.33 (m, 1 H), 1.29 (s, 9 H), 1.05 (dt, J1=13.5 Hz, 
J2=10.4 Hz, 1 H), 0.88 - 0.80 (m, 1 H), 0.62 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.9, 150.0 (d, J=1.0 Hz), 129.1 (q, J=32.1 Hz), 126.4, 125.8 
(q, J=3.8 Hz), 125.5 (q, J=271.7 Hz), 79.6, 57.3, 39.5, 38.7, 31.6, 28.6, 27.2, 21.8. 
19F-NMR (376 MHz, C6D6) δ: -61.98 (s). 
MS (70 eV, EI) m/z (%): 343 (1) [M+], 288 (19), 287 (73), 270 (16), 268 (11), 243 (15), 242 
(64), 228 (12), 200 (23), 199 (10), 187 (12), 186 (15), 172 (21), 159 (30), 142 (28), 98 (24), 
97 (14), 57 (100), 55 (10), 41 (22). 
IR (ATR) ν~  (cm-1): 2929 (w), 2871 (w), 1688 (s), 1619 (w), 1478 (w), 1455 (w), 1415 (m), 
1402 (m), 1392 (m), 1378 (w), 1365 (m), 1349 (w), 1323 (vs), 1290 (w), 1278 (w), 1243 (m), 
1223 (w), 1150 (s), 1120 (vs), 1111 (vs), 1090 (m), 1066 (vs), 1016 (m), 1000 (w), 971 (w), 
924 (w), 863 (w), 834 (m), 815 (w), 775 (m), 759 (w), 658 (w), 605 (w). 
HRMS (EI) for C18H24F3NO2 (343.1759): 343.1756. 
 
cis-t-butyl 2-(3-chlorophenyl)-4-methylpiperidine-1-carboxylate (173c) 
N
Me
Boc
Cl
 
Cross-coupling was performed according to TP13. 
column chromatography: SiO2; n-pentane/Et2O 5:1 
yield: 165 mg (76 %) 
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d.r.: 96:4. 
m.p.: 47.3 – 49.2 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.24 (s, 1 H), 7.05 (d, J=7.04 Hz, 1 H), 6.95 - 6.81 (m, 2 H), 
4.64 (dd, J1=10.1 Hz, , J2=6.2 Hz, 1 H), 3.91 (ddd, , J1=13.6 Hz, , J2=6.7 Hz, , J3=3.5 Hz, 1 
H), 3.09 - 3.00 (m, 1 H), 1.73 - 1.63 (m, 1 H), 1.48 - 1.44 (m, 1 H), 1.40 - 1.33 (m, 1 H), 1.31 
(s, 9 H), 1.10 - 1.00 (m, 1 H), 0.84 - 0.75 (m, 1 H), 0.61 (d, J=6.65 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.9, 148.2, 134.9, 130.2, 127.0, 126.5, 124.1, 79.6, 57.3, 
39.4, 38.7, 31.6, 28.7, 27.1, 21.8. 
MS (70 eV, EI) m/z (%): 309 (1) [M+], 255 (26), 254 (15), 253 (79), 236 (15), 210 (28), 209 
(16), 208 (87), 194 (12), 192 (10), 166 (19), 153 (10), 152 (11), 142 (27), 138 (14), 125 (21), 
98 (37), 97 (18), 57 (100), 41 (21). 
IR (ATR) ν~  (cm-1): 2916 (s), 2850 (m), 1682 (vs), 1476 (m), 1398 (s), 1362 (s), 1338 (m), 
1284 (s), 1244 (s), 1174 (s), 1148 (vs), 1122 (s), 1098 (s), 1088 (s), 1078 (s), 1034 (m), 1004 
(m), 906 (m), 864 (s), 852 (s), 790 (s), 778 (vs), 756 (s), 710 (s), 694 (vs), 676 (m). 
HRMS (EI) for C17H24ClNO2 (309.1496): 309.1487. 
 
cis-t-butyl 2-(3-cyanophenyl)-4-methylpiperidine-1-carboxylate (173d) 
N
Me
Boc
CN
 
Cross-coupling was performed according to TP13. 
column chromatography: SiO2; n-pentane/Et2O 4:1 
yield: 135 mg (64 %) 
d.r.: 97:3. 
m.p.: 77.8 – 79.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.22 (s, 1 H), 7.08 - 6.91 (m, 2 H), 6.76 (t, J=7.7 Hz, 1 H), 
4.49 (dd, J1=10.4 Hz, J2=5.9 Hz, 1 H), 3.79 (ddd, J1=13.7 Hz, J2=6.6 Hz, J3=3.9 Hz, 1 H), 
2.98 (ddd, J1=13.7 Hz, J2=9.8 Hz, J3=5.6 Hz, 1 H), 1.71 - 1.59 (m, 1 H), 1.40 - 1.29 (m, 2 H), 
1.29 - 1.15 (m, 9 H), 0.90 (dt, J1=13.1 Hz, J2=10.6 Hz, 1 H), 0.83 - 0.74 (m, 1 H), 0.60 (d, 
J=6.6 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 146.4, 129.6, 129.1, 128.9, 128.6, 118.6, 112.6, 79.0, 
56.5, 39.0, 37.9, 30.8, 27.8, 26.5, 21.1. 
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MS (70 eV, EI) m/z (%): 300 (1) [M+], 245 (16), 244 (37), 227 (11), 200 (32), 199 (100), 185 
(17), 171 (12), 157 (24), 144 (10), 143 (15), 142 (10), 129 (16), 116 (14), 98 (20), 57 (52), 41 
(17). 
IR (ATR) ν~  (cm-1): 2952 (w), 2920 (w), 2230 (w), 1682 (vs), 1482 (m), 1440 (w), 1404 (s), 
1374 (m), 1364 (m), 1338 (w), 1328 (w), 1288 (m), 1248 (m), 1182 (m), 1150 (vs), 1122 (m), 
1096 (m), 1010 (m), 924 (w), 874 (m), 862 (w), 798 (s), 778 (m), 758 (w), 734 (w), 694 (s), 
636 (w). 
HRMS (EI) for C18H24N2O2 (300.1838): 300.1860. 
 
cis-t-butyl 2-(4-(ethoxycarbonyl)phenyl)-4-methylpiperidine-1-carboxylate (173e) 
N
Me
Boc
CO2Et
 
Cross-coupling was performed according to TP13. 
column chromatography: SiO2; n-pentane/Et2O 4:1 
yield: 163 mg (67 %) 
d.r.: 98:2. 
m.p.: 108.8 – 110.3 °C.  
1H-NMR (400 MHz, C6D6) δ: 8.20 (d, J=8.4 Hz, 2 H), 7.12 (d, J=8.4 Hz, 2 H), 4.74 (dd, 
J1=9.7 Hz, J2=6.2 Hz, 1 H), 4.15 (q, J=7.1 Hz, 2 H), 3.96 (ddd, J1=13.7 Hz, J2=6.6 Hz, J3=3.7 
Hz, 1 H), 3.12 (ddd, J1=13.7, J2=10.2 Hz, J3=5.4 Hz, 1 H), 1.70 (dddd, J1=13.3 Hz, J2=10.2 
Hz, J3=7.1 Hz, J4=6.8 Hz, 1 H), 1.54 (ddd, J1=13.4 Hz, J2=5.9 Hz, J3=3.9 Hz, 1 H), 1.43 - 
1.36 (m, 1 H), 1.29 (s, 9 H), 1.13 (dt, J1=13.4 Hz, J2=10.2 Hz, 1 H), 1.03 (t, J=7.1 Hz, 3 H), 
0.89 - 0.80 (m, 1 H), 0.61 (d, J=7.1 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.5, 156.0, 151.1, 130.4, 129.8, 126.0, 79.6, 61.1, 57.6, 
39.4, 38.7, 31.6, 28.7, 27.2, 21.8, 14.6. 
MS (70 eV, EI) m/z (%): 347 (1) [M+], 292 (15), 291 (81), 262 (16), 247 (11), 246 (55), 219 
(15), 218 (100), 176 (10), 174 (11), 142 (14), 98 (20), 97 (17), 57 (42), 43 (10). 
IR (ATR) ν~  (cm-1): 2928 (w), 1715 (s), 1715 (s), 1689 (vs), 1610 (w), 1476 (w), 1455 (w), 
1401 (m), 1392 (m), 1364 (s), 1350 (w), 1326 (w), 1307 (m), 1271 (vs), 1245 (s), 1222 (m), 
1173 (s), 1149 (s), 1121 (s), 1101 (vs), 1066 (m), 1019 (m), 852 (m), 768 (m), 757 (m), 740 
(w), 705 (m).  
HRMS (EI) for C20H29NO4 (347.2097): 347.2099. 
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cis-t-butyl 4-methyl-2-(pyridin-4-yl)piperidine-1-carboxylate (173f) 
N
Me
Boc N
 
Cross-coupling was performed according to TP13. 
column chromatography: SiO2; Et2O 
yield: 141 mg (73 %) 
d.r.: 95:5. 
1H-NMR (300 MHz, C6D6) δ: 8.56 (dd, J1=4.6 Hz, J2=1.4 Hz, 2 H), 6.79 (d, J=5.6 Hz, 2 H), 
4.62 (dd, J1=9.3 Hz, J2=6.4 Hz, 1 H), 3.89 (ddd, J1=13.6 Hz, J2=6.6 Hz, J3=3.8 Hz, 1 H), 3.03 
(ddd, J1=13.8 Hz, J2=10.0 Hz, J3=5.3 Hz, 1 H), 1.72 - 1.59 (m, 1 H), 1.54 - 1.38 (m, 2 H), 
1.36 - 1.18 (m, 9 H), 1.09 - 0.97 (m, 1 H), 0.81 (dddd, J1=16.9 Hz, J2=5.2 Hz, J3=4.1 Hz, 
J4=3.9 Hz, 1 H), 0.58 (d, J=6.9 Hz, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 155.8, 153.9, 150.7, 121.0, 79.8, 56.5, 39.3, 38.0, 31.5, 28.6, 
27.1, 21.6. 
MS (70 eV, EI) m/z (%): 276 (10) [M+], 221 (40), 220 (78), 202 (17), 176 (55), 175 (73), 142 
(35), 133 (30), 120 (17), 119 (17), 106 (16), 98 (97), 57 (100), 56 (15), 55 (19), 41 (23), 41 
(23). 
IR (ATR) ν~  (cm-1): 2954 (w), 2928 (w), 1688 (vs), 1598 (m), 1478 (w), 1456 (w), 1404 (s), 
1364 (s), 1338 (m), 1316 (m), 1280 (m), 1246 (s), 1228 (m), 1174 (s), 1150 (vs), 1128 (m), 
1092 (m), 1064 (m), 1018 (m), 994 (m), 972 (w), 862 (m), 818 (m), 800 (m), 776 (m), 760 
(m), 634 (m). 
HRMS (EI) for C16H24N2O2 (276.1838): 276.1830. 
 
5.3. Typical Procedure 14: Cross-Coupling of (1-(t-Butoxycarbonyl)-4-
phenylpiperidin-2-yl)zinc Chloride (TP 14) (Table 11) 
 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t-butyl 4-phenylpiperidine-1-carboxylate (1 mmol; 0.26 g) and TMEDA (1 mmol; 
0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and s-BuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred 
for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The 
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reaction mixture was stirred for 15 min at -78 °C and was then allowed to warm to room 
temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the 
respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and Ru-Phos (23.3 mg; 
0.05 mmol) was prepared and stirred for 10 min. The piperidinylzinc reagent was added to 
this mixture at room temperature. The reaction mixture was then heated to 55 °C for 15 h. 
NH4Cl sat. aq. solution (20 mL) was added, the phases were separated and the aqueous phase 
was extracted with Et2O (4 x 10 mL). The combined organic layers were washed with brine 
(10 mL) and dried over Na2SO4. The solvents were evaporated and the residue was subjected 
to column chromatography yielding the respective title compound. 
 
cis-t-butyl 4-phenyl-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (173g) 
N
Boc
CF3
 
Cross-coupling was performed according to TP14. 
column chromatography: SiO2; toluene 
yield: 182 mg (64 %) 
d.r.: 97:3. 
1H-NMR (300 MHz, C6D6) δ: 7.40 (d, J=8.3 Hz, 2 H), 7.13 (d, J=8.0 Hz, 2 H), 7.10 - 7.04 
(m, 1 H), 6.98 (d, J=8.0 Hz, 2 H), 6.90 (d, J=7.2 Hz, 2 H), 4.65 (dd, J1=11.6 Hz, J2=6.1 Hz, 1 
H), 3.99 (ddd, J1=13.8 Hz, J2=7.2 Hz, J3=3.9 Hz, 1 H), 3.23 (ddd, J1=13.9 Hz, J2=9.5 Hz, 
J3=6.2 Hz, 1 H), 2.58 - 2.46 (m, 1 H), 2.06 – 1.92 (m, 1 H), 1.78 - 1.69 (m, 1 H), 1.55 - 1.45 
(m, 1 H), 1.43 - 1.33 (m, 1 H), 1.29 (s, 9 H). 
13C-NMR (75 MHz, C6D6) δ: 155.9, 149.9 (d, J=1.1 Hz), 146.4, 129.3 (q, J=32.1 Hz), 129.2, 
127.4, 127.0, 126.3, 125.9 (q, J=3.9 Hz), 125.5 (q, J=271.8 Hz), 79.8, 58.4, 40.3, 39.0, 38.6, 
31.8, 28.6. 
MS (70 eV, EI) m/z (%): 405 (1) [M+], 350 (24), 349 (100), 304 (21), 288 (10), 200 (13), 187 
(12), 186 (14), 172 (10), 159 (11), 118 (32), 104 (15), 90 (19); 59 (85); 41 (11). 
IR (ATR) ν~  (cm-1): 2976 (w), 2932 (w), 1688 (s), 1620 (w), 1478 (w), 1454 (w), 1402 (m), 
1366 (m), 1322 (vs), 1292 (m), 1248 (m), 1162 (s), 1120 (vs), 1110 (vs), 1066 (s), 1038 (w), 
1016 (m), 950 (w), 878 (w), 860 (w), 836 (m), 818 (w), 760 (m), 700 (s), 662 (w). 
HRMS (EI) for C23H26F3NO2 (405.1916): 405.1922. 
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cis-t-butyl 2-(4-cyanophenyl)-4-phenylpiperidine-1-carboxylate (173h) 
N
Boc
CN
 
Cross-coupling was performed according to TP14. 
column chromatography: SiO2; n-pentane/Et2O 5:1 
yield: 200 mg (79 %) 
d.r.: >99:1. 
m.p.: 137.0-138.3 °C 
1H-NMR (400 MHz, C6D6) δ: 7.19 – 7.15 (m, 2 H), 7.15 - 7.06 (m, 3 H), 6.89 (d, J=7.0 Hz, 2 
H), 6.79 (d, J=8.2 Hz, 2 H), 4.51 (dd, J1=11.7 Hz, J2=6.0 Hz, 1 H), 3.91 (ddd, J1=13.7 Hz, 
J2=7.07 Hz, J3=4.0 Hz, 1 H), 3.20 (ddd, J1=13.8 Hz, J1= 9.3 Hz, J1=6.1 Hz, 1 H), 2.52 - 2.42 
(m, 1 H), 2.00 - 1.90 (m, 1 H), 1.67 - 1.60 (m, 1 H), 1.45 - 1.32 (m, 2 H), 1.27 (s, 9 H). 
13C-NMR (101 MHz, C6D6) δ: 155.8, 150.7, 146.3, 132.6, 129.2, 127.4, 127.1, 126.4, 119.3, 
111.3, 79.9, 58.6, 40.5, 39.0, 38.4, 31.7, 28.6. 
IR (ATR) ν~  (cm-1): 2940 (w), 2922 (w), 2842 (w), 2222 (w), 1698 (s), 1604 (w), 1446 (w), 
1390 (m), 1366 (m), 1328 (m), 1280 (m), 1254 (s), 1166 (s), 1150 (vs), 1094 (w), 1024 (w), 
980 (w), 858 (w), 840 (m), 782 (m), 764 (m), 756 (m), 708 (m). 
MS (70 eV, EI) m/z (%): 363 (1) [M+H+], 306 (73), 262 (35), 261 (62), 184 (19), 157 (40), 
144 (27), 143 (45), 129 (28), 118 (36), 116 (18), 104 (37), 91 (25), 57 (100), 41 (26). 
HRMS (EI) for C23H27N2O2+ (363.2067) [M+H+]: 363.2060. 
 
cis-t-butyl 2-(4-(methoxycarbonyl)phenyl)-4-phenylpiperidine-1-carboxylate (173i) 
N
Boc
CO2Me
 
Cross-coupling was performed according to TP14. 
column chromatography: SiO2; n-pentane/Et2O 5:1 
yield: 185 mg (67 %) 
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d.r.: 99:1. 
1H-NMR (400 MHz, C6D6) δ: 8.13 (d, J=8.4 Hz, 2 H), 7.11 - 6.98 (m, 5 H), 6.84 (d, J=7.2 
Hz, 2 H), 4.63 (dd, J1=11.7 Hz, J2=6.0 Hz, 1 H), 4.00 (ddd, J1=13.7 Hz, J2= 7.4 Hz, J3= 3.6 
Hz, 1 H), 3.47 (s, 3 H), 3.21 (ddd, J1=13.8 Hz, J2= 9.6 Hz, J3=6.2 Hz, 1 H), 2.52 - 2.42 (m, 1 
H), 2.04 - 1.85 (m, 1 H), 1.74 - 1.67 (m, 1 H), 1.55 - 1.43 (m, 1 H), 1.36 - 1.27 (m, 1 H), 1.24 
(s, 9 H). 
13C-NMR (101 MHz, C6D6) δ: 167.0, 155.9, 151.2, 146.6, 130.5, 129.6, 129.1, 127.5, 126.9, 
126.0, 79.8, 58.8, 51.9, 40.2, 39.0, 38.5, 31.8, 28.7. 
MS (70 eV, EI) m/z (%): 395 (1) [M+], 340 (21), 339 (100), 295 (30), 294 (48), 280 (41), 190 
(19), 177 (17), 176 (27), 162 (29), 118 (23), 104 (25), 91 (21); 57 (45); 41 (19). 
IR (ATR) ν~  (cm-1): 2950 (w), 1720 (s), 1690 (vs), 1610 (w), 1434 (m), 1402 (s), 1366 (m), 
1324 (m), 1312 (m), 1276 (vs), 1248 (s), 1168 (s), 1148 (s), 1132 (s), 1104 (s), 1060 (w), 
1018 (m), 950 (w), 878 (w), 854 (m), 772 (m), 758 (s), 700 (s). 
HRMS (EI) for C24H29NO4 (395.2097): 395.2082. 
 
5.4. Typical Procedure 15: Cross-Coupling of (1-(t-Butoxycarbonyl)-4-
((triisopropylsilyl)oxy)piperidin-2-yl)zinc Chloride (TP 15) (Table 11) 
 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t-butyl 4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (1 mmol; 0.36 g) and 
TMEDA (1 mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and s-
BuLi (1.14 M in hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction 
mixture was stirred for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 
mL) was added. The reaction mixture was stirred for 15 min at -78 °C and was then allowed 
to warm to room temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a 
solution of the respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and Ru-
Phos (23.3 mg; 0.05 mmol) was prepared and stirred for 10 min. The piperidinylzinc reagent 
was added to this mixture at room temperature. The reaction mixture was then heated to 55 °C 
for 60 h. NH4Cl sat. aq. solution (20 mL) was added, the phases were separated and the 
aqueous phase was extracted with Et2O (4 x 10 mL). The combined organic layers were 
washed with brine (10 mL) and dried over Na2SO4. The solvents were evaporated and the 
residue was subjected to column chromatography yielding the respective title compound. 
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cis-t-butyl 2-(4-(ethoxycarbonyl)phenyl)-4-((triisopropylsilyl)oxy)piperidine-1-
carboxylate (173j) 
N
OTIPS
Boc
CO2Et
 
Cross-coupling was performed according to TP15. 
column chromatography: SiO2; n-pentane/Et2O 8:1 
yield: 297 mg (84 %) 
d.r.: 97:3. 
1H-NMR (400 MHz, C6D6) δ: 8.17 (d, J=8.4 Hz, 2 H), 7.20 (d, J=8.0 Hz, 2 H), 5.32 (dd, 
J1=6.2 Hz, J2=3.2 Hz, 1 H), 4.24 - 4.16 (m, 1 H), 4.13 (q, J=7.11 Hz, 2 H), 3.89 - 3.82 (m, 1 
H), 3.45 (td, J1=12.7 Hz, J2=3.5 Hz, 1 H), 2.06 (dt, J1=14.0 Hz, J2=3.5 Hz, 1 H), 1.78 (ddd, 
J1=14.1 Hz, J2=7.1 Hz, J3=3.0 Hz, 1 H), 1.58 - 1.49 (m, 1 H), 1.39 (s, 9 H), 1.31 (d, J=7.0 Hz, 
1 H), 1.02 (t, J=7.0 Hz, 3 H), 0.98 - 0.77 (m, 18 H), 0.77 - 0.69 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.6, 155.7, 149.7, 130.3, 129.4, 126.3, 79.8, 65.7, 61.0, 
53.3, 37.7, 36.6, 33.5, 32.7, 30.5, 30.5, 30.2, 28.7, 23.5, 18.5, 18.4, 14.7, 14.7, 12.7. 
MS (70 eV, EI) m/z (%): 505 (1) [M+], 407 (32), 406 (100), 363 (31), 362 (91), 231 (74), 230 
(85), 188 (21), 186 (85), 159 (38), 144 (23), 131 (44), 103 (21), 75 (22), 57 (29), 41 (19). 
IR (ATR) ν~  (cm-1): 2940 (m), 2924 (m), 2865 (m), 1717 (s), 1693 (vs), 1462 (m), 1414 (m), 
1403 (m), 1390 (m), 1381 (m), 1364 (s), 1271 (vs), 1254 (m), 1214 (m), 1170 (s), 1103 (vs), 
1080 (s), 1067 (s), 1044 (s), 1021 (s), 995 (m), 985 (m), 953 (m), 880 (s), 850 (m), 777 (m), 
773 (m), 721 (m), 713 (m), 679 (s), 660 (s), 631 (m). 
HRMS (EI) for C28H47NO5Si (505.3224): 505.3221. 
 
cis-t- butyl 2-(4-fluorophenyl)-4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (173k) 
N
Boc
OTIPS
F
 
Cross-coupling was performed according to TP15. 
column chromatography: SiO2; CH2Cl2 
yield: 275 mg (87 %) 
d.r.: 95:5. 
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1H-NMR (300 MHz, C6D6) δ: 7.04 (dd, J1=8.3 Hz, J2=5.3 Hz, 2 H), 6.83 (t, J=8.7 Hz, 2 H), 
5.30 - 5.25 (m, 1 H), 4.16 (ddd, J1=13.3 Hz, J2=4.7 Hz, J3=2.9 Hz, 1 H), 3.89 - 3.83 (m, 1 H), 
3.40 (td, J1=12.7 Hz, J2=3.5 Hz, 1 H), 2.06 - 1.97 (m, 1 H), 1.78 (ddd, J1=14.1 Hz, J2=6.9 Hz, 
J3=3.3 Hz, 1 H), 1.63 - 1.51 (m, 1 H), 1.40 (s, 9 H), 1.11 - 1.04 (m, 1 H), 1.02 - 0.83 (m, 18 
H), 0.83 - 0.73 (m, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 155.7, 162.2 (d, J=243.2 Hz), 139.9 (d, J=3.1 Hz), 127.9 (d, 
J=7.8 Hz), 115.4 (d, J=21.3 Hz), 79.7, 65.8, 52.8, 37.7, 36.4, 33.7, 28.8, 18.5, 18.5, 12.7. 
19F-NMR (282 MHz, C6D6) δ: -116.44 - -116.36 (m) (minor), -117.97 - -117.82 (m) (major). 
MS (70 eV, EI) m/z (%): 451 (1) [M+], 309 (22), 308 (86), 187 (18), 186 (100), 177 (87), 176 
(18), 174 (18), 173 (19), 159 (40), 157 (20), 156 (22), 150 (26), 144 (35), 142 (16), 131 (35), 
103 (24), 75 (25), 41 (17). 
IR (ATR) ν~  (cm-1): 2972 (w), 2932 (w), 2232 (w), 1684 (s), 1608 (w), 1508 (w), 1474 (w), 
1454 (m), 1434 (w), 1410 (m), 1392 (m), 1380 (m), 1364 (s), 1338 (s), 1312 (m), 1280 (m), 
1270 (m), 1248 (m), 1220 (m), 1156 (vs), 1104 (s), 1070 (m), 1056 (m), 1018 (m), 982 (s), 
964 (m), 910 (m), 870 (m), 854 (m), 838 (s), 794 (m), 780 (m), 758 (m), 724 (w), 680 (m), 
670 (m), 660 (m). 
HRMS (EI) for C25H42FNO3Si (451.2918): 451.2938. 
 
cis-t-butyl 2-(4-(trifluoromethyl)phenyl)-4-((triisopropylsilyl)oxy)piperidine-1-
carboxylate (173l) 
 
Cross-coupling was performed according to TP15. 
column chromatography: SiO2; CH2Cl2 
yield: 284 mg (81 %) 
d.r.: 95:5. 
m. p.: 94.8 – 95.9°C 
1H-NMR (400 MHz, C6D6) δ: 7.37 (d, J=8.2 Hz, 2 H), 7.10 (d, J=8.2 Hz, 2 H), 5.35 (d, J=5.1 
Hz, 1 H), 4.16 (d, J=12.9 Hz, 1 H), 3.85 - 3.80 (m, 1 H), 3.39 (td, J1=12.7 Hz, J2=3.6 Hz, 1 
H), 2.01 (d, J=14.3 Hz, 1 H), 1.73 (ddd, J1=14.1 Hz, J2=7.1 Hz, J3=3.0 Hz, 1 H), 1.53 - 1.47 
(m, 1 H), 1.41 (s, 9 H), 1.04 - 1.00 (m, 1 H), 0.84 - 0.80 (m, 18 H), 0.75 - 0.62 (m, 3 H). 
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13C-NMR (101 MHz, C6D6) δ: 155.7, 148.4 (d, J=1.0 Hz), 128.8 (q, J=32.3 Hz), 126.6, 125.7 
(q, J=3.7 Hz), 125.5 (q, J=271.6 Hz), 79.9, 65.5, 52.7, 37.4, 36.3, 33.4, 28.7, 18.5, 18.4, 12.7. 
19F-NMR (376 MHz, C6D6) δ: -62.12 (s) (major), -62.20 (s) (minor). 
MS (70 eV, EI) m/z (%): 501 (1) [M+], 403 (23), 402 (100), 358 (24), 230 (31), 186 (22), 131 
(22), 57 (12).  
IR (ATR) ν~  (cm-1): 2944 (m), 2868 (m), 1696 (s), 1418 (m), 1366 (m), 1328 (vs), 1164 (s), 
1126 (s), 1082 (m), 1070 (m). 
HRMS (EI) for C26H42F3NO3Si (501.2886): 501.2877. 
 
cis-t-butyl 2-(4-cyanophenyl)-4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (173m) 
 
Cross-coupling was performed according to TP15. 
column chromatography: SiO2; n-pentane/Et2O 4:1 
yield: 260 mg (81 %) 
d.r.: 97:3. 
1H-NMR (400 MHz, C6D6) δ: 7.09 (d, J=8.2 Hz, 2 H), 6.90 (d, J=8.0 Hz, 2 H), 5.21 (d, J=4.3 
Hz, 1 H), 4.08 (dd, J1=9.68 Hz, J2=3.42 Hz, 1 H), 3.79 - 3.75 (m, 1 H), 3.28 (td, J1=12.6 Hz, 
J2=3.7 Hz, 1 H), 1.89 (d, J=14.1 Hz, 1 H), 1.66 (ddd, J1=14.1 Hz, J2=7.1 Hz, J3=3.0 Hz, 1 H), 
1.50 - 1.41 (m, 2 H), 1.39 (s, 9 H), 0.80 (t, J=6.9 Hz, 18 H), 0.72 - 0.63 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.5, 149.4, 132.3, 126.9, 119.3, 110.8, 80.0, 65.4, 52.8, 
37.3, 36.3, 33.3, 28.8, 28.7, 18.6, 18.4, 18.4, 12.9, 12.6, 12.3. 
MS (70 eV, EI) m/z (%): 459 (1) [M+H+], 360 (19), 359 (65), 316 (27), 315 (100), 230 (18), 
187 (10), 186 (58), 184 (24), 159 (19), 157 (14), 156 (14), 144 (21), 131 (11), 75 (13), 57 
(10). 
IR (ATR) ν~  (cm-1): 2941 (m), 2865 (m), 1691 (vs), 1461 (m), 1414 (m), 1403 (m), 1390 
(m), 1381 (m), 1364 (s), 1355 (m), 1334 (m), 1281 (m), 1252 (m), 1215 (m), 1166 (s), 1127 
(m), 1117 (m), 1079 (s), 1067 (s), 1043 (s), 1021 (m), 1013 (s), 985 (s), 880 (s), 873 (s), 830 
(m), 796 (m), 771 (m), 746 (m), 697 (m), 680 (s), 659 (s), 641 (m), 636 (m). 
HRMS (EI) for C26H43N2O3Si+ (459.3037) [M+H+]: 459.3022. 
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5.5. Typical Procedure 16: Cross-Coupling of (trans-2-(t-
Butoxycarbonyl)decahydroisoquinolin-3-yl)zinc Chloride (TP 16) 
(Table 11) 
 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of trans-t-butyl octahydroisoquinoline-2(1H)-carboxylate (1 mmol; 0.24 g) and 
TMEDA (1 mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and s-
BuLi (1.14 M in hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction 
mixture was stirred for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 
mL) was added. The reaction mixture was stirred for 15 min at -78 °C and was then allowed 
to warm to room temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a 
solution of the respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and Ru-
Phos (23.3 mg; 0.05 mmol) was prepared and cooled to 0 °C. The piperidinylzinc reagent was 
added to this mixture and stirred for 4 h. The reaction mixture was then warmed to room 
temperature and stirred for 12 h and finally heated to 55 °C for 12 h. NH4Cl sat. aq. solution 
(20 mL) was added, the phases were separated and the aqueous phase was extracted with Et2O 
(4 x 10 mL). The combined organic layers were washed with brine (10 mL) and dried over 
Na2SO4. The solvents were evaporated and the residue was subjected to column 
chromatography yielding the respective title compound. 
 
t-butyl 3-(4-(trifluoromethyl)phenyl)octahydroisoquinoline-2(1H)-carboxylate (173n) 
 
Cross-coupling was performed according to TP16. 
column chromatography: SiO2; n-pentane/CH2Cl2 1:1 to 1:4 
yield: 185 mg (69 %) 
d.r.: >99:1. 
m.p.: 104.1 – 105.5 °C. 
1H-NMR (599 MHz, C6D6) δ: 7.42 (d, J=8.2 Hz, 2 H), 7.07 (d, J=8.2 Hz, 2 H), 4.16 (dd, 
J1=10.8 Hz, J2=5.1 Hz, 1 H), 4.04 (dd, J1=12.8 Hz, J2=5.1 Hz, 1 H), 2.65 (dd, J1=12.6 Hz, 
J2=10.7 Hz, 1 H), 1.56 (d, J=8.0 Hz, 2 H), 1.51 (ddd, J1=13.3 Hz, J2=4.8 Hz, J3=3.3 Hz, 1 H), 
1.44 - 1.36 (m, 2 H), 1.17 (s, 9 H), 1.10 - 0.95 (m, 4 H), 0.79 - 0.64 (m, 3 H). 
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13C-NMR (151 MHz, C6D6) δ: 156.9, 151.6 (d, J=1.4 Hz), 128.8 (q, J=32.3 Hz), 126.5, 125.7 
(q, J=3.6 Hz), 125.6 (q, J=271.8 Hz), 79.8, 59.6, 52.2, 41.6, 41.0, 39.9, 33.2, 31.2, 28.4, 26.7, 
26.4. 
19F-NMR (376 MHz, C6D6) δ: -61.83 (s). 
MS (70 eV, EI) m/z (%): 383 (1) [M+], 328 (24), 327 (100), 326 (10), 283 (27), 282 (67), 240 
(13), 182 (11), 182 (18), 181 (17), 177 (35), 138 (40), 137 (19), 57 (60). 
IR (ATR) ν~  (cm-1): 2920 (w), 2854 (w), 1680 (s), 1368 (m), 1326 (vs), 1306 (m), 1282 (m), 
1258 (m), 1250 (m), 1160 (vs), 1142 (m), 1118 (vs), 1104 (s), 1090 (m), 1068 (vs), 1020 (m), 
854 (m), 838 (s), 788 (m), 662 (m), 612 (m). 
HRMS (EI) for C21H28F3NO2 (383.2072): 383.2075. 
 
t-butyl 3-(4-cyanophenyl)octahydroisoquinoline-2(1H)-carboxylate (173o) 
 
Cross-coupling was performed according to TP16. 
column chromatography: SiO2; n-pentane/Et2O 5:1 
yield: 129 mg (54 %) 
d.r.: >99:1. 
m.p.: 83.3 – 84.6 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.11 (m, J=8.4 Hz, 2 H), 6.86 (m, J=8.2 Hz, 2 H), 4.04 - 3.94 
(m, 2 H), 2.56 (dd, J1=12.8 Hz, J2=10.8 Hz, 1 H), 1.55 (d, J=9.0 Hz, 2 H), 1.42 - 1.33 (m, 3 
H), 1.14 (s, 9 H), 1.09 - 1.01 (m, 2 H), 0.96 - 0.83 (m, 2 H), 0.77 - 0.62 (m, 3 H). 
13C-NMR (101 MHz, CDCl3) δ: 156.6, 152.1, 132.2, 126.4, 119.2, 110.4, 79.7, 59.6, 52.1, 
41.3, 40.7, 39.7, 32.9, 30.8, 28.2, 26.4, 26.1. 
MS (70 eV, EI) m/z (%): 340 (1) [M+], 284 (65), 240 (37), 239 (100), 182 (37), 143 (35), 138 
(37), 74 (45), 59 (73), 57 (89), 45 (51), 41 (63). 
IR (ATR) ν~  (cm-1): 2922 (m), 2844 (w), 2230 (w), 1686 (vs), 1372 (m), 1364 (m), 1328 (m), 
1306 (m), 1280 (m), 1252 (m), 1222 (m), 1162 (vs), 1140 (m), 1128 (m), 1118 (m), 1102 (m), 
836 (m), 788 (m). 
HRMS (EI) for C21H28N2O2 (340.2151): 340.2151. 
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t-butyl 3-(4-methoxyphenyl)octahydroisoquinoline-2(1H)-carboxylate (173p) 
 
Cross-coupling was performed according to TP16. 
column chromatography: SiO2; n-pentane/Et2O 6:1 
yield: 145 mg (60 %) 
d.r.: 97:3. 
m.p.: 73.1 – 74.7 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.19 (d, J=8.0 Hz 2 H), 6.85 (d, J=8.8 Hz, 2 H), 4.50 (dd, 
J1=10.1 Hz, J2=5.6 Hz, 1 H), 4.04 (dd, J1=13.0 Hz, J2=5.6 Hz, 1 H), 3.36 (s, 3 H), 2.89 (dd, 
J1=12.9 Hz, J2= 9.7 Hz, 1 H), 1.75 (ddd, J1=13.3 Hz, J2=5.6 Hz, J3=3.7 Hz, 1 H), 1.55 (d, 
J=8.0 Hz, 2 H), 1.44 (td, J1=6.0 Hz, J2=2.8 Hz, 2 H), 1.36 - 1.27 (m, 10 H), 1.14 - 1.01 (m, 3 
H), 0.89 - 0.69 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 159.0, 157.0, 139.0, 131.0, 127.4, 114.2, 79.2, 58.8, 55.2, 
51.6, 41.1, 40.8, 39.9, 33.5, 31.6, 30.6, 28.7, 26.9, 26.6. 
MS (70 eV, EI) m/z (%): 345 (2) [M+], 290 (20), 289 (100), 288 (36), 245 (20), 244 (85), 181 
(11), 137 (10), 136 (15), 121 (18), 57 (14). 
IR (ATR) ν~  (cm-1): 2930 (m), 2918 (m), 2854 (m), 1684 (vs), 1510 (s), 1466 (m), 1444 (m), 
1390 (m), 1366 (s), 1324 (m), 1304 (m), 1278 (m), 1238 (vs), 1224 (s), 1166 (vs), 1142 (s), 
1126 (s), 1102 (s), 1090 (m), 1078 (m), 1036 (s), 1018 (m), 976 (m), 876 (m), 858 (m), 828 
(vs), 816 (m), 786 (s), 764 (m).  
HRMS (EI) for C21H31NO3 (345.2304): 345.2296. 
 
5.6. Typical Procedure 17: Cross-Coupling of (1-(t-Butoxycarbonyl)-5-
methylpiperidin-2-yl)zinc Chloride (TP 17) (Table 11) 
 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t-butyl 3-methylpiperidine-1-carboxylate (1 mmol; 0.20 g) and TMEDA (1 mmol; 
0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and s-BuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred 
for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The 
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reaction mixture was stirred for 15 min at -78 °C and was then allowed to warm to room 
temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the 
respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and Ru-Phos (23.3 mg; 
0.05 mmol) was prepared and cooled to 0 °C. The piperidinylzinc reagent was added to this 
mixture at this temperature and stirred for 6 h. It was then kept at room temperature for 
further 12 h and eventually heated to 40 °C for 12 h. NH4Cl sat. aq. solution (20 mL) was 
added, the phases were separated and the aqueous phase was extracted with Et2O (4 x 10 mL). 
The combined organic layers were washed with brine (10 mL) and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography yielding 
the respective title compound. 
 
trans-t-butyl 2-(4-cyanophenyl)-5-methylpiperidine-1-carboxylate (173q) 
 
Cross-coupling was performed according to TP17. 
column chromatography: SiO2; n-pentane/Et2O 4:1 
yield: 128 mg (61 %) 
d.r.: 96:4. (10% regioisomer) 
1H-NMR (400 MHz, C6D6) δ: 7.04 (m, J=8.4 Hz, 2 H), 6.80 (d, J=8.0 Hz, 2 H), 5.22 (br. s., 1 
H), 3.67 (d, J=13.6 Hz, 1 H), 2.70 (dd, J1=13.4 Hz, J2=3.7 Hz, 1 H), 1.78 - 1.67 (m, 1 H), 1.41 
(s, 9 H), 1.39 - 1.28 (m, 3 H), 1.24 - 1.14 (m, 1 H), 0.90 (d, J=7.0 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.4, 146.3, 137.7, 132.4, 131.8, 126.7, 118.5, 110.6, 79.0, 
53.5, 45.1, 28.0, 27.7, 25.7, 23.0, 17.0. 
MS (70 eV, EI) m/z (%): 300 (1) [M+], 245 (23), 244 (87), 227 (17), 200 (30), 199 (96), 143 
(11), 142 (32), 129 (16), 116 (26), 98 (11), 57 (100), 43 (18), 41 (18). 
IR (ATR) ν~  (cm-1): 2960 (w), 2928 (w), 2228 (w), 1684 (s), 1476 (w), 1456 (m), 1414 (s), 
1392 (m), 1364 (s), 1328 (m), 1246 (m), 1172 (s), 1142 (vs), 1102 (w), 1084 (m), 1058 (m), 
1018 (w), 990 (m), 878 (w), 854 (m), 838 (m), 768 (m). 
HRMS (EI) for C18H24N2O2 (300.1838): 300.1840. 
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trans-t-butyl 2-(4-(ethoxycarbonyl)phenyl)-5-methylpiperidine-1-carboxylate (173r) 
 
Cross-coupling was performed according to TP17. 
column chromatography: SiO2; n-pentane/Et2O 5:1 
yield: 153 mg (63 %) 
d.r.: 95:5. 
1H-NMR (400 MHz, C6D6) δ: 8.17 (d, J=8.4 Hz, 2 H), 7.15 (d., 2 H), 5.41 (br. s., 1 H), 4.15 
(q, J=7.0 Hz, 2 H), 3.78 (d, J=13.4 Hz, 1 H), 2.88 (dd, J1=13.5 Hz, J2=3.6 Hz, 1 H), 1.87 - 
1.77 (m, 1 H), 1.62 - 1.54 (m, 1 H), 1.49-1.43 (m, 10 H), 1.40 - 1.27 (m, 2 H), 1.03 (t, J=7.1 
Hz, 3 H), 0.94 (d, J=7.0 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.5, 156.3, 147.2, 130.6, 130.5, 130.4, 129.8, 127.1, 79.6, 
61.1, 54.4, 45.8, 28.8, 28.5, 26.5, 23.9, 17.8, 14.7. 
MS (70 eV, EI) m/z (%): 347 (1) [M+], 292 (16), 291 (92), 262 (17), 247 (11), 246 (53), 219 
(15), 218 (100), 142 (13), 98 (12), 57 (18). 
IR (ATR) ν~  (cm-1): 2964 (w), 2932 (w), 1716 (s), 1686 (vs), 1610 (w), 1476 (w), 1456 (m), 
1416 (s), 1392 (m), 1364 (s), 1342 (w), 1324 (m), 1312 (m), 1270 (vs), 1246 (s), 1172 (s), 
1142 (vs), 1122 (s), 1102 (vs), 1058 (m), 1018 (s), 988 (m), 892 (w), 878 (m), 864 (m), 836 
(w), 766 (m), 746 (m), 724 (w), 696 (m).  
HRMS (EI) for C20H29NO4 (347.2097): 347.2096. 
 
5.7. Typical Procedure 18: Preparation of Piperidin-4-ylzinc Iodides (TP 18) 
(Table 12) 
 
Anhydrous LiCl (4.5 mmol; 0.19 g) was placed in an Ar-flushed flask and dried for 20 min at 
150-170 °C under high vacuum (1 mbar). Zn powder (9 mmol; 0.59 g; 150 mesh, Chemetall) 
was added under Ar and the heterogeneous mixture of Zn and LiCl was dried again under 
vigorous stirring for 20 min at 150-170 °C under high vacuum (1 mbar). The reaction mixture 
was evacuated and refilled with Ar three times. A catalytic amount of 1,2-dibromoethane and 
THF (6 mL) were added. The mixture was gently heated in order to activate the Zn surface. 
The respective 4-iodopiperidine was added neat at room temperature. The resulting reaction 
mixture was stirred for 4 h at ambient temperature. It was then separated from the remaining 
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Zn powder via syringe filter (25 mm with 1 µm glass fiber membrane) and transferred to an 
Ar-flushed Schlenk flask. The concentrations of all piperidinylzinc reagents were determined 
via titration with I2 (50 mg in 2 mL THF). 
 
(1-(t-butoxycarbonyl)-2-(4-(trifluoromethyl)phenyl)-piperidin-4-yl)zinc iodide (174a) 
 
Zn-insertion was performed according to TP18. 
0.35 M (70%) 
 
(1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)zinc iodide (174b) 
 
Zn-insertion was performed according to TP18. 
0.39 M (78%) 
 
(2-methyl-1-tosylpiperidin-4-yl)zinc iodide (174c) 
N
ZnI
Ts
Me
 
Zn-insertion was performed according to TP18. 
0.42 M (84%) 
 
5.8. Typical Procedure 19: Cross-Coupling of Piperidin-4-ylzinc Iodides (TP 19) 
(Table 12) 
 
A dry and Ar-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
septum was charged with TMPP2PdCl2 (0.05 mmol; 63 mg), the respective aryl iodide (0.8 
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mmol), THF (0.8 mL) and NEP (0.02 mL). The mixture was stirred for 5 min at room 
temperature and then cooled to -10 °C. The corresponding piperidin-4-ylzinc iodide (0.36 – 
0.39 M solution in THF) was slowly added via syringe. The reaction mixture was kept for 12 
h at -10 °C and subsequently 5 h at -5 °C. NH4Cl sat. aq. solution (20 mL) was added, the 
phases were separated and the aqueous phase was extracted with CH2Cl2 (4 x 20 mL). The 
combined organic layers were washed with brine (20 mL) and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography yielding 
the respective title compound. 
 
trans-t-butyl 4-(4-cyanophenyl)-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate 
(176a) 
N
Boc
CF3
CN
 
Cross-coupling was performed according to TP19. 
column chromatography: SiO2; n-pentane/Et2O 5:1 to 2:1 
yield: 255 mg (74 %) 
d.r.: 91:9. 
m.p.: 72.9 – 74.6 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.42 (d, J=8.2 Hz, 2 H), 7.08 (d, J=8.2 Hz, 2 H), 7.04 (d, J=8.0 
Hz, 2 H), 6.55 (d, J=8.0 Hz, 2 H), 5.59 (br. s., 1 H), 4.21 (br. s., 1 H), 2.66 - 2.57 (m, 1 H), 
2.22 - 2.12 (m, 1 H), 1.93 (d, J=13.7 Hz, 1 H), 1.59 (td, J1=13.4 Hz, J2= 5.5 Hz, 1 H), 1.49 (s, 
9 H), 1.33 - 1.20 (m, 2 H). 
13C-NMR (101 MHz, C6D6) δ: 154.7, 149.7, 144.2, 131.8, 129.0 (q, J=32.5 Hz), 126.9, 
126.6, 125.5 (q, J=3.7 Hz), 124.4 (q, J=271.9 Hz), 118.1, 110.9, 79.6, 52.9, 39.9, 36.9, 34.7, 
32.1, 28.0. 
19F-NMR (282 MHz, C6D6) δ: -62.14 (s) (minor), -62.19 (s) (major)  
MS (70 eV) m/z (%): 330 (20), 329 (19), 328 (11), 311 (14), 227 (19), 213 (33), 207 (21), 200 
(32), 188 (11), 187 (59), 186 (100), 185 (17), 173 (13). 
IR (ATR) ν~  (cm-1): 2976 (vw), 2932 (w), 2868 (vw), 2228 (w), 1686 (s), 1620 (w), 1608 
(w), 1506 (vw), 1478 (vw), 1454 (w), 1414 (m), 1366 (m), 1326 (vs), 1282 (m), 1258 (w), 
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1236 (w), 1218 (w), 1156 (vs), 1118 (vs), 1068 (s), 1016 (m), 986 (w), 968 (w), 912 (w), 886 
(w), 862 (w), 834 (s), 810 (w), 770 (w), 728 (w), 722 (w). 
HRMS (ESI) for C24H25F3N2O2Cl- (465.1557) [M+Cl-]: 465.1564.  
 
trans-t-butyl 4-phenyl-2-(4-(trifluoromethyl)phenyl)-piperidine-1-carboxylate (176b) 
N
Boc
CF3
 
Cross-coupling was performed according to TP19. 
column chromatography: SiO2; CH2Cl2 
yield: 162 mg (50 %) 
d.r.: 92:8. 
1H-NMR (400 MHz, C6D6) δ: 7.41 (d, J=8.2 Hz, 2 H), 7.16 - 7.02 (m, 5 H), 6.91 (d, J=7.4 
Hz, 2 H), 5.63 (br. s., 1 H), 4.25 (br. s., 1 H), 2.73 - 2.65 (m, 1 H), 2.38 (t, J=11.7 Hz, 1 H), 
2.15 (d, J=13.7 Hz, 1 H), 1.83 (td, J1=13.3 Hz, J2=5.5 Hz, 1 H), 1.54 - 1.40 (m, 11 H). 
13C-NMR (101 MHz, C6D6) δ: 155.7, 146.1, 145.6, 129.7 (q, J=32.5 Hz), 129.2, 127.6, 
127.3, 127.1, 126.2 (q, J=3.9 Hz), 126.1 (q, J=271.8 Hz), 80.1, 54.1, 41.2, 37.8, 36.2, 33.7, 
28.9. 
MS (70 eV, EI) m/z (%): 405 (1) [M+], 350 (22), 349 (100), 304 (21), 200 (14), 187 (10), 186 
(12), 159 (10), 118 (37), 104 (15), 90 (19), 59 (89), 41 (13); 18 (25). 
IR (ATR) ν~  (cm-1): 2976 (w), 2932 (w), 2868 (vw), 1688 (s), 1620 (w), 1494 (vw), 1478 
(w), 1454 (w), 1414 (m), 1394 (m), 1366 (m), 1324 (vs), 1300 (m), 1282 (m), 1268 (m), 1256 
(w), 1234 (m), 1214 (w), 1154(s), 1118 (vs), 1068 (s), 1016 (s), 986 (w), 964 (w), 912 (w), 
888 (w), 862 (w), 838 (m), 760 (m), 730 (w), 722 (w), 698 (s), 638 (w). 
HRMS (EI) for C23H26F3NO2 (405.1916): 405.1932. 
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4-(trans-1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (176c) 
N
Ts
CF3
CN
 
Cross-coupling was performed according to TP19. 
column chromatography: SiO2; n-pentane/Et2O 5:1 to 1:1 
yield: 271 mg (70 %) 
d.r.: >99:1. 
m.p.: 181.7 – 183.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.74 (d, J=8.2 Hz, 2 H), 7.35 (d, J=8.4 Hz, 2 H), 7.07 (d, J=8.2 
Hz, 2 H), 6.98 (m, J=8.4 Hz, 2 H), 6.83 (d, J=8.0 Hz, 2 H), 6.35 (d, J=8.2 Hz, 2 H), 5.38 (d, 
J=3.3 Hz, 1 H), 3.97 - 3.85 (m, 1 H), 2.69 - 2.58 (m, 1 H), 2.05 - 1.96 (m, 1 H), 1.94 (s, 3 H), 
1.76 (d, J=13.8 Hz, 1 H), 1.51 (td, J1=13.4 Hz, J2=5.3 Hz, 1 H), 1.16 (qd, J1=12.7 Hz, J2=4.4 
Hz, 1 H), 0.95 (d, J=12.9 Hz, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 150.0, 143.7, 143.5 (d, J=1.1 Hz), 139.6, 132.7, 130.3, 129.9 
(q, J=32.2 Hz), 127.8, 127.7, 127.7, 126.3 (q, J=3.7 Hz), 125.2 (q, J=271.7 Hz), 119.1, 111.5, 
55.5, 42.0, 37.0, 34.4, 31.8, 21.5. 
19F-NMR (282 MHz, C6D6) δ: -62.16 (s). 
MS (70 eV) m/z (%): 386 (37), 377 (25), 376 (100), 375 (21), 374 (16), 329 (17), 281 (10), 
208 (13), 207 (56), 200 (14), 199 (12), 186 (43); 172 (13); 159 (29); 155 (21); 131 (20); 103 
(10), 92 (10); 91 (73). 
IR (ATR) ν~  (cm-1): 2956 (w), 2930 (w), 2232 (m), 1412 (w), 1326 (vs), 1256 (m), 1158 (vs), 
1110 (s), 1094 (s), 1072 (s), 1018 (s), 944 (m), 928 (s), 906 (m), 838 (s), 826 (s), 800 (m), 716 
(s), 702 (s), 664 (vs), 650 (s). 
HRMS (ESI) for C26H23F3N2O2SCl- (519.1126) [M+Cl-]: 519.1122. 
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methyl 4-(trans-1-tosyl-2-(4-(trifluoromethyl)phenyl)-piperidin-4-yl)benzoate (176d) 
N
Ts
CF3
CO2Me
 
Cross-coupling was performed according to TP19. 
column chromatography: SiO2; n-pentane/Et2O 5:1 to 1:1 
yield: 286 mg (69 %) 
d.r.: 97:3. 
m.p.: 68.8 – 70.5 °C.  
1H-NMR (300 MHz, C6D6) δ: 8.06 (d, J=8.2 Hz, 2 H), 7.76 (d, J=8.2 Hz, 2 H), 7.36 (d, J=8.2 
Hz, 2 H), 7.14 (d, J=8.0 Hz, 3 H), 6.83 (d, J=8.0 Hz, 2 H), 6.68 (d, J=8.2 Hz, 2 H), 5.40 (d, 
J=3.4 Hz, 1 H), 3.94 (d, J=14.2 Hz, 1 H), 3.51 (s, 3 H), 2.74 - 2.63 (m, 1 H), 2.25 - 2.13 (m, 1 
H), 1.94 (s, 3 H), 1.87 (br. s., 1 H), 1.63 (dd, J1=13.4 Hz, J2=5.3 Hz, 2 H), 1.34 - 1.25 (m, 1 
H), 1.08 (d, J=14.6 Hz, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 166.8, 150.5, 143.7 (d, J=1.2 Hz), 143.6, 139.8, 130.6, 130.2, 
129.8 (q, J=32.3 Hz), 129.7, 128.0, 127.8, 127.2, 126.3 (q, J=3.8 Hz), 125.3 (q, J=272.0 Hz), 
55.7, 52.0, 42.2, 37.1, 34.4, 31.9, 21.5. 
MS (70 eV, EI) m/z (%): 517 (11) [M+], 371 (35), 362 (24), 361 (100), 360 (27), 359 (12), 
186 (21), 155 (11), 90 (22). 
IR (ATR) ν~  (cm-1): 2952 (vw), 2930 (vw), 2876 (vw), 1718 (s), 1610 (w), 1494 (vw), 1450 
(w), 1436 (w), 1412 (w), 1326 (vs), 1278 (s), 1182 (w), 1156 (vs), 1114 (vs), 1096 (s), 1068 
(s), 1016 (m), 954 (w), 932 (s), 908 (m), 840 (m), 816 (m), 802 (w), 770 (m), 742 (m), 716 
(m), 708 (m), 690 (s), 658 (s), 646 (m). 
HRMS (EI) for C27H26F3NO4S (517.1535): 517.1537. 
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4-(trans-2-methyl-1-tosylpiperidin-4-yl)benzonitrile (176e) 
N
CN
Ts
Me
 
Cross-coupling was performed according to TP19. 
column chromatography: SiO2; n-pentane/Et2O 5:1 to 1:1 
yield: 238 mg (84 %) 
d.r.: 97:3. 
m.p.: 106.2 – 107.1 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.77 (d, J=8.2 Hz, 2 H), 7.01 (m, J=8.2 Hz, 2 H), 6.85 (m, 
J=8.0 Hz, 2 H), 6.43 (d, J=8.2 Hz, 2 H), 4.41 - 4.33 (m, J1=6.2 Hz, J2=6.2 Hz, J3=6.1 Hz, 
J4=5.9 Hz, 1 H), 3.86 - 3.78 (m, 1 H), 2.64 (td, J1=12.9 Hz, J1= 3.0 Hz, 1 H), 2.24 - 2.15 (m, 
J1=12.5 Hz, J2=12.5 Hz, J3=3.7 Hz, J4=3.5 Hz, 1 H), 1.94 (s, 3 H), 1.38 (td, J1=13.1 Hz, 
J2=5.3 Hz, 1 H), 1.25 - 1.12 (m, 1 H), 1.12 - 1.06 (m, 1 H), 1.03 (dt, J1=13.1 Hz, J2=1.6 Hz, 1 
H), 0.80 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 150.6, 143.1, 139.9, 132.6, 130.1, 128.0, 127.8, 119.3, 111.3, 
48.8, 40.3, 37.8, 36.5, 32.6, 21.5, 15.6. 
MS (70 eV, EI) m/z (%): 354 (3) [M+], 340 (21), 339 (100), 155 (35), 90 (47), 58 (9). 
IR (ATR) ν~  (cm-1): 2982 (vw), 2946 (vw), 2918 (vw), 2868 (vw), 2226 (w), 1604 (w), 1504 
(w), 1446 (vw), 1370 (w), 1348 (w), 1332 (m), 1316 (w), 1302 (w), 1290 (w), 1276 (w), 1256 
(w), 1206 (w), 1178 (w), 1158 (s), 1148 (m), 1118 (w), 1104 (w), 1092 (m), 1070 (m), 1056 
(w), 1018 (w), 1012 (w), 996 (m), 972 (m), 930 (m), 880 (w), 858 (m),848 (w), 828 (m), 816 
(m), 800 (w), 722 (w), 710 (s), 698 (s), 652 (s), 624 (w). 
HRMS (EI) for C20H22N2O2S (354.1402): 354.1384. 
 
methyl 4-(trans-2-methyl-1-tosylpiperidin-4-yl)benzoate (176f) 
N
CO2Me
Ts
Me
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Cross-coupling was performed according to TP19. 
column chromatography: SiO2; n-pentane/Et2O 5:1 to 1:1 
yield: 276 mg (89 %) 
d.r.: 97:3. 
m.p.: 129.8 – 131.5 °C.  
1H-NMR (400 MHz, C6D6) δ: 8.08 (d, J=8.4 Hz, 2 H), 7.78 (m, J=8.2 Hz, 2 H), 6.84 (m, 
J=8.0 Hz, 2 H), 6.75 (d, J=8.4 Hz, 2 H), 4.39 (qd, J1=6.2 Hz, J2=6.0 Hz, 1 H), 3.88 - 3.81 (m, 
1 H), 3.52 (s, 3 H), 2.69 (td, J1=12.9 Hz, J2=3.0 Hz, 1 H), 2.36 (tt, J1=12.5 Hz, J2=3.6 Hz, 1 
H), 1.93 (s, 3 H), 1.51 (td, J1=13.1 Hz, J2=5.3 Hz, 1 H), 1.36 - 1.25 (m, 1 H), 1.25 - 1.19 (m, 1 
H), 1.15 (dt, J1=13.1 Hz, J2=1.7 Hz, 1 H), 0.84 (d, J=7.0 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 167.0, 151.1, 143.0, 140.0, 130.5, 130.1, 129.5, 127.8, 127.5, 
51.9, 49.0, 40.5, 38.0, 36.5, 32.8, 21.5, 15.7. 
MS (70 eV, EI) m/z (%): 387 (3) [M+], 372 (23), 371 (100), 210 (8), 155 (23), 90 (33), 58 (9). 
IR (ATR) ν~  (cm-1): 2984 (vw), 2960 (w), 2936 (w), 2910 (w), 2856 (w), 1720 (s), 1608 (w), 
1596 (w), 1434 (m), 1380 (w), 1330 (m), 1304 (m), 1280 (vs), 1252 (m), 1210 (w), 1198 (w), 
1188 (w), 1174 (m), 1156 (vs), 1142 (s), 1110 (m), 1094 (s), 1070 (m), 1056 (m), 1018 (w), 
994 (m), 970 (m), 958 (w), 926 (m), 882 (w), 864 (m), 848 (m), 824 (w), 814 (m), 798 (w), 
770 (m), 704 (s), 684 (s), 648 (m). 
HRMS (EI) for C21H25NO4S (387.1504): 387.1512. 
 
5.9. Typical Procedure 20: Cross-Coupling of (1-(t-Butoxycarbonyl)-6-
methylpiperidin-2-yl)zinc Chloride (TP 20) (Scheme 45) 
 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t- butyl 2-methylpiperidine-1-carboxylate (1 mmol; 0.20 g) and TMEDA (1 mmol; 
0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and s-BuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred 
for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The 
reaction mixture was stirred for 15 min at -78 °C and was then allowed to warm to room 
temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the 
respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and Ru-Phos (23.3 mg; 
0.05 mmol) was prepared and cooled to 0 °C. The piperidinylzinc reagent was added to this 
mixture and stirred for 12 h. The reaction mixture was then warmed to room temperature and 
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stirred for 12 h and finally heated to 40 °C for 12 h. NH4Cl sat. aq. solution (20 mL) was 
added, the phases were separated and the aqueous phase was extracted with Et2O (4 x 10 mL). 
The combined organic layers were washed with brine (10 mL) and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography yielding 
the respective title compound. 
 
trans-t-butyl 2-methyl-5-phenylpiperidine-1-carboxylate (181a) 
 
Cross-coupling was performed according to TP20. 
column chromatography: SiO2; CH2Cl2 
yield: 173 mg (90 %) 
d.r.: 93:7. 
1H-NMR (400 MHz, C6D6) δ: 7.34 (d, J=7.6 Hz, 2 H), 7.21 (t, J=7.7 Hz, 2 H), 7.08 (t, J=7.4 
Hz, 1 H), 4.41 - 4.33 (m, 2 H), 3.10 (dd, J1=14.0 Hz, J2=4.3 Hz, 1 H), 2.59 (br. s., 1 H), 1.75 - 
1.58 (m, 3 H), 1.58 - 1.39 (m, 9 H), 1.05 (d, J=6.8 Hz, 3 H), 0.94 - 0.88 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.2, 144.7, 128.9, 128.7, 128.3, 126.6, 126.4, 79.2, 47.3, 
42.5, 38.6, 28.9, 26.3, 26.1, 16.9. 
MS (70 eV, EI) m/z (%): 275 (1) [M+], 219 (29), 204 (44), 160 (24), 104 (16), 102 (17), 97 
(24), 85 (24), 83 (22), 71 (31), 69 (24), 59 (26), 57 (100), 55 (28), 43 (24), 41 (25). 
IR (ATR) ν~  (cm-1): 2930 (m), 2920 (w), 1684 (vs), 1452 (m), 1414 (m), 1390 (m), 1364 (s), 
1338 (m), 1326 (m), 1308 (m), 1278 (m), 1240 (s), 1166 (s), 1148 (s), 1116 (s), 1078 (m), 
1068 (m), 1050 (m), 1036 (m), 874 (m), 860 (m), 838 (m), 828 (m), 786 (m), 766 (m), 734 
(m), 698 (s), 640 (w). 
HRMS (EI) for C19H25NO2 (275.1885): 275.1874. 
 
trans-t-butyl 5-(4-methoxyphenyl)-2-methylpiperidine-1-carboxylate (181b) 
 
Cross-coupling was performed according to TP20. 
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column chromatography: SiO2; n-pentane/Et2O 8:1 
yield: 130 mg (61 %) 
d.r.: 94:6. 
1H-NMR (400 MHz, C6D6) δ: 7.27 (d, J=8.5 Hz, 2 H), 6.84 (d, J=8.5 Hz, 2 H), 4.42 - 4.33 
(m, 2 H), 3.34 (s, 3 H), 3.14 (dd, J1=13.9 Hz, J2=4.3 Hz, 1 H), 2.64 - 2.59 (m, 1 H), 1.77 - 
1.60 (m, 3 H), 1.58 - 1.52 (m, 1 H), 1.48 (s, 9 H), 1.07 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 158.8, 155.3, 136.4, 129.2, 127.4, 114.4, 114.3, 79.2, 55.1, 
47.3, 42.7, 37.8, 29.0, 28.8, 26.3, 16.9. 
MS (70 eV, EI) m/z (%): 305 (13) [M+], 249 (79), 234 (36), 232 (23), 204 (32), 190 (29), 175 
(21), 148 (35), 147 (22), 134 (57), 121 (46), 102 (37), 91 (23), 58 (31), 57 (100), 43 (79), 41 
(21). 
IR (ATR) ν~  (cm-1): 2972 (w), 2934 (w), 1684 (vs), 1612 (m), 1512 (s), 1456 (m), 1412 (s), 
1390 (m), 1364 (s), 1340 (m), 1306 (m), 1246 (vs), 1168 (vs), 1148 (vs), 1114 (s), 1090 (m), 
1036 (s), 878 (m), 828 (s), 808 (m), 768 (m).  
HRMS (EI) for C18H27NO3 (305.1991): 305.1990. 
 
trans-t-butyl 2-methyl-5-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (181c) 
 
Cross-coupling was performed according to TP20. 
column chromatography: SiO2; CH2Cl2 
yield: 197 mg (82 %) 
d.r.: 96:4. 
1H-NMR (400 MHz, C6D6) δ: 7.39 (d, J=8.2 Hz, 2 H), 7.18 (d, 2 H), 4.36 - 4.30 (m, 1 H), 
4.26 (d, J=14.4 Hz, 1 H), 2.98 (dd, J1=14.1 Hz, J2=4.4 Hz, 1 H), 2.41 (br. s., 1 H), 1.65 - 1.54 
(m, 1 H), 1.49 - 1.39 (m, 9 H), 1.35 (td, J1=11.6 Hz, J2=4.8 Hz, 2 H), 1.01 (d, J=6.8 Hz, 3 H), 
0.85 (ddd, J1=12.7 Hz, J2=4.3 Hz, J3=4.1 Hz, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 148.7 (d, J=1.1 Hz), 128.8 (q, J=32.2 Hz), 128.0, 125.7 
(q, J=3.8 Hz), 125.5 (q, J=271.7 Hz), 79.5, 47.1, 41.7, 38.2, 28.9, 26.1, 25.8, 16.6. 
19F-NMR (376 MHz, C6D6) δ: -61.92 (s) (minor), -62.05 (s) (major). 
MS (70 eV, EI) m/z (%): 343 (2) [M+], 288 (12), 287 (31), 273 (13), 272 (100), 270 (16), 242 
(10), 228 (52), 172 (14), 57 (82). 
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IR (ATR) ν~  (cm-1): 2980 (w), 2930 (w), 1680 (s), 1412 (m), 1366 (m), 1328 (s), 1310 (m), 
1254 (m), 1236 (m), 1162 (s), 1148 (s), 1116 (vs), 1090 (s), 1070 (s), 1054 (m), 1038 (m), 
1018 (m), 882 (m), 866 (m), 834 (s), 768 (m), 708 (m), 648 (m).  
HRMS (EI) for C18H24F3NO2 (343.1759): 343.1757. 
 
trans-t-butyl 5-(4-cyanophenyl)-2-methylpiperidine-1-carboxylate (181d) 
 
Cross-coupling was performed according to TP20. 
column chromatography: SiO2; n-pentane/Et2O 3:1 
yield: 111 mg (53 %) 
d.r.: 94:6. 
1H-NMR (400 MHz, C6D6) δ: 7.08 (d, J=8.4 Hz, 2 H), 6.99 (d, J=8.2 Hz, 2 H), 4.30 - 4.21 
(m, 1 H), 4.17 (d, J=14.2 Hz, 1 H), 2.92 (dd, J1=14.2 Hz, J2=4.3 Hz, 1 H), 2.32 (br. s., 1 H), 
1.61 - 1.51 (m, 1 H), 1.44 (s, 9 H), 1.34 - 1.26 (m, 2 H), 0.99 (d, J=6.8 Hz, 3 H), 0.87 - 0.79 
(m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.0, 149.5, 132.3, 128.8, 126.8, 126.2, 119.4, 110.8, 79.6, 
47.1, 41.4, 38.4, 28.9, 26.0, 25.6, 16.6. 
MS (70 eV, EI) m/z (%): 300 (4) [M+], 245 (13), 244 (36), 229 (64), 227 (16), 200 (12), 199 
(46), 185 (36), 142 (15), 130 (10), 129 (18), 58 (20), 57 (100), 43 (52), 41 (14). 
IR (ATR) ν~  (cm-1): 2972 (w), 2934 (w), 2228 (w), 1682 (vs), 1608 (w), 1476 (w), 1454 (w), 
1414 (s), 1392 (m), 1364 (s), 1340 (m), 1308 (m), 1256 (m), 1240 (m), 1166 (s), 1148 (s), 
1118 (m), 1100 (w), 1090 (m), 1052 (m), 1038 (w), 880 (w), 864 (w), 832 (m), 770 (w).  
HRMS (EI) for C18H24N2O2 (300.1838): 300.1831. 
 
trans-t-butyl 2-methyl-5-(pyridin-3-yl)piperidine-1-carboxylate (181e) 
 
Cross-coupling was performed according to TP20. 
column chromatography: SiO2; Et2O 
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yield: 116 mg (60 %) 
d.r.: 95:5. 
1H-NMR (400 MHz, C6D6) δ: 8.69 (d, J=2.1 Hz, 1 H), 8.47 (dd, J1=4.7 Hz, J2=1.4 Hz, 1 H), 
7.47 (d, J=7.8 Hz, 1 H), 6.79 (dd, J1=7.8 Hz, J2=4.9 Hz, 1 H), 4.31 (dd, J1=9.8 Hz, J2=6.3 Hz, 
1 H), 4.23 (d, J=14.1 Hz, 1 H), 2.96 (dd, J1=14.2 Hz, J2=4.4 Hz, 1 H), 2.39 (br. s., 1 H), 1.61 - 
1.52 (m, 1 H), 1.51-1.37 (m, 10 H), 1.36 - 1.29 (m, 1 H), 0.99 (d, J=6.8 Hz, 3 H), 0.88 - 0.80 
(m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 150.7, 148.3, 139.5, 134.8, 123.4, 79.5, 47.1, 41.8, 
36.3, 28.9, 26.1, 25.6, 16.6. 
MS (70 eV, EI) m/z (%): 276 (11) [M+], 221 (19), 220 (21), 205 (24), 203 (25), 176 (43), 175 
(15), 161 (75), 133 (16), 119 (27), 106 (40), 105 (17), 57 (100), 41 (15). 
IR (ATR) ν~  (cm-1): 2976 (w), 2934 (w), 1680 (vs), 1476 (w), 1408 (s), 1390 (m), 1382 (m), 
1364 (s), 1340 (s), 1312 (m), 1296 (w), 1256 (m), 1244 (m), 1232 (m), 1182 (m), 1172 (m), 
1146 (s), 1120 (s), 1088 (s), 1048 (m), 1040 (m), 1022 (m), 1000 (m), 986 (w), 912 (w), 878 
(m), 862 (m), 824 (m), 802 (m), 780 (m), 770 (s), 748 (w), 726 (w), 712 (s), 640 (m), 624 (m). 
HRMS (EI) for C16H24N2O2 (276.1838): 276.1834. 
 
5.10. Typical Procedure 21: Synthesis of N-Tosyl Piperidines (TP 21) 
 
To a solution of the respective t-butyl piperidine-1-carboxylate (Boc-protected amine) (1 
equiv.) in Et2O (3 mL per 1 mmol) was added trifluoroacetic acid (TFA; 40 equiv.) at 0 °C. 
The reaction mixture was stirred for 15 h at room temperature, then cooled to 0 °C and 
carefully neutralized using NaHCO3 sat. aq. solution. The resulting mixture was extracted 
with CH2Cl2 (4 x). The combined organic phases were washed with brine and dried over 
Na2SO4. The solvents were removed via rotary evaporation. The crude deprotected amine 
(quant. yield) was added to a solution of p-tolyl-1-sulfonyl chloride (2 equiv.) and NEt3 (2 
equiv.) in THF (0.2 M). The reaction mixture was stirred for 15 h. NH4Cl sat. aq. solution was 
added. The phases were separated and the aqueous layer was extracted with CH2Cl2 (4 x). The 
combined organic phases were washed with brine and dried over Na2SO4. The solvents were 
evaporated and the crude product was purified via column chromatography to give the 
respective title compound. 
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2-tosyl-3-(4-(trifluoromethyl)phenyl)decahydroisoquinoline (173na) 
 
Tosylation was performed according to TP21. 
column chromatography: SiO2; CH2Cl2 
yield: 136 mg (78 %; 0.4 mmol scale) 
m.p.: 194.1 – 195.6 °C.  
1H-NMR (300 MHz, CDCl3) δ: 7.50 (d, J=8.3 Hz, 2 H), 7.43 (d, J=8.3 Hz, 2 H), 7.39 (d, 
J=8.0 Hz, 2 H), 7.24 (d, J=8.0 Hz, 2 H), 4.12 (dd, J1=11.5 Hz, J2=3.7 Hz, 1 H), 3.91 (dd, 
J1=11.3 Hz, J2=3.6 Hz, 1 H), 2.56 - 2.37 (m, 4 H), 1.95 - 1.77 (m, 3 H), 1.73 (t, J=3.3 Hz, 1 
H), 1.70 - 1.49 (m, 3 H), 1.47 - 1.28 (m, 2 H), 1.17 - 0.98 (m, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 145.7 (d, J=1.3 Hz), 143.2, 134.8, 129.5, 129.2 (q, J=32.2 
Hz), 129.1, 128.4, 128.1, 127.9, 127.8, 127.4, 124.5 (q, J=3.9 Hz), 124.1 (q, J=272.1 Hz), 
63.1, 53.7, 43.6, 41.0, 40.7, 32.0, 29.9, 26.0, 25.6, 21.3. 
MS (70 eV, EI) m/z (%): 437 (12) [M+], 293 (17), 292 (100), 283 (14), 282 (74), 281 (44), 
280 (28), 159 (19), 155 (21), 91 (36), 67 (11). 
IR (ATR) ν~  (cm-1): 2922 (w), 2900 (w), 2846 (vw), 1600 (vw), 1446 (vw), 1426 (vw), 1344 
(m), 1326 (s), 1186 (w), 1160 (vs), 1126 (s), 1106 (m), 1086 (m), 1070 (m), 1046 (w), 1034 
(w), 1020 (w), 968 (w), 940 (w), 914 (w), 856 (w), 848 (w), 834 (w), 812 (w), 748 (w), 728 
(m), 708 (w), 666 (w), 654 (w). 
HRMS (EI) for C23H26F3NO2S (437.1636): 437.1635. 
 
4-(trans-5-methyl-1-tosylpiperidin-2-yl)benzonitrile (173qa) 
 
Tosylation was performed according to TP21. 
column chromatography: SiO2; CH2Cl2 
yield: 80 mg (75 %; 0.3 mmol scale) 
m.p.: 113.1 – 114.4 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.55 (d, J=8.2 Hz, 2 H), 7.01 (d, J=8.4 Hz, 2 H), 6.90 (d, J=8.2 
Hz, 2 H), 6.77 (d, J=8.0 Hz, 2 H), 4.58 (t, J=5.0 Hz, 1 H), 3.25 (dd, J1=12.9 Hz, J2=3.7 Hz, 1 
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H), 2.98 (dd, J1=12.9 Hz, J2=5.3 Hz, 1 H), 1.92 (s, 3 H), 1.60 - 1.50 (m, 1 H), 1.41 - 1.31 (m, 
2 H), 1.08 (dddd, J1=13.9 Hz, J2=9.9 Hz, J3=4.5 Hz, J4=4.3 Hz, 1 H), 0.71 - 0.64 (m, 1 H), 
0.62 (d, J=6.9 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 146.1, 143.3, 138.3, 132.3, 129.9, 128.5, 128.0, 119.2, 111.7, 
58.0, 49.6, 28.7, 27.6, 27.1, 21.5, 18.3. 
MS (70 eV, EI) m/z (%): 354 (10) [M+], 253 (16), 252 (100), 200 (14), 199 (99), 198 (28), 
197 (49), 155 (36), 129 (26), 116 (20), 91 (53), 65 (10). 
IR (ATR) ν~  (cm-1): 2952 (w), 2928 (w), 2226 (w), 1602 (w), 1456 (w), 1344 (s), 1320 (w), 
1304 (w), 1162 (vs), 1096 (m), 1086 (m), 1068 (m), 1052 (m), 1020 (w), 1012 (m), 928 (m), 
904 (m), 840 (m), 830 (m), 808 (s), 754 (w), 722 (vs), 656 (s). 
HRMS (EI) for C20H22N2O2S (354.1402): 354.1398. 
 
4-(trans-1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (176aa) 
N
Ts
CF3
CN
 
Tosylation was performed according to TP21. 
column chromatography: SiO2; ; n-pentane/Et2O 2:1 
yield: 174 mg (72 %; 0.5 mmol scale) 
m.p.: 182.6 – 183.1 °C.  
1H-NMR (400 MHz, CDCl3) δ: 7.82 (d, J=8.2 Hz, 2 H), 7.63 (d, J=8.2 Hz, 2 H), 7.56 (d, 
J=8.2 Hz, 2 H), 7.47 (d, J=8.2 Hz, 2 H), 7.37 (d, J=8.0 Hz, 2 H), 7.10 (d, J=8.2 Hz, 2 H), 5.52 
(d, J=3.5 Hz, 1 H), 4.08 (d, J=14.2 Hz, 1 H), 3.17 - 3.08 (m, 1 H), 2.73 - 2.64 (m, 1 H), 2.49 
(s, 3 H), 2.41 (d, J=13.5 Hz, 1 H), 1.91 (td, J1=13.5 Hz, J2=5.5 Hz, 1 H), 1.63 (d, J=12.9 Hz, 1 
H), 1.51 (qd, J1=12.7 Hz, J2=4.5 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3) δ: 149.9, 143.7, 142.5 (d, J=0.8 Hz), 138.0, 132.5, 129.9, 
129.6 (q, J=32.6 Hz), 127.4, 127.0, 127.0, 125.9 (q, J=3.7 Hz), 124.0 (q, J=272.1 Hz), 118.6, 
110.7, 55.0, 41.6, 36.8, 34.1, 31.3, 21.5. 
MS (70 eV, EI) m/z (%): 484 (11) [M+], 339 (43), 330 (25), 329 (100), 328 (24), 327 (12), 
186 (23), 172 (12), 159 (11), 155 (15), 90 (30). 
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IR (ATR) ν~  (cm-1): 2956 (vw), 2932 (w), 2232 (w), 1606 (w), 1598 (w), 1506 (vw), 1452 
(w), 1434 (w), 1412 (w), 1376 (w), 1348 (w),1328 (vs), 1290 (m), 1256 (w), 1196 (w), 1158 
(vs), 1110 (vs), 1096 (s), 1072 (s), 1034 (w), 1018 (m), 944 (m), 928 (m), 906 (m), 838 (s), 
802 (w), 738 (w), 716 (m), 702 (m), 664 (s), 650 (m), 634 (w). 
HRMS (EI) for C26H23F3N2O2S (484.1432): 484.1439. 
 
trans-2-methyl-1-tosyl-5-(4-(trifluoromethyl)phenyl)-piperidine (181ca) 
 
Tosylation was performed according to TP21. 
column chromatography: SiO2; CH2Cl2 
yield: 145 mg (73 %; 0.5 mmol scale) 
m.p.: 133.0 – 135.9 °C. 
1H-NMR (599 MHz, C6D6) δ: 7.63 (d, J=8.2 Hz, 2 H), 7.31 (d, J=8.0 Hz, 2 H), 7.04 (d, J=8.2 
Hz, 2 H), 6.77 (d, J=8.0 Hz, 2 H), 3.59 - 3.52 (m, 1 H), 3.43 (dd, J1=12.6 Hz, J2=3.8 Hz, 1 H), 
3.27 (dd, J1=12.6 Hz, J2=5.5 Hz, 1 H), 2.51 - 2.44 (m, 1 H), 1.91 (s, 3 H), 1.48 - 1.43 (m, 1 
H), 1.42 - 1.36 (m, 1 H), 1.16 (dddd, J1=13.2 Hz, J2=6.5 Hz, J3=6.4 Hz, J4=3.3 Hz, 1 H), 1.01 
- 0.97 (m, 1 H) 1.02 (d, J=6.6 Hz, 3 H).  
13C-NMR (151 MHz, CDCl3) δ: 147.7 (d, J=1.1 Hz), 143.1, 138.4, 129.9, 129.1 (q, J=32.0 
Hz), 128.7, 128.1, 125.8 (q, J=3.8 Hz), 125.5 (q, J=271.8 Hz), 51.5, 47.8, 39.4, 30.1, 26.8, 
21.4, 17.3. 
MS (70 eV, EI) m/z (%): 397 (2) [M+], 383 (19), 382 (100), 155 (18), 91 (12). 
IR (ATR) ν~  (cm-1): 2940 (w), 2926 (w), 1686 (w), 1446 (w), 1384 (w), 1322 (s), 1300 (m), 
1288 (m), 1264 (m), 1238 (m), 1196 (m), 1180 (m), 1154 (s), 1112 (vs), 1094 (s), 1082 (s), 
1066 (s), 1042 (m), 1016 (m), 994 (m), 978 (m), 966 (s), 960 (m), 908 (m), 872 (m), 840 (m), 
820 (s), 738 (w), 710 (s), 684 (s), 646 (s), 632 (m), 606 (m). 
HRMS (EI) for C20H22F3NO2S (397.1323): 397.1320. 
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cis-1-tosyl-2-(4-(trifluoromethyl)phenyl)-4-((triisopropylsilyl)oxy)piperidine 
 
Tosylation was performed according to TP21. 
column chromatography: SiO2; n-pentane/Et2O 10:1 
yield: 6.22 g (56 %; 20 mmol scale) 
m.p.: 93.8 – 95.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.68 (d, J=8.2 Hz, 2 H), 7.29 (d, J=8.2 Hz, 2 H), 7.14 (d, J=8.0 
Hz, 2 H), 6.79 (d, J=8.0 Hz, 2 H), 5.19 (d, J=2.9 Hz, 1 H), 3.71 (dt, J1=13.9 Hz, J2=3.8 Hz, 1 
H), 3.62 (br. s., 1 H), 3.55 - 3.47 (m, 1 H), 1.97 - 1.93 (m, 1 H), 1.93 (s, 3 H), 1.65 (ddd, 
J1=14.2 Hz, J2=6.6 Hz, J3=2.9 Hz, 1 H), 1.45 - 1.36 (m, 1 H), 1.26 - 1.19 (m, 1 H), 0.97 - 0.73 
(m, 18 H), 0.70 - 0.59 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 146.5 (d, J=1.1 Hz), 143.2, 139.7, 130.0, 129.1 (q, J=32.2 
Hz), 127.8, 127.4, 125.6 (q, J=3.8 Hz), 125.4 (d, J=271.8 Hz), 65.4, 54.8, 38.3, 37.4, 32.6, 
21.4, 18.4, 18.4, 12.6. 
MS (70 eV) m/z (%): 514 (13), 513 (34), 512 (100), 314 (14), 310 (44), 298 (40), 296 (15), 
284 (24), 272 (10), 242 (20), 159 (25), 157 (11), 155 (26); 129 (16); 101 (12); 91 (59); 87 
(11); 75 (20), 61 (10). 
IR (ATR) ν~  (cm-1): 2938 (w), 2866 (w), 1326 (vs), 1312 (s), 1302 (m), 1162 (s), 1156 (s), 
1124 (vs), 1110 (s), 1080 (s), 1070 (s), 1058 (m), 1036 (m), 1016 (s), 950 (m), 936 (s), 936 
(s), 898 (m), 882 (m), 820 (m), 746 (m), 716 (s), 688 (s), 678 (s), 658 (s), 650 (s), 630 (m). 
HRMS (ESI) for C28H41F3NO3SSi+ (556.2523) [M+H+]: 556.2524. 
 
2-methyl-1-tosyl-4-((triisopropylsilyl)oxy)piperidine 
N
Ts
Me
OTIPS
 
Tosylation was performed according to TP21. 
column chromatography: SiO2; CH2Cl2 
yield: 2.77 g (65 %; 10 mmol scale) 
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1H-NMR (300 MHz, C6D6) δ: 7.80 (d, J=8.3 Hz, 2 H), 6.82 (d, J=8.0 Hz, 2 H), 4.29 - 4.18 
(m, 1 H), 3.74 - 3.63 (m, 2 H), 3.48 - 3.37 (m, 1 H), 1.91 (s, 3 H), 1.56 - 1.43 (m, 2 H), 1.42 - 
1.34 (m, 2 H), 1.31 (d, J=7.2 Hz, 3 H), 1.08 - 0.92 (m, 18 H), 0.92 - 0.86 (m, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 142.7, 140.4, 130.0, 127.8, 65.9, 48.8, 37.9, 36.3, 33.6, 21.5, 
19.9, 18.6, 12.7. 
MS (70 eV, EI) m/z (%): 424 (1), 384 (12), 383 (26), 382 (100), 90 (12). 
IR (ATR) ν~  (cm-1): 2942 (m), 2890 (m), 2866 (m), 1598 (vw), 1494 (w), 1464 (m), 1380 
(w), 1346 (m), 1328 (m), 1250 (w), 1216 (w), 1162 (vs), 1130 (s), 1106 (m), 1088 (m), 1060 
(s), 1040 (s), 1018 (m), 988 (m), 966 (vs), 914 (s), 882 (s), 870 (s), 814 (m), 776 (m), 712 (s), 
700 (s), 678 (vs), 654 (s), 642 (s). 
HRMS (EI) for C21H36NO3SSi+ (410.2185) [M-CH3]+: 410.2207. 
 
5.11. Typical Procedure 22: TIPS Deprotection (TP 22) 
 
To a solution of the respective 4-((triisopropylsilyl)oxy)piperidine (1 equiv.) in THF (0.2 M) 
was added n-Bu4NF·3 H2O (2 equiv.) portionwise. The reaction mixture was stirred for 15 h 
at room temperature, then H2O was added, the phases were separated and the aqueous phase 
was extracted with CH2Cl2 (3 x). The combined organic layers were washed with brine and 
dried over Na2SO4. The solvents were evaporated and the crude product was subjected to 
column chromatography. 
 
t-butyl cis-2-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate 
 
Desilylation was performed according to TP22. 
column chromatography: SiO2; CH2Cl2/acetone 7:1 
yield: 1.54 g (89 %; 5 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.37 (d, J=8.3 Hz, 2 H), 7.09 (d, J=8.3 Hz, 2 H), 5.17 (br. s., 1 
H), 3.98 (ddd, J1=13.6 Hz, J2=5.0 Hz, J3=2.8 Hz, 1 H), 3.60 - 3.48 (m, 1 H), 3.20 (td, J1=12.9 
Hz, J2=3.5 Hz, 1 H), 1.85 - 1.72 (m, 1 H), 1.61 (ddd, J1=14.4 Hz, J2=6.8 Hz, J3=3.2 Hz, 1 H), 
1.53 - 1.41 (m, 1 H), 1.36 (s, 9 H), 1.28 - 1.14 (m, 1 H). 
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13C-NMR (75 MHz, C6D6) δ: 155.0, 147.3 (d, J=1.1 Hz), 128.2 (q, J=32.3 Hz), 126.1, 124.8 
(q, J=271.8 Hz), 125.0 (q, J=3.6 Hz), 79.3, 63.9, 52.2, 35.6, 35.5, 31.9, 27.9. 
MS (70 eV, EI) m/z (%): 345 (0.3) [M+], 290 (12), 289 (68), 270 (11), 244 (40), 228 (11), 200 
(18), 186 (11), 172 (15), 59 (100), 41 (13), 18 (11). 
IR (ATR) ν~  (cm-1): 3438 (w), 2978 (w), 2932 (w), 1664 (s), 1620 (w), 1478 (w), 1454 (w), 
1416 (m), 1394 (m), 1366 (m), 1324 (vs), 1280 (m), 1252 (m), 1210 (w), 1160 (s), 1112 (vs), 
1068 (vs), 1040 (s), 1016 (m), 988 (w), 970 (w), 958 (w), 940 (m), 862 (m), 838 (m), 830 (m), 
774 (w), 760 (w). 
HRMS (EI) for C17H22F3NO3 (345.1552): 345.1562. 
 
cis- 1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-ol 
 
Desilylation was performed according to TP22. 
column chromatography: SiO2; CH2Cl2/acetone 10:1 to 5:1 
yield: 3.48 g (87 %; 10 mmol scale) 
m.p.: 114.0 – 115.5 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.50 (d, J=8.2 Hz, 2 H), 7.21 (d, J=8.4 Hz, 2 H), 7.07 (d, J=8.2 
Hz, 2 H), 6.68 (d, J=7.9 Hz, 2 H), 4.85 (t, J=4.7 Hz, 1 H), 3.51 - 3.42 (m, 1 H), 3.40 - 3.30 
(m, 1 H), 3.26 (br. s., 1 H), 1.89 - 1.80 (m, 3 H), 1.64 (dt, J1=14.3 Hz, J2=4.1 Hz, 1 H), 1.47 
(ddd, J=14.3 Hz, J2=6.2 Hz, J3=3.3 Hz, 1 H), 1.36 - 1.28 (m, 1 H), 1.06 - 0.99 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 146.0 (d, J=1.2 Hz), 143.2, 139.2, 130.0, 129.3 (q, J=32.2 
Hz), 127.8, 127.8, 125.5 (q, J=3.9 Hz), 125.4 (q, J=271.3 Hz), 64.6, 55.4, 38.9, 36.6, 32.1, 
21.4. 
19F-NMR (376 MHz, C6D6) δ: -62.10 (s) (major), -62.25 (s) (minor). 
MS (70 eV) m/z (%): 399 (1) [M+], 254 (41), 245 (16), 244 (100), 243 (13), 242 (40), 226 
(35), 200 (12), 199 (13), 172 (25), 159 (19), 155 (32), 91 (61); 65 (12). 
IR (ATR) ν~  (cm-1): 2938 (w), 1622 (w), 1598 (w), 1456 (w), 1426 (w), 1326 (vs), 1260 (w), 
1162 (vs), 1116 (s), 1096 (m), 1068 (s), 1046 (s), 1020 (m), 982 (m), 932 (m), 854 (m), 832 
(m), 814 (s), 720 (s), 706 (m), 654 (s). 
HRMS (ESI) for C19H21F3NO3S+ (400.1189) [M+H+]: 400.1189. 
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2-methyl-1-tosylpiperidin-4-ol 
N
OH
Me
Ts
 
Desilylation was performed according to TP22. 
column chromatography: SiO2; n-pentane/Et2O 5:1 to Et2O (neat) 
yield: 1.38 g (73 %; 7 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.73 (d, J=8.0 Hz, 2 H), 6.80 (d, J=8.0 Hz, 2 H), 4.13 - 3.98 
(m, 1 H), 3.60 - 3.29 (m, 3 H), 1.91 (s, 3 H), 1.53 - 1.33 (m, 2 H), 1.23 (d, J=6.9 Hz, 3 H), 
1.17 (d, J=3.6 Hz, 2 H), 1.01 - 0.90 (m, 1 H).  
13C-NMR (75 MHz, C6D6) δ: 142.8, 140.0, 130.0, 127.8, 64.8, 48.9, 37.6, 36.7, 32.9, 21.5, 
19.6. 
MS (70 eV, EI) m/z (%): 269 (3) [M+], 255 (14), 254 (100), 210 (9), 155 (26), 90 (38). 
IR (ATR) ν~  (cm-1): 3516 (w), 2924 (w), 2882 (w), 1598 (w), 1494 (w), 1454 (w), 1424 (w), 
1402 (w), 1382 (w), 1366 (w), 1344 (m), 1322 (m), 1304 (m), 1288 (m), 1234 (w), 1216 (w), 
1184 (w), 1158 (s), 1148 (s), 1132 (s), 1098 (m), 1080 (s), 1056 (m), 1038 (m), 1018 (m), 
1008 (w), 982 (m), 942 (m), 912 (s), 890 (w), 852 (m), 814 (m), 788 (w), 732 (w), 710 (s), 
688 (vs), 642 (s). 
HRMS (EI) for C13H19NO3S (269.1086): 269.1078. 
 
5.12. Typical Procedure 23: Iodination85 (TP 23) 
 
In a dry and Ar-flushed Schlenk-flask I2 (1.2 equiv.) was dissolved in CH2Cl2 (0.6 M). The 
solution was cooled to 0 °C and PPh3 (1.2 equiv.) was added portionwise. The resulting 
yellow suspension was stirred for 1 h 30 min at 0 °C before N-methyl-imidazole (NMI; 1.25 
equiv.) was added. The respective piperidin-4-ol (1 equiv.) was transferred drop- or 
portionwise to this mixture. The reaction mixture was allowed to proceed for 6 h at 0 °C, then 
quenched with NaHSO3 sat. aq. solution. Phases were separated and the aqueous layer was 
extracted with CH2Cl2 (3x). Solvents were evaporated and the crude product was subjected to 
column chromatography. 
 
                                                 
85
 Lange, G. L. & Gottardo, C. Facile conversion of primary and secondary alcohols to alkyl iodides. Synth. 
Commun. 20, 1473-1479 (1990). 
 C. Experimental Section  195 
 
t-butyl 4-iodo-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (175a) 
 
Iodination was performed according to TP23. 
column chromatography: SiO2; n-pentane/Et2O 7:1 
yield: 2.17 g (68 %; 7 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.26 (d, J=8.3 Hz, 2 H), 6.78 (d, J=8.3 Hz, 2 H), 5.22 (br. s., 1 
H), 3.76 (d, J=13.0 Hz, 1 H), 3.53 (tt, J1=12.4 Hz, J2=3.9 Hz, 1 H), 2.50 (dt, J1=13.6 Hz, 
J2=1.8 Hz, 1 H), 2.26 - 2.07 (m, 2 H), 1.82 (qd, J1=12.4 Hz, J2=4.4 Hz, 1 H), 1.72 - 1.61 (m, 1 
H), 1.41 (s, 9 H). 
13C-NMR (75 MHz, C6D6) δ: 155.3, 143.6 (d, J=1.1 Hz), 129.6 (q, J=32.3 Hz), 129.0, 127.2, 
126.3 (q, J=3.9 Hz), 125.4, 125.2 (q, J=272.1 Hz), 80.4, 56.1, 42.4, 41.7, 39.6, 28.7, 20.3. 
MS (70 eV, EI) m/z (%): 455 (1) [M+], 399 (22), 328 (12), 272 (49), 228 (42), 199 (18), 159 
(16), 61 (13), 59 (100), 41 (13), 18 (38). 
IR (ATR) ν~  (cm-1): 2974 (w), 2932 (w), 2870 VW 1690 (s), 1620 (w), 1478 (w), 1452 (w), 
1412 (s), 1366 (m), 1324 (vs), 1264 (m), 1248 (m), 1154 (vs), 1122 (vs), 1068 (s), 1014 (m), 
1004 (m), 982 (m), 954 (w), 910 (m), 870 (w),852 (m), 836 (m), 794 (w), 772 (m), 732 (w),  
722 (w), 642 (w). 
HRMS (EI) for C17H21F3INO2 (455.0569): 455.0561. 
 
4-iodo-1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidine (175b) 
 
Iodination was performed according to TP23. 
column chromatography: SiO2; n-pentane/Et2O 10:1 
yield: 2.24 g (55 %; 8 mmol scale) 
m.p.: 132.6 – 133.8 °C. 
1H-NMR (400 MHz, C6D6) δ:7.64 (d, J=8.2 Hz, 2 H), 7.25 (d, J=8.4 Hz, 2 H), 6.95 (d, J=8.2 
Hz, 2 H), 6.78 (d, J=7.9 Hz, 2 H), 4.98 (d, J=2.9 Hz, 1 H), 3.51 - 3.38 (m, 2 H), 2.46 - 2.29 
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(m, 2 H), 1.99 (td, J1=13.4 Hz, J2=5.4 Hz, 1 H), 1.89 (s, 3 H), 1.66 (qd, J1=12.6 Hz, J2=4.6 
Hz, 1 H), 1.50 - 1.43 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 143.8, 142.4 (d, J=1.2 Hz), 139.3, 130.3, 129.9 (q, J=32.3 
Hz), 127.8, 127.6, 126.4 (q, J=3.7 Hz), 125.2 (q, J=272.0 Hz), 57.9, 43.7, 40.8, 38.3, 21.5, 
19.0. 
MS (70 eV) m/z (%): 509 (1) [M+], 383 (22), 382 (100), 226 (12), 199 (63), 186 (23), 185 
(10), 184 (53), 159 (54), 155 (87), 91 (67), 65 (11), 55 (10). 
IR (ATR) ν~  (cm-1): 1326 (vs), 1292 (m), 1154 (s), 1118 (s), 1102 (m), 1090 (s), 1070 (s), 
1058 (s), 1044 (m), 1016 (m), 998 (m), 954 (s), 930 (s), 906 (m), 854 (m), 844 (m), 828 (m), 
816 (s), 742 (m), 710 (s), 694 (s), 652 (vs). 
HRMS (ESI) for C19H19F3INO2SCl- (543.9827) [M+Cl-]:543.9817.  
 
2-methyl-4-iodo-1-tosylpiperidine (175c) 
N
I
Me
Ts
 
Iodination was performed according to TP23. 
column chromatography: SiO2; CH2Cl2 
yield: 1.12 g (59 %; 5 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.63 (d, J=8.3 Hz, 2 H), 6.77 (d, J=8.0 Hz, 2 H), 4.00 - 3.84 
(m, 1 H), 3.67 (tt, J1=12.3 Hz, J2=4.4 Hz, 1 H), 3.38 (dt, J1=13.8 Hz, J2=1.7 Hz, 1 H), 2.41 
(ddd, J1=13.7 Hz, J2=12.2 Hz, J3=3.2 Hz, 1 H), 1.99 - 1.90 (m, 1 H), 1.88 (s, 3 H), 1.81 - 1.67 
(m, 1 H), 1.67 - 1.57 (m, 2 H), 0.58 (d, J=6.9 Hz, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 143.1, 139.6, 130.1, 127.7, 51.4, 44.3, 42.2, 39.2, 21.5, 20.1, 
15.5. 
MS (70 eV, EI) m/z (%): 379 (1) [M+], 363 (12), 253 (15), 252 (100), 155 (51), 90 (61), 69 
(10), 66 (10), 58 (17), 56 (12). 
IR (ATR) ν~  (cm-1): 2974 (w),  2924 (w), 2870 (vw), 1598 (w), 1494 (vw), 1444 (w), 1380 
(w), 1330 (s), 1302 (m), 1258 (m), 1204 (w), 1178 (m), 1150 (vs), 1092 (s), 1070 (m), 1056 
(m), 1018 (w), 1008 (m), 988 (s), 964 (w), 914 (s), 878 (w), 852 (m), 814 (s), 724 (w), 708 
(m), 684 (vs), 644 (s). 
HRMS (EI) for C13H18INO2S (379.0103): 379.0118. 
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1. Data of X-ray Analysis 
1.1. Stereoselective Preparation, Configurational Stability and Reactivity of 
Substituted Cyclohexyllithium Derivatives 
 
(β-cholesteryl)(methyl)sulfane (β-(eq)-94a) (Table 2) 
 
 
Crystal Data 
net formula C28H48S 
Mr 416.73 
T[K] 100(2) 
Colour, habit colorless block 
Cryst. size, mm2 0.30 × 0.20 × 0.15 
Crystal system monoclinic 
Space group P21 (No. 4) 
a [Å] 12.7859(5) 
b [Å] 8.6507(3) 
c [Å] 13.0257(6) 
α [°] 90.0 
β [°] 118.159(4) 
γ [°] 90.0 
V [Å3] 1270.21(10) 
Z 2 
ρcalcd [g cm−3] 1.090 
µ [mm-1] 0.139 
F(000) 464 
hkl range -15 ≤ h ≤ 15 
 -10 ≤ k ≤ 10 
 -16 ≤ l ≤ 16 
Reflns. collected 12916 
Reflns. obsd. 4682 
Reflns. unique 4976 
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Rint 0.0251 
Param. refined 262 
θ range [°] 4.26 - 26.00 
R1, wR2 [I > 2σ(I)] 0.0343, 0.0870 
R1, wR2 (all data) 0.0374, 0.0889 
GooF 1.033 
Peak / hole [e Å3] 0.282, -0.161 
 
 
cis-1-(tert-butyl)-4-iodocyclohexane (cis-(ax)-78) (Scheme 28) 
 
 
Crystal Data 
Formula C10H19I 
Mr 266.15 
T[K] 173(2) 
Colour, habit colorless block 
Cryst. size, mm2 0.35 × 0.25 × 0.08 
Crystal system monoclinic 
Space group P21/c 
a [Å] 17.8172(9) 
b [Å] 6.0632(3) 
c [Å] 10.7371(5) 
α [°] 90.0 
β [°] 104.538(4) 
γ [°] 90.0 
V [Å3] 1122.78(10) 
Z 4 
ρcalcd [g cm−3] 1.575 
µ [mm-1] 2.799 
F(000) 528 
hkl range -21 ≤ h ≤ 21 
 -7 ≤ k ≤ 7 
 -12 ≤ l ≤ 12 
Reflns. collected 9572 
Reflns. obsd. 1708 
Reflns. unique 1972 
Rint 0.0386 
Param. refined 172 
θ range [°] 4.11 - 25.00 
R1, wR2 [I > 2σ(I)] 0.0255, 0.0635 
R1, wR2 (all data) 0.0326, 0.0675 
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GooF 1.072 
Peak / hole [e Å3] 0.905, -0.437 
 
 
 
((1S,2S,5R)-2-isopropyl-5-methylcyclohexyl)diphenylphosphine sulfide (neomen-(ax)-
91b) (Table 3) 
 
 
Crystal Data 
Formula C22H29PS 
Mr 356.48 
T[K] 100(2) 
Colour, habit colorless block 
Cryst. size, mm2 0.20 × 0.10 × 0.10 
Crystal system orthorhombic 
Space group P212121 
a [Å] 7.6548(3) 
b [Å] 14.5175(5) 
c [Å] 18.1211(7) 
α [°] 90.0 
β [°] 90.0 
γ [°] 90.0 
V [Å3] 2013.77(13) 
Z 4 
ρcalcd [g cm−3] 1.176 
µ [mm-1] 0.241 
F(000) 768 
hkl range -9 ≤ h ≤ 9 
 -17 ≤ k ≤ 17 
 -21 ≤ l ≤ 21 
Reflns. collected 18801 
Reflns. obsd. 3358 
Reflns. unique 3517 
Rint 0.0400 
Param. refined 313 
θ range [°] 4.30 - 25.00 
R1, wR2 [I > 2σ(I)] 0.0262, 0.0612 
R1, wR2 (all data) 0.0284, 0.0622 
GooF 1.067 
Peak / hole [e Å3] 0.243, -0.178 
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(trans-4-(tert-butyl)cyclohexyl)triphenylstannane (trans-(eq)-82f) (Table 1) 
 
 
Crystal Data 
Formula C28H34Sn 
Mr 489.24 
T[K] 173(2) 
Colour, habit colorless needle 
Cryst. size, mm2 0.30 × 0.10 × 0.05 
Crystal system monoclinic 
Space group P21/n 
a [Å] 6.9567(4) 
b [Å] 12.1094(5) 
c [Å] 29.0071(12) 
α [°] 90.0 
β [°] 94.261(4) 
γ [°] 90.0 
V [Å3] 2436.8(2) 
Z 4 
ρcalcd [g cm−3] 1.334 
µ [mm-1] 1.059 
F(000) 1008 
hkl range -8 ≤ h ≤ 8 
 -14 ≤ k ≤ 11 
 -34 ≤ l ≤ 34 
Reflns. collected 11403 
Reflns. obsd. 3631 
Reflns. unique 4270 
Rint 0.0343 
Param. refined 362 
θ range [°] 4.10 - 25.00 
R1, wR2 [I > 2σ(I)] 0.0283, 0.0618 
R1, wR2 (all data) 0.0369, 0.0649 
GooF 1.023 
Peak / hole [e Å3] 0.751, -0.298 
 
 
 D. Appendix  202 
 
1.2. Highly Diastereoselective Arylations of Substituted Piperidines 
 
cis-t-butyl 2-(3-cyanophenyl)-4-methylpiperidine-1-carboxylate (173d) 
 
C1
O1
O2
N1
C6
C8
C13
C12
C11
C10
C14
N2
C9
C5 C4
C7
C3
C2
C15
C18
C17
C16
 
 
Crystal Data 
net formula C18H24N2O2 
Mr/g mol−1 300.395 
crystal size/mm 0.60 × 0.13 × 0.07 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 6.3135(4) 
b/Å 10.2813(10) 
c/Å 13.8719(10) 
α/° 76.283(7) 
β/° 85.876(6) 
γ/° 77.838(7) 
V/Å3 854.90(12) 
Z 2 
calc. density/g cm−3 1.16698(16) 
µ/mm−1 0.076 
absorption correction 'multi-scan' 
transmission factor range 0.72269–1.00000 
refls. measured 5884 
Rint 0.0355 
mean σ(I)/I 0.0856 
θ range 4.24–26.33 
observed refls. 1872 
x, y (weighting scheme) 0.0371, 0 
hydrogen refinement constr 
refls in refinement 3435 
parameters 203 
restraints 0 
R(Fobs) 0.0427 
Rw(F2) 0.0891 
S 0.830 
shift/errormax 0.001 
max electron density/e Å−3 0.163 
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min electron density/e Å−3 −0.141 
 
 
cis-t-butyl 2-(3-cyanophenyl)-4-phenylpiperidine-1-carboxylate (173h) 
 
N2
C17
C14 C15
C16
C11
C12
C13
C5
C4
C3
C2
O1
C1
O2
N1
C6
C7
C8
C9
C10
C18
C19
C20
C21C22
C23
 
 
Crystal Data 
net formula C23H26N2O2 
Mr/g mol−1 362.465 
crystal size/mm 0.39 × 0.22 × 0.12 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group P21/c 
a/Å 14.5171(9) 
b/Å 11.6682(8) 
c/Å 12.0141(8) 
α/° 90 
β/° 98.276(7) 
γ/° 90 
V/Å3 2013.9(2) 
Z 4 
calc. density/g cm−3 1.19548(12) 
µ/mm−1 0.076 
absorption correction 'multi-scan' 
transmission factor range 0.96746–1.00000 
refls. measured 8788 
Rint 0.0314 
mean σ(I)/I 0.0756 
θ range 4.23–26.32 
observed refls. 2310 
x, y (weighting scheme) 0.0279, 0 
hydrogen refinement constr 
refls in refinement 4068 
parameters 247 
restraints 0 
R(Fobs) 0.0351 
Rw(F2) 0.0680 
S 0.806 
shift/errormax 0.001 
N
Boc
CN
eq
eq
cis
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max electron density/e Å−3 0.156 
min electron density/e Å−3 −0.144 
 
 
2-tosyl-3-(4-(trifluoromethyl)phenyl)decahydroisoquinoline (173na) 
 
C12
C11
C10
C9
C14C13
C8
N1
C16
C15
C17
C22
C21
C20
C19
C18
C23
F1
F2
F3
S1
O2
O1
C1
C2
C3
C4
C5
C6
C7
 
 
Crystal Data 
net formula C23H26F3NO2S 
Mr/g mol−1 437.519 
crystal size/mm 0.51 × 0.05 × 0.02 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group C2/c 
a/Å 31.5413(5) 
b/Å 5.49050(10) 
c/Å 25.8592(4) 
α/° 90 
β/° 110.7934(8) 
γ/° 90 
V/Å3 4186.55(12) 
Z 8 
calc. density/g cm−3 1.38831(4) 
µ/mm−1 0.201 
absorption correction none 
refls. measured 12910 
Rint 0.0338 
mean σ(I)/I 0.0306 
θ range 3.37–25.36 
observed refls. 3115 
x, y (weighting scheme) 0.0296, 5.6059 
hydrogen refinement constr 
refls in refinement 3826 
parameters 300 
restraints 0 
R(Fobs) 0.0383 
Rw(F2) 0.0938 
S 1.088 
shift/errormax 0.001 
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max electron density/e Å−3 0.223 
min electron density/e Å−3 −0.367 
 
F atoms disordered, split model applied, sof ratio about 1:1. 
 
 
4-(cis-5-methyl-1-tosylpiperidin-2-yl)benzonitrile (173qa) 
 
C14
C15
C16
C17
C20
C18
C19
S1
O1
O2
N1
C5
C6
C7
C8
C9
C13
N2
C10
C11
C4
C1
C3
C2
C12
 
 
Crystal Data 
net formula C20H22N2O2S 
Mr/g mol−1 354.467 
crystal size/mm 0.40 × 0.08 × 0.05 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 5.4884(2) 
b/Å 11.8978(8) 
c/Å 14.2002(7) 
α/° 77.357(5) 
β/° 86.323(4) 
γ/° 87.651(4) 
V/Å3 902.58(8) 
Z 2 
calc. density/g cm−3 1.30429(12) 
µ/mm−1 0.195 
absorption correction 'multi-scan' 
transmission factor range 0.98356–1.00000 
refls. measured 6364 
Rint 0.0211 
mean σ(I)/I 0.0554 
θ range 4.36–26.34 
observed refls. 2403 
x, y (weighting scheme) 0.0431, 0 
hydrogen refinement constr 
refls in refinement 3645 
parameters 228 
restraints 0 
R(Fobs) 0.0371 
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Rw(F2) 0.0847 
S 0.886 
shift/errormax 0.001 
max electron density/e Å−3 0.209 
min electron density/e Å−3 −0.269 
 
 
4-(trans-1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (176aa) 
 
S1
O1
O2
C1
C2
C3
C6
C5
C4
C7
N1
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
F3
F2F1
C20
C21
C22
C23
C24
C25
C26
N2
eq
ax
trans
N
Ts
CN
F3C
(from Boc-protected piperidine)
 
 
Crystal Data 
net formula C26H23F3N2O2S 
Mr/g mol−1 484.534 
crystal size/mm 0.35 × 0.04 × 0.04 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group C2/c 
a/Å 22.4013(9) 
b/Å 14.5197(5) 
c/Å 15.9116(7) 
α/° 90 
β/° 116.2671(19) 
γ/° 90 
V/Å3 4641.0(3) 
Z 8 
calc. density/g cm−3 1.38694(9) 
µ/mm−1 0.190 
absorption correction none 
refls. measured 14235 
Rint 0.0717 
mean σ(I)/I 0.0550 
θ range 3.15–25.34 
observed refls. 2969 
x, y (weighting scheme) 0.0316, 6.9720 
hydrogen refinement constr 
refls in refinement 4228 
parameters 308 
restraints 0 
R(Fobs) 0.0448 
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Rw(F2) 0.1096 
S 1.009 
shift/errormax 0.001 
max electron density/e Å−3 0.298 
min electron density/e Å−3 −0.337 
 
 
4-(trans-1-tosyl-2-(4-(trifluoro-methyl)phenyl)-piperidin-4-yl)benzonitrile (176c) 
 
N2
C26
C23
C22
C21
C20
C25
C24
C10
C11
C9
C8
N1
C12
C13
C14
C15
C16
C17
C18
C19
F1
F3
F2
S1
O2
O1
C1
C6
C5
C2
C3
C4
C7
 
 
Crystal Data 
net formula C26H23F3N2O2S 
Mr/g mol−1 484.534 
crystal size/mm 0.21 × 0.15 × 0.096 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group C2/c 
a/Å 22.3664(8) 
b/Å 14.5275(6) 
c/Å 15.9004(5) 
α/° 90 
β/° 116.2098(18) 
γ/° 90 
V/Å3 4635.3(3) 
Z 8 
calc. density/g cm−3 1.38865(9) 
µ/mm−1 0.191 
absorption correction none 
refls. measured 10097 
Rint 0.0369 
mean σ(I)/I 0.0542 
θ range 3.15–27.49 
observed refls. 3351 
x, y (weighting scheme) 0.0577, 3.2402 
hydrogen refinement constr 
refls in refinement 5236 
parameters 308 
restraints 0 
R(Fobs) 0.0484 
N
Ts
eq
ax
trans
CN
F3C
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Rw(F2) 0.1319 
S 1.037 
shift/errormax 0.001 
max electron density/e Å−3 0.361 
min electron density/e Å−3 −0.378 
 
 
4-(trans-2-methyl-1-tosylpiperidin-4-yl)benzonitrile (176e) 
 
 
 
C7
C4
C3
C2
C1
C6
C5
O1
S1
O2
C13
C12
N1
C9
C8
C10
C11
C14
C19
C15
C16
C17
C18
C20 N2
 
 
 
Crystal Data 
net formula C20H22N2O2S 
Mr/g mol−1 354.467 
crystal size/mm 0.22 × 0.16 × 0.06 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 7.4047(6) 
b/Å 9.5212(9) 
c/Å 13.7988(11) 
α/° 88.074(7) 
β/° 76.203(7) 
γ/° 87.599(7) 
V/Å3 943.66(14) 
Z 2 
calc. density/g cm−3 1.24751(19) 
µ/mm−1 0.186 
absorption correction 'multi-scan' 
transmission factor range 0.82353–1.00000 
refls. measured 4869 
Rint 0.0434 
mean σ(I)/I 0.1372 
θ range 4.29–23.29 
observed refls. 1212 
x, y (weighting scheme) 0.0470, 0 
hydrogen refinement constr 
refls in refinement 2651 
parameters 228 
restraints 0 
R(Fobs) 0.0539 
Rw(F2) 0.1174 
N
Ts
eq
ax
trans
CN
Me
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S 0.831 
shift/errormax 0.001 
max electron density/e Å−3 0.205 
min electron density/e Å−3 −0.200 
 
Crystal had poor scattering strength, data collection merely up to a resolution of 0.90 Å. 
 
 
trans-2-methyl-1-tosyl-5-(4-(trifluoromethyl)phenyl)-piperidine (181ca) 
 
C7
C4
C3
C2
C5
C6
C1
S1
O2
O1 N1
C8
C9
C14
C15
C16
C17
C19
C18
C20
F2
F3
F1
C10
C11
C12
C13
 
 
Crystal Data 
net formula C20H22F3NO2S 
Mr/g mol−1 397.455 
crystal size/mm 0.37 × 0.23 × 0.17 
T/K 243(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group P21/n 
a/Å 10.1552(5) 
b/Å 11.7039(5) 
c/Å 16.2918(8) 
α/° 90 
β/° 98.366(4) 
γ/° 90 
V/Å3 1915.76(16) 
Z 4 
calc. density/g cm−3 1.37804(12) 
µ/mm−1 0.212 
absorption correction 'multi-scan' 
transmission factor range 0.94343–1.00000 
refls. measured 7447 
Rint 0.0271 
mean σ(I)/I 0.0604 
θ range 4.30–26.33 
observed refls. 2580 
x, y (weighting scheme) 0.0432, 0 
hydrogen refinement constr 
refls in refinement 3883 
parameters 273 
restraints 10 
R(Fobs) 0.0368 
Rw(F2) 0.0840 
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S 0.881 
shift/errormax 0.001 
max electron density/e Å−3 0.284 
min electron density/e Å−3 −0.379 
 
The F atoms of the CF3 group are disordered over three sites. A split model has been applied. 
The sof ratios are 0.83:0.09:0.08. The F atoms on the highest occupied site have been refined 
anisotropically. 
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